Drug Expenditure in Canada 1985 to 2008

National Health Expenditure Database



Canadian Institute for Health Information

Institut canadien d'information sur la santé Production of this report is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying and recording, or by any information storage and retrieval system now known or to be invented, without the prior permission in writing from the owner of the copyright, except by a reviewer who wishes to quote brief passages in connection with a review written for inclusion in a magazine, newspaper or broadcast.

Requests for permission should be addressed to:

Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6

Phone: 613-241-7860 Fax: 613-241-8120 www.cihi.ca

ISBN 978-1-55465-510-6 (PDF)

© 2009 Canadian Institute for Health Information

How to cite this document: Canadian Institute for Health Information, *Drug Expenditure in Canada, 1985 to 2008* (Ottawa: CIHI, 2009).

Cette publication est aussi disponible en français sous le titre *Dépenses en médicaments au Canada, de 1985 à 2008.* ISBN 978-1-55465-511-3 (PDF)

Drug Expenditure in Canada, 1985 to 2008

Table of Contents

Executive Summary
Introduction 1
National Drug Expenditure Overview
The Share of Drugs in Total Health Expenditure
Total Drug Expenditure6
Total Drug Expenditure per Capita7
Drug Expenditure: Prescribed and Non-Prescribed Drugs
Prescribed Drug Expenditure by Source of Finance
Drug Expenditure in the Provinces and Territories17
The Share of Drugs in Total Health Expenditure
Total Drug Expenditure by Source of Finance
Total Drug Expenditure per Capita by Source of Finance
Drug Expenditure by Type of Drug and by Source of Finance
International Comparisons
Comparability of Health Expenditure Across Countries
Share of Drugs in Total Health Expenditure
Share of Public Expenditure in Total Expenditure on Drugs
Share of Drugs in Public Expenditure on Health
Factors Affecting Drug Expenditure in Canada
Methodological Notes
Background 43
Data Limitations
Collection and Non-Response
Sources of Data
Series A-Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2008
Series B-Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2008 65
Series C-International Comparisons 119
Appendix A-Comparison of Provincial and Territorial Drug Subsidy Programs
Reference List

List of Figures

Figure 1	Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 20083
Figure 2	Annual Growth Rate for Total Drug Expenditure, Total Health Expenditure and Consumer Price Index, Canada, 1985 to 20084
Figure 3	Total Health Expenditure and the Percentage Share by Use of Funds, Canada, 2008 (\$ Billions)5
Figure 4	Total Drug Expenditure, Canada, 1985 to 20086
Figure 5	Total Drug Expenditure per Capita, Current and Constant Dollars, Canada, 1985 to 20087
Figure 6	Total Drug Expenditure by Type, Canada, 1985 to 20089
Figure 7	Total Drug Expenditure by Source of Finance and Type, Canada, 2008 10
Figure 8	Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2008 11
Figure 9	Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 200812
Figure 10	Prescribed Drug Expenditure by Private-Sector Source of Finance, Canada, 1988 to 2008
Figure 11	Drug Expenditure as a Percentage of Total Health Expenditure, by Province/Territory and Canada, 1985 and 2008
Figure 12	Percentage of Total Drug Expenditure by Source of Finance, by Province/Territory and Canada, 2008
Figure 13	Total Drug Expenditure per Capita by Type and by Source of Finance, by Province/Territory and Canada, 2008
Figure 14	Annual Growth Rate for Public- and Private-Sector Prescribed (Rx) and Non-Prescribed (Non-Rx) Drug Expenditure per Capita, 2008
Figure 15	Average Annual Growth Rate for Prescribed Drug Expenditure per Capita by Source of Finance, by Province/Territory, Between 1985 and 2008 24
Figure 16	Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2008
Figure 17	Drug Expenditure per Capita, Selected Countries, 1985 to 2006
Figure 18	Composition of Total Health Expenditure, by Source of Finance
Figure 19	Patented Medicine Price Index (PMPI), Consumer Price Index (CPI) and Industrial Product Price Index (IPPI), 1985 to 2008 (1987 = 100)

List of Tables

Table 1	Distribution of Prescribed Drug Expenditure by Source of Finance, Canada, 1988 and 2008	13
Table 2	Drug Expenditure Summary, by Province/Territory and Canada, 2008	17
Table 3	Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Reporting OECD Comparator Countries, 2006	31
Table 4	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator Countries, 2006	34
Table 5	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Reporting OECD Comparator	~ ~
	Countries, 2006	36
Table 6	Factors That May Influence Drug Expenditure in Canada	40
Table 7	Provincial/Territorial Government Drug Expenditure Data	50
Table 8	Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2008	28

Executive Summary

Total expenditure on drugsⁱ in Canada was \$25.3 billionⁱⁱ in 2006, and is forecast to have reached \$29.8 billion in 2008. The share of drugs in total health expenditure was 9.5% in 1985. It increased each year thereafter to reach 16.7% in 2006, and is forecast to have grown to 17.4% in 2008. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals.

At the national level, 2007 and 2008 forecast data indicate that:

- The share of drugs in total health expenditure is forecast to have reached 17.0% in 2007 and 17.4% in 2008.
- Total drug expenditure is forecast to have reached \$27.5 billion in 2007 and \$29.8 billion in 2008, representing annual increases of 8.8% and 8.3%, respectively.
- Total drug expenditure per capita in Canada is expected to have reached \$835 in 2007 and \$897 in 2008, representing annual rates of increase of 7.7% and 7.4%, respectively.
- The share of prescribed drugs in total drug expenditure is forecast to have reached 83.7% in 2007 and 84.3% in 2008.
- Expenditure on prescribed drugs is expected to have reached \$23.1 billion in 2007 and \$25.1 billion in 2008, representing growth rates of 9.6% and 9.0%, respectively.
- Expenditure on non-prescribed drugs is forecast to have reached \$4.5 billion in 2007 and \$4.7 billion in 2008, representing increases of 4.5% and 4.6%, respectively.
- Public-sector expenditure on prescribed drugs is forecast to have reached \$10.5 billion in 2007 and \$11.2 billion in 2008, representing annual growth rates of 7.6% and 6.7%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$12.6 billion in 2007 and \$14.0 billion in 2008, with corresponding annual growth rates of 11.4% and 11.0%.

At the provincial level, 2008 forecast data indicate that:

- Total drug expenditure per capita is forecast to have ranged from \$774 in British Columbia and \$806 in Alberta to \$963 in Quebec and \$1,030 in Nova Scotia.
- The share of prescribed drug spending in total drug expenditure is forecast to have ranged from 80.8% in Alberta and 82.9% in Prince Edward Island to 87.3% in Quebec and 87.9% in Newfoundland and Labrador.
- The proportion of prescribed drugs financed by the public sector in 2008 varied across the provinces and is forecast to have ranged from 31.6% in New Brunswick and 34.3% in P.E.I. to 49.9% in Quebec and 53.7% in Saskatchewan.

i. Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX) and are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups and appropriate taxes. Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs (over-the-counter drugs and personal health supplies). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

ii. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

At the international level in 2006, the most recent year for which data were available, among 23 Organisation for Economic Co-operation and Development (OECD) comparator countries:^{III}

- Canada had the second-highest level of total drug expenditure per capita, after the United States.
- The public sector funded 39.2% of total drug expenditure in Canada. This was the fourth-lowest share, ahead of Poland (38.6%), the U.S. (30.2%) and Mexico (15.4%). The share of public drug expenditure in total drug expenditure was highest in Luxembourg, at 83.5%.
- Public drug expenditure accounted for 9.7% of public-sector health expenditure in Canada, as well as in Iceland and Sweden. This proportion places Canada, Iceland and Sweden ahead of the U.S. (8.3%), Mexico (8.0%), Luxembourg (7.8%), Norway (5.7%) and Denmark (5.6%). The share of public drug expenditure in public-sector health expenditure was highest in the Slovak Republic, at 31.7%.

Factors affecting drug expenditure:

Numerous factors, many of which are inter-related, may influence drug expenditure. Since drug prices, as measured by several price indices, have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

iii. Comparator countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Japan, Korea, Luxembourg, Mexico, Norway, Poland, Portugal, the Slovak Republic, Spain, Sweden, Switzerland and the United States.

Introduction

Pharmaceutical drugs play an essential role in modern medicine. Through the treatment of various diseases, they have become an increasingly significant component of the Canadian health care system.

Drug expenditure data in this report are primarily obtained from the National Health Expenditure Database (NHEX) maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1960. Drug expenditure data in NHEX are macrolevel data and do not allow for decomposition of prescription costs or drug classes.

The "Drugs" category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, including dispensing fees, mark-ups and appropriate taxes. NHEX data do not include drug expenditure by non-Canadian residents (for example, Americans purchasing drugs via Canadian internet pharmacies). This classification system used in NHEX is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

Drug expenditure estimates within NHEX provide insight into total drug expenditure^{iv} by public and private payers and by type of drugs (prescribed and non-prescribed) at the provincial/territorial and national levels. All drug expenditure estimates stated in this report are in current dollars (unadjusted for inflation) unless otherwise stated.

Drug Expenditure in Canada, 1985 to 2008 is an annual publication and provides updated information on drug expenditure trends in Canada. This publication includes:

- National drug expenditure;
- Provincial and territorial drug expenditure;
- International comparisons; and
- Factors that may affect drug expenditure.

More information on drug expenditure and the methods used in the preparation of this document is available by contacting the Pharmaceuticals department at CIHI by phone at 613-241-7860 or by email at drugs@cihi.ca.


iv. Total drug expenditure in this report includes expenditure on prescribed drugs and non-prescribed drugs. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

National Drug Expenditure Overview

The Share of Drugs in Total Health Expenditure Outlook – 2007 and 2008

The share of drugs in total health expenditure is forecast to have reached 17.0% in 2007 and 17.4% in 2008 (Figure 1).

Figure 1 Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2008




Source


National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Highlights-2006

Drugs have been one of the fastest-growing components of total health expenditure in Canada. From 1985 to 2006, total health spending grew at an average annual rate of 6.6%. During this period, total drug expenditure increased at an average annual rate of 9.4%. In every year, except 2005, the annual rate of growth for drugs exceeded the rate for total health expenditure (Figure 2).

Drug expenditure grew at an annual rate beyond what can be attributed to economy-wide inflation (as measured by the Consumer Price Index, or CPI) in every year between 1985 and 2006 (Figure 2). Total health expenditure grew at an annual rate above the rate of inflation in all years during this period, with the exception of 1995 and 1996.





Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Consumer Price Index, Statistics Canada.




Figure 3 Total Health Expenditure and the Percentage Share by Use of Funds, Canada, 2008^f (\$ Billions)

Note

f: forecast.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

NHEX provides an overview of all health spending in Canada by spending category and source of funding. Total health expenditure comprises nine major spending categories. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals (Figure 3).


Total drug expenditure grew at a higher rate than total hospital expenditure every year between 1985 and 2006.¹ During this period, total drug expenditure grew at an average annual rate of 9.4%, while total hospital expenditure grew at an average annual rate of 4.7%.


See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.

Total Drug Expenditure

Outlook - 2007 and 2008

Total drug expenditure is forecast to have reached \$27.5 billion^v in 2007 and \$29.8 billion in 2008, representing annual increases of 8.8% and 8.3%, respectively.





Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Highlights-2006

Canada's total drug expenditure increased steadily from \$3.8 billion in 1985 to \$25.3 billion in 2006 (Figure 4). The average annual rate of growth during this period was 9.4%.

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.


v. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

Total Drug Expenditure per Capita

Outlook-2007 and 2008

Total drug expenditure per capita in Canada is expected to have reached \$835 in 2007 and \$897 in 2008, representing annual rates of increase of 7.7% and 7.4%, respectively.

Figure 5 Total Drug Expenditure per Capita, Current and Constant* Dollars, Canada, 1985 to 2008



Note

* Figures are deflated using the Consumer Price Index to reflect 1985 dollars.

Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Consumer Price Index, Statistics Canada.

Highlights-2006

Per capita drug expenditure trends are similar to those of total drug spending, reflecting a 1.1% average annual rate of growth in the overall population in Canada from 1985 to 2006. Total drug expenditure increased from \$147 per capita in 1985 to \$776 in 2006 (Figure 5). The average annual growth rate during this period was 8.2%.

Typically, expenditure is deflated by a price index to measure change in quantity. There is no authoritative composite price index for all drugs sold in Canada.^{vi} However, measuring drug expenditure in constant dollars (adjusted for inflation) using the CPI^{vii} reported by Statistics Canada gives a sense of change in drug expenditure in the context of economywide inflation. Readers should cautiously interpret inflation-adjusted trends in expenditure, since drug-specific inflation may differ from that depending upon the broad basket of goods and services purchased by Canadians.

In terms of constant (1985) dollars, per capita drug expenditure increased from \$147 in 1985 to \$448 in 2006, reflecting an average annual growth rate of 5.4%. Trends in per capita drug expenditure measured in constant dollars are similar to those of per capita drug expenditure measured in current dollars, though growth between 1985 and 2006 is less pronounced when it is considered relative to economy-wide inflation (Figure 5).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.

Drug Expenditure: Prescribed and Non-Prescribed Drugs Outlook – 2007 and 2008

Expenditure on prescribed drugs^{viii} is expected to have reached \$23.1 billion in 2007 and \$25.1 billion in 2008, representing growth rates of 9.6% and 9.0%, respectively. Expenditure on non-prescribed drugs is forecast to have reached \$4.5 billion in 2007 and \$4.7 billion in 2008, representing increases of 4.5% and 4.6%, respectively.

Non-prescribed drugs, which are typically financed by consumers (households), include over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes).^{ix} Since NHEX consists of macro-level health expenditure data, some over-the-counter drugs and personal health supplies that are covered under some drug benefit plans^x may be counted as prescribed drug expenditures.

Prescribed drugs are expected to have accounted for 83.7% of total drug expenditure in Canada in 2007 and 84.3% in 2008. Conversely, the share of non-prescribed drugs in total drug expenditure is expected to have accounted for 16.3% in 2007 and 15.7% in 2008.

vi. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

vii. A measure of the average percentage change over time in the cost of a fixed basket of goods and services purchased by Canadian consumers.

viii. A prescribed drug is a substance considered to be a drug under the *Food and Drugs Act*, which is sold for human use as the result of a prescription from a health professional.

ix. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

x. For example, diabetic test strips, where covered under drug benefit plans, may be included in prescribed drug expenditure, subject to source of data.




Figure 6 Total Drug Expenditure by Type, Canada, 1985 to 2008

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Highlights-2006

From 1985 to 2006, expenditure on prescribed drugs grew from \$2.6 billion to \$21.0 billion, at an average annual rate of 10.5%. Spending on non-prescribed drugs increased from \$1.2 billion to \$4.3 billion, at an average of 6.1% per year (Figure 6). During this period, with the exception of 1987 and 1994, annual growth in drug spending was higher in prescribed drugs than in non-prescribed drugs. As a result, prescribed drugs captured a larger share of total drug spending, rising from 67.5% in 1985 to 83.1% in 2006.

Non-prescribed drug expenditure represented 16.9% of total drug expenditure in 2006. Over-the-counter drugs accounted for \$2.4 billion, or 9.3% of total drug expenditure, and personal health supplies accounted for \$1.9 billion, or 7.6%.

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.

Prescribed Drug Expenditure by Source of Finance

While non-prescribed drugs are typically financed out-of-pocket by consumers (households), multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial and federal drug subsidy programs and social security funds (such as workers' compensation boards, or WCBs). In the private sector, they include private insurers and households.

In 2008, \$11.2 billion in prescribed drugs are expected to have been financed by the public sector, while expenditure by the private sector is for both prescribed drugs (\$14.0 billion) and non-prescribed drugs (\$4.7 billion). In the private sector, prescribed drugs financed by private insurers are expected to have been \$9.3 billion, with the remainder financed by Canadian households (\$4.6 billion). Non-prescribed drugs are composed of over-the-counter drugs (\$2.6 billion) and personal health supplies (\$2.1 billion) (Figure 7).




Figure 7 Total Drug Expenditure by Source of Finance and Type, Canada, 2008^f

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. *Non-prescribed drugs* include over-the-counter drugs and personal health supplies. For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Outlook - 2007 and 2008

Public-sector expenditure on prescribed drugs is forecast to have reached \$10.5 billion in 2007 and \$11.2 billion in 2008 (Figure 8), representing annual growth rates of 7.6% and 6.7%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$12.6 billion in 2007 and \$14.0 billion in 2008, with corresponding annual growth rates of 11.4% and 11.0%.

The share of prescribed drug expenditure financed by the public sector is forecast to have fallen to 45.4% in 2007 and 44.5% in 2008, from a 10-year high of 46.8% in 2005.




Figure 8 Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2008

Notes

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. For detailed definitions please refer to the Methodological Notes.


Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Highlights-2006

The intersections of the two series depicted in Figure 9 (excluding forecasts for 2007 and 2008) identify four distinct periods of growth in publicly and privately financed prescribed drug expenditure.

Figure 9 Annual Growth Rate for Prescribed Drug Expenditure by Source of Finance, Canada, 1985 to 2008



Notes

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. For detailed definitions please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Between 1985 and 1992, expenditure on prescribed drugs in the public sector grew by an average annual rate of 14.6%, while this rate was 12.0% for prescribed drug expenditure financed by the private sector. Consequently, the share of prescribed drugs financed from public sources increased from 43.6% in 1985 to 47.7% in 1992.

From 1992 to 1997, spending on prescribed drugs by the private sector grew at an average annual rate of 9.1%, more than twice the 4.4% average annual rate of growth in publicly financed prescribed drug expenditure. Fiscal restraint introduced in several provinces led to negative growth in publicly financed prescribed drug expenditure in 1996. By 1997, the share of prescribed drugs financed from public sources had declined to 42.2%, below its share in 1985 (43.6%).

Between 1997 and 2005, expenditure on prescribed drugs by the public sector grew at an average annual rate of 12.2%, compared to 9.6% in the private sector. The share of prescribed drug expenditure financed by the public sector reached 46.3% in 2006.

A fourth period appears to have commenced in 2006, with the growth of private-sector funding of prescribed drugs (10.2%) exceeding that of the public sector (8.0%).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.

Two levels of government—provincial/territorial and federal—as well as social security funds, such as workers' compensation boards and the Quebec Fonds de l'assurance médicaments (Drug Insurance Fund), finance spending on prescribed drugs by the public sector. Private-sector expenditure on prescribed drugs is financed by two sources: private insurers and households (out-of-pocket). Table 1 shows the distribution of prescribed drug expenditure by these sources of finance.

	198	8	2008		
	\$ Millions	Percent	\$ Millions	Percent	
Provincial/Territorial Governments	1,592.7	42.6	9,505.6	37.8	
Federal Direct	89.3	2.4	689.3	2.7	
Social Security Funds:					
Workers' Compensation Boards	20.8	0.6	183.6	0.7	
Quebec Drug Insurance Fund*	N/A	N/A	799.0	3.2	
Subtotal Public Sources	1,702.8	45.6	11,177.4	44.5	
Private Insurers	1,130.3	30.2	9,330.4	37.1	
Households (out-of-pocket)	903.7	24.2	4,633.3	18.4	
Subtotal Private Sources	2,034.0	54.4	13,963.7	55.5	
Total All Sources	3,736.8	100.0	25,141.1	100.0	

Table 1Distribution of Prescribed Drug Expenditure by Source of Finance,
Canada, 1988 and 2008^f

Notes

f: forecast.

* Data not available prior to January 1, 1997, when the program was first introduced in Quebec.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Provincial/territorial government expenditure on prescribed drugs was almost \$1.6 billion in 1988, accounting for 42.6% of total expenditure on prescribed drugs. By 2008, provincial/ territorial government expenditure is forecast to have grown to \$9.5 billion, while its share of total expenditure on prescribed drugs is expected to have diminished to 37.8%.


All provinces/territories provide some form of prescribed drug coverage to seniors and social assistance recipients (see Appendix A for an overview of provincial and territorial drug subsidy programs).

Federal direct expenditure was \$89.3 million in 1988, equivalent to 2.4% of total expenditure on prescribed drugs. Federal direct expenditure is forecast to have increased to \$689.3 million in 2008, representing 2.7% of total expenditure on prescribed drugs. The federal government provides drug benefits to Aboriginal Canadians (as of the end of March 2007, about 792,600 Aboriginal Canadians had drug coverage through the Non-Insured Health Benefits Program of Health Canada²), veterans, members of the military and the RCMP, prisoners in federal correctional facilities and refugees.

Expenditure by social security funds was \$20.8 million in 1988, equivalent to 0.6% of total prescribed drug expenditure. In 2008, expenditure by social security funds is forecast to have reached \$982.6 million and to have accounted for 3.9% of total expenditure on prescribed drugs. Social security funds figures have largely represented spending by the Quebec Drug Insurance Fund since its institution in 1997. Quebec residents not otherwise covered by the provincial program or by private health insurance are insured by the fund through the compulsory payment of premiums.

Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.





Note

* Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Expenditure on prescribed drugs by private insurers amounted to more than \$1.1 billion in 1988, or 30.2% of prescribed drug expenditure. Private insurers' spending increased to \$9.3 billion in 2008, and their share of prescribed drug expenditure increased to 37.1%. Private insurers include group and individual insurance. Many employers offer group benefit plans covering prescribed drugs for employees and their families. In some cases, individuals will continue to be covered by a group plan even after they retire. Out-of-pocket spending by households was an estimated \$0.9 billion in 1988, representing 24.2% of total expenditure on prescribed drugs. By 2008, out-of-pocket prescribed drug expenditure is estimated to have risen to \$4.6 billion, while its share of prescribed drug expenditure will have decreased to 18.4% (Figure 10).

See Data Tables in Series A for more data on national drug expenditure from 1985 to 2008.

Drug Expenditure in the Provinces and Territories

There is considerable variation in the level and growth of drug expenditure across the provinces and territories. These variations are influenced by several factors, including differences in provincial/territorial drug subsidy programs (see Appendix A for an overview of provincial and territorial drug subsidy programs), existence of private insurance coverage, age and sex distribution of provincial/territorial populations, the health needs of targeted populations and the manner in which health care is delivered (including the balance between institutional and ambulatory care).³ Other possible sources of variation in drug expenditure are described in the section Factors Affecting Drug Expenditure in Canada. Table 2 provides an overview of provincial/territorial drug expenditure forecast for 2008.

	Total Drug Expenditure per Capita			Prescribed Drug Expenditure per Capita			Public Prescribed Drug Expenditure per Capita		
	Amount (Dollars)	Percent Change Over 2007	Percent of Total Health Exp. per Capita	Amount (Dollars)	Percent Change Over 2007	Percent of Total Drug Exp. per Capita	Amount (Dollars)	Percent Change Over 2007	Percent of Prescribed Drug Exp. per Capita
N.L.	895.92	11.1	16.6	787.49	12.3	87.9	297.21	19.5	37.7
P.E.I.	889.02	8.3	17.2	737.30	9.2	82.9	253.14	12.6	34.3
N.S.	1,029.81	10.1	18.9	864.50	11.0	83.9	359.30	15.2	41.6
N.B.	952.94	7.6	18.0	811.12	8.2	85.1	256.00	2.3	31.6
Que.	962.95	8.1	20.7	840.99	8.2	87.3	419.63	7.8	49.9
Ont.	924.60	5.9	17.7	767.03	6.7	83.0	338.28	4.5	44.1
Man.	835.51	8.9	15.0	708.94	10.1	84.9	311.54	2.4	43.9
Sask.	824.59	9.9	15.3	701.27	11.2	85.0	376.83	14.0	53.7
Alta.	805.96	7.8	14.1	651.26	8.9	80.8	285.84	4.8	43.9
B.C.	773.68	8.5	15.2	652.27	9.4	84.3	236.14	0.8	36.2
Y.T.	802.83	7.0	10.2	643.97	7.2	80.2	401.75	3.3	62.4
N.W.T.	612.74	11.0	6.3	527.23	12.6	86.0	282.41	9.1	53.6
Nun.	757.99	10.4	6.7	675.23	12.1	89.1	483.91	9.4	71.7
Canada	897.04	7.4	17.4	756.09	8.1	84.3	336.15	5.8	44.5

Table 2	Drug Expenditure Summary, by Province/Territory and Canada, 2008 ^f
---------	---

Notes

f: forecast.

Total drug expenditure consists of prescribed drugs and non-prescribed products purchased outside an institutional setting.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Public prescribed drug expenditure is the amount of prescribed drug expenditure financed by provincial, territorial and federal governments, as well as spending from social security funds.

For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Population, Statistics Canada.

In 2008, per capita expenditure on drugs is forecast to have accounted for 17.4% of total health expenditure in Canada. Among the provinces and territories, the share of drugs in total health expenditure is expected to have ranged from 6.3% in the Northwest Territories and 6.7% in Nunavut to 18.9% in Nova Scotia and 20.7% in Quebec.

Total drug expenditure per capita in Canada is expected to have been \$897 in 2008. Per capita spending on drugs in the provinces and territories is forecast to have ranged from \$613 and \$758 by the residents of the Northwest Territories and Nunavut, respectively, to \$963 and \$1,030 by the residents of Quebec and Nova Scotia, respectively.

Prescribed drug expenditure per capita is forecast to have accounted for 84.3% of total expenditure on drugs in Canada in 2008. Among the provinces and territories, the share of prescribed drugs in total drug expenditure is forecast to have ranged from 80.2% in the Yukon and 80.8% in Alberta to 87.9% in Newfoundland and Labrador and 89.1% in Nunavut.

In 2008, the proportion of prescribed drugs in Canada financed by the public sector is expected to be 44.5%. It is forecast that the proportion will be highest in Nunavut and the Yukon, at 71.7% and 62.4%, respectively, and the lowest in Prince Edward Island and New Brunswick, at 34.3% and 31.6%, respectively.

The Share of Drugs in Total Health Expenditure

The share of drugs in total health expenditure is forecast to have been higher in 2008 than in 1985 in all provinces and territories except P.E.I., and the Northwest Territories and Nunavut (Figure 11). It should be noted that in P.E.I., the share of drug expenditure in total health expenditure is expected to have grown between 1986 and 2008.




Figure 11 Drug Expenditure as a Percentage of Total Health Expenditure, by Province/Territory and Canada, 1985 and 2008^f

Notes

f: forecast.

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. **Source**

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

In 1985, expenditure on drugs accounted for 9.5% of total health expenditure in Canada. Newfoundland and Labrador, P.E.I., Nova Scotia, New Brunswick and Ontario exceeded the national average. P.E.I. had the highest share, at 18.0%, followed by Newfoundland and Labrador, at 16.3%, while among the other provinces and territories, shares ranged from 7.1% in the Northwest Territories and Nunavut to 9.3% in Manitoba.

In 2008, Nova Scotia, New Brunswick, Quebec and Ontario are forecast to have had drug expenditure as a percentage of total health expenditure above the Canadian average (17.4%), with Quebec (20.7%) and Nova Scotia (18.9%) having the highest share. Newfoundland and Labrador, P.E.I., Manitoba, Saskatchewan, Alberta and British Columbia are expected to have been below the Canadian average, with Alberta (14.1%) and Manitoba (15.0%) having the lowest share among the provinces. The Yukon and the Northwest Territories and Nunavut are forecast to have had lower shares than the provinces, at 10.2% and 6.5%, respectively.

See Data Tables in Series B for more data on drug expenditure by province/territory from 1985 to 2008.

Total Drug Expenditure by Source of Finance

In 2008, Quebec, Saskatchewan, the Yukon, the Northwest Territories and Nunavut are forecast to have had public shares of total drug expenditure that exceeded the national average (37.5%). The share of total drug expenditure funded by the public sector is expected to have ranged from 26.9% in New Brunswick and 28.5% in P.E.I. to 50.0% in the Yukon and 63.8% in Nunavut (Figure 12).




Figure 12 Percentage of Total Drug Expenditure by Source of Finance, by Province/Territory and Canada, 2008^f

Note

f: forecast.


Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Total Drug Expenditure per Capita by Source of Finance

In 2008, total drug expenditure per capita in Canada is forecast to have been \$897. Per capita prescribed drug spending financed by the public and private sectors is forecast to have amounted to \$336 and \$420, respectively (Figure 13).

Figure 13 Total Drug Expenditure per Capita by Type and by Source of Finance, by Province/Territory and Canada, 2008^f



Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Population, Statistics Canada.

In 2008, per capita spending on drugs by the public sector is forecast to have ranged from \$236 in B.C. and \$253 in P.E.I. to \$420 in Quebec and \$484 in Nunavut. In the same year, it is expected that Nova Scotia (\$359), Quebec (\$420), Ontario (\$338), Saskatchewan (\$377), the Yukon (\$402) and Nunavut (\$484) will have had publicly financed drug expenditure per capita above the Canadian average (\$336).

Prescribed drug expenditure per capita financed by the private sector is expected to have ranged from \$191 in Nunavut and \$242 in the Yukon to \$505 in Nova Scotia and \$555 in New Brunswick. Newfoundland and Labrador (\$490), P.E.I. (\$484), Nova Scotia (\$505), New Brunswick (\$555), Quebec (\$421) and Ontario (\$429) are forecast to have had privately financed prescribed drug expenditure per capita higher than the Canadian average (\$420).

It should be noted that public spending per capita may or may not accurately reflect the amount spent per person eligible for coverage because the proportion of the population eligible for coverage by the public sector varies significantly across provinces and territories.

See Data Tables in Series B for more data on drug expenditure by province/territory from 1985 to 2008.

Drug Expenditure by Type of Drug and by Source of Finance

Public- and Private-Sector Prescribed and Non-Prescribed Drug^{xi} Expenditure


In 2008, in Newfoundland and Labrador, P.E.I., Nova Scotia and Saskatchewan, the annual growth rate for prescribed drug spending per capita is forecast to have been higher in the public sector than in the private sector (Figure 14). For the remaining provinces and territories, private-sector growth is forecast to have been higher than that of the public sector.


The annual growth rate for prescribed drug spending per capita in the public sector ranged from 0.8% in B.C. and 2.3% in New Brunswick to 15.2% in Nova Scotia and 19.5% in Newfoundland and Labrador. The annual growth rate for prescribed drug spending per capita in the private sector ranged from 7.5% in P.E.I. and 8.1% in Nova Scotia to 17.0% in Manitoba and 19.3% in Nunavut.

Newfoundland and Labrador, P.E.I., Nova Scotia, Quebec, Saskatchewan, the Northwest Territories and Nunavut are expected to have had annual growth of publicly financed prescribed drug expenditure per person above the Canadian average (5.8%).

xi. Non-prescribed drugs are composed of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

Prescribed drug spending per capita is expected to have experienced a higher annual growth rate than non-prescribed drug spending per capita in all provinces and territories for 2008.





Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies. This expenditure is financed by the private sector, typically out-of-pocket by consumers (households). For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Population, Statistics Canada.

The analysis of annual growth rates should be interpreted cautiously. The actual change in drug spending associated with a given growth rate varies based on the initial level of expenditure. For example, a 10% growth rate for a higher initial level of expenditure would translate into a larger growth in dollar amounts than for a lower initial level of expenditure.

Public- and Private-Sector Prescribed Drug Expenditure

Between 1985 and 2008, publicly financed prescribed drug expenditure per capita grew at a lower average annual rate than privately financed prescribed drug expenditure per capita in Nova Scotia, New Brunswick, Saskatchewan and B.C. (Figure 15). During this period, average annual growth in public-sector prescribed drug spending per capita ranged from 7.3% in B.C. and 7.4% in New Brunswick to 11.8% in P.E.I. and 13.6% in the Yukon. Per capita prescribed drug expenditure financed by the private sector grew at average annual rates ranging from 5.1% in P.E.I. and 5.5% in Newfoundland and Labrador to 11.2% in Nova Scotia and 11.6% in Saskatchewan.




Figure 15 Average Annual Growth Rate for Prescribed Drug Expenditure per Capita by Source of Finance, by Province/Territory, Between 1985 and 2008^f

Notes

f: forecast.


* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories. *Prescribed drug expenditure* is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector. For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2008, Canadian Institute for Health Information; Population, Statistics Canada.

Figure 16 illustrates provincial/territorial trends in the share of publicly financed prescribed drug expenditure as a percentage of prescribed drug expenditure, from 1985 to 2006, with forecasts to 2008.


Figure 16 Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2008



Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Figure 16 Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2008 (cont'd)



Note

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

Source

National Health Expenditure Database, 2008, Canadian Institute for Health Information.

Between 1985 and 2006, the share of prescribed drug expenditure financed by the public sector increased in Newfoundland and Labrador, P.E.I., Quebec, Ontario, Manitoba, Alberta and the Yukon. Increases ranged from 3.7 and 7.4 percentage points in Ontario and Quebec, respectively, to 21.6 and 38.0 percentage points in P.E.I. and the Yukon, respectively. Decreases in the share of prescribed drug expenditure financed by the public sector occurred in Nova Scotia, New Brunswick, Saskatchewan, B.C. and the Northwest Territories. Decreases ranged from 3.2 and 10.5 percentage points in the Northwest Territories and B.C., respectively, to 14.7 and 23.8 percentage points in Nova Scotia and Saskatchewan, respectively.

In 2008, the share of prescribed drug expenditure financed by the public sector in Canada is expected to have been 44.5%. This is forecast to have been exceeded by Quebec (49.9%), Saskatchewan (53.7%), the Yukon (62.4%), the Northwest Territories (53.6%) and Nunavut (71.7%).

International Comparisons

Comparability of Health Expenditure Across Countries

In general, international comparisons should be interpreted with caution, as variation exists between countries with regard to reporting, inclusion and classification of health expenditure.

For the last eight annual updates of the health database maintained by the Organisation for Economic Co-operation and Development (OECD), member countries were asked to report health expenditure according to concepts presented in the OECD manual *A System of Health Accounts* (SHA), released in May 2000. Countries are at varying stages of reporting total health expenditure according to the boundary of health care proposed in the SHA manual. This means that data presented in *OECD Health Data 2008* are at varying levels of comparability.

There are 26 countries with health expenditure information that most closely follow the health care boundary proposed in the OECD manual. The OECD states that the data for those countries are believed to be fairly comparable, although some deviations from SHA definitions may still exist among the sub-aggregate variables of total health expenditure. The 26 countries are Australia, Austria, Belgium, Canada, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Japan, Korea, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Slovak Republic, Spain, Sweden, Switzerland, Turkey and the U.S.

Analysis in this section will exclude the Netherlands, New Zealand and Turkey due to the non-availability of data by use of funds from 2005 onwards.

Level of income and institutional characteristics also cause differences in drug expenditure across countries. Drugs consumed in low- or middle-income countries often originate from more developed countries with high living standards and high labour costs. Consequently, the share of drugs in total health expenditure tends to be higher in low- or middle-income countries because of the high price of drugs relative to other health goods and services.⁴ Differences in service delivery across countries will also cause differences in the share of drugs in total health expenditure.

Share of Drugs in Total Health Expenditure

The OECD maintains a comparative database on health-related statistics, including health expenditure. This database captures information on expenditure for pharmaceuticals and other medical non-durables outside an institutional setting (equivalent to drugs purchased in retail establishments in Canada). Pharmaceutical and other medical non-durables comprise prescribed drugs, over-the-counter drugs and a wide range of medical non-durables such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In 1985, drug expenditure in Canada represented $9.6\%^{xii}$ of total health expenditure. Korea had the largest share of drug expenditure in total health expenditure, at 33.6%, and Denmark had the lowest, at 6.6%.^{xiii, xiv}

By 2006, the most recent year for which data were available, drug expenditure in Canada had increased its share in total health expenditure by just less than eight percentage points, to 17.4%. Luxembourg had the lowest share of drug expenditure in total health expenditure, at 8.4%, and Hungary had the highest, at 31.0% (Table 3).

xii. OECD data are standardized for international comparability; consequently, figures calculated from these data may differ from those calculated from the national health accounts of member countries. Specific to Canada, expenditure on health research and the training of health care workers with concomitant care of patients is included in the national health accounts, but excluded from OECD health expenditure data.

xiii. The OECD did not provide data for Austria, the Czech Republic, Hungary, Mexico, Poland or the Slovak Republic in 1985.

xiv. Of the comparator countries, only Canada and Korea conformed to SHA guidelines in 1985.

Country	GDP per Capita		Total Dı Expendit per Cap	ure	Total Hea Expendit per Cap	ure	Total Drug Expenditure as a Percentage of Total Health Expenditure	
	(CA\$, PPP) [†]	Rank	(CA\$, PPP)⁺	Rank	(CA\$, PPP)⁺	Rank	Percent	Rank
Australia	43,296	7	520	12	3,783	13	13.7	15
Austria	42,987	8	541	10	4,343	6	12.4	19
Belgium	40,358	11	703	3	4,169	7	16.9	11
Canada	44,335	5	770	2	4,429	5	17.4	10
Czech Republic	26,545	18	420	20	1,817	18	23.1	5
Denmark	42,412	9	344	21	4,049	10	8.5	21
Finland	39,414	12	468	15	3,213	14	14.6	14
France	37,713	15	679	4	4,154	8	16.4	12
Germany	38,476	14	602	7	4,060	9	14.8	13
Hungary	21,864	20	561	8	1,811	19	31.0	1
Iceland	44,030	6	529	11	4,022	11	13.1	17
Japan	38,540	13	609	6	3,105	15	19.6	9
Korea	27,744	17	458	18	1,763	20	25.9	4
Luxembourg [‡]	71,265	1	424	19	5,182	4	8.4	23
Mexico	14,560	23	219	23	956	23	22.9	6
Norway	62,559	2	462	17	5,443	2	8.5	21
Poland	17,672	22	299	22	1,096	22	27.2	3
Portugal	25,111	19	543	9	2,553	17	21.3	8
Slovak Republic	21,176	21	468	15	1,575	21	29.7	2
Spain	35,385	16	642	5	2,960	16	21.7	7
Sweden	41,993	10	513	14	3,856	12	13.3	16
Switzerland [‡]	45,906	4	518	13	5,192	3	10.5	20
United States	52,825	3	1,015	1	8,086	1	12.6	18

Table 3Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of
Total Health Expenditure, Reporting OECD Comparator Countries, 2006*

Notes

* Canadian data reported by the OECD are as of October 2008. In November 2008, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2009.

† Converted to Canadian dollars using purchasing power parities (PPP) for gross domestic product (GDP).

‡ 2005 data were used for Total Drug Expenditure per Capita and Total Drug Expenditure as a Percentage of Total Health Expenditure.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Figure 17 illustrates the trends of drug expenditure per capita (CA\$, PPP)^{xv} in five selected OECD comparator countries.xvi




Figure 17 Drug Expenditure per Capita, Selected Countries,* 1985 to 2006

Notes

[†] Converted to Canadian dollars using purchasing power parities (PPP) for gross domestic product (GDP).

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Between 1985 and 2006, per capita drug expenditure grew at a faster average annual rate in Canada (8.2%) than in Belgium, Denmark, Finland, France, Germany, Iceland, Japan, Norway, Portugal, Sweden and Switzerland.^{xvii} During this period, Iceland experienced the lowest average annual growth rate in per capita drug expenditure (3.9%); Korea experienced the highest growth rate at 9.7%. xviii

^{*} Comparator countries that are also G8 members.

Although using purchasing power parity-adjusted dollars (PPP\$) accounts for the relative change in xv. inflation between countries, average annual growth rates should still be considered in the context of economy-wide inflation.

Comparator countries that are also G8 members. xvi.

xvii. The OECD did not provide data for Switzerland in 2006; therefore, 2005 data were used.

xviii. The average annual rate between 1985 and 2006 could not be calculated for Austria, the Czech Republic, Hungary, Luxembourg, Mexico, Poland and the Slovak Republic as data for 1985 were not available.

Share of Public Expenditure in Total Expenditure on Drugs

The OECD database on health contains statistics on total expenditure on pharmaceutical goods and public expenditure on pharmaceutical goods. In Canada, drug expenditure by the public sector rose from 29.4% of total expenditure on pharmaceutical goods in 1985 to 39.2% in 2006.

In OECD countries, with the exception of those in North America, the entire population usually has coverage for prescribed drugs through public insurance. Most countries have formularies restricting the number of drugs covered under public insurance and impose cost-sharing (deductibles, co-insurance or copayments) with waivers for certain groups of beneficiaries.

Table 4 shows that, among the 23 OECD comparator countries in 2006, France had the highest level of public drug spending per capita (\$472), the U.S. had the highest level of total drug expenditure per capita (\$1,015) and Luxembourg had the highest public share of total drug spending (83.5%).

The high share of total drug expenditure financed by the public sector in some European countries (for example, Luxembourg, Germany and Spain) reflects the inclusion of drug benefits provided through employment-related social security funds in publicly financed drug expenditure (see Series C for more data on international comparisons). These funds are social insurance programs covering the community as a whole or large sections of the community and are imposed or controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. In some European countries, expenditure by social security funds represents the major share of public expenditure on drugs (for example, 94.3% in Germany⁵ and 97.9% in France⁶ in 2006).

By contrast, in Canada, until 1996, drug benefits under social security funds included only spending by WCBs and they represented less than 2% of public expenditure on drugs in retail establishments. Starting in 1997, they also included expenditure by the Quebec Drug Insurance Fund. The share of social security funds in public expenditure on drugs in Canada increased from 6.0% in 1997 to 8.9% in 2006. The Quebec Drug Insurance Fund, which is financed by the mandatory payment of premiums, covers residents not otherwise insured by the provincial program (for seniors, social assistance recipients, etc.) or by private health insurance generally offered through employment.

Group insurance plans offered by employers, unions and professional associations that resemble the European model do exist in Canada; however, since a government authority does not impose group health insurance in Canada, and policy-holders may voluntarily opt out (except in Quebec), they are considered privately financed. Private health insurance, composed mainly of group insurance, accounted for 29.0% of total drug expenditure in retail establishments in Canada in 2006.

Table 4Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage
of Total Expenditure on Pharmaceutical Goods, Reporting OECD Comparator
Countries, 2006*

Country	Public Dru Expenditure per		Total Drug Expenditur per Capita	е	Public Drug Expenditure as a Percentage of Total Drug Expenditure		
	(CA\$, PPP) [†]	Rank	(CA\$, PPP) [↑]	Rank	Percent	Rank	
Australia	285	17	520	12	55.0	17	
Austria	372	6	541	10	68.9	8	
Belgium	353	8	703	3	50.1	19	
Canada	302	14	770	2	39.2	20	
Czech Republic	297	16	420	20	70.8	6	
Denmark	191	21	344	21	55.5	15	
Finland	260	19	468	15	55.4	16	
France	472	1	679	4	69.4	7	
Germany	447	3	602	7	74.3	2	
Hungary	377	5	561	8	67.2	10	
Iceland	318	11	529	11	60.2	11	
Japan	436	4	609	6	71.7	5	
Korea	243	20	458	18	53.1	18	
Luxembourg [‡]	353	7	424	19	83.5	1	
Mexico	34	23	219	23	15.4	23	
Norway	261	18	462	17	56.5	13	
Poland	116	22	299	22	38.6	21	
Portugal	302	14	543	9	55.7	14	
Slovak Republic	342	10	468	15	72.9	3	
Spain	464	2	642	5	72.3	4	
Sweden	305	13	513	14	59.2	12	
Switzerland [‡]	351	9	518	13	67.7	9	
United States	307	12	1,015	1	30.2	22	

Notes

* Canadian data reported by the OECD are as of October 2008. In November 2008, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2009.

† Converted to Canadian dollars using purchasing power parities (PPP) for gross domestic product (GDP).

‡ 2005 data.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Share of Drugs in Public Expenditure on Health

In Canada, drugs accounted for only 3.8% of health expenditure by the public sector in 1985. This proportion increased to 9.7% in 2006, reflecting substantially higher growth in drug expenditure than in other types of public-sector health expenditure between 1985 and 2006. Among the comparator countries for which data were available^{xix} in 1985, the share of drugs in public-sector health expenditure ranged from 2.1% in the U.S. to 30.1% in Portugal. In 2006, the share of drugs in public-sector health expenditure ranged from 5.6% in Denmark to 31.7% in the Slovak Republic.

In 2006, the share of drug spending in public-sector health expenditure was lower than the share of drug spending in total health expenditure in each of the comparator countries except the Slovak Republic, Spain and Switzerland, reflecting generally higher cost-sharing for drugs than for other health expenditure.^{xx} In the case of Canada, the low share of drugs in total public expenditure on health (9.7% in 2006), when compared with the share of drugs in total health expenditure (17.4% in 2006), also reflects the absence of universal coverage of prescribed drugs by public insurance, while there exists universal and full coverage of medically necessary hospital and physician services.

xix. The OECD did not provide data for Austria, Belgium, the Czech Republic, Hungary, Mexico, Poland, the Slovak Republic or Switzerland in 1985.

xx. The OECD did not provide data for public drug expenditure as a percentage of public health expenditure for Belgium.

Table 5Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage
of Public-Sector Health Expenditure, Reporting OECD Comparator
Countries, 2006*

Country	Public Drug Expend per Capi		Public-Sec Health Expen per Capit	diture	Public Drug Expenditure as a Percentage of Public- Sector Health Expenditure		
	(CA\$, PPP) [†]	Rank	(CA\$, PPP) [↑]	Rank	Percent	Rank	
Australia	285	17	2,563	12	11.2	13	
Austria	372	6	3,309	6	11.3	12	
Belgium [‡]	353	8	N/A	N/A	N/A	N/A	
Canada	302	14	3,120	10	9.7	15	
Czech Republic	297	16	1,599	17	18.6	5	
Denmark	191	21	3,405	4	5.6	22	
Finland	260	19	2,441	14	10.6	14	
France	472	1	3,312	5	14.2	10	
Germany	447	3	3,120	10	14.3	9	
Hungary	377	5	1,284	18	29.4	2	
lceland	318	11	3,297	7	9.7	15	
Japan	436	4	2,523	13	17.3	6	
Korea	243	20	981	20	24.8	3	
Luxembourg ^s	353	7	4,709	1	7.8	20	
Mexico	34	23	423	22	8.0	19	
Norway	261	18	4,552	2	5.7	21	
Poland	116	22	766	21	15.0	8	
Portugal	302	14	1,800	16	16.8	7	
Slovak Republic	342	10	1,077	19	31.7	1	
Spain	464	2	2,109	15	22.0	4	
Sweden	305	13	3,149	8	9.7	15	
Switzerland [§]	351	9	3,128	9	11.9	11	
United States	307	12	3,702	3	8.3	18	

Notes

* Canadian data reported by the OECD are as of October 2008. In November 2008, updated and revised Canadian data were released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2009.

† Converted to Canadian dollars using purchasing power parities (PPP) for gross domestic product (GDP).

‡ OECD did not provide data on public health expenditure for Belgium from 1997 onwards.

§ 2005 data used for Public Drug Expenditure per Capita and Public Drug Expenditure as a Percentage of Public Sector Health Expenditure.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Factors Affecting Drug Expenditure in Canada

Numerous factors (see Table 6), many of which are inter-related, may influence drug expenditure. Since drug prices, as measured by several price indices,^{xxi} have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

Although some literature exists on the effects of various factors on drug expenditure, more research is required to quantify the effect of each factor and to inform the relationship between drug expenditure and other health care spending.

The following review of some of the factors affecting drug expenditure is intended to facilitate discussion and is not meant to be a systemic review of all relevant literature.

Cost-Related Factors

Although the ingredient prices of drugs, once on the market, are relatively stable, the introductory price and overall cost of drugs may be influenced by several factors. These factors include international pricing, inflation, changes in retail or wholesale markups and other market forces. Market forces can be competitive forces (for example, the introduction of new products can increase drug expenditures while generics can decrease drug expenditure by offering a lower-priced alternative) or regulatory forces (for example, changes in price controls or extending patent legislation that prevents a less-expensive alternative from coming to the market).

Quantity-Related Factors

There are many factors that can affect the quantity of drugs dispensed. A change in quantity can be a result of a change in the number of users or a change in the volume of drugs used.

Population-Related Factors

Population size affects the number of potential users in an area (for example, P.E.I. versus Ontario). Demographics such as age, gender and ethnic distribution, as well as changes in health status, also play a role in determining levels of drug expenditure. Changes in the health status of the population can be the result of the emergence of new diseases, epidemics and changes in the prevalence or severity of existing disease. Typically, healthier populations use fewer drugs.

xxi. For more information on price indices, see the Data Limitations section of the Methodological Notes.

Health System–Related Factors

The health system also plays a role in drug expenditure. Changes in policies and programs, including regulations around drug plan eligibility and co-insurance, the extent of formulary listings and the availability of and access to third-party insurance coverage can all affect drug spending.⁷ In general, the more accessible and more generous insurance coverage is, the less costly drugs are to the end consumer and the more likely people are to consume drugs.

New Drugs

New drugs introduced to the market have an influence on drug expenditure. New drugs can result in switching between classes of drugs used to treat similar conditions (for example, switching from metformin to rosiglitazone for diabetes) or switching between drugs within a class (for example, switching between the cholesterol-lowering drugs simvastatin and rosuvastatin). Provided there is a difference in price, any switching will affect drug expenditure.

New drugs may be safer or have fewer potential side effects while being an alternative to, or even a replacement for, existing non-drug therapies (for example, surgery). In addition, new drugs may be used to treat or slow the progression of diseases or symptoms of diseases that were previously undertreated or untreatable.

Other Factors

Aside from the development of new drugs, the pharmaceutical industry plays a role in influencing the trends in drug expenditure. Pharmaceutical companies promote their products to prescribers (for example, physicians, dentists, nurse practitioners) and pharmacists through a practice known as detailing, as well as by advertising to the general public, known as direct-to-consumer advertising (DTCA). Although regulated in Canada, Canadians are exposed to DTCA through international media.

Changes in clinical practice guidelines, prescribing practices or consumer preferences can also lead to changes in the amount or types of drugs dispensed. Changes in pharmaceutical care practices by pharmacists can improve a person's compliance with a treatment regimen, resulting in improved health outcomes, improved utilization of first-line therapies (thereby decreasing use of more costly alternative treatments) or decreasing the use of other health care resources that may be more costly, such as hospital visits. Adoption of primary prevention strategies, such as promoting improved diet, exercise or other forms of healthy living, can improve the health status of the population.

What We Know:

- Drug expenditure rose every year between 1985 and 2008, with an average annual growth rate of 9.4%.
- New drugs are often introduced at much higher prices than existing therapies.⁸
- In 2007, 64 new patented drugs were introduced to the market for human consumption in Canada.⁹
- Since 1988, the price of patented medicines in Canada rose at a lower rate than economy-wide inflation in every year but one (1992).^{9, xxii}
- Some new drugs have reduced overall medical expenditures.^{10, 11}
- An increasing number of drug therapies is being administered outside of the hospital setting, thereby shifting costs from hospitals^{xxiii} to the community (for example, in-home cancer treatments).¹²
- The Canadian population has been growing at roughly 1.1% per year since 1985. The proportion of the population age 65 and older increased by just more than one percentage point between 1997 and 2007.¹³ These changes were gradual and did not have a great impact on drug expenditure.¹⁴

What We Don't Know:

- Whether increases in total drug expenditure negatively or positively affect overall health outcomes.
- Will increased drug use reduce spending in other sectors of health care (for example, decreased hospitalization)?
- To what degree does each of the possible influencing factors discussed in the section above affect drug expenditure?
- How does direct-to-consumer advertising affect the marketplace, prescribing practices, physician-patient communication and the public's understanding of drug therapy in Canada?¹⁵

xxii. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

xxiii. Drugs paid through hospital budgets are not identified separately in the NHEX database but are classified as hospital expenditure.

Table 6 Factors That May Influence Drug Expenditure in Canada

Prices

- Changes in the unit prices of drugs (both patented and non-patented)
- Changes in retail and wholesale mark-ups and professional fees
- Availability of generics
- International prices
- Inflation

Entry of New Drug Chemicals

Volume of Drug Use

- Population-Related
 - Changes in population size
 - Changes in population structure/distribution
 - Age, gender and ethnicity
 - Changes in health status of a population
 - Emergence of new diseases
 - Epidemics
 - Prevalence and severity of disease
- System-Related
 - Changes and transition associated with health system reform
 - Availability of and access to third-party insurance coverage
 - Changes in policies and programs
 - The extent of formulary listings
 - Eligibility and copayments
- Research- and Technology-Related
 - New treatment approaches
 - Drugs replacing surgery
 - Drug therapy for previously untreatable or undertreated diseases
 - Availability of more and/or improved diagnostic technology
 - Outcomes research, evidence-based preventive or curative approaches in diagnosis or treatment
 - Use of programs and technology in monitoring patients

Table 6 Factors That May Influence Drug Expenditure in Canada (cont'd)

- Pharmaceutical Industry
 - Development of new drug products (for example, new strengths, new drug forms and presentations)
 - Promotion of drugs to physicians
 - Drug sampling
 - Direct-to-consumer advertising
- Practice- and People-Related (health care providers and consumers)
 - Changes in prescribing and dispensing practices
 - Number and mix of prescribers (specialists, general practitioners, nurse practitioners and others)
 - Multiple doctoring
 - Consumers' expectations and behaviours
 - Adherence to treatment

Methodological Notes

Background

Drug expenditure data in this report are obtained from the National Health Expenditure Database (NHEX), which is maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1960. Drug expenditure data in NHEX are macrolevel data and do not allow for decomposition of prescription costs or drug classes.

The Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from community pharmacies. Drug expenditure data in NHEX are estimates that represent the final costs to Canadian consumers, which include dispensing fees, mark-ups and appropriate taxes. NHEX data do not account for drug expenditure by non-Canadians (for example, Americans' purchases from Canadian pharmacies). The classification system employed is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

National Health Expenditure Database

The mandate of the NHEX database is twofold:

- 1. To support the development and evaluation of health programs in Canada by all levels of government and within the private sector.
- 2. To compile information on health expenditure that will accurately portray the importance of health care as a component of national expenditure.

Health Expenditure—includes any type of expenditure for which the primary objective is to improve or prevent the deterioration of health status.

This definition allows economic activities to be measured according to primary purpose and secondary effects. Activities that are undertaken with the direct purpose of improving or maintaining health are included. Other activities are not included, even though they may impact health. For example, housing and income support policies have social welfare goals as their primary purpose and are not considered to be health expenditure, yet they are recognized as powerful factors in determining population health.

Source of Finance

National health expenditure is reported based on the principle of *responsibility for payment* rather than on the source of the funds. It is for this reason, for example, that federal health transfers to the provinces/territories are included in the provincial/territorial government sector, since it is the responsibility of provincial/territorial governments to expend federal transfers on health services. The exception to this principle is that provincial/territorial government health transfers to municipal governments are included in the provincial/territorial health territorial government sector. The following figure depicts the composition of total health expenditure by source of finance.




Figure 18 Composition of Total Health Expenditure, by Source of Finance

Public Sector—includes health care spending by governments and government agencies. It is subdivided into Provincial Government Sector and Other Public Sector, as described below:

- 1. The *Provincial Government Sector* includes health spending from provincial/ territorial government funds, federal health transfers to the provinces/territories and provincial/territorial government health transfers to municipal governments.
- 2. The *Federal Direct Sector* refers to direct health care spending by the federal government in relation to health care services for special groups, such as Aboriginals, the military and veterans. Federal direct health expenditure does not include federal health transfers to the provinces.
- 3. The *Municipal Government Sector* expenditure includes health care spending by municipal governments for institutional services, public health, capital construction and equipment, and dental services provided by municipalities in the provinces of Nova Scotia, Manitoba and British Columbia. Designated funds transferred by provincial governments for health purposes are not included in the municipal sector but are included with provincial government expenditure. Currently, no estimates of drug spending are included in this sector.
- 4. Social Security Funds are social insurance programs that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by workers' compensation boards (WCBs) and the Drug Insurance Fund component of the Quebec ministère de la Santé et des Services sociaux drug subsidy program.

- Health spending by WCBs includes what the provincial boards commonly refer to as medical aid. Non-health related items often reported by the WCBs as medical aid expenditure—such as funeral expenses, travel and clothing—are removed.
- On January 1, 1997, the Quebec ministère de la Santé et des Services sociaux, through the Régie de l'assurance maladie du Québec, introduced a drug insurance plan that covered residents of the province who were not otherwise covered by the provincial program or by private health insurance generally offered through employment. Drug claims for these participants are paid from the Drug Insurance Fund. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). Premiums are compulsory payments generally financed by the self-employed and employees of organizations that do not offer private drug insurance as a benefit of employment.

Private Sector—includes health care spending by individuals and private sources as described below:

- 1. Non-consumption includes non-patient revenues received by health care institutions, such as donations and investment income, private spending on health-related capital construction and equipment and health research funded by private sources. Currently, no estimates of drug spending are included in this portion of the private sector.
- 2. Out-of-pocket includes health expenditures made by individuals for health care goods and services.
- 3. Private health insurance includes health expenditure paid by commercial and not-forprofit insurance firms, as well as the cost of administering those claims.

Hierarchy of Classification

National health expenditure in Canada is based on a system of classification that is consistent with international standards developed by the OECD for reporting health expenditure.^{xxiv}

National health expenditure is grouped within the broad categories of Personal Health Care or Other Health Expenses:

Personal health care consists of expenditure for health goods and services used by individuals.

Other health expenses consist of expenditure on behalf of society, such as public health; expenditure made as investments for purposes of future consumption, such as capital expenditure; the administrative expenses of planning and managing the health care system; and research.

xxiv. Statistics Canada (Public Institutions Division) publishes estimates of government health expenditure as part of its comprehensive reporting system of all government expenditure, the Financial Management System (FMS). The FMS public-sector health spending estimates are lower than those reported by CIHI because different classification methods are applied and a narrower definition of health expenditure is used in the FMS.

Personal health expenditure is classified within categories that describe the type of health care used. Certain categories overlap. The hierarchy of classification that is used to allocate overlapping categories of expenditure is as follows:

Institutional setting—health care services consumed in hospitals or other institutions are allocated to the institutional category if the institution purchases the services on behalf of its patients. For example, drugs paid through hospital budgets are classified as hospital expenditure. This allocates expenditure to the supplier actually paid by patients or their agents in the form of government or insurance companies. It also reflects data availability.

Self-employed provider of service—for example, all expenses of physicians' practices are considered to be expenditure for physician services, even though some of these expenses would be for employment of other health professionals, drugs or personal health supplies.

Type of good or service-drugs and personal health supplies are examples.

One of the categories of health expenditure within NHEX is Drugs. Other categories include Hospitals, Other Institutions, Physicians, Other Professionals, Capital, Public Health and Administration, and Other Health Spending. In NHEX, these categories are also named Use of Funds.

Below is a description of the drug category within NHEX; it is not a definition supplied by the OECD.

Drugs—at the aggregate level, include expenditure on prescribed drugs and nonprescribed products purchased in retail stores. Estimates represent the final costs to consumers, including dispensing fees, mark-ups and appropriate taxes. The breakdown in NHEX of prescribed drugs, over-the-counter drugs and personal health supplies is parallel with the breakdown in OECD. This category has been disaggregated at the "Canada" level in the data tables to provide information on the following sub-categories:

Prescribed drugs—substances considered as drugs under the *Food and Drugs Act* and sold for human use as the result of a prescription from a health professional.

Non-prescribed drugs^{xxv}—include two sub-components: over-the-counter drugs and personal health supplies.

Over-the-counter drugs—therapeutic drug products not requiring a prescription and purchased as such.

Personal health supplies—include items used primarily to promote or maintain health; for example, oral hygiene products, diagnostic items such as diabetic test strips and medical items such as incontinence products.

xxv. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

The Drugs category in NHEX does not include drugs dispensed in hospitals and generally in other institutions. These are included in health expenditure figures for Hospitals or Other Institutions.

Other Terms

Gross domestic product (GDP)¹⁶—GDP implicit price index (in 1997 dollars) is used to compare annual percentage change of drug expenditure with inflation in the Canadian economy. GDP is the unduplicated value of production originating within the boundaries of Canada, regardless of the ownership of the factors of production.

Purchasing power parity (PPP)¹⁷—PPPs are the rates of currency conversion that equalize the purchasing power of different currencies. This means that a given sum of money, when converted into different currencies at the PPP rates, will buy the same basket of goods and services in all countries. Thus PPPs are the rates of currency conversion, which eliminate differences in price levels between countries.

Data Limitations

Data contained in NHEX are estimates. The data are collected from diverse sources and include varying classes of financial information. The data are collected and classified according to methods established by a review committee. CIHI analysts and external experts continue to improve the comprehensiveness, accuracy and currency of the data in order to provide the most complete and objective estimates possible. Notwithstanding these improvements, national health expenditure data are estimates and should be used accordingly.

Most private-sector expenditure is estimated from survey data. Prior to 1996, the Family Expenditure Survey by Statistics Canada,¹⁸ an important source of private-sector data, was not carried out annually; therefore, trend data were imputed for years between surveys. Private-sector data were revised following a methodology review in the early 1990s. The revised private-sector data incorporated information estimated directly from new sources for 1988 and subsequent years. Prior years were estimated using trend data. As a result, readers should use caution when using the private-sector expenditure data for small provinces and for years prior to 1988.


Drugs in Hospitals


The NHEX database at CIHI uses a classification system that is consistent with international standards developed by the OECD for the reporting of health expenditure. Similar to the functional category Pharmaceutical and Other Medical Non-Durables in the OECD *System of Health Accounts*, the Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drugs in hospitals are considered as inputs (intermediate consumption) to the production of health care in hospitals. Consequently, drugs paid through hospital budgets are not identified separately in NHEX but are classified as hospital expenditure. Similarly, drugs purchased by residential care facilities for their residents are classified as institutional expenditure. All expenses of physicians' and dentists' practices, including drugs, are considered to be expenditure for physicians' and dentists' services. Some drug expenditure is also included in the NHEX category of public health (for example, vaccines).

While the above hierarchy of classification is essential in allocating overlapping categories of expenditure, it also reflects data availability. For example, data on expenditure by provincial/ territorial governments are usually extracted from provincial/territorial government public accounts. In the accounts, it is generally not possible to isolate drug spending from other categories of expenditure within program areas (for example, hospitals or public health). While there exist other possible data sources, the use of a single data source for the different categories of provincial government health expenditure—such as the provincial/ territorial public accounts—has the major advantage of minimizing the risk of double counting.

Measuring Drug Prices

There is no authoritative composite price index for all drugs sold in Canada. The difficulty lies in the fact that traditional statistical measurement considers the price of tablets or capsules rather than measuring the nature of the product itself (that is, its therapeutic properties). In pure economic terms, the price of a drug is the price per unit of health gain attained. From a practical perspective, however, people buy tablets, capsules or other forms of medication, some of which may contain multiple active ingredients.





Sources

Consumer Price Index and Industrial Product Price Index, Statistics Canada; Patented Medicine Price Index, Patented Medicine Prices Review Board.

There are several commonly accepted price indices that can potentially be used to measure shifts in drug prices at the retail level. These include the Consumer Price Index (CPI), the pharmaceutical component of the Industrial Product Price Index (IPPI [pharma]) and the Patented Medicine Price Index (PMPI). Each index is built upon a unique set of assumptions pertaining to inclusion criteria, definitions, updating and weighting methodologies. As a result, these indices produce differing results (Figure 19).

It is important to determine whether two different products with similar therapeutic elements used to treat similar health conditions are essentially different. Several price indices assume they are different products. The consequence is that when new products enter the market, price indices do not compare their prices to existing products; they are simply added to the basket of goods.

Collection and Non-Response

The definitions and methods used in the preparation of this document are for the most part based on those adopted in 1994 by the National Health Expenditure Methodology Review Committee. This committee included representation from Health Canada, Statistics Canada, the Quebec ministère de la Santé et des Services sociaux, the Canadian Medical Association and the Canadian Healthcare Association. Some of the recommendations for change made during that process are still under development.

General Methods

The following is intended as a general overview of the methods applied to calculate estimates of drug expenditure in Canada. More detailed information can be obtained by contacting the National Health Expenditures program area by phone at 613-241-7860, by fax at 613-241-8120 or by email at nhex@cihi.ca.

Provincial/Territorial Government

Provincial/territorial government expenditure principally includes drugs that are dispensed through provincial/territorial drug subsidy programs (see Appendix A). These drug expenditure data are extracted predominantly from audited and consolidated provincial/territorial documents detailing provincial government expenditure (Table 7).

Provincial/territorial government drug spending figures include spending by the provincial/ territorial ministry responsible for health, as well as by other departments that may provide drug coverage. CIHI's estimates of provincial and territorial government drug expenditure were submitted to provincial and territorial departments of health for review and validation.

Provincial/territorial government figures identified as forecasts are based on the growth rates of major programs reported in provincial and territorial government main estimates and budgets.

Province/ Territory		Description
Newfoundland and Labrador	Drug Expenditure Data Source	Drug expenditure data are collected from the <i>Provincial</i> <i>Public Accounts Volume III, Consolidated Revenue Fund</i> supplementary statements and schedules for three drug programs: indigents, seniors and the special drug programs.
Prince Edward Island	Drug Expenditure Data Source	The Drug Cost Assistance Program is reported under the Provincial Pharmacy program in the Queens Region Health and Community Services operating statement, which is reported in <i>P.E.I. Provincial Public Accounts Volume II</i> .
Nova Scotia	Drug Expenditure Data Source	Drugs data are extracted from three sources: the <i>N.S.</i> <i>Supplementary Estimates Details</i> , special tabulations from the N.S. Seniors' Pharmacare Program and the N.S. Department of Community Services, Income Assistance and Employment Support Services.
New Brunswick	Drug Expenditure Data Source	Drugs data are provided through special reports from the Department of Health and Community Services and the Department of Human Resources. A small component of drug expenditure by the provincial government is from the <i>N.B.</i> <i>Public Accounts Volume 2</i> , under Payments to Vendors and Grants and Contribution Payments.
Quebec	Drug Expenditure Data Source	Provincial government expenditure is extracted from Volume 2 of the Quebec provincial public accounts. Spending on drugs by the provincial government is represented by total transfers of Program 5, Régie de l'assurance maladie du Québec, for "médicaments et services pharmaceutiques." See also the section, below, on Social Security Funds and the Quebec Drug Insurance Fund.
Ontario	Drug Expenditure Data Source	Data are collected from Volume 1 of the <i>Ontario Provincial</i> <i>Public Accounts</i> . Information is collected for the drug programs provided by the Ministry of Health and Long-Term Care (Ontario Drug Benefit Program, Trillium Drug Program, Special Drug Program) and by the Ministry of Community and Social Services, under Social Assistance and Employment under the Adult and Children's Service Program.
Manitoba	Drug Expenditure Data Source	Data are from Manitoba Health's Pharmacare Program under the Health Services Insurance Fund. Data are also collected from the annual report of the Manitoba Department of Family Services under Income Assistance of the Employment and Income Assistance Program.

Table 7 Provincial/Territorial Government Drug Expenditure Data

Province/ Territory		Description
Saskatchewan	Drug Expenditure Data Source	Data sources include the Saskatchewan Public Accounts Volume 2 and the Saskatchewan Health Annual Statistical Report for the Drug Plan and Extended Benefits Branch. Data are collected for the Saskatchewan Prescription Drug Plan from the annual report. A total for the Supplementary Health Program (SHP) is also extracted from the annual report. The distribution of detailed expenditure of the Supplementary Health Program provided in the Statistical Report for the Drug Plan and Extended Benefits is applied to the total for the SHP extracted from the public accounts. One of the components of the SHP that is also collected is "non-formulary drugs." Drug expenditure amounts are collected under the Ministry of Social Services in the Supplier Payments section of the public accounts.
Alberta	Drug Expenditure Data Source	Drug expenditure data from Alberta Health and Wellness are extracted from its annual report. Detailed claims summary data are provided by Alberta Blue Cross Non-Group Benefits. The largest single expenditure component of Alberta Blue Cross Non-Group Benefits is drug benefits. The detailed claims distribution is applied to the total for Blue Cross Non-Group Benefits under Practitioner Services, extracted from the annual report of the Ministry of Health and Wellness.
		Drug expenditure information is also collected from Children's Services, the Department of Community Development and the Department of Human Resources and Employment. Drug expenditure amounts are compiled from various income assistance programs, including Income Support to Individuals and Families, Social Support to Individuals and Families and Services to Persons with Disabilities.
British Columbia	Drug Expenditure Data Source	Data are received in the <i>Financial Management Reports</i> (FMRs) from the Ministry of Health Services. Control totals for major programs are from the public accounts. With few exceptions, expenditure items from the FMRs sum to the control totals. The Ministry of Health Services administers drug subsidization for all targeted groups (seniors, income assistance recipients and families) under the Medical Services Program.
Yukon Territory	Drug Expenditure Data Source	Control totals on major programs are extracted from the Yukon public accounts. Additional details are in a special tabulation provided by the territorial Ministry of Health and Social Services on spending for pharmacare, prescription drugs, under the Chronic Disease Program and Extended Health Benefits for Seniors.

Table 7 Provincial/Territorial Government Drug Expenditure Data (cont'd)

Province/ Territory	Description						
Northwest Territories	Drug Expenditure Data Source	Drug expenditure data are provided by the Finance Division of the Department of Health and Social Services under the Extended Health Benefits of the Supplementary Health Programs.					
Nunavut	Drug Expenditure Data Source	The government of Nunavut is unable to provide drug expenditure amounts to CIHI. The method used to estimate expenditure in Nunavut was to allocate the same proportion that drugs were in the Northwest Territories of the aggregate of individual programs in the Northwest Territories that make up the Supplementary Health Benefits Program in Nunavut.					

Table 7 Provincial/Territorial Government Drug Expenditure Data (cont'd)

Federal Direct

Prescribed drug data are derived from information provided by federal government organizations supplemented with information from the national public accounts. Federal government health care spending is generally provided according to the province in which the expenditure was made. Some data, however, are provided only at the national level; in these cases, they are distributed by the appropriate provincial or territorial population.

Social Security Funds

Social security funds are financially autonomous social insurance schemes that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms by which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by WCBs and the Drug Insurance Fund component of the Quebec ministère de la Santé et des Services sociaux drug subsidy program.

Workers' compensation boards—prescribed drug expenditure for the WCBs and the Commission de la santé et de la sécurité du travail du Québec are collected through special tabulations from contacts in each provincial or territorial WCB.

Quebec Drug Insurance Fund—on January 1, 1997, the Quebec ministère de la Santé et des Services sociaux, through the Régie de l'assurance maladie du Québec, introduced a drug insurance plan that covered residents of the province who were not otherwise covered by the provincial program or by private health insurance generally offered through employment. Drug claims for these participants are paid from the Drug Insurance Fund. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). Premiums are compulsory payments generally financed by the self-employed and employees of organizations that do not offer private drug insurance as a benefit of employment.

The premiums are calculated as the difference between the total Drug Insurance Fund, extracted from Régie de l'assurance maladie du Québec annual reports, and the fund financed by the ministère de la Santé et des Services sociaux, extracted from Quebec public accounts.

Private Sector

Private-sector drug data were revised in 1995 following a methodology review that began in the early 1990s. Private-sector data under the revised methodology incorporated information estimated directly from new sources for 1988 and subsequent years. Expenditure amounts prior to 1988 were estimated using trend data. Therefore, readers should exercise caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

The recommendations pertaining to prescribed and non-prescribed drugs that were ultimately implemented included the following:

- Data on drug benefits paid by private insurers were to be estimated based on information provided by the Canadian Life and Health Insurance Association (CLHIA) and from surveys of non-profit insurers.
- Out-of-pocket expenditure on prescribed drugs was to be estimated from Statistics Canada's Family Expenditure in Canada survey (FAMEX), renamed in 1997 to the Survey of Household Spending (SHS).
- Non-prescribed drug estimates would include two components: over-the-counter drugs and personal health supplies. Estimates would be based on information from the market research firm A. C. Nielsen.

As part of the original agreement with the not-for-profit insurance firms that provide data to NHEX, the administrators of NHEX agreed not to report the components of the private sector—insurance and out-of-pocket expenditure—at the provincial/territorial level. The purpose was to protect the proprietary nature of the information of the not-for-profit insurance firms. Consequently, CIHI only reports the private-sector sum of components by province and the out-of-pocket and insurance components of the private sector at the national level.

The data sources and methodologies related to these recommendations are described below.

Health insurance drug claims paid are collected from eight not-for-profit insurance companies and the CLHIA. The CLHIA data are based on its survey of member companies. Currently, drug spending that may occur by insurance companies providing casualty insurance is not included in the estimates.

Out-of-pocket prescribed drug expenditure is based on purchased data from the SHS fielded by Statistics Canada. Specifically, average household costs associated with question 14, in Section P of the SHS, relating to medicines, drugs and pharmaceutical products **prescribed by a doctor** are the basis of the estimates. The average household expenditure of prescribed drugs is multiplied by the number of estimated households reported in the survey.

The SHS is an annual survey which began in 1996. Prior to 1996, full surveys that included both urban and rural areas were carried out in 1986 and 1992. In 1990, a survey was conducted that included only metropolitan areas. In years when complete surveys were carried out, data are available for the 10 provinces and for 17 urban centres. The urban centres included Yellowknife and Whitehorse, which were used to derive estimates of expenditure in the territories. Metropolitan expenditure per household tends to be somewhat higher than provincial estimates. All relevant categories were updated in complete survey years. In years when only urban surveys were carried out, the percentage changes in urban expenditure within each province or territory were used to update category estimates from complete survey years. Between 1992 and 1996, when no surveys were conducted, historical provincial growth rates of the SHS variables of drug and drug sundries were used to impute missing years.

The non-prescribed drug estimate is based on data from the market research firm A. C. Nielsen, which tracks consumer sales of non-prescribed drugs sold in Canada at retail. Each year, A. C. Nielsen reports retail sales data for two consistent years for more than 48 non-prescribed drug categories. Data are reported by sales channel,^{xxvi} total dollar sales volume and regional sales distribution for five regions that include nine provinces. Newfoundland and Labrador and the territories are not included. The data are processed by classifying the non-prescribed drug categories as either over-the-counter drugs or personal health supplies. Regional sales amounts are separated into nine provinces, and estimates for Newfoundland and Labrador and the territories are calculated using provincial distributions of "direct costs for health care" from the SHS. Appropriate provincial and federal sales taxes are incorporated into the estimates.

The following list provides the various drug classes that are supplied to CIHI by A. C. Nielsen. The choice of classes to be included in the non-prescribed drug expenditure estimate and the classification according to which drugs are included as over-the-counter or personal health supplies was made by the NHEX Drug Expenditure Review Committee during the NHEX methodology review and adopted in 1995.

xxvi. As a general rule, Statistics Canada definitions govern the classification of stores by class of trade. Sales channels include drug stores; food stores with pharmacies; grocery banners; mass merchandiser and warehouse clubs, which are estimated from A. C. Nielsen's household panel data.

Over-the-Counter Drugs	Personal Health Supplies
Analgesic rubs	Adhesive bandages and dressing strips
Anti-fungals (external)	Antiperspirants
Athletes' foot products (included in	Artificial sweeteners
anti-fungals in later years)	Athletic supports/braces
Cold remedies	Condoms
Cough remedies	Contact lens preparations
Diarrhea remedies	Cotton swabs
Dietary aids	Cover and tape products
Headache remedies	Dental floss
Headache remedies-child's acetaminophen	Dentifrice
Hemorrhoidal remedies	Denture adhesives
Infant feeding products	Denture cleansers
Laxatives	Diabetic test strips
Medical nutritional supplements	Disposable diabetic syringes
Milk-intolerant products	Elastic bandages
Nasal preparations	Eye drops and lotions
Oral backache remedies	Feminine hygiene products
Pediculicides	Fever thermometers
Personal lubricants	Incontinence products
Premenstrual products	Medical supports/braces
Sleeping aids	Oral antiseptics
Throat remedies	Pregnancy test kits
Topical wound care	Sanitary pads
Upset stomach remedies	Selected hot/cold compresses
Vitamins-children's	Selected insoles
Vitamins-adults'	Tampons
Wart removers	Toothbrushes (includes denture brushes)

Calculation Methods

Calculation of Average Annual Rate of Growth

The average annual rate of growth is the constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. The formula used to calculate the average annual rate of growth is:

= (e $(\ln(value at end of period) - \ln(value at beginning of period))/(T-1)$) - 1

Where the constant e equals 2.718, which is the base of the natural logarithm, and T equals the number of years in the period.

Calculation of Calendar Year

Some information sources provide data in fiscal years. Calendar-year data were derived by adding three-quarters of one fiscal year to one-quarter of the previous fiscal year.

Calculation of per Capita Dollars

Per capita expenditure was calculated using the most recent revised population estimates and forecasts from the Demography Division of Statistics Canada. These take into account the results of the census adjustment for net census under-count, non-permanent residents and returning Canadians.

Calculation of Total Health Expenditure

"Total health expenditure" refers to the sum of the public and private sectors. "Canada" refers to the sum of the 10 provinces and three territories. "Canada average" is the sum of provincial and territorial expenditure divided by the sum of provincial and territorial data of another variable, such as population.

Calculation of Deflated Drug Expenditure per Capita Using CPI

Where drug expenditure per capita is presented in constant 1985 dollars, constant dollar drug expenditure per capita was calculated using the CPI, provided by Statistics Canada. A more complete explanation of the methodology for calculating the Consumer Price Index is available from Statistics Canada.¹⁹

Forecasting Methods

Provincial government-sector drug spending forecasts are based on the growth rates of drug subsidy programs of provincial health departments reported in provincial main estimates and budgets. In the case of territorial government forecasts of the Northwest Territories and Nunavut, estimates were based on amounts reported in their main estimates. In other sectors, the figures for these two territories were calculated by developing a forecast for the Northwest Territories, including Nunavut. The share of Nunavut spending in the last year of actual data of the combined total of the Northwest Territories and Nunavut was used as a proxy to break out the forecasts for the Northwest Territories and Nunavut. Forecasts for federal direct, WCBs and private sector were entirely based on econometric analysis of time series trends. For each series, up to 40 different univariate forecasting specifications were evaluated, and the best one (based on the root mean square error of prediction) was selected. The functional forms studied included the exponential smoothing family (simple, double, Holt, Brown, Winters, damped trend, etc.); time trends; ARIMA specifications; etc. Logarithmic transformations were used when the data warranted their use.

Forecasts of health expenditure are identified in the figures by special symbols and in the data tables by the letter "f."

Sources of Data

Drug expenditure estimates from NHEX are compiled based on information from the following sources.

Provincial Government Sector

- Provincial public accounts and main estimates
- Provincial departments of health annual reports and statistical supplements, where available
- Annual reports of various foundations, agencies and commissions
- Special tabulations and specific information from various provincial departments reporting health expenditure

Federal Direct Sector

- Public Accounts of Canada
- Special tabulations and information from:
 - Health Canada
 - Veterans Affairs Canada
 - Department of National Defence
 - Solicitor General of Canada
 - Statistics Canada
 - Citizenship and Immigration Canada

Social Security Funds Sector

- Special tabulations on medical aid spending provided by the provincial and territorial WCBs
- Annual reports of provincial and territorial WCBs
- Annual report of the Régie de l'assurance maladie du Québec

Private Sector

- Private insurance component:
 - The not-for-profit portion is captured from special tabulations provided by the not-for-profit insurance companies.
 - The commercial portion is captured by a special tabulation provided by the Canadian Life and Health Insurance Association.
- Out-of-pocket component:
 - Survey of Household Spending, Statistics Canada (formerly the FAMEX).
 - Over-the-Counter Drugs and Personal Health Supplies—Market Review of Selected Drug Categories at Retail, a special tabulation purchased from A. C. Nielsen Canada.

Economic and Demographic Data

- Gross domestic product:
 - 1985 to 2006: purchased from National Accounts and Environment Division, Statistics Canada.
 - 2007: purchased from the Conference Board of Canada (GDP growth rates).
- Population: purchased from Demography Division, Statistics Canada.
- Provincial government expenditure: special tabulation purchased from Public Institutions Division, Statistics Canada.
- Price indices:
 - Patented Medicine Price Index (PMPI): from Patented Medicine Prices Review Board.
 - Consumer Price Index (CPI) and Industrial Product Price Index (IPPI): purchased from the Prices Division, Statistics Canada.

Series A

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2008

				Prescrib	ed Drugs				Non-	Prescribed Dr	ruas
Provincial/ Territorial	Federal	Public Social Secu WCB	urity Funds Drug	Subtotal Public	Insurers	Private Out-of- Pocket	Subtotal Private	Total Prescribed		te (Out-of-Poo Personal Health	
			Insurance Fund		(\$ Milli			Drugs	Counter Drugs	Supplies	Drugs
1,048.1	58.0	12.6		1,118.7	(\$ Willi 		1,447.7	2,566.5			1,23
1,240.6	63.3	15.2		1,319.2			1,698.8	3,018.0			1,39
1,406.7	68.2	17.8		1,492.7			1,800.4	3,293.1			1,62
1,592.7	89.3	20.8		1,702.8	1,130.3	903.7	2,034.0	3,736.8			1,78
1,838.0	110.0	22.9		1,970.9	1,260.6	1,031.4	2,292.0	4,262.9			1,97
2,120.2	130.3	27.5		2,278.0	1,466.8	1,127.0	2,593.9	4,871.8			2,05
2,428.0	145.6	33.2		2,606.7	1,671.5	1,190.4	2,861.9	5,468.7	1 200 0	1 1 2 2 1	2,23
2,710.7 2,817.0	159.7 187.6	38.1 40.2		2,908.5 3,044.9	1,947.3 2,089.3	1,244.9 1,469.4	3,192.3 3,558.7	6,100.7 6,603.5	1,290.0 1,373.0	1,128.1 1,203.1	2,41 2,57
2,845.0	207.1	35.5		3,087.6	2,105.2	1,568.2	3,673.3	6,760.9	1,475.1	1,288.9	2,76
3,099.7 3,053.4	227.8 234.0	37.8 41.4		3,365.3 3,328.8	2,350.1 2,476.6	1,683.6 1,796.7	4,033.8 4,273.3	7,399.0 7,602.1	1,474.2 1,508.0	1,314.2 1,338.8	2,78 2,84
3,133.7	252.5	42.7	172.0	3,601.0	2,785.2	2,148.0	4,933.2	8,534.2	1,568.2	1,407.6	2,97
3,462.5	283.7	47.9	218.2	4,012.3	3,220.5	2,223.0	5,443.5	9,455.9	1,661.7	1,509.7	3,17
3,914.2	321.0	53.7	264.0	4,552.9	3,387.0	2,302.0	5,689.0	10,241.9	1,782.1	1,576.7	3,35
4,559.3	343.3	64.8	332.3	5,299.7	3,866.8	2,562.5	6,429.3	11,729.0	1,815.3	1,605.0	3,42
5,228.8	343.3	75.8	379.9	6,076.5	4,489.0	2,502.5	7,102.5	13,179.0	1,815.5	1,654.0	3,42
5,865.5	448.2	86.5	450.4	6,850.7	5,009.4	2,934.4	7,943.9	14,794.5	1,972.2	1,712.5	3,68
6,417.0	508.2	102.8	595.0	7,622.9	5,703.9	3,155.9	8,859.8	16,482.8	2,047.5	1,714.5	3,76
7,048.8	528.6	121.1	642.2	8,340.6	6,258.4	3,364.8	9,623.2	17,963.8	2,159.3	1,770.9	3,93
7,658.2	564.3	133.5	659.2	9,015.3	6,768.6	3,484.1	10,252.7	19,268.0	2,245.5	1,838.6	4,08
8,259.5	609.9	148.6	719.8	9,737.7	7,353.5	3,945.5	11,298.9	21,036.6	2,361.5	1,923.0	4,2
8,932.2	641.5	166.5	738.7	10,479.0	8,361.9	4,222.8	12,584.7	23,063.7	2,500.1	1,978.7	4,4
9,505.6	689.3	183.6	799.0	11,177.4	9,330.4	4,633.3	13,963.7	25,141.1	2,615.3	2,071.4	4,68
					(Annual Percen	tage Change)					
18.4	9.2	20.9		17.9			17.3	17.6			1
13.4	7.7	16.9		13.2			6.0	9.1			1
13.2	30.9	16.6		14.1			13.0	13.5			1
15.4	23.2	10.0		15.7	11.5	14.1	12.7	14.1			
15.4	18.4	20.0		15.6	16.4	9.3	13.2	14.3			
14.5	11.7	20.8		14.4	14.0	5.6	10.3	12.3			
11.6	9.7	14.8		11.6	16.5	4.6	11.5	11.6			
3.9	17.5	5.7		4.7	7.3	18.0	11.5	8.2	6.4	6.6	
1.0	10.4	-11.9		1.4	0.8	6.7	3.2	2.4	7.4	7.1	
9.0	10.0	6.5		9.0	11.6	7.4	9.8	9.4	-0.1	2.0	
-1.5	2.7	9.6		-1.1	5.4	6.7	5.9	2.7	2.3	1.9	
2.6	7.9	3.3		8.2	12.5	19.6	15.4	12.3	4.0	5.1	
10.5 13.0	12.4 13.1	12.0 12.1	26.8 21.0	11.4 13.5	15.6 5.2	3.5 3.6	10.3 4.5	10.8 8.3	6.0 7.2	7.3 4.4	
16.5	7.0	20.8	25.9	16.4	14.2	11.3	13.0	14.5	1.9	1.8	
14.7	14.2	17.0	14.3	14.7	16.1	2.0	10.5	12.4	3.7	3.1	
12.2 9.4	14.3 13.4	14.1 18.8	18.6 32.1	12.7 11.3	11.6 13.9	12.3 7.5	11.8 11.5	12.3 11.4	4.8 3.8	3.5 0.1	
9.4	4.0	10.0	7.9	9.4	9.7	6.6	8.6	9.0	5.5	3.3	
8.6	6.8	10.3	2.7	8.1	8.2	3.5	6.5	7.3	4.0	3.8	
7.9 8.1	8.1 5.2	11.3 12.1	9.2	8.0 7.6	8.6 13.7	13.2	10.2	9.2	5.2 5.9	4.6	
8.1 6.4	5.2 7.4	12.1 10.2	2.6 8.2	7.6 6.7	13.7	7.0 9.7	11.4 11.0	9.6 9.0	5.9	2.9 4.7	
0.4	7.4	10.2	0.2					0.0	4.0	4.7	
					centage Share of To	nai Drug Expe					
27.6	1.5	0.3		29.4			38.1	67.5			3
28.1 28.6	1.4 1.4	0.3 0.4		29.9 30.4			38.5 36.6	68.3 67.0			:
28.6 28.8	1.4 1.6	0.4		30.4 30.8	20.5	16.4	36.6	67.0			3
29.5	1.8	0.4		31.6	20.5	16.5	36.7	68.3			
30.6 31.5	1.9	0.4		32.9	21.2	16.3	37.4	70.3			2
31.5 31.8	1.9 1.9	0.4 0.4		33.8 34.1	21.7 22.9	15.4 14.6	37.1 37.5	71.0 71.6	 15.1	 13.2	1
31.8	2.0	0.4		33.2	22.9	14.6	37.5	71.9	15.0	13.2	-
29.9	2.0	0.4		32.4	22.0	16.5	38.6	71.0	15.5	13.1	
30.4	2.2	0.4		33.0	23.1	16.5	39.6	72.6	14.5	12.9	2
29.2 27.2	2.2 2.2	0.4 0.4		31.9 31.3	23.7 24.2	17.2 18.7	40.9 42.9	72.8 74.1	14.4 13.6	12.8 12.2	2
27.2	2.2	0.4	1.5 1.7	31.3	24.2	18.7	42.9	74.1	13.5	12.2	2
28.8	2.4	0.4	1.9	33.5	24.9	16.9	41.8	75.3	13.1	11.6	2
30.1	2.3	0.4	2.2	35.0	25.5	16.9	42.4	77.4	12.0	10.6	
31.3	2.3	0.5	2.3	36.4	26.9	15.6	42.5	78.8	11.3	9.9	-
31.7	2.4	0.5	2.4	37.1	27.1	15.9	43.0	80.1	10.7	9.3	
31.7 32.2	2.5 2.4	0.5 0.6	2.9 2.9	37.7 38.1	28.2 28.6	15.6 15.4	43.8 44.0	81.4 82.0	10.1 9.9	8.5 8.1	
32.8	2.4	0.6	2.8	38.6	29.0	14.9	43.9	82.5	9.6	7.9	
32.6	2.4	0.6	2.8	38.5	29.0	15.6	44.6	83.1	9.3	7.6	
32.4 31.9	2.3	0.6 0.6	2.7 2.7	38.0 37.5	30.4 31.3	15.3 15.5	45.7 46.8	83.7 84.3	9.1 8.8	7.2 6.9	
	2.3										

	Ex		Drugs by Type, by				Table Private and	A Canada	– Tota
			Total Health Expen	ditures, Canada	a, 1985 to 2	Share of Drugs	in Public, Private	and	
-	Public	All Drugs Private	Total	Hea Public	Ith Expenditure Private	Total	Total He Public	alth Expenditures Private	Total
			(\$ Millions)				(Perc	entage Share)	
-	1,118.7	2,683.6	3,802.3	30,094.9	9,746.9	39,841.7	3.7	27.5	9.5
	1,319.2	3,097.9	4,417.1	32,528.6	10,808.7	43,337.3	4.1	28.7	10.2
	1,492.7 1,702.8	3,422.2 3,818.9	4,914.9 5,521.7	35,054.7 38,162.8	11,733.5 12,796.4	46,788.2 50,959.2	4.3 4.5	29.2 29.8	10.5 10.8
	1,970.9	4,267.7	6,238.5	41,911.1	14,184.3	56,095.5	4.7	30.1	11.1
	2,278.0	4,652.5	6,930.5	45,445.5	15,577.1	61,022.6	5.0	29.9	11.4
	2,606.7	5,098.5	7,705.3	49,382.2	16,906.9	66,289.1	5.3	30.2	11.6
	2,908.5 3,044.9	5,610.4 6,134.7	8,518.8 9,179.6	51,637.3 51,920.8	18,112.0 19,578.1	69,749.2 71,498.9	5.6 5.9	31.0 31.3	12.2 12.8
	3,044.9	6,437.4	9,524.9	52,535.5	20,574.2	73,109.7	5.9	31.3	12.0
	3,365.3	6,822.2	10,187.4	52,719.1	21,370.1	74,089.2	6.4	31.9	13.8
	3,328.8	7,120.0	10,448.9	52,823.0	21,910.5	74,733.5	6.3	32.5	14.0
	3,601.0	7,908.9	11,509.9	55,226.8	23,532.1	78,758.9	6.5	33.6	14.0
	4,012.3 4,552.9	8,614.9 9,047.9	12,627.2 13,600.7	59,212.8 63,198.5	24,768.3 26,998.8	83,981.1 90,197.3	6.8 7.2	34.8 33.5	15.0 15.1
	5,299.7 6,076.5	9,849.6 10,638.9	15,149.3 16,715.5	69,271.2 75,019.1	29,160.7 32,061.0	98,431.9 107,080.1	7.7 8.1	33.8 33.2	15.4 15.0
	6,850.7	11,628.6	18,479.2	80,193.9	34,997.1	115,191.0	8.5	33.2	16.
	7,622.9	12,621.8	20,244.8	86,985.6	36,935.6	123,921.3	8.8	34.2	16.
	8,340.6	13,553.4	21,894.0	92,600.3	39,488.0	132,088.3	9.0	34.3	16.
	9,015.3	14,336.8	23,352.1	99,274.1	42,088.7	141,362.8	9.1	34.1	16.
f	9,737.7 10,479.0	15,583.4 17,063.5	25,321.1 27,542.5	105,785.8 113,205.9	45,492.7 48,370.3	151,278.5 161,576.2	9.2 9.3	34.3 35.3	16. 17.
f	11,177.4	18,650.5	29,827.9	120,274.9	51,633.7	171,908.6	9.3	36.1	17.
			(Annual Percentage	Change)					
_									
	17.9	15.4	16.2	8.1	10.9	8.8			
	13.2	10.5	11.3	7.8	8.6	8.0			
	14.1	11.6	12.3	8.9	9.1	8.9			
	15.7	11.8	13.0	9.8	10.8	10.1			
	15.6	9.0	11.1	8.4	9.8	8.8			
	14.4 11.6	9.6 10.0	11.2 10.6	8.7 4.6	8.5 7.1	8.6 5.2			
	4.7	9.3	7.8	0.5	8.1	2.5			
	1.4	4.9	3.8	1.2	5.1	2.3			
	9.0	6.0	7.0	0.3	3.9	1.3			
	-1.1	4.4	2.6	0.2	2.5	0.9			
	8.2 11.4	11.1 8.9	10.2 9.7	4.6 7.2	7.4 5.3	5.4 6.6			
	13.5	5.0	7.7	6.7	9.0	7.4			
	16.4	8.9	11.4	9.6	8.0	9.1			
	14.7	8.0	10.3	8.3	9.9	8.8			
	12.7	9.3	10.6	6.9	9.2	7.6			
	11.3 9.4	8.5 7.4	9.6 8.1	8.5 6.5	5.5 6.9	7.6 6.6			
	8.1 8.0	5.8 8.7	6.7 8.4	7.2 6.6	6.6 8.1	7.0 7.0			
f	7.6	9.5	8.8	7.0	6.3	6.8			
f	6.7	9.3	8.3	6.2	6.7	6.4			
_	(Percentag	e Share of Total Dr	ug Expenditure)						
	29.4	70.6	100.0						
	29.9	70.1	100.0						
	30.4 30.8	69.6 69.2	100.0 100.0						
	30.8 31.6	68.4	100.0						
	32.9	67.1	100.0						
	32.9	66.2	100.0						
	34.1	65.9	100.0						
	33.2 32.4	66.8 67.6	100.0						
			100.0						
	33.0	67.0	100.0						
	31.9 31.3	68.1 68.7	100.0 100.0						
	31.8	68.2	100.0						
	33.5	66.5	100.0						
	35.0	65.0	100.0						
	36.4	63.6	100.0						
	37.1	62.9	100.0						
	37.7 38.1	62.3 61.9	100.0 100.0						
	38.6 38.5	61.4 61.5	100.0 100.0						
f	38.0	62.0	100.0						
f	37.5	62.5	100.0						

CA

CA

					Prescribe	ed Drugs				Non-	Prescribed Dr	ugs
			Public			<u> </u>	Private		-		te (Out-of-Poo	
	Provincial/ Territorial	Federal	Social Secu WCB	Drug Insurance	Subtotal Public	Insurers	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Tota Non-Pr Drug
Year				Fund		(\$ per C	Capita)			Drugs		
1985	40.56	2.24	0.49		43.29			56.02	99.31			4
1986	47.53	2.43	0.58		50.54			65.09	115.63			5
1987 1988	53.18 59.44	2.58 3.33	0.67 0.78		56.44 63.55	42.18	33.72	68.07 75.91	124.51 139.46			6
1989	67.37	4.03	0.84		72.24	46.21	37.81	84.01	156.25			7
1990	76.55	4.70	0.99		82.24	52.96	40.69	93.65	175.89			7
1991	86.62	5.19	1.18		92.99	59.63	42.47	102.10	195.09			7
1992	95.56	5.63	1.34		102.53	68.65	43.89	112.53	215.07	45.48	39.77	8
1993 1994	98.22 98.11	6.54 7.14	1.40 1.22		106.16 106.47	72.84 72.59	51.23 54.08	124.07 126.67	230.23 233.14	47.87 50.87	41.95 44.45	8 9
1995 1996	105.78 103.12	7.78 7.90	1.29 1.40		114.85 112.42	80.20 83.64	57.46 60.68	137.66 144.32	252.51 256.73	50.31 50.93	44.85 45.21	9
1997	104.78	8.44	1.43	5.75	120.41	93.13	71.82	164.95	285.35	52.43	47.07	g
1998	114.81	9.41	1.59	7.24	133.05	106.79	73.71	180.51	313.55	55.10	50.06	10
1999	128.74	10.56	1.77	8.68	149.75	111.40	75.71	187.12	336.86	58.61	51.86	11
2000	148.57	11.19	2.11	10.83	172.69	126.00	83.50	209.50	382.19	59.15	52.30	11
2001	168.56	12.64	2.44	12.25	195.88	144.71	84.25	228.96	424.84	60.68	53.32	11
2002 2003	186.96 202.58	14.29 16.04	2.76 3.24	14.36 18.78	218.36 240.65	159.68 180.07	93.53 99.63	253.21 279.70	471.58 520.35	62.86 64.64	54.59 54.13	11 11
2004	220.31	16.52	3.78	20.07	260.68	195.61	105.17	300.77	561.45	67.49	55.35	12
2005	237.01	17.46	4.13	20.40	279.01	209.48	107.83	317.30	596.31	69.49	56.90	12
2006	252.97	18.68	4.55	22.05	298.25	225.22	120.84	346.07	644.32	72.33	58.90	13
2007 f	270.87	19.45	5.05	22.40	317.78	253.57	128.06	381.63	699.41	75.81	60.00	13
2008 f	285.87	20.73	5.52	24.03	336.15	280.60 (Annual Percen	139.34	419.94	756.09	78.65	62.30	14
						(Annual Percen	tage Change)					
1985 1986	17.2	 8.1	19.7		 16.8			16.2	16.4			
1987	11.9	6.3	15.4		11.7			4.6	7.7			
1988	11.8	29.2	15.1		12.6			11.5	12.0			
1989	13.3	21.0	8.1		13.7	9.5	12.1	10.7	12.0			
1990	13.6	16.7	18.2		13.8	14.6	7.6	11.5	12.6			
1991	13.2	10.4	19.4		13.1	12.6	4.4	9.0	10.9			
1992 1993	10.3 2.8	8.4 16.2	13.4 4.5		10.3 3.5	15.1 6.1	3.3 16.7	10.2 10.3	10.2 7.1	 5.3	5.5	
1994	-0.1	9.2	-12.8		0.3	-0.3	5.6	2.1	1.3	6.3	6.0	
1995	7.8	8.9	5.4		7.9	10.5	6.3	8.7	8.3	-1.1	0.9	
1996	-2.5	1.6	8.5		-2.1	4.3	5.6	4.8	1.7	1.2	0.8	
1997	1.6	6.8	2.2		7.1	11.3	18.4	14.3	11.1	3.0	4.1	
1998	9.6 12.1	11.4 12.2	11.1	25.8	10.5	14.7	2.6 2.7	9.4	9.9 7.4	5.1	6.4	
1999			11.2	20.0	12.6	4.3		3.7		6.4	3.6	
2000	15.4	6.0	19.6	24.7	15.3	13.1	10.3	12.0	13.5	0.9	0.9	
2001 2002	13.5 10.9	13.0 13.1	15.7 12.8	13.1 17.2	13.4 11.5	14.8 10.3	0.9 11.0	9.3 10.6	11.2 11.0	2.6 3.6	1.9 2.4	
2002	8.4	12.3	17.7	30.8	10.2	12.8	6.5	10.5	10.3	2.8	-0.8	
2004	8.8	3.0	16.6	6.9	8.3	8.6	5.6	7.5	7.9	4.4	2.3	
2005	7.6	5.7	9.2	1.6	7.0	7.1	2.5	5.5	6.2	3.0	2.8	
2006	6.7	7.0	10.1	8.1	6.9	7.5	12.1	9.1	8.1	4.1	3.5	
2007 f	7.1	4.1	11.0	1.6	6.5	12.6	6.0	10.3	8.6	4.8	1.9	
2008 f	5.5	6.6	9.3	7.3	5.8	10.7	8.8	10.0	8.1	3.7	3.8	
					Annual Percentage	Change in Excess	of Inflation in	the Canadian				
1985												
1986 1987	14.4 7.1	5.3 1.6	16.9 10.6		14.0 6.9			13.4 -0.2	13.6 2.9			
1988	7.2	24.7	10.6		8.1			7.0	7.5			
1989	8.8	16.4	3.5		9.1			6.1	7.5			
1990	10.6	13.6	15.2		10.8			8.4	9.5			
1991	10.4	7.6	16.6		10.3			6.3	8.2			
1992 1993	9.1 1.3	7.1 14.7	12.2 3.1		9.0 2.1			9.0 8.8	9.0 5.6	 3.8	4.0	
1993 1994	-1.2	8.1	-13.9		-0.8			8.8	0.2	3.8 5.2	4.0	
1995	5.5	6.5	3.0		5.5			6.3	6.0	-3.4	-1.4	
1995	-4.2	0.0	3.0 6.8		-3.8			3.2	0.0	-3.4	-1.4	
1997	0.6	5.8	1.2		6.1			13.3	10.2	2.0	3.1	
1998	10.0	11.9	11.5	26.2	10.9			9.9	10.3	5.5	6.8	
1999	10.3	10.4	9.4	18.2	10.7			1.9	5.6	4.6	1.8	
2000	11.3	1.9	15.5	20.6	11.2			7.9	9.4	-3.2	-3.3	
2001 2002	12.1	11.6 12.0	14.4	11.7 16.2	12.1 10.4			7.9	9.8 10.0	1.2 2.6	0.6	
2002 2003	9.9 5.5	12.0 9.4	11.8 14.8	16.2 27.9	10.4			9.5 7.6	7.4	-0.1	1.3 -3.7	
2004	6.2	0.4	14.1	4.3	5.7			4.9	5.3	1.8	-0.3	
2005	4.5	2.6	6.1	-1.5	3.9			2.4	3.1	-0.1	-0.3	
2006	4.3	4.5	7.7	5.7	4.5			6.7	5.6	1.7	1.1	
2007 f	3.9	0.9	7.8		3.3			7.1	5.3			

	r	vnenditure or	Drugs Per Capita b		Source of Fina	nce and Public		Canada—Per Capita
	E	•	n Drugs Per Capita by Total Health Expendi				, Private and	
							GDP Implicit	
=	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price Index-Canada	
Year _			(\$ per Capita)				(1997 = 100)	
1985	43.29	103.84	147.13	1,164.54	377.16	1,541.70	73.6	
1986 1987	50.54	118.69	169.23	1,246.25		1,660.36 1,769.01	75.6	
1988	56.44 63.55	129.39 142.52	185.82 206.07	1,325.38 1,424.23		1,901.79	79.2 82.8	
1989	72.24	156.43	228.67	1,536.23	519.92	2,056.15	86.6	
1990	82.24	167.98	250.22	1,640.78		2,203.18	89.2	
1991 1992	92.99 102.53	181.89 197.78	274.88 300.31	1,761.68 1,820.34		2,364.82 2,458.83	91.6 92.8	
1993	106.16	213.89	320.05	1,810.23	682.59	2,492.83	94.1	
1994	106.47	221.98	328.46	1,811.62		2,521.10	95.2	
1995 1996	114.85 112.42	232.82 240.45	347.67 352.87	1,799.15 1,783.90		2,528.45 2,523.85	97.4 99.0	
1997	120.41	264.45	384.85	1,846.59		2,633.42	100.0	
1998 1999	133.05 149.75	285.67	418.71	1,963.48 2,078.63		2,784.79	99.6 101.4	
		297.59	447.34			2,966.64		
2000 2001	172.69 195.88	320.95 342.96	493.64 538.84	2,257.20 2,418.31		3,207.40 3,451.83	105.5 106.9	
2002	218.36	370.66	589.03	2,556.18	1,115.53	3,671.71	108.1	
2003 2004	240.65 260.68	398.47 423.61	639.12 684.29	2,746.10 2,894.19		3,912.14 4,128.38	111.2 114.1	
2004	279.01	423.01	722.70	3,072.35		4,128.38	114.1	
2006	298.25	477.29	775.54	3,240.04		4,633.41	120.5	
2007 f	317.78	517.45	835.23	3,432.98		4,899.81	124.3	
2008 f	336.15	560.89	897.04 (Annual P	3,617.14 Percentage Cha		5,169.97	128.6	
1985								
1986	16.8	14.3	15.0	7.0		7.7	2.8	
1987 1988	11.7 12.6	9.0 10.2	9.8 10.9	6.3 7.5		6.5 7.5	4.7 4.5	
1989	13.7	9.8	11.0	7.9		8.1	4.6	
1990	13.8	7.4	9.4	6.8	8.2	7.2	3.0	
1991	13.1	8.3	9.9	7.4	7.2	7.3	2.8	
1992 1993	10.3 3.5	8.7 8.1	9.3 6.6	3.3 -0.6		4.0 1.4	1.3 1.4	
1994	0.3	3.8	2.6	0.1		1.1	1.1	
1995	7.9	4.9	5.8	-0.7	2.8	0.3	2.3	
1996	-2.1	3.3	1.5	-0.8		-0.2	1.7	
1997 1998	7.1 10.5	10.0 8.0	9.1 8.8	3.5		4.3 5.7	1.0 -0.4	
1999	12.6	4.2	6.8	5.9		6.5	1.8	
2000	15.3	7.8	10.4	8.6		8.1	4.1	
2001	13.4	6.9	9.2	7.1		7.6	1.4	
2002 2003	11.5 10.2	8.1 7.5	9.3 8.5	5.7 7.4		6.4 6.5	1.0 2.9	
2004	8.3	6.3	7.1	5.4		5.5	2.6	
2005	7.0	4.7	5.6	6.2	5.5	6.0	3.1	
2006 2007 f	6.9 6.5	7.6 8.4	7.3 7.7	5.5		5.9 5.7	2.4 3.2	
2007 f	5.8	8.4	7.4	5.4		5.5	3.4	
_		(Annual Percenta	age Change in Excess of Inflat	tion in the Cana	adian Economy)			
1985								
1986	14.0	11.5	12.2	4.2		4.9		
1987 1988	6.9 8.1	4.3 5.6	5.1 6.4	1.6 2.9		1.8 3.0		
1989	9.1	5.2	6.4	3.3		3.6		
1990	10.8	4.4	6.4	3.8	5.1	4.1		
1991 1992	10.3 9.0	5.5 7.5	7.1 8.0	4.6		4.6 2.7		
1992	9.0	6.7	5.1	-2.0		-0.1		
1994	-0.8	2.7	1.5	-1.0	2.8	0.0		
1995	5.5	2.5	3.5	-3.0		-2.0		
1996 1997	-3.8 6.1	1.6 9.0	-0.2 8.1	-2.5		-1.9 3.4		
1998	10.9	8.5	9.2	6.8	4.8	6.2		
1999	10.7	2.4	5.0	4.1	6.3	4.7		
2000	11.2	3.7	6.2	4.5		4.0		
2001 2002	12.1 10.4	5.5 7.0	7.8 8.3	5.8		6.3 5.3		
2003	7.3	4.6	5.6	4.5	i 1.6	3.7		
2004	5.7	3.7	4.5	2.8		2.9		
2005 2006	3.9 4.5	1.6 5.2	2.5 4.9	3.0 3.0		2.9 3.5		
2007 f	4.5	5.2	4.5	2.7		2.5		
2008 f	2.4	5.0	4.0	1.9	2.4	2.1		
f: forecast.								Source: NHEX, CIHI, 2008

CA

Series B

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2008

					Prescrib	ed Drugs				Non	-Prescribed Dr	rugs
	Provincial	Federal	Public Social Secu WCB	Drug	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed	Over- the-	te (Out-of-Poo Personal Health	cket No
·				Insurance Fund		(* B.8	Wana)		Drugs	Counter Drugs	Supplies	
' ear 985	18.0	2.3	0.1		20.4	(\$ 101	llions)	82.8	103.2			
986	21.4	2.7	0.2		24.4			51.6	76.0			
987 988	24.7 28.2	3.1 1.6	0.3 0.4		28.1 30.2			55.1 58.7	83.2 88.9			
989	31.2	1.3	0.4		32.9			62.5	95.4			
990	35.3	1.6	0.6		37.5			64.7	102.2			
991	40.3	1.7	0.8		42.8			65.8	108.5			
992	43.9	1.7	1.1		46.6			72.9	119.5	20.6	17.9	
993 994	47.8 52.1	2.2 2.5	1.2 1.2		51.1 55.8			76.1 77.9	127.2 133.7	21.7 22.9	18.2 18.3	
995 996	54.5 54.5	2.8 2.7	1.5 1.8		58.8 59.0			85.6 90.0	144.4 149.0	22.5 24.7	19.9 21.9	
997	53.6	3.3	1.9		58.8			87.9	146.7	21.1	18.9	
998	56.1	3.7	2.4		62.1			93.7	155.8	23.3	21.0	
999	60.0	4.1	2.8		66.9			103.3	170.2	25.6	22.5	
000	68.0	5.8	3.8		77.6			119.9	197.5	26.1	22.2	
001 002	77.9	6.6 7.4	4.2		88.7			129.2	217.9	25.8	22.6	
002	86.9 96.0	7.4 8.1	5.0 4.9		99.3 109.0			150.2 169.0	249.5 278.0	26.6 26.9	23.0 22.4	
:004	101.7	7.8	4.9		114.4			178.4	292.8	20.9	22.4	
005	106.0	8.0	5.1		119.0			196.7	315.8	27.4	22.4	
006	108.1	7.7	5.1		121.0			208.4	329.4	30.1	22.4	
007 f	113.0	7.8	5.1		125.9			229.0	354.9	29.8	23.5	
008 f	136.8	8.3	5.2		150.3			247.9	398.1	30.7	24.1	
						(Annual Perce	ntage Change)				
985												
986	19.2	20.4	35.5		19.4			-37.6	-26.3			
987	15.4	13.5	34.3		15.3			6.7	9.4			
988 989	13.9 10.6	-48.0 -20.2	50.0 14.5		7.4 9.0			6.6 6.6	6.8 7.4			
990 991	13.4 14.1	21.5 9.6	38.7 25.5		14.0 14.1			3.4 1.7	7.1 6.2			
992	8.8	-3.5	40.5		8.9			10.8	10.1			
993	8.9	31.4	9.2		9.7			4.5	6.5	5.4	1.1	
994	9.1	12.4	7.4		9.2			2.3	5.1	5.3	0.8	1
995	4.6	12.3	22.5		5.4			9.9	8.0	-1.8	8.6	
996 997	0.0 -1.6	-2.7 23.0	18.8		0.4 -0.4			5.1 -2.3	3.2 -1.5	10.1 -14.5	10.3 -14.0	
997 998	-1.6	10.5	3.4 28.6		-0.4			-2.3	6.2	-14.5	-14.0	
999	7.0	12.0	16.0		7.7			10.3	9.3	9.9	7.0	
000	13.4	40.7	37.7		16.1			16.0	16.0	2.2	-1.4	÷
001	14.5	15.5	8.8		14.3			7.8	10.3	-1.4	1.7	
002	11.5	11.9	20.2		12.0			16.2	14.5	3.3	2.1	
003 004	10.6 5.9	8.3 -3.0	-1.8 -1.2		9.8 4.9			12.5 5.5	11.4 5.3	1.0 3.4	-2.6 2.8	
005 006	4.2 2.0	1.8 -3.1	4.6 1.5		4.1 1.6			10.3 5.9	7.9 4.3	-1.6 9.9	-2.9 3.0	
000 f	4.5	0.7	-0.8		4.0			9.9	4.3	-1.0	1.7	
008 f	21.0	7.2	1.4		19.4			8.2	12.2	2.9	2.9	
					(P	ercentage Share of	Total Drug Exp	enditure)				
985	14.0	1.8	0.1		15.9		g =xp	64.6	80.6			
986	20.6	2.6	0.2		23.4			49.6	73.0			
987	21.3	2.7	0.2		24.3			47.5	71.8			
988 989	23.2 24.4	1.3 1.0	0.3		24.9 25.8			48.4 49.1	73.3 74.9			
990 991	25.9 27.5	1.2 1.2	0.4 0.5		27.5 29.2			47.4 44.9	74.9 74.2			
992	27.8	1.1	0.7		29.5			46.1	75.6	13.0	11.4	
993	28.6	1.3	0.7		30.6			45.6	76.1	13.0	10.9)
994	29.8	1.4	0.7		31.9			44.6	76.5	13.1	10.5	
995	29.2	1.5	0.8		31.5			45.9	77.3	12.0	10.6	
996	27.9	1.4	0.9		30.2			46.0	76.2	12.6	11.2	
997 998	28.7 28.0	1.8 1.8	1.0 1.2		31.5 31.0			47.1 46.8	78.6 77.9	11.3 11.6	10.1 10.5	
999	27.5	1.9	1.3		30.6			47.3	78.0	11.7	10.3	
000	27.7	2.3	1.6		31.6			48.8	80.3	10.6	9.0	
001	29.3	2.5	1.6		33.3			48.5	81.8	9.7	8.5	
002	29.0	2.5	1.7		33.2			50.2	83.4	8.9	7.7	
003	29.3	2.5	1.5		33.3			51.6	84.9	8.2	6.9	
004	29.6	2.3	1.4		33.3			51.9	85.2	8.1	6.7	
005	29.0	2.2	1.4		32.6			53.8	86.4	7.5	6.1	
006 007 f	28.3	2.0	1.3		31.6			54.5	86.1	7.9	6.0	
007 f 008 f	27.7 30.2	1.9 1.8	1.3 1.1		30.8 33.2			56.1 54.7	86.9 87.9	7.3 6.8	5.7 5.3	

			•			r, 1985 to 2008	Share of Drugs	in Public, Private an	nd
-		ll Drugs Private	Total	Healtl Public	h Expenditure Private	Total	Total Hea	Ith Expenditures Private	Total
			(\$ Millions)				(Perce	ntage Share)	
	20.4	107.7	128.1	588.8	197.1	785.8	3.5	54.6	16.3
	24.4	79.8	104.2	642.9	169.6	812.5	3.8	47.1	12.8
	28.1 30.2	87.8 91.0	115.9 121.2	693.6 733.8	188.0 197.1	881.6 930.9	4.1 4.1	46.7 46.2	13.1 13.0
	32.9	94.6	127.4	787.7	203.9	991.6	4.2	46.4	12.9
	37.5 42.8	99.0 103.6	136.5 146.4	875.9 905.7	220.6 247.5	1,096.4 1,153.2	4.3 4.7	44.9 41.8	12.4 12.7
	46.6	111.4	158.0	928.3	269.1	1,197.4	5.0	41.4	13.2
	51.1	116.0	167.1	924.9	284.2	1,209.1	5.5	40.8	13.8
	55.8	119.1	174.9	948.1	301.1	1,249.3	5.9	39.6	14.0
	58.8	128.0	186.7	973.1	296.4	1,269.4	6.0	43.2	14.7
	59.0	136.7	195.6	974.4	279.0	1,253.4	6.1	49.0	15.6
	58.8	127.9	186.7	1,020.8	284.2	1,305.1	5.8	45.0	14.3
	62.1 66.9	138.0 151.4	200.1 218.3	1,107.8 1,250.8	324.1 330.4	1,431.9 1,581.2	5.6 5.3	42.6 45.8	14.0 13.8
	77.6 88.7	168.2 177.5	245.8 266.2	1,318.7	366.4 385.7	1,685.1	5.9 6.3	45.9 46.0	14.6 14.8
	99.3	177.5	299.2	1,415.5 1,510.4	385.7 415.0	1,801.2 1,925.3	6.6	48.2	14.8
	109.0	218.3	327.3	1,592.2	469.2	2,061.4	6.8	46.5	15.9
	114.4	229.2	343.6	1,630.0	507.4	2,137.4	7.0	45.2	16.1
	119.0	246.5	365.5	1,687.0	548.7	2,235.8	7.1	44.9	16.3
	121.0	261.6	382.6	1,785.5	549.0	2,334.5	6.8	47.7	16.4
	125.9	282.3	408.2	1,917.7	583.1	2,500.8	6.6	48.4	16.3
	150.3	302.7	453.0	2,104.4	623.2	2,727.6	7.1	48.6	16.6
			(Annual Percentage (Change)					
	19.4	-25.9	-18.6	9.2	-13.9	3.4			
	15.3	9.9	11.2	7.9	10.9	8.5			
	7.4	3.7	4.6	5.8	4.8	5.6			
	9.0	3.9	5.1	7.4	3.4	6.5			
	14.0	4.7	7.1	11.2	8.2	10.6			
	14.1	4.7	7.3	3.4	12.2	5.2			
	8.9	7.6	8.0	2.5	8.7	3.8			
	9.7 9.2	4.1 2.7	5.8 4.7	-0.4 2.5	5.6 6.0	1.0 3.3			
	5.4	7.4	6.8	2.6	-1.6	1.6			
	0.4 -0.4	6.8 -6.4	4.8 -4.6	0.1 4.8	-5.9 1.9	-1.3 4.1			
	5.6	7.8	7.2	8.5	14.0	9.7			
	7.7	9.7	9.1	12.9	1.9	10.4			
	16.1	11.1	12.6	5.4	10.9	6.6			
	14.3	5.6	8.3	7.3	5.2	6.9			
	12.0	12.6	12.4	6.7	7.6	6.9			
	9.8	9.2	9.4	5.4	13.1	7.1			
	4.9	5.0	5.0	2.4	8.1	3.7			
	4.1	7.5	6.4	3.5	8.2	4.6			
	1.6	6.1	4.7	5.8	0.0	4.4			
	4.0 19.4	7.9 7.2	6.7 11.0	7.4 9.7	6.2 6.9	7.1 9.1			
	(Percentage Si	nare of Total Dru	a Expenditure)						
	15.9	84.1	100.0						
	23.4	84.1 76.6	100.0						
	24.3	75.7	100.0						
	24.9	75.1	100.0						
	25.8	74.2	100.0						
	27.5	72.5	100.0						
	29.2	70.8	100.0						
	29.5 30.6	70.5 69.4	100.0 100.0						
	31.9	68.1	100.0						
	31.5 30.2	68.5 69.8	100.0 100.0						
	30.2	69.8	100.0						
	31.0	69.0	100.0						
	30.6	69.4	100.0						
	31.6	68.4	100.0						
	33.3	66.7	100.0						
	33.2	66.8	100.0						
	33.3	66.7	100.0						
	33.3	66.7	100.0						
	32.6	67.4	100.0						
	31.6	68.4	100.0						
	30.8 33.2	69.2 66.8	100.0 100.0						

Table B N.L.—Per Capita

N.L.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2008

			Public		Prescribe	ed Drugs	Drivota				-Prescribed Dr	
	Provincial	Federal	Public Social Security	y Funds	Subtotal	Insurers*	Private Out-of-	Subtotal	Total	Over-	te (Out-of-Poo Personal	cket) Total
		=	WCB	Drug nsurance	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Pres Drugs
Year				Fund		(\$ per	Capita)		·	Drugs		
1985	31.05	3.94	0.24		35.23			142.89	178.12			4:
1986	37.19	4.77	0.32		42.28			89.58	131.86			48
1987 1988	43.00 49.00	5.42 2.82	0.44 0.66		48.86 52.48			95.77 102.08	144.63 154.56			5
1989	54.05	2.25	0.75		57.04			108.52	165.56			5
1990	61.11	2.72	1.03		64.87			111.92	176.79			59
1991	69.56	2.97	1.30		73.83			113.48	187.30			6
1992 1993	75.61 82.36	2.87 3.77	1.82 1.99		80.30 88.12			125.66 131.28	205.95 219.40	35.54 37.46	30.94 31.30	
1994	90.69	4.28	2.15		97.12			135.64	232.75	39.83	31.86	
1995	96.05	4.86	2.67		103.58			150.89	254.47	39.59	35.02	7-
1996 1997	97.36 97.30	4.80 6.00	3.22 3.38		105.37 106.67			160.78 159.58	266.15 266.25	44.17 38.38	39.17 34.22	
1998	103.81	6.76	4.43		115.01			173.46	288.47	43.13	34.22	
1999	112.49	7.67	5.20		125.36			193.70	319.07	47.96	42.18	
2000	128.84	10.90	7.24		146.98			226.98	373.96	49.52	42.00	9
2001 2002	149.21	12.73	7.97		169.91			247.46	417.37 480.27	49.41	43.21	
2002 2003	167.25 185.27	14.32 15.54	9.63 9.48		191.20 210.29			289.07 325.97	480.27 536.27	51.30 51.89	44.35 43.26	
2004	196.64	15.11	9.38		221.14			344.79	565.92	53.78	44.57	
2005	206.17	15.48	9.87		231.52			382.64	614.16	53.25	43.54	96
2006	212.06	15.12	10.09		237.28			408.72	646.00	59.02	45.23	
2007 f 2008 f	223.23 270.51	15.33 16.46	10.09 10.25		248.66 297.21			452.33 490.27	700.98 787.49	58.88 60.68	46.34 47.76	
						(Annual Perce	ntage Change)					
1985						(Annual 1 erce						
1986	19.8	21.0	36.2		20.0			-37.3	-26.0			
1987	15.6	13.7	34.7		15.6			6.9	9.7			
1988 1989	14.0 10.3	-48.0 -20.4	50.0 14.2		7.4 8.7			6.6 6.3	6.9 7.1			
1990	13.1	21.2	38.3		13.7			3.1	6.8			
1991	13.8	9.3	25.2		13.8			1.4	5.9			1
1992	8.7	-3.5	40.4		8.8			10.7	10.0			
1993 1994	8.9 10.1	31.4 13.4	9.3 8.4		9.7 10.2			4.5 3.3	6.5 6.1	5.4 6.3	1.2 1.8	
1995	5.9	13.7	24.1		6.7			11.2	9.3	-0.6	9.9	
1996	1.4	-1.3	20.4		1.7			6.6	4.6	11.6	11.8	1
1997 1998	-0.1 6.7	25.0 12.8	5.1 31.2		1.2 7.8			-0.7 8.7	0.0 8.3	-13.1 12.4	-12.6 13.8	
1998	8.4	12.8	17.4		9.0			0.7 11.7	10.6	12.4	8.3	
2000	14.5	42.2	39.1		17.2			17.2	17.2	3.2	-0.4	
2001	15.8	16.8	10.1		15.6			9.0	11.6	-0.2	2.9	
2002 2003	12.1 10.8	12.5 8.5	20.8 -1.6		12.5 10.0			16.8 12.8	15.1 11.7	3.8 1.2	2.6 -2.5	
2003	6.1	-2.8	-1.0		5.2			5.8	5.5	3.6	-2.5	
2005	4.8	2.5	5.2		4.7			11.0	8.5	-1.0	-2.3	
2006	2.9	-2.3	2.3		2.5			6.8	5.2	10.8	3.9	
2007 f 2008 f	5.3 21.2	1.4 7.3	0.0 1.6		4.8 19.5			10.7 8.4	8.5 12.3	-0.2 3.1	2.5 3.1	
2008 1	21.2	7.5	1.0							3.1	3.1	
1985					(Annual Percentag	e Change in Excess	of Inflation in	the Canadian Ed	conomy)			
1986	17.0	18.2	33.4		17.2			-40.1	-28.8			
1987 1988	10.9 9.4	9.0 -52.5	29.9 45.5		10.8 2.9			2.2 2.1	4.9 2.3			
1989	5.7	-25.0	9.6		4.1			1.7	2.6			
1990	10.0	18.2	35.3		10.7			0.1	3.8			
1991	11.1	6.6	22.4		11.1			-1.4	3.2			
1992 1993	7.4 7.5	-4.8 29.9	39.1 7.8		7.5 8.3			9.5 3.0	8.7 5.1	 4.0	 -0.3	
1994	9.0	12.3	7.3		9.1			2.2	5.0	5.2	0.7	
	3.6	11.4	21.7		4.3			8.9	7.0	-2.9	7.6	
1995	-0.3	-3.0	18.7		0.1			4.9	2.9	9.9	10.2	
1996	-1.1	24.0 13.2	4.1 31.7		0.2 8.3			-1.7 9.1	-1.0 8.8	-14.1 12.8	-13.6 14.2	
1995 1996 1997 1998	7.1	11.6	15.6		7.2			9.9	8.8	9.4	6.5	
1996 1997	7.1 6.6		35.0		13.1			13.1	13.1	-0.9	-4.5	
1996 1997 1998 1999		38.1			14.2			7.7	10.3	-1.6	1.5	
1996 1997 1998 1999 2000 2001	6.6 10.4 14.5	15.4	8.8					15.8	14.0	2.8	1.6	
1996 1997 1998 1999 2000 2001 2002	6.6 10.4 14.5 11.0		8.8 19.8 -4.5		11.5			9.9	8.8	-1.7	-5.3	
1996 1997 1998 1999 2000 2001 2002 2003	6.6 10.4 14.5	15.4 11.4	19.8		11.5							
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005	6.6 10.4 14.5 11.0 7.9 3.6 1.7	15.4 11.4 5.6 -5.4 -0.7	19.8 -4.5 -3.6 2.1		11.5 7.1 2.6 1.6			9.9 3.2 7.9	8.8 2.9 5.4	-1.7 1.1 -4.1	-5.3 0.4 -5.4	
1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006	6.6 10.4 14.5 11.0 7.9 3.6 1.7 0.4	15.4 11.4 5.6 -5.4 -0.7 -4.8	19.8 -4.5 -3.6 2.1 -0.1		11.5 7.1 2.6 1.6 0.1			9.9 3.2 7.9 4.4	8.8 2.9 5.4 2.8	-1.7 1.1 -4.1 8.4	-5.3 0.4 -5.4 1.5	
1996 1997 1998	6.6 10.4 14.5 11.0 7.9 3.6 1.7	15.4 11.4 5.6 -5.4 -0.7	19.8 -4.5 -3.6 2.1		11.5 7.1 2.6 1.6			9.9 3.2 7.9	8.8 2.9 5.4	-1.7 1.1 -4.1	-5.3 0.4 -5.4	

		•	on Drugs per Cap alth Expenditures		•			
_	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price Index – Canada	
			(\$ per Capi	ita)			(1997 = 100)	
	35.23	185.85	221.08	1,016.34	340.16	1,356.50	73.6	
	42.28	138.46	180.75	1,115.18		1,409.34	75.6	
	48.86	152.59	201.45	1,205.91		1,532.79	79.2	
	52.48 57.04	158.33 164.05	210.81 221.09	1,276.14 1,366.63		1,618.95 1,720.39	82.8 86.6	
	64.87 73.83	171.22 178.73	236.09 252.56	1,515.29 1,562.86		1,896.84 1,989.99	89.2 91.6	
	80.30	192.14	272.44	1,600.38		2,064.37	92.8	
	88.12	200.04	288.16	1,594.84		2,084.83	94.1	
	97.12	207.33	304.44	1,650.45	524.20	2,174.65	95.2	
	103.58	225.50	329.08	1,714.87		2,237.14	97.4	
	105.37	244.12	349.49	1,740.60		2,238.91	99.0	
	106.67 115.01	232.18 255.52	338.85 370.54	1,852.68 2,051.73		2,368.53 2,652.03	100.0 99.6	
	125.36	283.85	409.21	2,344.87		2,964.36	101.4	
	146.98 169.91	318.50 340.09	465.48 510.00	2,497.29 2,711.82		3,191.26 3,450.70	105.5 106.9	
	191.20	340.05	575.92	2,907.60		3,706.44	108.1	
	210.29	421.13	631.42	3,071.16	905.01	3,976.16	111.2	
	221.14	443.14	664.27	3,150.95	980.77	4,131.72	114.1	
	231.52	479.42	710.95	3,281.27	1,067.26	4,348.53	117.6	
	237.28	512.98	750.25	3,501.37		4,577.92	120.5	
	248.66	557.55	806.21	3,787.89		4,939.67	124.3	
	297.21	598.71	895.92 (A n	4,162.29 nual Percentage Cha		5,394.83	128.6	
	20.0 15.6	-25.5 10.2	-18.2 11.5	9.7 8.1	-13.5 11.1	3.9 8.8	2.8 4.7	
	7.4	3.8	4.6	5.8		5.6	4.5	
	8.7	3.6	4.9	7.1	3.2	6.3	4.6	
	13.7	4.4	6.8	10.9	7.9	10.3	3.0	
	13.8	4.4	7.0	3.1	11.9	4.9	2.8	
	8.8	7.5	7.9	2.4		3.7	1.3	
	9.7	4.1	5.8	-0.3		1.0	1.4	
	10.2	3.6	5.6	3.5	7.0	4.3	1.1	
	6.7	8.8	8.1	3.9		2.9	2.3	
	1.7 1.2	8.3 -4.9	6.2 -3.0	1.5 6.4		0.1 5.8	1.7 1.0	
	7.8	10.1	9.4	10.7	16.4	12.0	-0.4	
	9.0	11.1	10.4	14.3		11.8	1.8	
	17.2	12.2	13.7	6.5	12.0	7.7	4.1	
	15.6	6.8	9.6	8.6		8.1	1.4	
	12.5	13.1	12.9	7.2		7.4	1.0	
	10.0	9.5	9.6	5.6		7.3	2.9	
	5.2	5.2	5.2	2.6	8.4	3.9	2.6	
	4.7	8.2	7.0	4.1	8.8	5.2	3.1	
	2.5 4.8	7.0 8.7	5.5 7.5	6.7 8.2	0.9 7.0	5.3 7.9	2.4 3.2	
	4.8 19.5	8.7 7.4	7.5	8.2		7.9 9.2	3.2	
	10.0		ge Change in Excess of I				0	
	 17.2	 -28.3		 6.9	 -16.3	 1.1		
	10.8	5.5	6.7	3.4		4.0		
	2.9	-0.8	0.1	1.3	0.4	1.1		
	4.1	-1.0	0.3	2.5	-1.4	1.7		
	10.7	1.3	3.8	7.9	4.8	7.2		
	11.1	1.6	4.2	0.4	9.2	2.2		
	7.5	6.2	6.6	1.1		2.5		
	8.3	2.7 2.5	4.3	-1.8 2.4		-0.4 3.2		
	9.1		4.6					
	4.3	6.4	5.8	1.6		0.5		
	0.1	6.6 -5.9	4.5 -4.0	-0.2		-1.6 4.8		
	8.3	-5.9	9.8	11.2		4.8		
	7.2	9.3	8.6	12.5		10.0		
	13.1	8.1	9.6	2.4		3.6		
	13.1	5.4	9.6	2.4		3.b 6.8		
	11.5	12.1	11.9	6.2	7.1	6.4		
	7.1	6.6	6.7	2.7		4.4		
	2.6	2.6	2.6	0.0	5.8	1.3		
	1.6	5.1	3.9	1.0		2.1		
		4.6	3.1	1 2	-1.5	2.9		
	0.1			4.3				
	0.1 1.6 16.1	5.5 4.0	4.2	4.3 5.0 6.5	3.8	4.7		

N.L.

					Prescrib	ed Drugs				Non	Prescribed Dru	ugs
	Provincial	Federal	Public Social Secu WCB	urity Funds Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Priva Over- the- Counter	te (Out-of-Poc Personal Health Supplies	ket) Tot Non-Pr Dru
r				Fund		(ś Mi	llions)			Drugs		
5	1.7	0.8	0.0		2.5			19.5	22.0			
6	2.1	0.8	0.0		3.1			12.9	16.0			
7	3.5	1.0	0.1		4.6			10.2	14.7			
8	4.6	0.6	0.1		5.3			12.4	17.7			
9	5.5	0.5	0.1		6.0			15.0	21.0			
)	6.5 7.4	0.6	0.1 0.1		7.3			18.0	25.3			
1 2	7.4	0.7 0.7	0.1		8.2 8.6			17.1 18.8	25.3 27.5	8.6	7.8	
3	7.5	0.8	0.3		8.6			21.8	30.5	9.0	8.4	
1	7.7	0.9	0.3		8.9			23.8	32.8	9.2	8.7	
	8.5	1.0	0.4		9.8			28.4	38.3	8.5	8.3	
	8.5	1.0	0.4		9.8			29.7	39.5	6.8	6.3	
7	9.1	1.0	0.4		10.6			28.8	39.4	7.1	6.9	
8 9	10.4 12.0	1.2 1.4	0.5 0.6		12.2 13.9			33.0 33.6	45.1 47.6	8.6 9.1	8.5 8.5	
D 1	14.0 15.7	2.3 2.7	0.7 0.8		17.0 19.1			36.0 43.0	53.0 62.2	8.8 9.7	8.0 8.4	
	16.9	2.7	0.8		20.3			43.0 38.1	58.4	9.7	8.4 9.0	
3	18.4	2.9	0.7		22.0			43.7	65.7	10.6	9.0	
4	19.9	2.9	0.7		23.4			47.8	71.2	10.7	8.9	
5	22.3	2.9	0.7		25.9			52.2	78.1	10.2	8.4	
6	24.2	2.8	0.8		27.8			56.8	84.6	10.6	8.8	
f	27.4	2.9	0.9		31.2			62.4	93.6	11.3	9.0	
f	31.4	2.9	0.9		35.2			67.4	102.6	11.8	9.4	
						(Annual Perce	ntage Change)					
	27.8	16.1	44.0		24.4			-34.1	-27.5			
,	63.7	12.6	39.7		48.5			-21.0	-7.6			
3	32.4	-40.9	20.2		16.1			21.5	19.8			
	17.9	-17.4	0.9		13.7			21.5	19.1			
	19.8	30.7	20.5		20.7			19.8	20.1			
	13.5	7.0	-0.4		12.7			-4.7	0.3			
	2.5 -1.7	-4.5	218.0 -13.7		5.2 -0.3			10.0 15.9	8.5 10.8		7 0	
3 1	-1.7 2.8	24.8 12.0	-13.7		-0.3			9.2	7.6	4.9 1.7	7.8 3.7	
	10.2 0.0	8.6 -3.8	9.8 4.4		10.0 -0.2			19.2 4.3	16.7 3.2	-7.1 -20.6	-5.1 -24.1	
	7.4	8.3	14.7		7.8			-3.0	-0.3	5.4	9.2	
	14.6	16.2	21.0		15.1			14.5	14.6	21.2	23.2	
	14.7	14.0	11.9		14.5			2.0	5.4	5.7	0.1	
)	16.8	66.4	26.3		22.1			7.2	11.6	-3.7	-6.0	
	12.4	16.8	4.4		12.6			19.4	17.2	10.0	5.3	
2	7.7	0.7	-9.4		6.0			-11.5	-6.1	7.4	7.2	
3	9.2 7.7	6.4 0.4	-1.6 -2.8		8.4 6.5			14.8 9.3	12.6 8.3	2.1 1.0	-0.1 -0.6	
	12.4	-0.1	7.6		10.7			9.3	9.8	-5.0	-6.4	
6 / f	8.2 13.5	-1.4 1.8	9.7 7.0		7.1 12.1			8.8 10.0	8.2 10.7	4.6 5.8	5.0 2.2	
f	14.7	-1.0	8.2		13.0			7.9	9.6	4.4	4.4	
					-							
						ercentage Share of 1						
5	5.1 7.6	2.3 3.2	0.1		7.6 11.0			59.7 45.9	67.3 56.9			
5 7	7.6	3.2 3.5	0.2		15.9			45.9 35.3	56.9			
3	15.7	2.0	0.3		18.1			42.0	60.0			
9	17.6	1.6	0.3		19.6			48.5	68.1			
D	18.2	1.8	0.3		20.3			50.1	70.4			
	19.1	1.8	0.3		21.2			44.1	65.2			
2	17.3	1.5	0.9		19.7			42.9	62.6	19.6	17.8	
3	15.6	1.7	0.7		18.0			45.6	63.6	18.8	17.6	
4	15.2	1.8	0.7		17.6			47.1	64.7	18.1	17.2	
	15.4	1.8	0.7		17.8			51.6	69.5	15.5	15.1	
6 7	16.1	1.8	0.7		18.7			56.5	75.1	12.9	12.0	
	17.0 16.8	1.9 1.9	0.8 0.9		19.8 19.5			54.0 53.0	73.8 72.5	13.4 13.9	12.9 13.6	
3	18.4	2.1	0.9		21.4			53.0	73.0	14.0	13.0	
)	20.0 19.6	3.3	1.1 1.0		24.4 23.9			51.6 53.6	76.0 77.5	12.6 12.1	11.4 10.5	
2	19.6	3.3 3.5	1.0		23.9			53.6 49.0	77.5	12.1	10.5 11.6	
3	21.7	3.4	0.8		25.8			51.2	77.0	12.4	10.5	
	21.9	3.2	0.7		25.8			52.6	78.4	11.8	9.8	
5	23.1	3.0	0.8		26.8			54.0	80.8	10.5	8.6	
	23.2	2.7	0.8		26.7			54.6	81.3	10.2	8.4	
f	24.1	2.5	0.8		27.4			54.9	82.2	9.9	7.9	
f	25.4	2.3	0.7		28.5			54.5	82.9	9.5	7.6	

	E			, by Source of Fina tures, Prince Edwa			lic, Private and	able B P.E.	. — I otal
-		All Drugs		Healt	h Expenditure		Share of Drugs Total Hea	in Public, Private a Ith Expenditures	
	Public	Private	Total	Public	Private	Total	Public	Private	Total
-			(\$ Millio	ns)			(Perce	ntage Share)	
	2.5	30.2	32.7	128.3	52.9	181.2	1.9	57.1	18.0
	3.1	25.0	28.0	138.0	49.6	187.6	2.2	50.3	15.0
	4.6 5.3	24.2 24.1	28.8 29.4	149.7 163.0	53.3 56.5	202.9 219.5	3.1 3.3	45.4 42.6	14.2 13.4
	6.0	24.9	30.9	174.4	64.9	239.3	3.5	38.3	12.9
	7.3	28.6	35.9	186.3	70.0	256.2	3.9	40.9	14.0
	8.2	30.6	38.8	203.8	76.8	280.6	4.0	39.9	13.8
	8.6	35.2	43.9	209.2	85.8	295.0	4.1	41.1	14.9
	8.6 8.9	39.3 41.8	47.9 50.7	218.2 217.0	93.5 96.7	311.7 313.7	4.0 4.1	42.0 43.2	15.4 16.2
	9.8 9.8	45.2 42.7	55.1 52.5	222.8 233.0	104.6 106.1	327.4 339.1	4.4 4.2	43.2 40.3	16.8 15.5
	10.6	42.8	53.4	229.9	110.4	340.3	4.6	38.8	15.7
	12.2	50.1	62.2	245.5	115.9	361.4	5.0	43.2	17.2
	13.9	51.2	65.2	259.0	119.7	378.7	5.4	42.8	17.2
	17.0	52.8	69.8	278.1	123.7	401.8	6.1	42.7	17.4
	19.1 20.3	61.1 57.5	80.2 77.7	329.0 366.8	147.5 139.8	476.4 506.5	5.8 5.5	41.4 41.1	16.8 15.3
	20.3	63.3	85.3	381.2	161.3	542.5	5.8	39.3	15.7
	23.4	67.4	90.8	377.6	162.3	539.8	6.2	41.5	16.8
	25.9	70.7	96.7	414.8	163.2	578.0	6.3	43.3	16.7
	27.8	76.2	104.0	435.8	178.3	614.1	6.4	42.7	16.9
	31.2 35.2	82.7 88.5	113.8 123.7	473.3 516.2	191.4 204.8	664.7 720.9	6.6 6.8	43.2 43.2	17.1 17.2
	35.2	66.5	123.7	510.2	204.8	720.5	0.8	43.2	17.2
_			(Annual Percenta	ige Change)					
	24.4	-17.3	-14.2	7.6	-6.3	3.5			
	48.5	-3.1	2.6	8.5	7.4	8.2			
	16.1 13.7	-0.3 3.1	2.3 5.0	8.9 7.0	6.2 14.8	8.2 9.0			
	20.7 12.7	14.9 7.2	16.0 8.3	6.8 9.4	7.7 9.8	7.0 9.5			
	5.2	15.1	13.0	2.7	11.6	5.1			
	-0.3	11.4	9.1	4.3	9.0	5.7			
	3.5	6.3	5.8	-0.6	3.4	0.6			
	10.0	8.4	8.7	2.7	8.2	4.4			
	-0.2 7.8	-5.6 0.2	-4.6 1.6	4.6 -1.3	1.4 4.1	3.5 0.4			
	15.1	17.0	16.6	6.8	5.0	6.2			
	14.5	2.3	4.7	5.5	3.3	4.8			
	22.1	3.1	7.1	7.4	3.3	6.1			
	12.6	15.7	14.9	18.3	19.3	18.6			
	6.0 8.4	-6.0 10.2	-3.1 9.7	11.5 3.9	-5.2 15.4	6.3 7.1			
	6.5	6.5	6.5	-1.0	0.6	-0.5			
	10.7	5.0	6.4	9.9	0.6	7.1			
	7.1	7.7	7.6	5.1	9.2	6.2			
	12.1	8.5	9.4	8.6	7.4	8.2			
	13.0	7.0	8.7	9.1	7.0	8.5			
	(Percentag	e Share of Total D	rug Expenditure)						
-	7.6	92.4	100.0						
	11.0	89.0	100.0						
	15.9	84.1	100.0						
	18.1 19.6	81.9 80.4	100.0 100.0						
	20.3 21.2	79.7 78.8	100.0 100.0						
	19.7	80.3	100.0						
	18.0	82.0	100.0						
	17.6	82.4	100.0						
	17.8	82.2	100.0						
	18.7	81.3	100.0						
	19.8 19.5	80.2 80.5	100.0 100.0						
	21.4	78.6	100.0						
	24.4 23.9	75.6 76.1	100.0 100.0						
	23.9	73.9	100.0						
	25.8	74.2	100.0						
	25.8	74.2	100.0						
	26.8	73.2	100.0						
	26.7	73.3	100.0						
	27.4 28.5	72.6 71.5	100.0 100.0						
	20.0	/1.5	100.0						

Table B P.E.I. – Per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2008 Prescribed Drugs Non-Prescribed Drugs Public Private Private (Out-of-Pocket) Social Security Funds WCB Drug Provincial Federal Subtotal Insurers* Out-of-Subtotal Total Over Personal Total Pocket Prescribed Health Drug Public Private the-Non-Presc Insurance Drugs Counte Supplies Drugs Fund Drugs (\$ per Capita) 'ea 1985 13.08 6.01 6.94 0.33 19.42 152.95 172.37 83.63 16.61 27.17 0.47 24.02 100.25 124.27 94.14 986 1987 7.80 0.66 35.62 79.09 114.72 109.04 1988 35.77 4.59 0.79 41.15 95.54 136.69 90.98 1989 41.92 3.77 0.79 ----46.48 --------115.34 161.82 --------75.86 1990 50.03 4.91 0.95 55.88 137.70 193.59 81.26 56.89 58.12 5.26 5.01 0.94 63.09 66.12 131.41 144.08 194.50 210.20 103.63 125.41 1991 ----1992 65.73 59.68 1993 56.53 6.18 2.56 65.27 --------165.28 230.55 68.24 63.70 131.94 57.56 2.49 134.19 1994 6.86 66.91 178.75 245.65 68.75 65.44 1995 284.62 125.04 62.95 7.39 2.72 73.06 --------211.56 63.37 61.67 1996 62.35 7.04 2.81 72.20 218.51 290.71 49.84 46.35 96.19 1997 66.82 7.61 3.21 ----77.64 --------211.50 289.13 52.38 50.46 102.85 1998 76.76 8.86 3.90 89.52 ----242.67 332.19 63.65 62.32 125.97 1999 87.75 10.07 4.35 102.17 246.71 348.88 67.05 62.19 129.24 58.37 61.36 2000 102.36 16.74 5.48 124.58 -------264.09 388.67 64.46 122.84 70.80 132.16 2001 114.85 19.53 5.72 140.10 314.79 454.89 2002 123.41 19.63 5.17 148.21 278.01 426.22 75.90 65.64 141.54 2003 134.35 20.82 5.08 160.24 318.33 478.57 77.29 65.36 142.65 2004 144.18 20.83 4.91 169.92 -------346.45 516.37 77.74 64.73 142.46 161.68 20.75 5.28 187.71 377.81 565.52 73.65 60.47 134.12 2005 2006 175.09 20.48 5.79 ----201.36 --------411.36 612.72 77.15 63.58 140.73 2007 197.80 20.76 6.17 ----224.73 450.38 675.12 81.25 64.67 145.91 2008 226.00 20.49 6.65 253.14 484.16 737.30 84.48 67.24 151.72 (Annual Percentage Change) 1985 27.0 63.5 1986 15.4 43.2 23.7 -----34.5 -27.9 ----12.6 ----1987 12.4 -21.1 39.5 48.3 -7.7 15.8 1988 31.7 -41.2 19.5 15.5 --------20.8 19.2 ---------16.6 1989 17.2 -17.9 0.3 13.0 20.7 -16.6 18.4 1990 19.3 20.1 20.2 30.2 19.4 19.6 7.1 ----27.5 1991 13.7 7.2 -0.2 12.9 -----4.6 0.5 -4.8 1992 2.2 216.8 ----4.8 9.6 8.1 21.0 6.7 3.8 23.5 1993 -2.7 -14.6 -1.3 14.7 9.7 5.2 1994 1.8 10.9 -2.4 2.5 --------8.1 6.6 0.8 2.7 1.7 1995 94 7.8 -4.7 9.0 9.2 -1.2 --------18.4 15.9 -78 -5.8 -6.8 -----0.9 -24.8 1996 3.4 3.3 2.1 -21.4 -23.1 1997 7.2 8.0 14.4 7.5 ---------3.2 -0.5 5.1 8.9 6.9 1998 14.9 21.3 ----14.9 23.5 22.5 16.5 14.7 21.5 15.3 1999 14.3 13.6 11.5 14.1 --------1.7 5.0 5.3 -0.2 2.6 2000 21.9 16.7 66.2 26.2 --------7.0 11.4 -3.9 -6.1 -5.0 12.2 16.7 4.3 ----19.2 7.6 2001 12.5 17.0 9.8 5.1 2002 7.5 0.5 -9.6 5.8 ---------11.7 -6.3 7.2 7.0 7.1 2003 8.9 6.1 -1.8 ----8.1 14.5 12.3 -0.4 0.8 1.8 2004 7.3 0.0 -3.2 ----6.0 --------8.8 7.9 0.6 -1.0 -0.1 2005 12.1 -0.3 7.4 ----10.5 --------9.1 9.5 -5.3 -6.6 -5.9 2006 8.3 -1.3 9.8 ----7.3 8.9 8.3 4.7 5.1 4.9 13.0 2007 1 1.4 6.6 ----11.6 --------9.5 10.2 5.3 1.7 3.7 2008 14.3 -1.3 7.8 12.6 7.5 4.0 4.0 4.0 9.2 al Percentage Change in Excess of Inflation in the Ca idian Econ (Anr 1985 ----24.2 58.8 1986 12.6 40.4 20.9 -37.3 -30.7 ----9.8 -----12.4 11.1 1987 34.8 43.6 -25.8 7.7 1988 27.2 12.6 -45.7 15.0 ----11.0 ----16.3 16.2 14.6 -21.1 -22.4 -21.2 13.8 1989 8.4 -----4.3 1990 16.3 27.2 17.1 ----17.2 ----16.4 16.6 --------4.1 1991 10.9 4.4 -3.0 10.1 -----7.3 -2.3 ----24.8 215.6 0.9 -6.1 8.4 6.8 19.8 1992 3.5 2.4 5.3 1993 -4.2 22.1 -16.1 -2.7 13.3 8.2 3.8 1994 0.7 1.4 7.0 -0.3 0.6 9.8 -3.5 5.5 1.6 1995 7.0 -2.6 5.5 -6.4 6.7 1.7 6.9 --------16.0 13.5 -10.2 -8.1 -9.2 -24.7 -26.5 1996 -2.8 1.6 0.5 -23.0 1997 6.2 7.1 16.9 13.4 21.7 6.5 -----4.2 -1.5 4.1 7.9 5.9 15.3 ----21.9 23.9 22.9 15.7 15.2 1998 15.3 1999 12.5 11.8 9.7 12.3 ---------0.1 3.2 3.5 -2.0 0.8 12.5 17.8 -9.1 2000 62.1 22.1 --------2.9 7.3 -8.0 -10.2 6.2 10.8 11.1 ----17.8 2001 15.3 3.0 15.7 8.5 3.8 2002 6.4 -0.6 -10.6 4.7 -12.7 -7.3 6.1 5.9 6.1 5.2 3.5 2003 6.0 3.2 4.7 --------11.6 9.4 5.3 -1.1 -3.3 -2.1 4.7 -2.5 -5.8 -3.6 -2.7 2004 6.2 -2.0 2005 9.0 -3.5 4.3 7.4 5.9 6.4 -8.4 -9.0 -9.7 2006 5.9 -3.7 7.4 4.9 6.5 5.9 2.3 2.7 2.5 2007 1 9.7 -1.8 -4.7 3.4 8.4 6.3 7.0 0.5 ----2.1 -1.5 10.8 4.3 0.6 0.6 0.6 2008 1 9.2 4.1 5.8 forecast * Note: Confidentiality precludes reporting provincial-level insurance data. Source: NHEX, CIHI, 2008.

P.E.I.

		•	• •		by Source of Fir dward Island, 1		olic, Private and	B P.E.I.—Per Cap
-	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price Index – Canada	
			(\$ per C	apita)			(1997 = 100)	
	19.42	236.58	256.00	1,004.7	4 414.66	1,419.40	73.6	
	24.02	194.39	218.41	1,074.5		1,460.70	75.6	
	35.62 41.15	188.13 186.53	223.76 227.67	1,164.1 1,260.7		1,578.34 1,698.12	79.2 82.8	
	46.48	191.20	237.68	1,340.8		1,840.01	86.6	
	55.88	218.96	274.84	1,426.8	3 535.91	1,962.74	89.2	
	63.09	235.04	298.14	1,563.8		2,153.50	91.6	
	66.12	269.50	335.62	1,599.5		2,255.45	92.8	
	65.27 66.91	297.22 312.94	362.49 379.85	1,651.4 1,626.4		2,358.94 2,351.09	94.1 95.2	
	73.06	336.60	409.66				97.4	
	73.06	336.60	386.90	1,657.7 1,716.3		2,436.16 2,497.61	97.4 99.0	
	77.64	314.34	391.98	1,689.1		2,500.34	100.0	
	89.52	368.63	458.15	1,807.7		2,660.92	99.6	
	102.17	375.95	478.12	1,900.3		2,778.63	101.4	
	124.58	386.93	511.51	2,037.8		2,943.87	105.5	
	140.10 148.21	446.95 419.55	587.05 567.76	2,407.0 2,678.4		3,485.98 3,699.16	106.9 108.1	
	160.24	460.98	621.22	2,078.4		3,950.30	111.2	
	169.92	488.91	658.83	2,738.7		3,915.68	114.1	
	187.71	511.94	699.64	3,001.4	1 1,181.22	4,182.63	117.6	
	201.36	552.09	753.45	3,157.2		4,448.80	120.5	
	224.73 253.14	596.30 635.88	821.03 889.02	3,414.0 3,710.2		4,794.72 5,181.99	124.3 128.6	
	233.14	000.00		Annual Percentage Cl		3,101.33	120.0	
	23.7	-17.8	-14.7	7.		2.9	2.8	
	48.3 15.5	-3.2 -0.9	2.4 1.7	8. 8.		8.1 7.6	4.7 4.5	
	13.0	2.5	4.4	6.		8.4	4.6	
	20.2	14.5	15.6	6.		6.7	3.0	
	12.9	7.3	8.5	9.		9.7	2.8	
	4.8	14.7	12.6	2.		4.7	1.3	
	-1.3 2.5	10.3 5.3	8.0 4.8	3. -1.		4.6 -0.3	1.4 1.1	
	9.2 -1.2	7.6 -6.5	7.8 -5.6	1. 3.		3.6 2.5	2.3 1.7	
	7.5	-0.1	1.3	-1.		0.1	1.0	
	15.3	17.3	16.9	7.		6.4	-0.4	
	14.1	2.0	4.4	5.	1 2.9	4.4	1.8	
	21.9	2.9	7.0	7.		5.9	4.1	
	12.5 5.8	15.5 -6.1	14.8 -3.3	18. 11.		18.4 6.1	1.4 1.0	
	8.1	9.9	9.4	3.		6.8	2.9	
	6.0	6.1	6.1	-1.		-0.9	2.6	
	10.5	4.7	6.2	9.	6 0.4	6.8	3.1	
	7.3	7.8	7.7	5.	2 9.3	6.4	2.4	
	11.6	8.0	9.0	8.		7.8	3.2	
	12.6	6.6	8.3	8.		8.1	3.4	
—		(Annual Percenta	age Change in Excess o	f Inflation in the Can	adian Economy)			
	20.9	-20.6	-17.5	4.	1 -9.7	0.1		
	43.6	-8.0	-2.3	3.		3.3		
	11.0 8.4	-5.4 -2.1	-2.8 -0.2	3. 1.		3.1 3.8		
	17.2 10.1	11.5 4.6	12.6 5.7	3. 6.		3.6 7.0		
	3.5	13.4	11.3	1.		3.5		
	-2.7	8.8	6.6	1.		3.1		
	1.4	4.2	3.7	-2.		-1.4		
	6.9	5.2	5.5	-0.		1.3		
	-2.8 6.5	-8.2 -1.1	-7.2 0.3	1. -2.		0.9 -0.9		
	15.7	17.7	17.3	-2. 7.		-0.9		
	12.3	0.2	2.5	3.		2.6		
	17.8	-1.2	2.9	3.	1 -1.0	1.8		
	11.1	14.2	13.4	16.	8 17.7	17.1		
	4.7	-7.2	-4.3	10.		5.1		
	5.2 3.5	7.0 3.5	6.5 3.5	0. -3.		3.9 -3.5		
	7.4					3.7		
	7.4	1.6 5.4	3.1 5.3	6. 2.		3.7 3.9		
	8.4	4.8	5.7	4.	9 3.7	4.6		
	9.2	3.2	4.9	5.	3 3.2	4.7		

P.E.I.

		LAPE			y Type, by So Health Expen	ditures, Nova						
					-	ed Drugs				Non-	Prescribed Dr	ugs
			Public				Private				te (Out-of-Poo	
	Provincial	Federal	Social Secu WCB	Drug Insurance	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Pres Drugs
ar				Fund		(\$ Mi	llions)			Drugs		
85	45.5	2.3	0.2		48.0			38.7	86.7			6
86	53.1	2.4	0.2		55.7			59.6	115.3			6
87 88	62.3 72.2	2.6 3.4	0.2		65.1 76.0			67.7 74.8	132.8 150.8			8
89	82.1	4.2	0.3		86.6			82.5	169.1			7
90	83.0	5.0	0.3		88.3			96.0	184.2			7
91	83.0	5.6	0.5		89.1			106.2	195.3			ε
92	89.0	5.9	0.5		95.4			118.4	213.8	48.7	44.3	9
93 94	88.5 83.2	6.8 7.3	0.6 0.6		95.9 91.1			132.7 137.8	228.6 228.9	51.3 51.8	47.9 49.3	9 10
95	83.9	8.9	0.7		93.5			148.7	242.2	47.8	46.5	9
96	83.3	8.4	0.7		92.5			159.4	251.8	53.8	50.0	10
97	86.8	9.8	0.7		97.3			170.5	267.9	49.2	47.4	9
98 99	99.5 110.7	14.4 14.8	0.8 1.1		114.7 126.5			198.7 201.5	313.4 328.0	54.8 55.5	53.7 51.5	10 10
00	117.3	18.8	1.4		137.4			227.3	364.7	55.3	50.1	10
01	128.7	22.3	1.9		152.9			247.5	400.4	60.5	52.4	11
02	140.8	24.2	2.2		167.2			282.2	449.5	64.6	55.9	12
)3)4	156.2 170.0	25.9 26.4	2.5 3.0		184.6 199.4			299.5 324.5	484.1 523.9	68.7 72.1	58.1 60.0	1:
	186.1	27.4	3.4		216.8			359.9	576.7	71.6	58.8	13
05 06	231.8	34.7	4.8		271.3			396.8	668.1	74.1	61.0	13
07 f	249.2	36.5	5.6		291.3			436.6	727.8	81.3	64.7	14
08 f	288.7	41.1	6.5		336.3			472.8	809.1	86.1	68.6	15
						(Annual Perce	ntage Change)					
35												
86 87	16.7 17.2	3.8 8.3	16.4 4.2		16.1 16.8			54.0 13.6	33.0 15.1			
38	16.0	32.7	48.7		16.8			10.4	13.5			
89	13.7	21.9	-7.8		14.0			10.4	12.2			
0	1.0	20.1	6.4		1.9			16.3	8.9			
91 92	0.1 7.2	12.4 5.3	41.5 2.6		0.9 7.1			10.6 11.5	6.0 9.5			1
93	-0.5	15.4	20.2		0.6			12.1	6.9	5.2	8.1	
94	-6.0	6.6	6.1		-5.0			3.9	0.1	1.0	3.0	
95	0.8	21.6	15.7		2.6			7.9	5.8	-7.8	-5.7	-
96 97	-0.7 4.2	-5.0 16.2	5.2 -1.0		-1.1 5.3			7.2 7.0	4.0 6.4	12.7 -8.6	7.7 -5.4	1
98	4.2	47.4	16.2		17.9			16.5	17.0	11.6	13.4	1
99	11.3	2.5	27.0		10.3			1.4	4.7	1.2	-4.1	
00	5.9	27.1	28.6		8.6			12.8	11.2	-0.3	-2.7	
01 02	9.8 9.4	18.6 8.6	39.0 18.0		11.3 9.4			8.9 14.0	9.8 12.2	9.3 6.8	4.6 6.6	
03	10.9	7.0	12.3		10.4			6.1	7.7	6.4	4.0	
04	8.8	2.0	19.2		8.0			8.4	8.2	4.9	3.3	
05	9.5	3.7	12.0		8.7			10.9	10.1	-0.7	-2.1	
06	24.6	26.9	41.6		25.1			10.2	15.8	3.4	3.8	
07 f 08 f	7.5 15.8	5.0 12.8	17.6 15.2		7.3 15.5			10.0 8.3	8.9 11.2	9.8 6.0	6.0 6.0	
					(D		atal Dava Eva	n diture)				
85	30.8	1.5	0.1		32.5	ercentage Share of 1	otal Drug Expe	26.2	58.7			4
36	28.8	1.3	0.1		30.2			32.3	62.5			:
37	29.2	1.2	0.1		30.5			31.8	62.3			3
38 39	31.5 33.3	1.5 1.7	0.1 0.1		33.1 35.1			32.5 33.4	65.6 68.5			3
90 91	31.5 30.1	1.9 2.0	0.1		33.5 32.3			36.4 38.5	69.9 70.8			3
92	29.0	1.9	0.2		31.1			38.6	69.7	15.9	14.4	3
93 94	27.0 25.2	2.1 2.2	0.2		29.3 27.6			40.5 41.8	69.8 69.4	15.6 15.7	14.6 14.9	3
95 96	24.9 23.4	2.6 2.4	0.2		27.8 26.0			44.2 44.8	72.0 70.8	14.2 15.1	13.8 14.1	2
97	23.8	2.7	0.2		26.7			46.8	73.5	13.5	13.0	2
98	23.6	3.4	0.2		27.2			47.1	74.3	13.0	12.7	2
99	25.4	3.4	0.2		29.1			46.3	75.4	12.8	11.8	2
DO D1	24.9 25.1	4.0 4.3	0.3 0.4		29.2 29.8			48.4 48.2	77.6 78.0	11.8	10.7 10.2	2
02	25.1	4.3	0.4		29.8			48.2	78.0	11.8 11.3	9.8	2
03	25.6	4.2	0.4		30.2			49.0	79.2	11.3	9.5	2
04	25.9	4.0	0.5		30.4			49.5	79.9	11.0	9.2	2
05	26.3	3.9	0.5		30.7			50.9	81.6	10.1	8.3	1
06	28.9 28.5	4.3 4.2	0.6 0.6		33.8 33.3			49.4 50.0	83.2 83.3	9.2 9.3	7.6 7.4	1
07 f												

N.S.

					to 2008 (cont'd		in Public, Private ar	nd
Public	All Drugs Private	Total	Heal Public	Ith Expenditure Private	Total	Total Hea	Alth Expenditures Private	Total
		(\$ Millio	ns)			(Perce	entage Share)	
48.0	99.8	147.8	947.2	285.3	1,232.5	5.1	35.0	12.0
55.7	128.8	184.5	1,023.2	353.7	1,376.9	5.4	36.4	13.4
65.1 76.0	147.9 153.7	213.0 229.7	1,165.5 1,165.0	395.0 420.3	1,560.6 1,585.2	5.6 6.5	37.4 36.6	13.6 14.5
86.6	160.2	246.8	1,281.5	470.3	1,751.8	6.8	34.1	14.1
88.3	175.3	263.5	1,376.6	490.4	1,866.9	6.4	35.7	14.1
89.1	186.8	275.9	1,451.2	518.8	1,970.0	6.1	36.0	14.0
95.4	211.4	306.8	1,477.0	554.5	2,031.6	6.5	38.1	15.1
95.9 91.1	231.8 238.9	327.7 330.0	1,445.5 1,413.1	579.5 610.2	2,025.0 2,023.4	6.6 6.4	40.0 39.1	16.2 16.3
93.5								
93.5	242.9 263.2	336.4 355.7	1,440.0 1,438.2	621.3 650.8	2,061.3 2,089.0	6.5 6.4	39.1 40.4	16.3 17.0
97.3	267.1	364.4	1,669.3	694.5	2,363.8	5.8	38.5	15.4
114.7	307.2	421.9	1,786.8	757.3	2,544.2	6.4	40.6	16.6
126.5	308.5	435.0	1,899.7	765.6	2,665.3	6.7	40.3	16.3
137.4	332.7	470.1	1,968.4	856.0	2,824.3	7.0	38.9	16.6
152.9 167.2	360.4 402.7	513.3 569.9	2,082.7 2,269.5	921.8 1,035.3	3,004.5 3,304.8	7.3 7.4	39.1 38.9	17.1 17.2
184.6	426.4	611.0	2,491.4	1,106.4	3,597.7	7.4	38.5	17.0
199.4	456.7	656.1	2,594.2	1,131.0	3,725.2	7.7	40.4	17.6
216.8	490.3	707.1	2,826.8	1,202.5	4,029.4	7.7	40.8	17.5
271.3	531.8	803.2	3,181.1	1,311.9	4,493.0	8.5	40.5	17.9
291.3 336.3	582.6 627.5	873.8 963.8	3,414.8 3,618.7	1,390.6 1,483.1	4,805.4 5,101.8	8.5 9.3	41.9 42.3	18.2 18.9
		(Annual Percenta						
16.1	29.1	24.9	8.0	24.0	11.7			
16.8	14.9	15.4	13.9	11.7	13.3			
16.8 14.0	3.9 4.2	7.8 7.5	-0.1 10.0	6.4 11.9	1.6 10.5			
1.9 0.9	9.4 6.6	6.8 4.7	7.4 5.4	4.3 5.8	6.6 5.5			
7.1	13.2	11.2	1.8	6.9	3.1			
0.6	9.6	6.8	-2.1	4.5	-0.3			
-5.0	3.1	0.7	-2.2	5.3	-0.1			
2.6	1.7	2.0	1.9	1.8	1.9			
-1.1 5.3	8.3 1.5	5.7 2.4	-0.1 16.1	4.7 6.7	1.3 13.2			
17.9	15.0	15.8	7.0	9.0	7.6			
10.3	0.4	3.1	6.3	1.1	4.8			
8.6	7.9	8.1	3.6	11.8	6.0			
11.3	8.3	9.2	5.8	7.7	6.4			
9.4 10.4	11.7 5.9	11.0 7.2	9.0 9.8	12.3 6.9	10.0 8.9			
8.0	7.1	7.4	4.1	2.2	3.5			
8.7	7.4	7.8	9.0	6.3	8.2			
25.1	8.5	13.6	12.5	9.1	11.5			
7.3 15.5	9.5 7.7	8.8 10.3	7.3 6.0	6.0 6.7	7.0 6.2			
(Percentage	e Share of Total Dr	ug Expenditure)						
32.5	67.5	100.0						
30.2	69.8	100.0						
30.5 33.1	69.5 66.9	100.0 100.0						
35.1	64.9	100.0						
33.5	66.5	100.0						
33.5	67.7	100.0						
31.1	68.9	100.0						
29.3	70.7	100.0						
27.6	72.4	100.0						
27.8	72.2	100.0						
26.0 26.7	74.0 73.3	100.0 100.0						
27.2	72.8	100.0						
29.1	70.9	100.0						
29.2	70.8	100.0						
29.8	70.2	100.0						
29.3	70.7	100.0						
30.2 30.4	69.8 69.6	100.0 100.0						
30.7	69.3	100.0						
30.7	66.2	100.0						
33.3	66.7	100.0						
34.9	65.1	100.0						

Table B N.S. – Per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2008 Prescribed Drugs Non-Prescribed Drugs Public Private Private (Out-of-Pocket) Social Security Funds WCB Drug Provincial Federal Subtotal Insurers* Out-of-Subtotal Total Over Personal Total Pocket Prescribed Health Drug Public Private the Non-Presci Insurance Drugs Counter Supplies Drugs Fund Drugs (\$ per Capita) /ear 1985 51.41 2.59 0.21 54.21 43.74 97.94 69.01 986 59.72 2.67 0.24 62.63 67.05 129.68 77.77 1987 69.69 2.88 0.25 72.82 75.80 148.61 89.77 1988 80.51 3.81 0.37 84.68 83.31 167.99 87.95 1989 90.89 4.61 0.34 95.83 --------91.30 187.13 --------85.92 1990 91.20 5.50 0.36 97.05 105.50 202.55 87.16 1991 1992 90.73 96.80 6.14 6.44 0.50 0.51 97.37 103.75 116.04 128.74 88.07 101.14 ----213.41 232.49 53.01 48.13 51.79 53.16 1993 95.81 7.39 0.61 ----103.82 143.56 247.38 55.48 107.28 1994 ----89.76 7.86 0.65 98.27 148.69 246.96 55.85 109.01 1995 90.40 100.69 160.23 260.92 101.52 9.54 0.75 ------------51.45 50.07 1996 89.46 9.03 0.78 99.28 171.12 270.39 57.77 53.72 111.49 1997 93.13 10.48 0.78 ----104.39 182.88 287.28 52.72 50.79 103.51 1998 106.74 15.46 0.90 123.11 --------213.19 336.30 58.85 57.63 116.48 1999 118.53 15.82 1.14 135.49 215.75 351.24 59.42 55.12 114.55 53.64 56.20 2000 125.55 20.11 1.47 ----147.13 243.42 390.56 59.24 112.88 --------2.05 2001 138.03 23.89 163.96 265.49 429.45 64.85 121.05 2002 150.66 25.89 2.41 178.95 302.01 480.96 69.13 59.79 128.92 2003 166.78 27.63 2.70 197.11 319.83 516.95 73.40 62.08 135.48 2004 181.22 28.16 3.21 ----212.59 --------346.01 558.60 76.87 64.01 140.88 2005 198.78 29.26 231.64 616.15 76.53 62.83 139.36 3.60 384.51 2006 247.92 37.16 5.11 ----290.18 424.33 714.52 79.20 65.26 144.46 2007 f 266.75 39.04 6.01 ----311.80 --------467.35 779.15 87.03 69.27 156.29 2008 1 308.43 43.96 6.91 359.30 505.20 864.50 92.04 73.26 165.30 (Annual Percentage Change) 1985 16.2 16.7 1986 3.3 15.8 ----15.5 ----53.3 32.4 ----12.7 1987 14.6 15.4 7.8 3.7 16.3 13.0 1988 15.5 32.1 48.1 ----16.3 --------9.9 13.0 -----2.0 1989 12.9 21.0 -8.5 13.2 ----9.6 11.4 -2.3 1990 0.3 15.6 1.4 19.3 5.8 1.3 8.2 ------------1991 -0.5 11.7 40.7 0.3 10.0 5.4 1.0 6.7 6.5 8.9 1992 4.8 2.1 ----10.9 14.8 ----7.6 4.7 6.1 1.6 1993 -1.0 14.8 19.7 0.1 11.5 6.4 1994 -6.3 6.3 5.7 -----5.3 ---3.6 -0.2 0.7 2.6 1995 0.7 21.4 15.6 ----2.5 -1.4 --------7.8 5.7 -7.9 -5.8 -6.9 ----6.8 3.6 12.3 1996 -1.0 -5.3 4.8 7.3 9.8 16.0 1997 4.1 -1.1 ----5.2 --------6.9 6.2 -8.7 -5.5 -7.2 14.6 47.5 16.3 --------13.5 12.5 1998 17.9 17.1 11.6 16.6 1999 11.0 2.3 26.7 10.1 1.2 4.4 1.0 -4.3 -1.7 -1.5 2000 5.9 27.1 28.5 ----8.6 --------12.8 11.2 -0.3 -2.7 9.9 18.8 39.3 ----11.4 7.2 2001 9.1 10.0 9.5 4.8 2002 9.1 8.4 17.7 ----9.1 --------13.8 12.0 6.6 6.4 6.5 2003 10.7 6.8 12.0 10.2 6.2 3.8 5.1 5.9 7.5 2004 8.7 1.9 19.0 ----7.9 --------8.2 8.1 4.7 3.1 4.0 2005 9.7 3.9 12.2 ----9.0 --------11.1 10.3 -0.5 -1.8 -1.1 2006 24.7 27.0 41.7 ----25.3 ----10.4 16.0 3.5 3.9 3.7 2007 7.6 5.1 17.7 ----7.4 --------10.1 9.0 9.9 6.1 8.2 2008 15.6 12.6 15.2 11.0 5.8 5.8 5.8 15.0 8.1 al Percentage Change in Excess of Inflation in the Ca dian Econor 1985 13.4 11.9 1986 0.5 13.0 12.7 50 5 29.6 --------99 1987 11.5 10.7 3.1 -1.0 8.3 9.9 1988 11.0 8.3 27.6 16.4 43.6 ----11.8 --------5.4 8.5 -----6.5 -6.9 -13.1 1989 ----5.0 6.8 8.6 1990 -2.7 16.3 2.7 -----1.8 ----12.5 5.2 ---------1.6 1991 -3.3 9.0 37.9 -2.4 --------7.2 2.6 -----1.7 1992 3.6 ----5.3 7.7 13.6 5.4 0.9 9.7 3.2 6.2 1993 -2.5 13.4 18.2 -1.4 10.1 5.0 4.6 1994 -7.4 -6.4 2.5 0.5 5.2 4.6 -1.3 -0.4 1.5 1995 -1.6 -2.7 19.1 -7.0 13.3 ----0.1 -3.1 --------5.4 5.1 3.3 2.0 -10.2 -8.2 -9.2 8.2 1996 3.1 10.6 5.6 1997 3.1 15.1 48.0 -2.1 16.7 ----4.2 --------5.9 17.0 5.3 17.5 -9.7 12.1 -6.5 13.9 -8.1 13.0 15.0 --------1998 18.4 1999 9.2 0.5 24.9 8.2 -----0.6 2.6 -0.8 -6.2 -3.5 8.7 -6.8 -5.6 2000 1.8 23.0 24.4 4.5 ----7.1 -4.4 ----37.9 7.7 2001 8.6 17.4 10.1 8.6 8.1 5.9 3.4 2002 8.1 7.3 16.7 8.1 12.7 10.9 5.6 5.3 5.5 3.9 -0.7 2003 7.8 9.1 7.3 5.3 ----3.0 4.6 3.3 0.9 2.2 6.1 16.4 2.1 0.5 1.4 2004 5.6 5.5 2005 6.6 0.8 9.1 5.9 8.0 7.2 -3.6 -4.2 -5.0 2006 22.3 24.6 39.3 22.9 7.9 13.6 1.1 1.5 1.2 2007 4.4 1.9 14.5 4.2 6.9 4.7 2.9 5.0 --------5.8 6.7 11.8 12.2 7.5 2.3 2008 f 9.2 11.6 2.3 2.3 forecast. * Note: Confidentiality precludes reporting provincial-level insurance data. Source: NHEX, CIHI, 2008.

		Expenditure	on Drugs per Ca	pita by Type, by	Source of Fir	nance and Pub	olic, Private and	
			Total Health Expe	enditures, Nova	Scotia, 1985	to 2008 (con	t'd) GDP Implicit	
-	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Price Index-Canada	
ar			(\$ per Cap	pita)			(1997 = 100)	
985	54.21	112.74	166.95	1,070.18	322.36	1,392.54	73.6	
986 987	62.63 72.82	144.82 165.57	207.46 238.39	1,150.53 1,304.53	397.71 442.14	1,548.24 1,746.68	75.6 79.2	
88	84.68	171.26	255.94	1,298.16	468.32	1,766.48	82.8	
989	95.83	177.23	273.06	1,417.87	520.32	1,938.19	86.6	
990 991	97.05 97.37	192.66 204.11	289.71 301.48	1,513.31 1,585.86	539.08 566.94	2,052.39 2,152.81	89.2 91.6	
92	103.75	229.88	333.62	1,606.22	603.05	2,209.26	92.8	
93 94	103.82 98.27	250.84 257.70	354.66 355.97	1,564.33 1,524.47	627.19 658.31	2,191.52 2,182.78	94.1 95.2	
95 96	100.69 99.28	261.74 282.61	362.43 381.89	1,551.41 1,544.13	669.35 698.71	2,220.76 2,242.84	97.4 99.0	
97	104.39	286.40	390.79	1,790.15	744.81	2,534.96	100.0	
998 999	123.11 135.49	329.67 330.30	452.78 465.79	1,917.40 2,034.29	812.66 819.86	2,730.06 2,854.15	99.6 101.4	
000 001	147.13 163.96	356.30 386.53	503.43 550.50	2,107.72 2,233.74	916.57 988.65	3,024.29 3,222.38	105.5 106.9	
002	178.95	430.93	609.88	2,428.56	1,107.86	3,536.42	108.1	
003 004	197.11 212.59	455.31 486.90	652.43 699.49	2,660.25 2,765.77	1,181.36 1,205.78	3,841.61 3,971.55	111.2 114.1	
005	231.64	523.86	755.50	3,020.17	1,284.76	4,304.94	117.6	
006	290.18	568.79	858.98	3,402.01	1,403.07	4,805.08	120.5	
007 f	311.80	623.64	935.44	3,655.52	1,488.66	5,144.19	124.3	
008 f	359.30	670.50	1,029.81	3,866.41 nnual Percentage Chan	1,584.66	5,451.07	128.6	
-								
985 986	 15.5	28.5	24.3	7.5	23.4	11.2	2.8	
87	16.3	14.3	14.9	13.4	11.2	12.8	4.7	
988 989	16.3 13.2	3.4 3.5	7.4 6.7	-0.5 9.2	5.9 11.1	1.1 9.7	4.5 4.6	
990 991	1.3 0.3	8.7 5.9	6.1 4.1	6.7 4.8	3.6 5.2	5.9 4.9	3.0 2.8	
992	6.5	12.6	10.7	1.3	6.4	2.6	1.3	
993 994	0.1 -5.3	9.1 2.7	6.3 0.4	-2.6 -2.5	4.0 5.0	-0.8 -0.4	1.4 1.1	
995	2.5	1.6	1.8	1.8	1.7	1.7	2.3	
996	-1.4	8.0	5.4	-0.5	4.4	1.0	1.7	
997	5.2	1.3	2.3	15.9	6.6	13.0	1.0	
198 199	17.9 10.1	15.1 0.2	15.9 2.9	7.1 6.1	9.1 0.9	7.7 4.5	-0.4 1.8	
000	8.6	7.9	8.1	3.6	11.8	6.0	4.1	
001	11.4	8.5	9.3	6.0	7.9	6.5	1.4	
002 003	9.1	11.5	10.8	8.7	12.1	9.7	1.0	
)03)04	10.2 7.9	5.7 6.9	7.0 7.2	9.5 4.0	6.6 2.1	8.6 3.4	2.9 2.6	
005	9.0	7.6	8.0	9.2	6.6	8.4	3.1	
006	25.3	8.6	13.7	12.6	9.2	11.6	2.4	
007 f 008 f	7.4	9.6	8.9	7.5	6.1	7.1 6.0	3.2	
0001	15.2	7.5	10.1	5.8	6.4	6.0	3.4	
-		(Annual Percent	age Change in Excess of	Inflation in the Canadia	in Economy)			
86	12.7	25.7	21.5	4.7	20.6	8.4		
987	11.5	9.6	10.2	8.6	6.4	8.1		
188 189	11.8 8.6	-1.1 -1.1	2.8 2.1	-5.0 4.7	1.4 6.5	-3.4 5.2		
90	-1.8	5.7	3.1	3.7	0.6	2.9		
991	-2.4	3.2	1.3	2.0	2.4	2.1		
992 993	5.3	11.4 7.7	9.4	0.0	5.1	1.4		
993 994	-1.4 -6.4	1.6	4.9 -0.7	-4.0 -3.6	2.6 3.9	-2.2 -1.5		
95	0.1	-0.8	-0.5	-0.6	-0.7	-0.6		
96	-3.1	-0.8 6.3	3.7	-0.8	2.7	-0.8		
97	4.2	0.3	1.3	14.9	5.6	12.0		
198 199	18.4 8.2	15.5 -1.6	16.3 1.1	7.5 4.3	9.5 -0.9	8.1 2.7		
000	4.5	3.8	4.0	-0.5	7.7	1.9		
001	10.1	7.1	8.0	4.6	6.5	5.2		
102 103	8.1 7.3	10.4 2.8	9.7 4.1	7.7 6.6	11.0 3.7	8.7 5.7		
004	5.3	4.4	4.1	1.4	-0.5	0.8		
005	5.9	4.5	4.9	6.1	3.4	5.3		
006	22.9	6.2	11.3	10.2	6.8	9.2		
007 f 008 f	4.2 11.8	6.4 4.1	5.7 6.7	4.2 2.3	2.9 3.0	3.8 2.5		
	11.0	4.1	5.7	2.3	3.0	2.0		

N.S.

					Prescril	bed Drugs				Non-	Prescribed Dr	ruas
	Provincial	Federal	Public Social Secu	ırity Funds	Subtotal	Insurers*	Private Out-of-	Subtotal	Total	Priva Over-	te (Out-of-Poo Personal	cket) Total
		_	WCB	Drug Insurance	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Pres Drugs
ar				Fund		(\$ Mi	llions)			Drugs		
35	33.9	1.7	0.1		35.7			38.8	74.4			
36	39.6	1.8	0.2		41.5			45.6	87.1			1
37 38	46.2 48.5	1.9 2.7	0.2		48.4 51.4			56.1 61.4	104.5 112.7			
39	52.7	3.1	0.3		56.0			67.1	123.1			
90	58.3	3.7	0.4		62.4			80.3	142.7			
1	62.4	4.1	0.4		67.0			88.8	155.8			
2	60.0	4.2	0.5		64.8			102.2	167.0	35.6	32.3	
1	56.8 56.0	5.2	0.6 0.6		62.5			111.3 118.4	173.8 180.7	37.0 37.3	34.5	
		5.7			62.3						35.5	
5	58.3	6.4	0.6 0.7		65.4			127.8	193.1	34.4	33.5	
,	54.8 56.1	6.4 7.1	0.7		61.9 64.0			126.7 143.9	188.6 207.9	32.9 44.2	30.6 42.6	
	62.1	8.6	0.9		71.6			149.7	221.3	42.5	41.6	
Ð	69.0	10.8	1.1		80.8			167.0	247.8	47.6	44.1	
)	78.4	14.2	1.4		94.0			187.7	281.6	47.6	43.1	
-	90.1	17.2	1.7		109.0			218.9	327.9	46.5	40.3	
2	101.3	18.8	2.1		122.2			241.9	364.1	49.7	43.0	
3	112.3	21.0	2.6		135.9			271.4	407.2	50.6	42.8	
1	124.4	21.6	3.3		149.3			276.1	425.4	52.2	43.5	
5	135.8	22.3	3.7		161.9			327.0	488.9	50.0	41.1	
6	146.4	22.7	4.0		173.0			343.7	516.7	52.9	43.6	
f	160.1 163.8	23.6 24.2	4.0 4.1		187.7 192.2			374.1 416.7	561.9 608.9	57.0 59.3	45.4 47.2	1
	103.8	24.2	4.1		192.2			410.7	008.9	55.5	47.2	
						(Annual Perce	ntage Change)					
5	16.9	7.6	14.5		16.4			17.6	17.1			
7	16.8	9.3	15.9		16.4			23.0	19.9			
3	5.0	36.1	18.5		6.3			9.3	7.9			
	8.6	17.3	15.6		9.1			9.3	9.2			
	10.7	18.6	56.5		11.4			19.7	15.9			
	7.0	12.5	11.2		7.4			10.6	9.2			
2	-3.9 -5.4	2.0 22.5	24.7 3.7		-3.4 -3.5			15.1 8.9	7.1 4.1	 3.9	 6.8	
	-1.4	10.6	5.4		-0.4			6.4	4.0	0.9	2.9	
	4.2	11.6	8.4		4.9			7.9	6.9	-7.8	-5.7	
5	-6.0	0.1	13.1		-5.2			-0.8	-2.3	-7.8	-5.7	
	2.5	11.0	0.1		3.3			13.6	10.2	34.1	38.9	
:	10.7	21.1	19.3		12.0			4.0	6.4	-3.7	-2.1	
)	11.0	25.2	23.4		12.9			11.6	12.0	11.8	6.0	
С	13.6	31.9	28.3		16.2			12.4	13.6	0.1	-2.3	
	14.9	20.8	25.8		16.0			16.6	16.4	-2.3	-6.5	
	12.5	9.3	19.0		12.1			10.5	11.0	6.7	6.5	
3 4	10.8 10.8	11.7 3.1	25.8 25.2		11.2 9.9			12.2 1.8	11.8 4.5	2.0 3.1	-0.3 1.5	
5	9.2	3.3	13.9		8.4			18.4	14.9	-4.2	-5.5	
i 'f	7.8 9.4	1.7 3.7	6.6 1.5		6.9 8.5			5.1 8.9	5.7 8.7	5.7 7.8	6.1 4.1	
B f	2.3	2.7	3.1		2.4			11.4	8.4	4.0	4.0	
						Percentage Share of 1	Total Drug Exp					
5	27.6	1.3	0.1		29.0			31.6	60.6			
	27.9	1.3	0.1		29.2			32.1	61.4			
;	27.5 27.8	1.2 1.5	0.1		28.8 29.5			33.4 35.2	62.2 64.7			
)	28.8	1.5	0.1		30.7			36.7	67.4			
C	28.6	1.8	0.2		30.6			39.4	70.1			
	28.6	1.8	0.2		30.6			39.4 40.0	70.1			
	25.5	1.8	0.2		27.6			43.5	71.1	15.2	13.8	
	23.1	2.1	0.2		25.5			45.4	70.9	15.1	14.1	
Ļ	22.1	2.3	0.2		24.6			46.7	71.3	14.7	14.0	
5	22.3	2.5	0.2		25.0			49.0	74.0	13.2	12.8	
6	21.7	2.5	0.3		24.6			50.2	74.8	13.1	12.1	
7	19.1	2.4	0.2		21.7			48.9	70.6	15.0	14.4	
3	20.3 20.3	2.8 3.2	0.3 0.3		23.4 23.8			49.0 49.2	72.4	13.9	13.6 13.0	
									73.0	14.0		
)	21.0	3.8	0.4		25.2			50.4	75.6	12.8	11.6	
1 2	21.7	4.1	0.4		26.3			52.8	79.1	11.2	9.7	
2 3	22.2 22.4	4.1 4.2	0.5 0.5		26.7 27.1			53.0 54.2	79.7 81.3	10.9 10.1	9.4 8.6	
4	23.9	4.2	0.5		28.6			53.0	81.6	10.1	8.3	
5	23.4 23.9	3.9 3.7	0.6 0.6		27.9 28.2			56.4 56.0	84.3 84.3	8.6 8.6	7.1 7.1	
f	23.9	3.7 3.5	0.6		28.2			56.0	84.3 84.6	8.6	6.8	

			n Drugs by Type, otal Health Expen				blic, Private and t'd)	Table B N.	
		All Drugs			lealth Expenditure			in Public, Private a Ith Expenditures	and
-	Public	Private	Total	Public	Private	Total	Public	Private	Total
			(\$ Millio	ns)			(Perce	entage Share)	
-	35.7	87.2	122.9	752.2	274.1	1,026.2	4.7	31.8	12.0
	41.5	100.4	142.0	805.3	285.9	1,091.1	5.2	35.1	13.0
	48.4 51.4	119.7 122.9	168.1 174.3	888.9 961.0	305.1 330.5	1,194.0 1,291.5	5.4 5.3	39.2 37.2	14.1 13.5
	56.0	122.5	182.8	1,047.7	352.4	1,400.1	5.3	36.0	13.1
	62.4	141.2	203.7	1,136.1	397.4	1,533.5	5.5	35.5	13.3
	67.0	154.9	221.9	1,186.9	442.4	1,629.3	5.6	35.0	13.6
	64.8	170.1	234.9	1,233.1	466.7	1,699.8	5.3	36.4	13.8
	62.5 62.3	182.8 191.2	245.3 253.5	1,236.1 1,272.2	503.0 520.8	1,739.1 1,793.0	5.1 4.9	36.3 36.7	14.1 14.1
	65.4 61.9	195.6 190.3	261.0 252.2	1,323.0 1,325.3	496.4 488.4	1,819.3 1,813.7	4.9 4.7	39.4 39.0	14.3 13.9
	64.0	230.7	294.6	1,305.7	551.1	1,856.8	4.9	41.9	15.9
	71.6	233.8	305.5	1,370.6	553.6	1,924.2	5.2	42.2	15.9
	80.8	258.7	339.5	1,469.5	607.0	2,076.5	5.5	42.6	16.4
	94.0	278.4	372.3	1,580.0	638.6	2,218.6	5.9	43.6	16.8
	109.0 122.2	305.8 334.6	414.7 456.7	1,740.0 1,833.2	727.8 786.5	2,467.8 2,619.7	6.3 6.7	42.0 42.5	16.8 17.4
	122.2	364.8	500.7	1,033.2	840.9	2,794.2	7.0	42.5	17.9
	149.3	371.8	521.1	2,120.5	864.5	2,985.0	7.0	43.0	17.5
	161.9	418.1	579.9	2,316.5	984.1	3,300.6	7.0	42.5	17.6
	173.0	440.1	613.2	2,532.6	1,043.0	3,575.6	6.8	42.2	17.1
	187.7 192.2	476.5 523.2	664.2 715.3	2,675.0 2,785.3	1,102.6 1,178.1	3,777.7 3,963.4	7.0 6.9	43.2 44.4	17.6 18.0
	192.2	523.2	/15.3	2,765.3	1,176.1	3,903.4	0.9	44.4	18.0
_			(Annual Percenta	ge Change)					
	16.4	15.2	15.6	7.1	4.3	6.3			
	16.4	19.2	18.4	10.4	6.7	9.4 8.2			
	6.3 9.1	2.7 3.1	3.7 4.8	8.1 9.0	8.3 6.6	8.4			
	11.4	11.5	11.4	8.4	12.8	9.5			
	7.4	9.6	9.0	4.5	12.8	6.2			
	-3.4	9.8	5.8	3.9	5.5	4.3			
	-3.5	7.4	4.4	0.2	7.8	2.3			
	-0.4	4.6	3.3	2.9	3.5	3.1			
	4.9	2.3	3.0	4.0	-4.7	1.5			
	-5.2 3.3	-2.7 21.2	-3.3 16.8	0.2	-1.6 12.8	-0.3 2.4			
	12.0	1.4	3.7	5.0	0.5	3.6			
	12.9	10.6	11.1	7.2	9.6	7.9			
	16.2	7.6	9.7	7.5	5.2	6.8			
	16.0	9.8	11.4	10.1	14.0	11.2			
	12.1 11.2	9.4 9.1	10.1 9.6	5.4 6.6	8.1 6.9	6.2 6.7			
	9.9	1.9	4.1	8.6	2.8	6.8			
	8.4	12.4	11.3	9.2	13.8	10.6			
	6.9	5.3	5.7	9.3	6.0	8.3			
	8.5	8.3	8.3	5.6	5.7	5.6			
	2.4	9.8	7.7	4.1	6.8	4.9			
	(Percenta	ge Share of Total Dr	ug Expenditure)						
-	29.0	71.0	100.0	_					
	29.0	70.8	100.0						
	28.8	71.2	100.0						
	29.5 30.7	70.5 69.3	100.0 100.0						
	30.6	69.4	100.0						
	30.2 27.6	69.8 72.4	100.0 100.0						
	25.5	74.5	100.0						
	24.6	75.4	100.0						
	25.0	75.0	100.0						
	24.6	75.4	100.0						
	21.7 23.4	78.3 76.6	100.0 100.0						
	23.4 23.8	76.2	100.0						
	25.2 26.3	74.8 73.7	100.0 100.0						
	26.7	73.3	100.0						
	27.1	72.9	100.0						
	28.6	71.4	100.0						
	27.9	72.1	100.0						
	28.2	71.8	100.0						
	28.3 26.9	71.7 73.1	100.0 100.0						

					Dreesrik	ed Drugs				Nee	Dresselland Dr	
			Public			-	Private		;	Priva	Prescribed Dr te (Out-of-Poo	cket)
	Provincial	Federal	Social Security WCB	Drug nsurance	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Tota Non-Pre Drug
Year				Fund		(\$ per	Capita)			Drugs		
1985	46.80	2.29	0.19		49.28			53.60	102.88			
1986 1987	54.59 63.50	2.46 2.68	0.22 0.25		57.26 66.43			62.92 77.12	120.18 143.55			
1988	66.43	3.63	0.30		70.36			84.01	154.37			
1989	71.66	4.23	0.34		76.23			91.22	167.45			
1990	78.82	4.99	0.53		84.34			108.44	192.78			
1991 1992	83.75 80.19	5.57 5.66	0.59 0.73		89.90 86.57			119.11 136.60	209.01 223.17	47.57	43.20	
1993	75.83	6.92	0.75		83.50			148.60	232.11	49.37	46.09	
1994	74.59	7.64	0.79		83.03			157.80	240.84	49.72	47.33	
1995	77.65	8.52	0.86		87.02			170.11	257.14	45.80	44.57	
1996 1997	72.83 74.59	8.51 9.45	0.97 0.97		82.31 85.01			168.45 191.27	250.76 276.28	43.79 58.69	40.72 56.54	1
1998	82.80	11.47	1.16		95.43			199.42	294.85	56.66	55.47	
1999	91.89	14.36	1.43		107.68			222.50	330.18	63.36	58.77	
2000	104.41	18.94	1.84		125.19			250.06	375.25	63.43	57.44	1
2001 2002	120.09 135.05	22.90 25.01	2.31 2.75		145.31 162.81			291.92 322.44	437.23 485.25	62.06 66.19	53.78 57.25	1
2003	149.49	27.91	3.46		180.86			361.25	542.11	67.41	57.01	1
2004	165.45	28.74	4.33		198.52			367.17	565.69	69.43	57.81	1
2005	180.77	29.73	4.93		215.43			435.23	650.66	66.58	54.66	
2006 2007 f	195.35 213.59	30.32 31.42	5.27 5.35		230.95 250.36			458.69 498.99	689.64 749.35	70.58 76.04	58.16 60.52	
2008 f	218.26	32.23	5.51		256.00			555.12	811.12	78.96	62.85	
						(Annual Perce	ntage Change)					
985												
986 987	16.6 16.3	7.4 8.9	14.3 15.5		16.2 16.0			17.4 22.6	16.8 19.4			
988	4.6	35.6	18.1		5.9			8.9	7.5			
989	7.9	16.6	14.8		8.3			8.6	8.5			
990	10.0	17.8	55.5		10.6			18.9	15.1			
991 992	6.3 -4.3	11.6 1.6	10.4 24.3		6.6 -3.7			9.8 14.7	8.4 6.8			
993	-5.4	22.4	3.6		-3.5			8.8	4.0	3.8	6.7	
994	-1.6	10.4	5.2		-0.6			6.2	3.8	0.7	2.7	
995	4.1	11.5	8.3		4.8			7.8	6.8	-7.9	-5.8	
996 997	-6.2 2.4	-0.1 11.0	12.9 0.1		-5.4 3.3			-1.0 13.5	-2.5 10.2	-4.4 34.0	-8.6 38.8	
998	11.0	21.4	19.6		12.3			4.3	6.7	-3.5	-1.9	
999	11.0	25.2	23.4		12.8			11.6	12.0	11.8	5.9	
000	13.6	31.9	28.3		16.3			12.4	13.6	0.1	-2.3	
2001 2002	15.0 12.5	20.9 9.2	25.9 18.9		16.1 12.0			16.7 10.5	16.5 11.0	-2.2 6.7	-6.4 6.5	
2003	10.7	11.6	25.7		11.1			12.0	11.7	1.8	-0.4	
004	10.7	3.0	25.0		9.8			1.6	4.4	3.0	1.4	
2005	9.3	3.4	14.0		8.5			18.5	15.0	-4.1	-5.5	
2006 2007 f	8.1 9.3	2.0 3.6	6.9 1.4		7.2 8.4			5.4 8.8	6.0 8.7	6.0 7.7	6.4 4.1	
008 f	2.2	2.6	2.9		2.3			11.2	8.2	3.9	3.9	
					(Annual Percentag	je Change in Excess	of Inflation in	the Canadian E	conomy)			
1985												
1986	13.8	4.6	11.5		13.4			14.6	14.0			
1987 1988	11.6 0.1	4.2 31.1	10.7 13.6		11.3 1.4			17.8 4.4	14.7 3.0			
989	3.3	12.0	10.3		3.8			4.0	3.9			
990	7.0	14.8	52.5		7.6			15.8	12.1			
991	3.5	8.9	7.6		3.8			7.1	5.7			
992 993	-5.5 -6.9	0.3 21.0	23.0 2.2		-5.0 -5.0			13.4 7.3	5.5 2.6	2.3	 5.3	
994	-2.7	9.3	4.1		-1.7			5.1	2.7	-0.4	1.6	
995	1.8	9.1	6.0		2.5			5.5	4.4	-10.2	-8.2	
996	-7.9	-1.8	11.2		-7.1			-2.7	-4.2	-6.1	-10.3	
997 998	1.4 11.4	10.0 21.8	-0.9 20.1		2.3 12.7			12.6 4.7	9.2 7.2	33.1 -3.0	37.9 -1.5	
1999	9.2	23.4	21.5		11.0			9.8	10.2	10.0	4.1	
2000	9.5	27.8	24.2		12.2			8.3	9.5	-4.0	-6.4	
001	13.7	19.6	24.6		14.7			15.4	15.2	-3.5	-7.7	
2002 2003	11.4 7.8	8.2 8.7	17.9 22.8		11.0 8.2			9.4 9.1	9.9 8.8	5.6 -1.0	5.4 -3.3	
2004	8.1	0.4	22.5		7.2			-0.9	1.8	0.4	-1.2	
005	6.2	0.3	10.9		5.4			15.4	11.9	-7.2	-8.6	
2006	5.7 6.1	-0.4 0.4	4.5 -1.8		4.8 5.2			3.0 5.6	3.6 5.4	3.6 4.5	4.0 0.8	
007 f												

		•	• •	pita by Type, by S Iditures, New Brui			lic, Private and	B N.B.—Per Capit
							GDP Implicit	
-	Public	All Drugs Private	Total	Hea Public	th Expenditure Private	Total	Price Index—Canada	
ar _			(\$ per Ca	pita)			(1997 = 100)	
85	49.28	120.48	169.76	1,039.37	378.68	1,418.05	73.6	
86 87	57.26 66.43	138.51 164.45	195.77 230.88	1,110.46 1,221.26	394.24 419.14	1,504.71 1,640.40	75.6 79.2	
88	70.36	168.31	238.67	1,315.80	452.46	1,768.26	82.8	
89	76.23	172.34	248.57	1,425.04	479.28	1,904.32	86.6	
90	84.34	190.84	275.18	1,535.00	536.96	2,071.96	89.2	
91 92	89.90	207.73	297.63	1,592.01	593.38	2,185.39	91.6	
92 93	86.57 83.50	227.37 244.07	313.94 327.57	1,648.30 1,650.79	623.91 671.67	2,272.21 2,322.46	92.8 94.1	
94	83.03	254.85	337.88	1,695.79	694.18	2,389.97	95.2	
95	87.02	260.48	347.50	1,761.67	660.95	2,422.62	97.4	
96	82.31	252.96	335.27	1,761.66	649.20	2,410.86	99.0	
97 98	85.01 95.43	306.51 311.55	391.52 406.98	1,735.08 1,826.14	732.28 737.64	2,467.36 2,563.77	100.0 99.6	
99	107.68	344.63	452.31	1,957.71	808.66	2,766.37	101.4	
00	125.19	370.93	496.12	2,105.17	850.90	2,956.07	105.5	
01	145.31	407.76	553.07	2,320.35	970.56	3,290.91	106.9	
02	162.81	445.88	608.69	2,443.17 2,600.15	1,048.19 1,119.42	3,491.37	108.1	
03 04	180.86 198.52	485.67 494.42	666.53 692.94	2,600.15 2,819.65	1,119.42 1,149.59	3,719.57 3,969.24	111.2 114.1	
05	215.43	556.47	771.90	3,083.23	1,309.81	4,393.04	117.6	
06	230.95	587.43	818.38	3,380.34	1,392.12	4,772.46	120.5	
07 f	250.36	635.55	885.91	3,567.72	1,470.62	5,038.34	124.3	
08 f	256.00	696.94	952.94	3,710.39	1,569.44	5,279.83	128.6	
_			(A	nnual Percentage Change)				
85								
86	16.2	15.0	15.3	6.8	4.1	6.1	2.8	
87	16.0	18.7	17.9	10.0	6.3	9.0	4.7	
88 89	5.9 8.3	2.4 2.4	3.4 4.1	7.7 8.3	7.9 5.9	7.8 7.7	4.5 4.6	
90	10.6	10.7	10.7	7.7	12.0	8.8	3.0	
91	6.6	8.9	8.2	3.7	10.5	5.5	2.8	
92	-3.7	9.5	5.5	3.5	5.1	4.0	1.3	
93 94	-3.5 -0.6	7.3 4.4	4.3 3.1	0.2 2.7	7.7 3.4	2.2 2.9	1.4 1.1	
95 96	4.8 -5.4	2.2 -2.9	2.8 -3.5	3.9 0.0	-4.8 -1.8	1.4 -0.5	2.3 1.7	
97	3.3	21.2	16.8	-1.5	12.8	2.3	1.0	
98	12.3	1.6	3.9	5.2	0.7	3.9	-0.4	
99	12.8	10.6	11.1	7.2	9.6	7.9	1.8	
00	16.3	7.6	9.7	7.5	5.2	6.9	4.1	
01 02	16.1 12.0	9.9 9.3	11.5 10.1	10.2 5.3	14.1 8.0	11.3 6.1	1.4 1.0	
03	11.1	8.9	9.5	6.4	6.8	6.5	2.9	
04	9.8	1.8	4.0	8.4	2.7	6.7	2.6	
05	8.5	12.5	11.4	9.3	13.9	10.7	3.1	
06	7.2	5.6	6.0	9.6	6.3	8.6	2.4	
07 f 08 f	8.4 2.3	8.2 9.7	8.3 7.6	5.5 4.0	5.6 6.7	5.6 4.8	3.2 3.4	
-		(Annual Percenta	ge Change in Excess of	Inflation in the Canadian	Economy)			
85								
36 37	13.4 11.3	12.2 14.0	12.5 13.2	4.0 5.2	1.3 1.6	3.3 4.3		
38	1.4	-2.2	-1.1	3.2	3.4	3.3		
39	3.8	-2.2	-0.4	3.7	1.4	3.1		
90	7.6	7.7	7.7	4.7	9.0	5.8		
91	3.8	6.1	5.4	1.0	7.7	2.7		
92 93	-5.0 -5.0	8.2 5.9	4.2 2.9	2.3 -1.3	3.9 6.2	2.7 0.8		
94	-1.7	3.3	2.0	1.6	2.3	1.8		
95	2.5	-0.1	0.5	1.5	-7.1	-1.0		
96	-7.1	-4.6	-5.2	-1.7	-3.4	-2.2		
97 98	2.3 12.7	20.2 2.1	15.8 4.4	-2.5 5.7	11.8 1.2	1.4 4.3		
99	12.7	8.8	9.3	5.4	7.8	6.1		
00	12.2	3.5	5.6	3.4	1.1	2.8		
01	12.2	8.6	10.1	3.4 8.9	12.7	10.0		
02	11.0	8.3	9.0	4.2	7.0	5.0		
03 04	8.2 7.2	6.0 -0.8	6.6 1.4	3.5 5.9	3.9 0.1	3.6 4.1		
05 06	5.4 4.8	9.4 3.1	8.3 3.6	6.2 7.2	10.8 3.9	7.6 6.2		
07 f	5.2	5.0	5.0	2.3	2.4	2.3		
08 f	-1.2	6.2	4.1	0.6	3.3	1.4		

I.					Prescrib	ed Drugs				Non	-Prescribed Dr	rug
	Provincial	Federal _	Public Social Secu WCB	Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Poo Personal Health Supplies	cke N
Year				Fund		(\$ Mi	llions)			Drugs		
1985	250.4	7.4	2.1		260.0			342.6	602.6			
1986 1987	291.2 333.8	8.1 8.8	2.7 3.2		301.9 345.8			463.0 466.6	764.9 812.4			
1988	384.1	10.7	3.2		398.0			523.3	921.4			
1989	437.1	12.8	3.5		453.4			582.4	1,035.8			
1990 1991	502.9 604.0	15.3 16.7	4.2 4.9		522.4 625.6			638.9 709.4	1,161.2 1,335.0			
1992	650.5	18.1	5.1		673.7			770.9	1,444.6	306.5	264.2	
1993 1994	686.1 742.1	21.1 23.0	5.0 5.6		712.3 770.7			882.3 898.5	1,594.6 1,669.2	312.4 326.8	280.8 306.6	
1995	807.0	24.1	6.3		837.4			1,005.9	1,843.3	334.4	314.5	
1996	734.5	24.0	6.9		765.4			1,079.9	1,845.2	322.1	314.6	
1997 1998	700.6 779.8	26.0 29.5	7.4 8.1	172.0 218.2	906.0 1,035.6			1,227.2 1,228.4	2,133.2 2,264.0	293.5 312.2	294.6 316.7	
1998	918.6	29.5 34.4	9.3	216.2	1,226.2			1,228.4	2,659.8	312.2	316.7	
2000	1,118.4	35.0	11.1	332.3	1,496.8			1,612.8	3,109.7	321.2	324.3	
2001	1,309.4	38.4	13.5	379.9	1,741.1			1,752.2	3,493.3	337.0	331.7	
2002 2003	1,439.5 1,538.9	44.7 50.7	15.4 18.0	450.4 595.0	1,950.0 2,202.6			1,968.7 2,130.9	3,918.7 4,333.5	347.1 350.7	340.6 340.4	
2004	1,678.1	53.5	21.1	642.2	2,394.9			2,357.0	4,751.9	371.7	352.4	
2005	1,798.7	57.2	23.0	659.2	2,538.2			2,492.4	5,030.6	426.3	385.1	
2006 2007 f	1,955.6 2,163.4	62.2 65.6	26.4 29.6	719.8 738.7	2,764.0 2,997.3			2,706.9 2,985.9	5,470.9 5,983.3	441.5 468.6	401.0 406.2	
2008 f	2,347.1	69.8	32.9	799.0	3,248.8			3,262.2	6,511.0	505.8	438.4	
1						(Annual Perce	ntage Change					
1985												
1986	16.3	8.4	27.3		16.1			35.1	26.9			
1987 1988	14.6 15.1	9.1 21.6	19.2 1.0		14.5 15.1			0.8 12.2	6.2 13.4			
1989	13.8	20.0	7.2		13.9			11.3	12.4			
1990	15.0	19.2	20.8		15.2			9.7	12.1			
1991 1992	20.1 7.7	9.4 8.2	16.6 3.3		19.8 7.7			11.0 8.7	15.0 8.2			
1993	5.5	16.7	-0.1		5.7			14.4	10.4	1.9	6.3	
1994	8.2	8.7	11.7		8.2			1.8	4.7	4.6	9.2	
1995 1996	8.7 -9.0	5.0 -0.7	12.1 9.7		8.7 -8.6			11.9 7.4	10.4 0.1	2.3 -3.7	2.6 0.0	
1997	-4.6	8.5	6.2		18.4			13.6	15.6	-8.9	-6.4	
1998 1999	11.3 17.8	13.4 16.6	10.0 15.1	26.8 21.0	14.3 18.4			0.1 16.7	6.1 17.5	6.4 7.0	7.5 5.0	
2000	21.8	1.9	19.7	25.9	22.1			12.5	16.9	-3.9	-2.5	
2001	17.1	9.6	20.8	14.3	16.3			8.6	12.3	4.9	2.3	
2002 2003	9.9 6.9	16.6 13.4	14.3 17.1	18.6 32.1	12.0 13.0			12.4 8.2	12.2 10.6	3.0 1.0	2.7 -0.1	
2004	9.0	5.5	17.3	7.9	8.7			10.6	9.7	6.0	3.5	
2005	7.2	6.9	9.0	2.7	6.0			5.7	5.9	14.7	9.3	
2006 2007 f	8.7 10.6	8.6 5.5	14.7 11.9	9.2 2.6	8.9 8.4			8.6 10.3	8.8 9.4	3.6 6.1	4.1 1.3	
2007 f	8.5	6.4	11.5	8.2	8.4			9.3	8.8	7.9	7.9	
					(Pe	ercentage Share of 1	Total Drug Exp	enditure)				
1985	30.1	0.9	0.3		31.2			41.1	72.3			
1986 1987	28.4 29.9	0.8 0.8	0.3 0.3		29.4 31.0			45.1 41.8	74.6 72.9			
1988	29.8	0.8	0.3		30.9			40.6	71.5			
1989	29.5	0.9	0.2		30.6			39.3	70.0			
1990 1991	30.9 32.3	0.9	0.3 0.3		32.1 33.5			39.2 37.9	71.3 71.4			
1992	32.3	0.9	0.3		33.4			38.3	71.7	15.2	13.1	
1993 1994	31.4 32.2	1.0 1.0	0.2		32.6 33.5			40.3 39.0	72.9 72.5	14.3 14.2	12.8 13.3	
1995	32.2		0.2					40.4				
1995	32.4 29.6	1.0 1.0	0.3		33.6 30.8			40.4	74.0 74.3	13.4 13.0	12.6 12.7	
1997	25.7	1.0	0.3	6.3	33.3			45.1	78.4	10.8	10.8	
1998 1999	27.0 27.6	1.0 1.0	0.3 0.3	7.5 7.9	35.8 36.9			42.5 43.1	78.3 80.0	10.8 10.0	10.9 10.0	
2000	29.8	0.9	0.3	8.8	39.9			43.0	82.8	8.6	8.6	
2001	31.5	0.9	0.3	9.1	41.8			42.1	83.9	8.1	8.0	
2002 2003	31.2 30.6	1.0 1.0	0.3 0.4	9.8 11.8	42.3 43.8			42.7 42.4	85.1 86.2	7.5 7.0	7.4 6.8	
2003 2004	30.6	1.0	0.4	11.8	43.8			42.4	86.8	6.8	6.4	
2005	30.8	1.0	0.4	11.3	43.4			42.7	86.1	7.3	6.6	
2006 2007 f	31.0 31.5	1.0 1.0	0.4 0.4	11.4 10.8	43.8 43.7			42.9 43.5	86.7 87.2	7.0 6.8	6.4 5.9	
2007 f 2008 f	31.5	0.9	0.4	10.8	43.7			43.5	87.2	6.8	5.9	

	I	Expenditure or		e, by Source of Fin expenditures, Queb			c, Private and		
	Public	All Drugs Private	Total		th Expenditure Private	Total	Total Hea	in Public, Private a alth Expenditures Private	nd Total
r			(\$ Millio	ons)			(Perce	entage Share)	
5	260.0	573.1	833.0	7,927.6	2,104.4	10,031.9	3.3	27.2	8.3
6 7	301.9 345.8	724.0 769.3	1,025.9 1,115.1	8,051.3 8,636.4	2,486.1 2,632.2	10,537.4 11,268.6	3.7 4.0	29.1 29.2	9.7 9.9
38	398.0	890.3	1,288.3	9,428.4	2,850.8	12,279.2	4.2	31.2	10.5
19	453.4	1,027.2	1,480.7	10,108.6	3,181.7	13,290.3	4.5	32.3	11.1
0	522.4	1,107.1	1,629.5	10,814.1	3,497.4	14,311.5	4.8	31.7	11.4
91 92	625.6 673.7	1,243.8 1,341.6	1,869.5 2,015.3	11,815.3 12,234.5	3,819.3 4,141.5	15,634.6 16,376.1	5.3 5.5	32.6 32.4	12.0 12.3
93	712.3	1,475.4	2,187.7	12,459.6	4,444.6	16,904.2	5.7	33.2	12.9
94	770.7	1,532.0	2,302.6	12,674.4	4,653.5	17,327.9	6.1	32.9	13.3
95	837.4	1,654.9	2,492.3	12,708.9	4,663.6	17,372.5	6.6	35.5	14.3
96 97	765.4 906.0	1,716.6 1,815.2	2,481.9 2,721.2	12,254.7 13,041.2	4,727.9 4,976.0	16,982.6 18,017.3	6.2 6.9	36.3 36.5	14.6 15.1
98	1,035.6	1,857.3	2,892.8	14,133.1	5,000.5	19,133.6	7.3	37.1	15.1
99	1,226.2	2,100.1	3,326.4	14,463.6	5,551.0	20,014.5	8.5	37.8	16.6
00	1,496.8	2,258.3	3,755.1	15,710.1	5,905.4	21,615.5	9.5	38.2	17.4
01 02	1,741.1 1,950.0	2,420.9 2,656.4	4,161.9 4,606.4	17,004.5 17,975.5	6,561.5 7,079.2	23,565.9 25,054.8	10.2 10.8	36.9 37.5	17.7 18.4
03	2,202.6	2,856.4	4,606.4 5,024.5	19,060.7	7,606.9	26,667.6	10.8	37.5	18.4
04	2,394.9	3,081.0	5,475.9	20,284.7	7,833.0	28,117.7	11.8	39.3	19.5
05	2,538.2	3,303.8	5,842.0	21,381.0	8,513.5	29,894.5	11.9	38.8	19.5
06 07 f	2,764.0 2,997.3	3,549.4 3,860.7	6,313.3 6,858.0	22,719.2 24,213.0	9,042.9 9,686.6	31,762.1 33,899.6	12.2 12.4	39.3 39.9	19.9 20.2
D8 f	3,248.8	4,206.4	7,455.2	25,630.1	9,888.8	36,021.2	12.4	40.5	20.2
			(Annual Percent						
85 86	 16.1	26.3	23.2	 1.6	 18.1	5.0			
B7	14.5	6.3	8.7	7.3	5.9	6.9			
88	15.1	15.7	15.5	9.2	8.3	9.0			
39	13.9	15.4	14.9	7.2	11.6	8.2			
90 91	15.2 19.8	7.8 12.3	10.0 14.7	7.0 9.3	9.9 9.2	7.7 9.2			
92	7.7	7.9	7.8	3.5	8.4	4.7			
93	5.7	10.0	8.6	1.8	7.3	3.2			
94	8.2	3.8	5.3	1.7	4.7	2.5			
95 96	8.7 -8.6	8.0 3.7	8.2 -0.4	0.3 -3.6	0.2	0.3			
97	18.4	5.7	9.6	6.4	5.2	6.1			
98	14.3	2.3	6.3	8.4	0.5	6.2			
99	18.4	13.1	15.0	2.3	11.0	4.6			
00 01	22.1 16.3	7.5 7.2	12.9 10.8	8.6 8.2	6.4 11.1	8.0 9.0			
02	12.0	9.7	10.7	5.7	7.9	6.3			
03	13.0	6.2	9.1	6.0	7.5	6.4			
04	8.7	9.2	9.0	6.4	3.0	5.4			
05 06	6.0 8.9	7.2 7.4	6.7 8.1	5.4 6.3	8.7 6.2	6.3 6.2			
07 f	8.4	8.8	8.6	6.6	7.1	6.7			
08 f	8.4	9.0	8.7	5.9	7.3	6.3			
	(Percenta	ge Share of Total Dri	ug Expenditure)						
85	31.2	68.8	100.0						
86	29.4	70.6	100.0						
37 38	31.0 30.9	69.0 69.1	100.0 100.0						
39	30.6	69.4	100.0						
90	32.1	67.9	100.0						
91	33.5	66.5	100.0						
92 93	33.4 32.6	66.6 67.4	100.0 100.0						
94	33.5	66.5	100.0						
95	33.6	66.4	100.0						
6	30.8	69.2	100.0						
97 98	33.3 35.8	66.7 64.2	100.0 100.0						
99	36.9	63.1	100.0						
00	39.9	60.1	100.0						
D1	41.8	58.2	100.0						
02 03	42.3 43.8	57.7 56.2	100.0 100.0						
)3)4	43.8	56.2	100.0						
05	43.4	56.6	100.0						
06	43.8	56.2	100.0						
07 f 08 f	43.7	56.3	100.0						
1 01	43.6	56.4	100.0						

le.

					Prescribe	ed Drugs					-Prescribed D	
	Provincial	Federal	Public Social Securit WCB	Drug nsurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	<u>ite (Out-of-Po</u> Personal Health Supplies	CK(
Year				Fund		(\$ per	Capita)			Drugs		
1985 1986	37.57	1.12	0.32		39.00			51.40	90.40			
1986 1987	43.40 49.21	1.20 1.30	0.40 0.47		45.00 50.98			69.01 68.80	114.02 119.78			
1988 1989	56.16	1.56	0.47 0.50		58.20			76.52	134.72			
	63.09	1.85			65.44			84.06	149.50			
1990 1991	71.80 85.50	2.18 2.37	0.60 0.69		74.58 88.56			91.21 100.41	165.80 188.97			
1992	91.52	2.55	0.71		94.78			108.46	203.23	43.12	37.17	
993 994	95.89 103.18	2.95 3.20	0.71 0.78		99.55 107.16			123.31 124.94	222.86 232.10	43.65 45.44	39.24 42.63	
95 96	111.78 101.35	3.34 3.31	0.88 0.96		116.00 105.61			139.34 149.01	255.33 254.62	46.32 44.45	43.57 43.42	
97	96.31	3.57	1.01	23.65	124.54			168.69	293.23	40.34	40.50)
998 999	106.88 125.43	4.04 4.69	1.11 1.27	29.91 36.05	141.94 167.44			168.37 195.75	310.31 363.19	42.79 45.62	43.40 45.40	
000 001	152.02 177.02	4.76 5.19	1.51 1.82	45.17 51.36	203.46 235.38			219.22 236.88	422.68 472.26	43.66 45.56	44.07 44.84	
002	193.33	6.01	2.07	60.49	261.90			264.41	526.31	46.61	45.74	
2003 2004	205.33 222.29	6.77 7.09	2.40 2.80	79.39 85.06	293.89 317.24			284.32 312.23	578.21 629.47	46.79 49.24	45.41 46.68	
	222.29			86.76								
2005 2006	236.74 255.59	7.53 8.13	3.03 3.45	94.08	334.06 361.25			328.03 353.80	662.09 715.05	56.11 57.70	50.68 52.41	
007 f	280.94	8.52	3.84	95.93	389.22			387.74	776.96	60.85	52.74	
08 f	303.16	9.02	4.26	103.20	419.63			421.35	840.99	65.33	56.63	
						(Annual Perce	ntage Change)					
985												
986 987	15.5 13.4	7.7 7.9	26.4 17.9		15.4 13.3			34.3 -0.3	26.1 5.1			
88	14.1	20.6	0.1		14.1			11.2	12.5			
89	12.3	18.4	5.8		12.4			9.8	11.0			
90 91	13.8	17.9	19.5		14.0			8.5	10.9			
92	19.1 7.0	8.4 7.6	15.6 2.6		18.7 7.0			10.1 8.0	14.0 7.5			
93	4.8	15.9	-0.8		5.0			13.7	9.7	1.2	5.6	
94	7.6	8.2	11.2		7.6			1.3	4.1	4.1	8.6	5
95	8.3	4.6	11.7		8.2			11.5	10.0	1.9	2.2	
96 97	-9.3 -5.0	-1.1 8.0	9.2 5.8		-9.0 17.9			6.9 13.2	-0.3 15.2	-4.1 -9.2	-0.3 -6.7	
98	11.0	13.1	9.7	26.5	14.0			-0.2	5.8	6.1	7.2	
99	17.4	16.2	14.6	20.5	18.0			16.3	17.0	6.6	4.6	5
000 001	21.2 16.4	1.4 9.0	19.1 20.1	25.3 13.7	21.5 15.7			12.0 8.1	16.4 11.7	-4.3 4.4	-2.9 1.7	
002	9.2	15.8	13.5	13.7	11.3			11.6	11.4	2.3	2.0	
03	6.2	12.7	16.4	31.2	12.2			7.5	9.9	0.4	-0.7	
04	8.3	4.7	16.4	7.2	7.9			9.8	8.9	5.2	2.8	
05 De	6.5	6.3	8.3	2.0	5.3			5.1	5.2	14.0	8.6	
06 07 f	8.0 9.9	7.9 4.8	13.9 11.1	8.4 2.0	8.1 7.7			7.9 9.6	8.0 8.7	2.8 5.5	3.4 0.6	
08 f	7.9	5.8	10.9	7.6	7.8			8.7	8.2	7.4	7.4	
					(Annual Percentag	e Change in Excess	of Inflation in	the Canadian E	conomy)			
85												
86 87	12.7 8.7	4.9 3.2	23.6 13.1		12.6 8.5			31.5 -5.1	23.3 0.3			
88	9.6	16.0	-4.4		9.6			-5.1	8.0			
39	7.8	13.9	1.2		7.9			5.3	6.4			
90	10.8	14.9	16.4		10.9			5.5	7.9			
91 92	16.3 5.8	5.7 6.3	12.9 1.4		16.0 5.8			7.3 6.8	11.2 6.3			
192 193	5.8 3.3	6.3 14.5	-2.2		3.6			12.3	8.2	-0.2	4.1	
994	6.5	7.1	10.1		6.5			0.2	3.0	3.0	7.5	
995	6.0	2.2	9.3		5.9			9.2	7.7	-0.4	-0.1	
996 997	-11.0 -6.0	-2.7 7.0	7.6 4.8		-10.6 16.9			5.3 12.2	-1.9 14.2	-5.7 -10.2	-2.0 -7.7	
997 998	-6.0 11.4	13.5	4.8	26.9	14.4			0.2	6.3	-10.2	-7.7	
999	15.6	14.4	12.8	18.7	16.2			14.5	15.2	4.8	2.8	
000	17.1	-2.7	15.0	21.2	17.4			7.9	12.3	-8.4	-7.0	
001 002	15.1 8.2	7.6 14.8	18.8 12.5	12.4 16.8	14.3 10.2			6.7 10.6	10.4 10.4	3.0 1.3	0.4 1.0	
203	3.3	9.8	13.5	28.3	9.3			4.6	7.0	-2.5	-3.6	
04	5.7	2.2	13.9	4.6	5.4			7.2	6.3	2.6	0.2	
5	3.4	3.1	5.2	-1.1	2.2			2.0	2.1	10.9	5.5	
6 7 f	5.6 6.7	5.5 1.6	11.5 7.9	6.0 -1.3	5.7 4.5			5.4 6.4	5.6 5.4	0.4 2.2	1.0 -2.6	
08 f	4.5											

		Expenditure	on Drugs per Ca <mark>r</mark> Total Health E	pita by Type, by kpenditures, Qu			c, Private and	
						2000 (00111 0)	GDP Implicit	
_		All Drugs			Health Expenditure		Price Index-Canada	
	Public	Private	Total	Public	Private	Total		
			(\$ per Cap	pita)			(1997 = 100)	
	39.00	85.97	124.97	1,189.31	315.70	1,505.01	73.6	
	45.00 50.98	107.92 113.42	152.93 164.40	1,200.16 1,273.33	370.59 388.08	1,570.76 1,661.41	75.6 79.2	
	58.20	130.18	188.37	1,378.61	416.85	1,795.46	82.8	
	65.44	148.26	213.70	1,458.95	459.21	1,918.16	86.6	
	74.58	158.07	232.66	1,544.02	499.35	2,043.36	89.2	
	88.56	176.07	264.62	1,672.46	540.63	2,213.09	91.6	
	94.78	188.75	283.53	1,721.23	582.66	2,303.89	92.8	
	99.55	206.20	305.75	1,741.32	621.16	2,362.48	94.1	
	107.16	213.01	320.17	1,762.32	647.05	2,409.37	95.2	
	116.00	229.23	345.22	1,760.37	645.98	2,406.35	97.4	
	105.61	236.87	342.48	1,691.02	652.41	2,343.43	99.0	
	124.54	249.53	374.07	1,792.70	684.03	2,476.73	100.0	
	141.94 167.44	254.56 286.77	396.50 454.21	1,937.11 1,975.01	685.38 757.99	2,622.49 2,732.99	99.6 101.4	
	203.46	306.95	510.41	2,135.38 2,298.84	802.69	2,938.07	105.5	
	235.38 261.90	327.28 356.76	562.65 618.66	2,298.84 2,414.20	887.04 950.78	3,185.88 3,364.98	106.9 108.1	
	293.89	376.53	670.41	2,543.23	1,014.97	3,558.20	111.2	
	317.24	408.14	725.38	2,687.07	1,037.62	3,724.70	114.1	
	334.06	434.82	768.88	2,814.02	1,120.48	3,934.50	117.6	
	361.25	463.91	825.16	2,969.42	1,181.92	4,151.35	120.5	
	389.22	501.34	890.56	3,144.22	1,257.86	4,402.08	124.3	
	419.63	543.31	962.95	3,310.49	1,342.15	4,652.64	128.6	
			(Ai	nnual Percentage Char	nge)			
_								
	15.4	25.5	22.4	0.9	17.4	4.4	2.8	
	13.3	5.1	7.5	6.1	4.7	5.8	4.7	
	14.1	14.8	14.6	8.3	7.4	8.1	4.5	
	12.4	13.9	13.4	5.8	10.2	6.8	4.6	
	14.0	6.6	8.9	5.8	8.7	6.5	3.0	
	18.7	11.4	13.7	8.3	8.3	8.3	2.8	
	7.0	7.2	7.1	2.9	7.8	4.1	1.3	
	5.0	9.2	7.8	1.2	6.6	2.5	1.4	
	7.6	3.3	4.7	1.2	4.2	2.0	1.1	
	8.2	7.6	7.8	-0.1	-0.2	-0.1	2.3	
	-9.0 17.9	3.3 5.3	-0.8 9.2	-3.9 6.0	1.0 4.8	-2.6 5.7	1.7 1.0	
	14.0	2.0	6.0	8.1	4.8	5.9	-0.4	
	18.0	12.7	14.6	2.0	10.6	4.2	1.8	
	21.5	7.0	12.4	8.1	5.9	7.5	4.1	
	15.7	6.6	10.2	7.7	10.5	8.4	1.4	
	11.3	9.0	10.0	5.0	7.2	5.6	1.0	
	12.2	5.5	8.4	5.3	6.8	5.7	2.9	
	7.9	8.4	8.2	5.7	2.2	4.7	2.6	
	5.3	6.5	6.0	4.7	8.0	5.6	3.1	
	8.1	6.7	7.3	5.5	5.5	5.5	2.4	
	7.7	8.1	7.9	5.9	6.4	6.0	3.2	
	7.8	8.4	8.1	5.3	6.7	5.7	3.4	
		(Annual Percenta	age Change in Excess of	Inflation in the Canadi	ian Economy)			
	12.6	22.7	19.6	-1.9	14.6	1.6		
	8.5	0.4	2.8	-1.5	0.0	1.0		
	9.6	10.3	10.1	3.7	2.9	3.5		
	7.9	9.3	8.9	1.3	5.6	2.3		
	10.9	3.6	5.8	2.8	5.7	3.5		
	16.0	8.6	11.0	5.6	5.5	5.5		
	5.8	5.9	5.9	1.7	6.5	2.8		
	3.6	7.8	6.4	-0.3	5.2	1.1		
	6.5	2.2	3.6	0.1	3.1	0.9		
	5.9	5.3	5.5	-2.4	-2.5	-2.5		
	-10.6	1.7	-2.5	-5.6	-0.7	-4.3		
	16.9 14.4	4.4 2.5	8.2 6.4	5.0 8.5	3.9 0.6	4.7 6.3		
	14.4 16.2	10.8	12.7	8.5	8.8	6.3 2.4		
	17.4	2.9	8.3	4.0	1.8	3.4		
	14.3 10.2	5.3 8.0	8.9 8.9	6.3 4.0	9.2 6.1	7.1 4.6		
	9.3	2.6	5.5	2.4	3.9	2.8		
	5.4	5.8	5.6	3.1	-0.4	2.1		
	2.2	3.4	2.9	1.6	4.9	2.5		
	5.7	4.3	4.9	3.1	3.1	3.1		
	4.5	4.8	4.7	2.7	3.2	2.8		
	4.5	5.0	4.7	1.9	3.3	2.3		

Ont.

					Prescrib	ed Drugs				Non-	Prescribed Dr	ugs
	Provincial	Federal	Public Social Secu	rity Eurodo	Subtotal	Insurers*	Private Out-of-	Subtotal	Total	Privat Over-	te (Out-of-Poo Personal	cket) Tota
	Provincial	rederai _	WCB	Drug Insurance	Public	insurers -	Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Pre Drug
r				Fund		(\$ Mi	lions)			Drugs		
5	399.4	13.8	7.2		420.5			579.4	999.9			
6 7	481.2 574.4	14.5 15.4	8.8 10.1		504.5 599.9			706.8 748.2	1,211.2 1,348.1			
8	663.8	24.5	12.0		700.4			845.3	1,545.6			
9	749.5	30.7	13.5		793.8			951.9	1,745.7			
0	881.2	36.2	16.2		933.6			1,089.7	2,023.3			
1	1,012.7	37.9	20.2		1,070.8			1,201.1	2,271.9			;
2 3	1,183.6 1,248.0	41.0 46.7	23.3 24.2		1,247.8 1,318.9			1,376.9 1,482.1	2,624.8 2,801.0	521.5 558.9	455.3 478.5	1,0
4	1,235.8	50.7	18.5		1,305.1			1,508.7	2,813.7	616.3	516.1	1,
5	1,379.6	52.9	19.5		1,452.0			1,660.0	3,112.0	615.7	528.8	1,
6	1,362.7	53.9	21.6		1,438.2			1,735.3	3,173.5	641.2	540.5	
7	1,407.6	57.6	22.3		1,487.5			2,103.4	3,590.9	710.3	603.4	
8	1,550.0	65.9	23.9		1,639.8			2,466.3	4,106.1	750.6	646.0	
9	1,700.0	73.7	25.4		1,799.2			2,387.7	4,186.9	799.7	679.7	1,
0	1,943.4	72.6	31.1		2,047.0			2,719.9	4,767.0	824.7	699.8	
1 2	2,212.6 2,536.2	83.0 94.5	35.4 41.4		2,330.9 2,672.1			3,016.0 3,344.4	5,346.9 6,016.5	840.5 887.8	719.6 740.5	1, 1,
3	2,829.4	106.6	51.9		2,987.8			3,766.1	6,753.9	910.1	728.3	1,
4	3,141.0	108.8	63.3		3,313.0			4,034.1	7,347.1	954.0	750.1	1,
5	3,439.1	121.3	71.7		3,632.1			4,290.8	7,922.9	978.4	770.5	1,
6	3,693.4	131.2	79.4		3,904.0			4,634.6	8,538.6	1,022.3	804.1	1,
f	3,913.0 4,126.3	137.9 147.6	92.8 104.3		4,143.7 4,378.2			5,061.4 5,549.0	9,205.1 9,927.3	1,113.9 1,150.8	860.1 888.6	1, 2,
	4,120.3	147.0	104.3		4,378.2			5,549.0	9,927.3	1,150.8	000.0	Ζ,
						(Annual Perce	ntage Change)					
	20.5 19.4	4.8 5.9	20.8 15.2		20.0 18.9			22.0 5.9	21.1 11.3			
3	15.6	59.4	19.2		16.7			13.0	14.6			
	12.9	25.3	12.6		13.3			12.6	12.9			
	17.6	18.0	19.8		17.6			14.5	15.9			
	14.9	4.8	24.4		14.7			10.2	12.3			
2	16.9	8.0	15.4		16.5			14.6	15.5			
3 1	5.4 -1.0	13.9 8.7	3.9 -23.3		5.7			7.6 1.8	6.7 0.5	7.2 10.3	5.1 7.8	
					-1.0							
; ;	11.6 -1.2	4.3 1.8	5.1 10.9		11.3 -1.0			10.0 4.5	10.6 2.0	-0.1 4.1	2.5 2.2	
,	3.3	7.0	2.9		3.4			21.2	13.2	10.8	11.6	
3	10.1	14.4	7.4		10.2			17.3	14.3	5.7	7.1	
)	9.7	11.9	6.3		9.7			-3.2	2.0	6.5	5.2	
)	14.3	-1.6	22.3		13.8			13.9	13.9	3.1	3.0	
	13.9	14.3	13.8		13.9			10.9	12.2	1.9	2.8	
2	14.6 11.6	13.9 12.8	17.0 25.2		14.6 11.8			10.9 12.6	12.5 12.3	5.6 2.5	2.9 -1.6	
4	11.0	2.0	22.0		10.9			7.1	8.8	4.8	3.0	
	9.5	11.5	13.3		9.6			6.4	7.8	2.6	2.7	
5	7.4	8.1	10.7		7.5			8.0	7.8	4.5	4.4	
f	5.9	5.1	16.9		6.1			9.2	7.8	9.0	7.0	
B f	5.5	7.1	12.4		5.7			9.6	7.8	3.3	3.3	
					(P	ercentage Share of 1	otal Drug Expe	enditure)				
5 6	26.8	0.9	0.5		28.3			38.9	67.2			
5 7	27.3 28.9	0.8 0.8	0.5 0.5		28.6 30.2			40.1 37.6	68.7 67.8			
B	29.4	1.1	0.5		31.0			37.5	68.5			
9	29.6	1.2	0.5		31.3			37.6	68.9			
D	31.0	1.3	0.6		32.9			38.4	71.2			
	32.1	1.2	0.6		33.9			38.1	72.0			
2	32.9	1.1	0.6		34.6			38.2	72.9	14.5	12.6	
3 4	32.5 31.3	1.2 1.3	0.6 0.5		34.4 33.1			38.6 38.2	73.0 71.3	14.6 15.6	12.5 13.1	
5 6	32.4 31.3	1.2 1.2	0.5 0.5		34.1 33.0			39.0 39.8	73.1 72.9	14.5 14.7	12.4 12.4	
7	28.7	1.2	0.5		30.3			42.9	73.2	14.5	12.4	
3	28.2	1.2	0.4		29.8			44.8	74.6	13.6	11.7	
)	30.0	1.3	0.4		31.8			42.1	73.9	14.1	12.0	
	30.9	1.2	0.5		32.5			43.2	75.8	13.1	11.1	
1 2	32.0	1.2	0.5		33.7			43.7	77.4	12.2	10.4	
2 3	33.2 33.7	1.2 1.3	0.5 0.6		35.0 35.6			43.7 44.9	78.7 80.5	11.6 10.8	9.7 8.7	
ļ.	34.7	1.3	0.8		36.6			44.9	80.5	10.8	8.3	
5	35.6	1.3	0.7		37.6			44.4	81.9	10.1	8.0	
	35.6	1.3	0.8		37.7			44.7	82.4	9.9	7.8	
f	35.0	1.2	0.8		37.1			45.3	82.3	10.0	7.7	
f	34.5	1.2	0.9		36.6			46.4	83.0	9.6	7.4	

	I	Expenditure or	• • • •	, by Source of Fin xpenditures, Onta				Table B Ont.	— Total
						2000 (cont u)		in Public, Private and	i i
-	Public	All Drugs Private	Total	Public Heal	th Expenditure Private	Total		Ith Expenditures Private	Total
-			(\$ Millio					entage Share)	
	420.5	1,067.2	1,487.7	10,443.3	3,999.5	14,442.8	4.0	26.7	10.3
	504.5 599.9	1,259.2 1,388.9	1,763.7 1,988.8	11,730.2 13,011.9	4,367.1 4,854.5	16,097.2 17,866.4	4.3 4.6	28.8 28.6	11.0 11.1
	700.4	1,556.3	2,256.7	14,497.9	5,321.9	19,819.8	4.8	29.2	11.4
	793.8	1,741.1	2,534.9	16,093.9	5,876.9	21,970.8	4.9	29.6	11.5
	933.6	1,906.2	2,839.8	17,332.8	6,466.2	23,799.1	5.4	29.5	11.9
	1,070.8	2,084.6	3,155.4	19,156.1	7,038.2	26,194.3	5.6	29.6	12.0
	1,247.8 1,318.9	2,353.7 2,519.6	3,601.5 3,838.5	20,001.5 19,821.7	7,573.7 8,253.2	27,575.2 28,074.9	6.2 6.7	31.1 30.5	13.1 13.7
	1,305.1	2,641.0	3,946.1	20,008.0	8,740.7	28,748.7	6.5	30.2	13.7
	1,452.0	2,804.5	4,256.5	19,874.7	9,411.7	29,286.4	7.3	29.8	14.5
	1,438.2	2,917.0	4,355.2	20,038.0	9,655.3	29,693.3	7.2	30.2	14.7
	1,487.5	3,417.2	4,904.7	20,480.8	10,314.0	30,794.8	7.3	33.1	15.9
	1,639.8 1,799.2	3,862.9 3,867.1	5,502.8 5,666.3	22,029.7 23,344.6	11,054.0 12,033.6	33,083.7 35,378.2	7.4	34.9 32.1	16.6 16.0
	2,047.0 2,330.9	4,244.5 4,576.2	6,291.5 6,907.1	25,957.7 27,606.2	13,023.2 14,136.1	38,981.0 41,742.3	7.9 8.4	32.6 32.4	16.1 16.5
	2,672.1	4,972.6	7,644.8	29,626.1	15,796.5	45,422.6	9.0	31.5	16.8
	2,987.8	5,404.4	8,392.3	33,229.2	16,404.9	49,634.2	9.0	32.9	16.9
	3,313.0	5,738.2	9,051.2	35,657.2	17,667.2	53,324.4	9.3	32.5	17.0
	3,632.1 3,904.0	6,039.7 6,461.0	9,671.8 10,365.0	38,015.6 40,221.1	18,698.5 19,764.4	56,714.2 59,985.6	9.6 9.7	32.3 32.7	17.1 17.3
	4,143.7	7,035.5	11,179.1	43,019.3	20,890.3	63,909.7	9.6	33.7	17.5
	4,378.2	7,588.4	11,966.6	45,652.5	22,026.2	67,678.6	9.6	34.5	17.7
			(Annual Descente	(hones)					
-			(Annual Percenta	ige Change)					
	20.0 18.9	18.0 10.3	18.6 12.8	12.3 10.9	9.2 11.2	11.5 11.0			
	16.7	12.1	13.5	11.4	9.6	10.9			
	13.3	11.9	12.3	11.0	10.4	10.9			
	17.6	9.5	12.0	7.7	10.0	8.3			
	14.7	9.4	11.1	10.5	8.8	10.1			
	16.5 5.7	12.9 7.0	14.1 6.6	4.4 -0.9	7.6 9.0	5.3 1.8			
	-1.0	4.8	2.8	0.9	5.9	2.4			
	11.3	6.2	7.9	-0.7	7.7	1.9			
	-1.0	4.0	2.3	0.8	2.6	1.4			
	3.4	17.1	12.6	2.2	6.8	3.7			
	10.2 9.7	13.0 0.1	12.2 3.0	7.6 6.0	7.2 8.9	7.4 6.9			
	13.8 13.9	9.8 7.8	11.0 9.8	11.2 6.4	8.2 8.5	10.2 7.1			
	14.6	8.7	10.7	7.3	11.7	8.8			
	11.8	8.7	9.8	12.2	3.9	9.3			
	10.9	6.2	7.9	7.3	7.7	7.4			
	9.6	5.3	6.9	6.6	5.8	6.4			
	7.5 6.1	7.0 8.9	7.2 7.9	5.8 7.0	5.7 5.7	5.8 6.5			
	5.7	7.9	7.0	6.1	5.4	5.9			
	-		- Former day						
-		je Share of Total Dru		_					
	28.3	71.7	100.0						
	28.6 30.2	71.4 69.8	100.0 100.0						
	31.0	69.0	100.0						
	31.3	68.7	100.0						
	32.9	67.1	100.0						
	33.9	66.1	100.0						
	34.6 34.4	65.4 65.6	100.0 100.0						
	33.1	66.9	100.0						
	34.1	65.9	100.0						
	33.0	67.0	100.0						
	30.3	69.7	100.0						
	29.8 31.8	70.2 68.2	100.0 100.0						
	32.5	67.5	100.0						
	33.7 35.0	66.3 65.0	100.0 100.0						
	35.6	64.4	100.0						
	36.6	63.4	100.0						
	37.6	62.4	100.0						
	37.7	62.3	100.0						
	37.1 36.6	62.9 63.4	100.0 100.0						
	55.0	00.4							

					Prescribe	d Drugs					-Prescribed Dr	
	Provincial	Federal		Funds Drug surance Fund	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Priva Over- the- Counter Drugs	te (Out-of-Poo Personal Health Supplies	cket) To Non- Dr
Year				T UNU		(\$ per	Capita)			Diuga		
1985 1986	42.96 50.99	1.49 1.54	0.78 0.93		45.23 53.45			62.31 74.88	107.54 128.33			
1987	59.56	1.59	1.05		62.20			77.58	139.78			
1988 1989	67.45 74.16	2.49 3.04	1.22 1.34		71.16 78.53			85.88 94.18	157.04 172.71			
1990	85.57	3.52	1.58		90.66			105.82	196.48			
1991	97.11	3.64	1.93		102.68			115.18	217.86			
1992 1993	111.98 116.76	3.88 4.37	2.20 2.26		118.06 123.39			130.27 138.67	248.33 262.06	49.33 52.29	43.07 44.77	
994	114.23	4.69	1.71		120.64			139.46	260.09	56.97	47.71	
995	125.99	4.83	1.78		132.60			151.60	284.20	56.23	48.29	
996 997	122.95 125.36	4.86 5.13	1.95 1.98		129.76 132.48			156.57 187.33	286.34 319.81	57.86 63.26	48.77 53.74	
1998	136.36	5.80	2.10		144.26			216.97	361.23	66.04	56.83	
1999	147.75	6.41	2.21		156.37			207.51	363.88	69.50	59.07	
2000 2001	166.31 185.97	6.21 6.97	2.66 2.97		175.18 195.91			232.76 253.50	407.94 449.41	70.58 70.64	59.89 60.49	
2002	209.57	7.81	3.42		220.80			276.35	497.15	73.36	61.19	
2003 2004	230.73 252.89	8.69 8.76	4.23 5.09		243.65 266.74			307.12	550.77 591.54	74.22 76.81	59.39 60.39	
								324.80				
2005 2006	273.69 290.70	9.66 10.32	5.71 6.25		289.06 307.27			341.47 364.78	630.53 672.05	77.86 80.46	61.32 63.29	
2007 f	305.61	10.77	7.25		323.63			395.30	718.93	87.00	67.18	
008 f	318.82	11.41	8.06		338.28			428.74	767.03	88.91	68.66	
						(Annual Perce	ntage Change)					
985 986	 18.7	3.3	19.0		18.2			20.2	19.3			
987	16.8	3.6	12.8		16.4			3.6	8.9			
988 989	13.2 9.9	56.2 22.0	16.8 9.6		14.4 10.4			10.7 9.7	12.3 10.0			
1990	15.4	15.8	17.6		15.4			12.4	13.8			
991	13.5	3.5	22.8		13.3			8.8	10.9			
992	15.3	6.5	13.8		15.0			13.1	14.0			
1993 1994	4.3 -2.2	12.6 7.4	2.7 -24.2		4.5 -2.2			6.4 0.6	5.5 -0.8	6.0 8.9	3.9 6.6	
995	10.3	3.1	3.9		9.9			8.7	9.3	-1.3	1.2	
996	-2.4	0.6	9.6		-2.1			3.3	0.8	2.9	1.0	
997 998	2.0 8.8	5.6 13.0	1.6 6.1		2.1 8.9			19.6 15.8	11.7 13.0	9.3 4.4	10.2 5.7	
999	8.4	10.5	5.0		8.4			-4.4	0.7	5.2	3.9	
000	12.6	-3.1	20.4		12.0			12.2	12.1	1.5	1.4	
001 002	11.8 12.7	12.3 12.0	11.8 15.1		11.8 12.7			8.9 9.0	10.2 10.6	0.1 3.8	1.0 1.2	
003	10.1	11.3	23.6		10.4			11.1	10.8	1.2	-2.9	
004	9.6	0.7	20.5		9.5			5.8	7.4	3.5	1.7	
005	8.2	10.3	12.0		8.4			5.1 6.8	6.6	1.4 3.3	1.5	
2008 2007 f	6.2 5.1	6.9 4.3	9.5 16.0		6.3 5.3			8.4	6.6 7.0	8.1	3.2 6.1	
008 f	4.3	5.9	11.2		4.5			8.5	6.7	2.2	2.2	
					(Annual Percentag	e Change in Excess	of Inflation in	the Canadian E	conomy)			
1985 1986	 15.9	 0.5	16.2		15.4			 17.4	16.5			
987	12.1	-1.1	8.0		11.6			-1.1	4.2			
988 989	8.7	51.6 17.4	12.3		9.9			6.2 E 1	7.8			
	5.4		5.0		5.8			5.1	5.4			
990 991	12.4 10.7	12.8 0.7	14.6 20.0		12.4 10.5			9.3 6.1	10.7 8.1			
992	14.1	5.3	12.6		13.7			11.8	12.7			
993 994	2.8 -3.3	11.2 6.3	1.3 -25.3		3.1 -3.3			5.0 -0.5	4.1 -1.8	4.6 7.8	2.5 5.5	
995	8.0	0.7	1.5		7.6			6.4	6.9	-3.6	-1.1	
996	-4.1	-1.1	7.9		-3.8			1.6	-0.9	1.2	-0.7	
997 998	1.0 9.2	4.6 13.4	0.6 6.6		1.1 9.3			18.7 16.3	10.7 13.4	8.3 4.8	9.2 6.2	
999	6.5	8.7	3.2		6.6			-6.2	-1.1	4.8	2.1	
000	8.5	-7.2	16.3		7.9			8.1	8.0	-2.6	-2.7	
001	10.5	10.9	10.4		10.5			7.6	8.8	-1.3	-0.4	
002 003	11.6 7.2	10.9 8.4	14.0 20.7		11.7 7.5			8.0 8.2	9.6 7.9	2.8 -1.7	0.1 -5.8	
004	7.0	-1.8	17.9		6.9			3.2	4.8	0.9	-0.9	
005	5.1	7.1	8.9		5.3			2.0	3.5	-1.7	-1.6	
006 007 f	3.8 1.9	4.5 1.1	7.0 12.8		3.9 2.1			4.4 5.1	4.2 3.8	0.9 4.9	0.8	
2007 f	0.9	1.1	12.0		4.1				0.0			

CIHI 2009

988 4.2.4 114.2 114.0.7 1132.2 40.0.7 153.40 724 987 4.2.4 144.0 92.47 1.342.1 84.0.2 1.342.3 1.34			Evnanditura		nite by Type by	Source of Fir	anaa and Rubli		B Ont. – Per Capita
			Expenditure					c, Private and	
	-	Public		Total			Total	Price Index—Canada	
ab <	Year			(\$ per Ca	apita)			(1997 = 100)	
ab <	1985	45.23	114.79	160.01	1,123,23	430.17	1,553.40	73.6	
No. No. No. No. No. No. No. No. 36.46 165.17 20.77 1.472.03 60.77 2.172.70 60.67 No. 36.46 165.17 20.77 1.462.13 67.72 2.172.70 60.67 No. 36.46 165.17 2.172.70 2.012.71 2.012.70 80.67 No. 12.38 2.017.71 2.012.70 2.012.70 80.67 80.67 No. 12.38 2.017.71 2.012.70 80.67 80.67 80.67 No. 12.38 2.017.71 2.012.71 2.012.71 80.67 No. 12.37 2.023.91 1.014.61 2.023.91 1.016.62 100.71 No. 12.37 2.024.81 1.012.91 2.012.11 11.114.8 2.024.91 100.72 No. 12.37 2.024.81 1.027.17 2.024.11 1.014.8 2.024.91 11.112.1 No. 2.027.21 1.114.8 2.024.91 1.012.1 1.012.1 1.012.1 1.012.1 No. 2.027.21 1.011.81 2.024.91 1.012.1 1.012.1 1.012.1 1.012.1 1.012.1 1.012.1 No. 2.027.21	1986	53.45	133.42	186.87	1,242.85	462.71	1,705.55	75.6	
Bits PA-85 PI-22 PI-07 TABE 7 PI-16 PI-27 PI-16 000 10.44 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10.24 10.90 10	1987								
	1988 1989								
99 122.68 192.92 22.58 1.29.27 74.42 2.51.19 91.5 121.41 22.41.2 34.57 1.44.41 857.80 2.65.77 85.7 121.41 22.41.2 34.57 1.44.41 857.80 2.65.77 85.7 121.41 22.41.2 34.57 1.44.41 857.80 2.75.74 85.7 121.41 22.42.2 54.44 1.45.94 857.80 2.75.74 1.86.7 121.41 22.42.2 54.44 2.27.71 1.14.14 2.07.64 1.15.7 121.41 22.42.2 54.44 2.27.71 1.14.14 2.07.64 1.15.7 121.41 3.86.64 9.95.64 2.27.71 1.14.14 3.07.65 1.15.7 121.41 4.86.75 9.95.64 2.27.71 1.14.14 3.07.65 1.15.7 121.41 4.86.75 9.95.64 2.27.71 1.14.14 3.07.65 1.15.7 121.41 4.86.75 9.95.64 1.92.67 4.97.25 1.16.1 121.41 4.87.85 1.97.64 4.97.25 1.16.1 1.17.1 121.41 4.87.85 1.97.64 4.97.25 1.16.1 1.17.1 121.41 1.26.7<									
999 118.04 22.24 24.07 1.92.22 7.64.4 2.85.87 24.13 999 12.34 24.01 33.92 1.91.95 2.85.87 2.45.87 2.95.87 999 12.24 20.01 33.92 1.91.95 87.92 2.95.87 7.95 999 12.24 20.03 33.92 1.91.95 87.92 2.95.87 7.95 999 12.24 20.23 2.94.92 1.24.9 2.95.97 7.95 7.95 999 12.24 20.23 2.94.92 1.95.94 7.95.93 7.95.94 7.95.94 900 175.16 32.92.3 2.94.92 1.14.14 3.256.97 7.95.94 7.95.94 900 175.16 32.92.3 1.94.94 3.256.97 7.95.94 7.95.94 900 175.16 32.92.9 2.94.99 2.94.92.9 7.95.94 7.95.94 900 175.16 32.92.9 1.94.94 3.25.97 7.95.1 7.95.1 7.95.9 901 2.92.91 1.91.94 3.25.97 7.95.1 7.95.1 7.95.9 7.95.1 901 3.33.99 1.92.97 1.92.97.1 7.95.1 7.95.1 7.95.1 7.95.1 <td>1990</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1990								
98 120.4 24.13 24.17 1.08.47 107.95 2.87.43 97.43 989 120.2 2.80.12 38.22 1.00.20 88.18 2.87.43 2.87.43 989 120.2 2.80.23 822.41 1.00.20 87.18 2.87.16 2.97.17 989 119.3 323.66 424.40 2.00.21 1.11.44 2.30.65 1.00.20 119.3 33.66 424.40 2.00.21 1.11.44 3.35.67 1.00.20 001 120.40 84.40 80.04 2.20.21 1.11.81 4.04.45 1.01.3 001 240.40 40.40 2.40.21 1.42.40 4.24.20 1.42.40 4.24.20 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.24.42 1.42.40 4.44.42 <	1992								
999 1030 19492 9972 10104 19592 27446 944 997 10344 30434 41841 103404 01837 274281 000 1040 10342 30444 41841 103404 01837 274281 0104 001 17518 41823 31844 20233 11444 203587 1015 002 22000 41009 01199 224802 10353 37330 0113 003 22000 41009 01199 224802 13053 47330 1113 004 22001 40043 78071 202541 14860 473130 1226 005 22002 78071 202511 14162 420143 1226 007 2264 40314 120 42014 120 126 007 2264 40314 120 120 42014 120 126 007 2264 40314 120 120 42014 120 120 007 2264 101 225 74 101 120 120 001 122 103 120 70 120 120 120	1993								
986123761232612326120739971.182.72.1010098711326323.68422.482.222.841.235.22101.49871195.31333.68422.492.222.841.235.23101.619871195.31345.43400.412.222.311.146.443.356.65100.35987123.90410.99411.942.327.311.146.443.356.65101.35987123.93442.492.227.351.146.443.356.65113.15987123.93444.492.377.311.146.442.328.15113.15987123.93444.492.377.311.145.404.373.30113.15988123.9394.492.377.311.164.404.473.30123.55988124124.501.455.404.571.504.271.20123.55989124124.501.455.404.571.504.271.20123.55989124124.501.455.404.51.504.271.20123.55989124124.501.455.404.51.504.514.51.50989124.50124.501.455.404.51.504.514.51.50989124.50124.501.45.504.514.51.504.51989124.50124.501.45.504.524.514.51.50989124.50124.501.45.504.524.514.51.50989124.501.45.501.45.50<	1994	120.64	244.13	364.76	1,849.47	807.95	2,657.43	95.2	
907 102.4 904.54 48.61 1.02.04 918.67 2.72.61 100.0 999 110.77 325.06 42.0 2.00.04 7.05.2 3.307.00 100.1 0001 17.18 3.05.00 01.04 2.20.20.04 1.00.20 100.2 0021 2.20.00 10.08 01.04 2.20.00 1.00.20 100.2 0021 2.20.00 10.08 01.04 2.20.00 1.00.20 111.2 0021 2.20.00 01.04 2.20.00 1.00.20 111.2 0021 2.20.00 02.00 02.01 0.30.00 1.00.11 1.00.00 1.11.1 0021 2.20.00 02.00 02.01 0.30.00 1.00.11 1.00.00 1.01.00 1.01.00 0021 2.20.00 0.00.00 0.00.11 0.00.00 1.0	1995								
abel biol14.28 biol33.84 biol49.4 									
999 196.27 32.628 42.42 2.22.84 1.45.22 1.07.46 10.4 001 15.631 344.83 60.64 2.230.31 1.148.14 3.258.45 100.9 002 15.641 344.83 60.64 2.230.31 1.148.14 3.258.45 100.9 004 15.640 7.121.44 2.270.28 1.422.45 4.233.33 114.1 005 2.027.27 0.06.85 91.50.7 3.216.80 4.721.29 114.1 006 2.07.27 0.06.85 91.62.97 7.27 4.06 12.25 007 0.06.7 0.06.7 0.06.80 4.21.35 12.23 12.25 928 1.04 0.80 9.44 0.0 7.7 0.0 0.3 2.20 929 1.04 0.80 9.44 0.0 7.7 0.0 0.3 2.00 929 1.04 0.80 0.97 0.3 0.40 0.20 0.10 929 1.14	1997								
	1999								
	2000	175 18	363.23	538 /1	2 221 39	1 114 49	3 335 87	105.5	
	2000								
000 22070 42070 72070 72070 42230 42230 141 000 20272 500.3 810.90 310.658 120.658 4212120 120.65 320.20 500.63 810.30 227.27 100.11 320.20 120.11 120.65 120.20 120.20 320.20 500.63 810.30 227.27 100.11 522.21 120.20 120.20 800 7 </td <td>2002</td> <td>220.80</td> <td>410.89</td> <td>631.69</td> <td>2,448.02</td> <td>1,305.28</td> <td>3,753.30</td> <td>108.1</td> <td></td>	2002	220.80	410.89	631.69	2,448.02	1,305.28	3,753.30	108.1	
0000 000000 000000 000000 000000	2003								
0000 1 002.7 1 00.40.40 1 01.60.60 1 1.65.60 1 4.271.29 1 120.5 1 0001 1 01.60.40 1 0.22.7 1 0.21.17 1 0.20.17 1 0.21.17 1 0.20.17 1 0.21.17 1 0.20.17 1 0.21.17 1 0.20.17 1 <	2004	266.74	462.00	728.74	2,870.88	1,422.45	4,293.33	114.1	
0071 33.8.8 54.8.8 67.1.1 3.36.9.2 1.53.1.2 1.53.1.2 1.53.1.2 1.53.1.2 1.53.1.2 2001 20.2.2.1 20.4.2 20.2.1 20.4.2 20	2005			769.71	3,025.41	1,488.09	4,513.50		
00011 128.28 128.28 128.40 129.20 129.14 128.29 128.29 Loward Pocentize Departing 1004 0	2006								
Ububu bubu bubu bubu bubu bubu bubu bub									
	20001	556.20	300.31				3,223.13	120.0	
888 18.2 16.2 16.8 10.6 7.8 88 2.8 989 16.4 9.8 11.2 9.2 7.4 8.7 4.5 980 15.4 7.5 10.0 5.7 8.0 6.3 2.8 981 13.3 6.0 8.7 8.0 6.7 2.8 3.0 2.8 982 15.0 11.4 12.6 3.0 6.2 3.9 1.3 984 4.2 2.8 6.6 1.8 6.4 0.8 2.3 984 4.1 2.8 1.1 0.3 4.4 0.8 2.3 984 4.1 2.8 1.1 1.7 4.7 7.8 6.6 1.8 989 4.4 1.1 1.7 4.7 7.8 6.6 1.8 989 4.3 1.8 7.8 7.8 6.6 1.8 4.1 989 1.6 7.8 7.8 6.6 1.8 4.1 4.1 989 1.4 7.8 7.8 6.6									
887 164 7,9 10,4 8,6 8,8 8,7 4,7 989 16,4 8,8 11,2 7,5 7,9 4,6 989 16,4 7,8 9,7 3,1 7,5 8,7 2,8 991 15,0 11,4 12,8 3,0 9,7 3,1 7,5 8,7 2,8 992 16,0 11,4 12,8 3,0 4,0 4,2 1,1 994 4,2 5,0 1,4 4,0 4,4 4,2 1,1 994 4,2 5,0 1,1 4,0 4,4 4,2 1,1 995 4,6 1,1 1,7 4,7 7,5 6,6 1,2 1,1 996 8,4 1,1 1,7 4,7 7,5 6,7 1,2 1,4 901 11,8 5,9 7,8 6,8 6,7 4,1 1,2 902 1,4 4,0 8,8 5,5 6,8 4,7 2,8 1,2 903 1,4 4,8									
989 144 9.8 1.2 9.2 7.4 9.7 4.5 990 16.4 7.5 10.0 7.7 8.0 8.7 2.0 992 15.0 1.1.4 1.2.0 3.0 9.2 3.9 1.3 992 4.5 5.0 1.4 2.0 3.0 7.2 3.0 1.2 992 4.2 3.0 1.0 -0.3 6.8 1.2 1.1 994 4.2 3.0 1.0 -0.3 6.8 2.2 1.1 995 2.1 1.5.8 1.1 -0.4 1.4 0.2 1.1 996 2.1 1.5.8 1.1 -0.4 1.4 0.2 1.1 997 2.1 1.5.8 1.1 -0.4 1.4 0.2 1.1 998 1.0 1.0 1.0 1.0 1.0 1.0 1.0 999 1.0 1.0 1.0 1.0 1.0 1.0 1.0 999 1.0 1.0 1.0 1.0 1.0 1.0 1.0 990 1.0 1.0 1.0 1.0 1.0 1.0 1.0 991 1.0 <	1987								
989 114 2.5 10.0 7.7 8.0 6.3 2.0 982 115.0 11.4 1.2.6 3.0 6.2 3.9 1.3 984 6.5 6.4 2.0 7.8 0.7 1.1 1.2 1.1 984 2.2 3.6 1.6 0.3 4.6 1.2 1.1 985 9.4 6.6 1.1 0.4 1.4 0.2 7.7 986 9.9 1.1 1.0.6 6.2 5.9 6.1 0.4 989 8.4 1.1.7 1.0.8 6.2 5.9 6.1 0.4 0001 12.0 8.1 9.3 7.7 5.6 6.1 1.4 0021 12.7 6.8 6.5 5.9 6.3 6.1 2.0 0023 0.4 7.3 8.3 1.0.7 2.5 7.8 1.4 0024 9.5 4.8 6.5 5.9 6.3 6.1 2.0 0026 6.3 5.8 6.0 4.6 <td< td=""><td>1988</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	1988								
991 13.3 8.0 9.7 9.1 7.5 8.7 9.7 9.1 7.5 8.7 9.7	1989	10.4	8.9	9.4	8.1	7.5	7.9	4.6	
991 13.3 8.0 9.7 9.1 7.5 8.7 9.7 9.1 7.5 8.7 9.7	1990	15.4	7.5	10.0	5.7	8.0	6.3	3.0	
989 4.5 5.9 5.4 2.0 7.8 0.7 1.4 996 4.2 3.6 1.9 6.4 0.6 2.3 997 2.1 1.5.6 1.12 0.9 5.4 2.4 1.0 997 2.1 1.5.6 1.1.2 0.9 5.4 2.4 1.0 998 8.9 1.1.7 1.0 8.5 6.6 5.2 1.6 1.4 999 8.4 1.1.1 1.7 4.7 7.5 5.6 1.8 0001 1.1.8 5.9 7.8 4.5 6.6 5.2 1.4 001 1.1.8 5.9 7.8 4.5 6.6 5.2 1.4 002 1.7 6.8 8.5 5.9 6.3 6.1 3.1 003 1.0.4 7.9 5.0 4.8 6.7 2.6 2.6 0036 8.4 4.0 5.6 5.6 5.0 3.2 2.6 2.6 0037 6.3 6.7 7.7 5.0	1991								
994 -2.2 3.6 1.6 -0.3 4.6 1.2 1.1 985 9.3 4.9 6.6 -1.9 6.4 0.6 2.3 986 2.1 2.6 1.2 0.6 4.4 0.6 1.0 986 4.9 1.1.7 1.0 0.6 4.4 0.6 1.8 980 6.4 -1.1 9.7 4.7 7.6 5.6 4.1 000 12.0 8.1 9.3 0.5 6.6 5.2 1.4 001 11.8 5.9 7.8 4.5 6.6 5.2 1.4 002 12.7 6.8 8.6 5.5 9.9 7.8 2.8 005 6.3 5.8 6.0 4.6 4.5 4.8 2.4 006 6.3 5.8 6.0 4.6 4.8 3.4 3.4 007 4.5 6.7 7.8 4.8 7.9 3.4 008 5.8 4.4 4.8 3.5 3.0 3.4	1992								
995 9.5 4.5 6.6 1.6 6.4 0.6 2.3 997 2.1 2.6 1.2 0.4 1.4 0.4 1.0 998 3.1 1.1 1.7 0.4 7.5 5.8 1.8 999 5.4 1.1 1.7 4.7 7.5 5.8 1.8 000 12.0 8.1 9.3 9.5 6.6 8.5 1.4 001 1.8 6.3 7.8 4.5 6.6 8.5 1.4 002 1.8 6.3 7.8 6.5 5.9 6.3 6.1 2.6 003 1.0.4 4.8 0.5 5.9 6.3 6.1 2.4 004 6.3 5.8 6.0 4.6 4.5 4.6 2.4 005 6.4 4.0 5.6 5.9 6.3 6.7 2.2 996 1.6 7.0 7.0 7.0 7.0 3.4 7.0 2.4 997 1.6 5.2 7.0 7.7 <t< td=""><td>1993</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>	1993								
996 2.1 2.8 1.1 0.4 1.4 0.2 1.7 997 2.1 15.6 1.2 0.9 5.4 2.4 1.0 998 8.8 1.1.7 10.8 6.2 5.9 6.1 0.4 000 12.0 8.1 9.3 9.5 6.6 8.5 1.8 001 11.8 5.9 7.8 4.5 6.6 6.5 1.4 002 12.7 6.8 8.8 5.5 9.9 7.0 1.0 003 10.4 7.3 8.3 10.7 2.5 7.8 2.9 004 6.5 5.0 6.3 6.1 2.4 2.9 005 6.4 6.6 5.1 2.4 2.9 0061 6.5 5.0 6.3 6.1 2.4 0061 6.5 5.0 6.3 6.1 2.4 0061 6.5 5.0 6.3 6.1 2.4 0061 6.4 4.6 6.1 2.4 2.4 <tr< td=""><td>1994</td><td>-2.2</td><td>3.6</td><td>1.6</td><td>-0.3</td><td>4.6</td><td>1.2</td><td>1.1</td><td></td></tr<>	1994	-2.2	3.6	1.6	-0.3	4.6	1.2	1.1	
997 2.1 15.6 11.2 0.9 5.4 2.4 1.0 998 8.4 1.1 1.7 4.7 7.5 5.6 1.8 999 8.4 1.1 1.7 4.7 7.5 5.6 1.8 000 12.0 8.1 9.3 9.5 6.6 8.5 4.1 001 11.5 5.9 7.8 6.5 9.9 7.0 1.0 002 10.4 7.3 8.3 0.07 2.5 7.8 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 3.1 3.1 005 8.4 4.0 5.6 5.4 4.6 5.7 3.2 0061 6.3 5.8 6.0 4.6 4.6 5.1 3.1 0061 5.3 6.7 7.9 6.7 3.2 3.4 3.4 0061 5.4 4.8 7.6 3.2 3.4 3.4 3.4 0061 15.4 13.4 14.0 7.8 3.8 <td>1995</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1995								
989 8.9 11.7 10.8 6.2 5.9 6.1 -0.4 000 12.0 8.1 9.3 9.5 6.6 8.5 4.1 001 11.8 5.9 7.8 4.5 6.6 6.2 1.4 001 11.8 5.9 7.8 4.5 6.6 6.2 1.0 003 10.4 7.3 8.3 10.7 2.5 7.8 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 2.4 005 6.4 4.6 5.1 3.1 3.2 3.2 3.2 006 6.3 5.8 6.1 4.6 5.1 3.4 0071 5.3 6.1 7.0 4.2 3.4 3.4 0072 5.3 6.1 7.8 7.0 3.4 3.4 0074 3.2 5.6 7.8 7.0 3.4 3.4 0074 3.2 5.6 7.7 5.9 3.1 3.4 015 5.2 7.0									
989 8.4 -1.1 1.7 4.7 7.5 5.6 1.8 000 12.0 6.1 9.3 9.5 6.8 8.5 4.1 001 11.8 5.9 7.6 6.8 6.5 1.4 002 12.7 6.8 8.6 5.5 9.9 7.6 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 3.1 005 6.4 4.0 5.6 5.4 4.6 5.6 4.2 006 6.3 5.8 6.0 4.6 4.6 5.7 3.2 0061 6.3 5.8 6.0 6.1 4.8 3.4 3.4 0071 5.3 6.7 5.9 5.0 4.3 4.8 3.4 988 9.9 5.3 6.7 4.7 2.9 3.4 3.4 989 5.8 4.4 4.8 3.5 3.0 3.4 3.4 989 5.8 4.4 4.8 3.5 3.0 3.4	1998								
001 11.8 5.9 7.8 4.5 6.6 5.2 1.4 003 10.4 7.3 8.3 10.7 2.5 7.8 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 2.6 005 8.4 4.0 5.6 5.4 4.6 5.1 3.1 006 6.3 5.8 6.0 4.6 4.5 4.6 2.4 0071 5.3 8.1 7.0 6.1 4.9 5.7 3.2 0081 4.5 6.7 5.9 5.0 4.3 4.8 3.4 Chrueze in fices of Inflation in the Canadian Economy 987 15.4 13.4 14.0 7.8 4.8 7.0 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 9.1 991 10.5 5.2 7.0 6.4 </td <td>1999</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1999								
001 11.8 5.9 7.8 4.5 6.6 5.2 1.4 003 10.4 7.3 8.3 10.7 2.5 7.8 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 2.6 005 8.4 4.0 5.6 5.4 4.6 5.1 3.1 006 6.3 5.8 6.0 4.6 4.5 4.6 2.4 0071 5.3 8.1 7.0 6.1 4.9 5.7 3.2 0081 4.5 6.7 5.9 5.0 4.3 4.8 3.4 Chrueze in fices of Inflation in the Canadian Economy 987 15.4 13.4 14.0 7.8 4.8 7.0 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 9.1 991 10.5 5.2 7.0 6.4 </td <td>2000</td> <td>12.0</td> <td>8.1</td> <td>9.3</td> <td>9.5</td> <td>6.6</td> <td>8.5</td> <td>4.1</td> <td></td>	2000	12.0	8.1	9.3	9.5	6.6	8.5	4.1	
003 10.4 7.3 8.3 10.7 2.5 7.8 2.9 004 9.5 4.8 6.5 5.9 6.3 6.1 2.6 005 8.4 4.0 5.6 5.4 4.6 4.5 4.6 2.4 006 6.3 6.7 5.9 5.0 4.3 4.8 3.4 0071 5.3 6.1 7.0 6.1 4.9 5.7 3.4 0081 4.5 6.7 5.9 5.0 4.3 4.8 3.4 907 1.6 7.8 4.8 7.0 5.9 3.4 3.4 987 15.4 13.4 14.0 7.8 4.8 7.0 3.4 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.1 4.4 4.0 3.4 6.3 -0.8 992	2001								
004 9.8 4.8 6.5 5.9 6.3 6.1 2.8 005 8.4 4.0 5.6 5.4 4.6 5.1 3.1 0061 5.3 8.1 7.0 6.1 4.9 5.7 3.2 0071 4.5 6.7 5.9 5.0 4.3 4.8 3.4 Interpreting the careful to in the Ca	2002	12.7	6.8	8.8	5.5	9.9	7.0	1.0	
005 8.4 4.0 5.6 5.4 4.6 5.1 3.1 2.4 006 6.3 5.8 6.0 4.6 4.5 4.6 2.4 2.4 007 3.3 8.1 7.0 5.0 5.0 4.3 4.8 3.1 008 1.4.5 6.7 5.9 5.0 4.3 4.8 3.1 (Ancurrente Concurrente Textuare Tex	2003								
006 6.3 5.8 6.0 4.6 4.5 4.6 2.4 0071 4.5 6.7 5.9 5.0 4.3 4.8 3.2 0081 4.5 6.7 5.9 5.0 4.3 4.8 3.4 Intercettage Character as the flattoin in the Caracter as the flattoin in the Ca	2004	9.5	4.8	6.5	5.9	6.3	6.1	2.6	
0071 5.3 8.1 7.0 6.1 4.9 5.7 3.2 0081 4.5 6.7 5.9 5.0 4.8 3.4 Intercentage Change in Excess of Inflation in the Canculan Economy 985 986 15.4 13.4 14.0 7.8 4.8 7.0 3.2 987 16.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.3 2.5 0.5 1.14 3.5 0.1 994 -3.3 2.5 0.5 1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 1.4 1.4 996 3.3 12.1 1.3	2005	8.4	4.0	5.6	5.4	4.6	5.1	3.1	
008 f 4.5 6.7 5.9 5.0 4.3 4.8 3.4 Lanual Percentage Change in Excess of Inflation in the Candian Eccomony. 985 986 16.4 13.4 14.0 7.8 4.8 7.0 3.9 987 11.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.1 4.4 4.0 3.4 6.3 -0.8 993 3.1 4.4 4.0 3.4 6.3 -0.8 994 -3.3 2.5 0.5 1.1 -0.6 -2.1 -0.3 -1.5 995 7.6 2.6 4.2 -4.2 4.0 -1.7 -3.8 -3.8 997 1.1 14.6 10.	2006								
Annu Percentage Change in Excess of Inflation In the Canadian Economy 985 986 15.4 13.4 14.0 7.8 4.8 7.0 987 11.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 6.9 2.7 5.0 3.3 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 3.8 1.1 0.6 2.1 -0.3 6.6 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 6.6 -2.9 -0.1 2.9 5.8									
985 986 15.4 13.4 14.0 7.8 4.8 7.0 987 11.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 3.4 6.3 0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.2 4.0 -1.7 996 6.6 2.9 -0.1 2.9 5.7 3.8 0000 7.9 4.0 5.2 5.4 2.5 4.4 001 0.5 <td>2008 1</td> <td>4.5</td> <td></td> <td></td> <td></td> <td></td> <td>4.0</td> <td>3.4</td> <td></td>	2008 1	4.5					4.0	3.4	
986 15.4 13.4 14.0 7.8 4.8 7.0 987 11.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 -6.6 -2.9 -0.1 2.9 5.7 3.8 0001 7.9 4.0 5.2 5.1 5.3 3.8 0021 11.7	-				r Inflation in the Canadia				
987 11.6 3.2 5.6 3.8 4.0 3.9 988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 3.4 6.3 0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 6.6 -2.9 -0.1 2.9 5.7 3.8 0001 10.5 4.5 7.8 4.5 3.6 5.9 003 <td< td=""><td>1985</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	1985								
988 9.9 5.3 6.7 4.7 2.9 4.2 989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 988 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 0001 10.5 4.5 6.5 3.1 5.3 3.8 0020 7.7 5.4 7.8 7.8 0.4 4.9 003 7.5 4.4	1986 1987								
989 5.8 4.4 4.8 3.5 3.0 3.4 990 12.4 4.4 6.9 2.7 5.0 3.3 991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 -3.4 6.3 -0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 3.8 1.1 -0.6 -2.1 0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 -0.4 4.9 9.9 003 7.5 4.4 <	1988								
991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 -3.4 6.3 -0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 988 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.6 3.1 5.3 3.8 002 11.7 5.8 7.8 -0.4 4.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2	1989								
991 10.5 5.2 7.0 6.4 4.7 5.9 992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 -3.4 6.3 -0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 988 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.6 3.1 5.3 3.8 002 11.7 5.8 7.8 -0.4 4.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2	1990	12.4	4.4	6.9	2.7	5.0	3.3		
992 13.7 10.1 11.3 1.8 4.9 2.6 993 3.1 4.4 4.0 -3.4 6.3 -0.8 994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 -4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.4 4.9 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 <	1991								
994 -3.3 2.5 0.5 -1.4 3.5 0.1 995 7.6 2.6 4.2 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.4 7.8 0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 0	1992	13.7	10.1	11.3	1.8	4.9	2.6		
995 7.6 2.6 4.2 4.2 4.0 -1.7 996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 -0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.9 1.7 2.5 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f	1993								
996 -3.8 1.1 -0.6 -2.1 -0.3 -1.5 997 1.1 14.6 10.2 -0.1 4.4 1.4 998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 -0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.9 1.7 2.5 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	1994	-3.3	2.5	0.5	-1.4	3.5	0.1		
9971.114.610.2 -0.1 4.41.4 998 9.3 12.111.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 $007 f$ 2.1 4.8 3.8 2.9 1.7 2.5 $008 f$ 1.1 3.3 2.5 1.6 0.9 1.3	1995								
998 9.3 12.1 11.3 6.7 6.3 6.6 999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	1996								
999 6.6 -2.9 -0.1 2.9 5.7 3.8 000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 -0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	1997								
000 7.9 4.0 5.2 5.4 2.5 4.4 001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 1.7 2.5 006 3.9 3.4 3.6 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	1998								
001 10.5 4.5 6.5 3.1 5.3 3.8 002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 1.7 2.5 006 1.1 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3									
002 11.7 5.8 7.8 4.5 8.8 5.9 003 7.5 4.4 5.4 7.8 -0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	2000								
003 7.5 4.4 5.4 7.8 -0.4 4.9 004 6.9 2.2 3.9 3.4 3.7 3.5 005 5.3 0.9 2.5 2.3 1.5 2.0 006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	2001								
0055.30.92.52.31.52.00063.93.43.62.22.12.2007 f2.14.83.82.91.72.5008 f1.13.32.51.60.91.3	2003								
x006 3.9 3.4 3.6 2.2 2.1 2.2 x007 f 2.1 4.8 3.8 2.9 1.7 2.5 x008 f 1.1 3.3 2.5 1.6 0.9 1.3	2004	6.9	2.2	3.9	3.4	3.7	3.5		
006 3.9 3.4 3.6 2.2 2.1 2.2 007 f 2.1 4.8 3.8 2.9 1.7 2.5 008 f 1.1 3.3 2.5 1.6 0.9 1.3	2005	5.3	0.9	2.5	2.3	1.5	2.0		
008 f 1.1 3.3 2.5 1.6 0.9 1.3	2006			3.6	2.2		2.2		
	2007 f								
: forecast. Source: NHEX, CIHI, 2004	2008 T	1.1	3.3	2.5	1.6	0.9	1.3		
: forecast. Source: NHEX, CIHI, 2004									
	f: forecast.								Source: NHEX, CIHI, 2008.

					I Health Expe							
			Public		Prescribe		Private			Priva	-Prescribed Di te (Out-of-Poe	
	Provincial	Federal _	Social Secu WCB	urity Funds Drug Insurance Fund	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter Drugs	Personal Health Supplies	To Non-I Dr
'ear						(\$ Mi	lions)			•		
85 86	32.5 34.6	6.5 7.2	0.3 0.4		39.2 42.2			60.0 68.2	99.2 110.4			
987	42.3	7.7	0.4		50.4			61.9	112.3			
988 989	47.5 45.5	9.3 11.5	0.5 0.6		57.3 57.6			68.1 74.9	125.4 132.5			
990	48.5	13.8	0.7		62.9			86.2	149.1			
991	48.5 55.4	16.2	0.7		72.4			95.8	168.2			
992 993	68.1	18.6	0.8		87.5			101.6	189.1	51.5	41.6	
993 994	68.1 61.1	21.9 24.6	0.7 0.8		90.7 86.5			118.5 129.1	209.2 215.6	50.4 52.3	41.9 42.5	
95	79.6	27.8	0.8		108.3			148.0	256.3	50.8	41.7	
96	73.8	28.6	0.9		103.2			163.4	266.7	54.2	47.3	
97 98	73.7 85.9	31.3 33.7	1.0 1.0		106.0 120.5			186.7 189.0	292.7 309.5	48.1 55.3	43.7 50.9	
90 99	105.6	36.9	1.0		143.6			189.0	324.2	55.3	50.9	
00	130.9	38.4	1.3		170.7			205.3	376.0	60.8	52.6	
01	160.8	44.5	1.6		207.0			212.3	419.3	64.0	53.6	
002 003	189.6 217.7	52.0 60.7	1.7 2.1		243.3 280.4			239.4 266.7	482.7 547.1	65.6 68.3	54.8 56.3	
003 004	234.6	65.3	2.1		302.2			200.7	579.4	71.9	58.0	
005	249.5	70.9	2.3		322.7			293.3	616.1	74.0	60.1	
006	260.2	79.4	2.5		342.2			344.8	686.9	78.9	63.4	
07 f 08 f	273.4 279.9	85.0 89.1	2.6 2.7		361.1 371.6			402.9 474.0	764.0 845.6	82.8 85.5	63.4 65.5	
						(Annual Daraa	ntene Chennel					
85						(Annual Perce						
36	6.6	11.1	23.4		7.4			13.7	11.3			
87	22.2	7.4	10.2		19.6			-9.3	1.7			
88 89	12.4 -4.1	19.8 24.1	25.2 8.5		13.6 0.5			10.1 10.1	11.7 5.7			
0	6.5	19.7	16.1		9.3			15.0	12.5			
91	14.3	17.8	7.1		15.0			11.2	12.8			
92 93	22.9 -0.1	14.4 17.9	17.9 -10.4		20.9 3.6			6.1 16.6	12.5 10.6		 0.6	
93	-10.2	17.9	-10.4		-4.7			8.9	3.0	-2.3	1.6	
95	30.2	13.3	9.2		25.2			14.6	18.9	-2.9	-1.9	
96	-7.3	2.8	4.7		-4.6			10.4	4.1	6.7	13.3	
97 98	-0.1 16.5	9.6 7.4	7.9 2.5		2.7 13.7			14.2 1.2	9.7 5.7	-11.2 15.0	-7.6 16.6	
9	22.9	9.7	13.8		19.2			-4.5	4.7	5.6	-0.2	
00	24.0	4.0	20.6		18.8			13.7	16.0	4.1	3.4	
01	22.8	16.0	18.0		21.3			3.4	11.5	5.3	2.0	
02 03	17.9 14.8	16.7 16.7	7.9 19.9		17.6 15.3			12.8 11.4	15.1 13.3	2.4 4.1	2.2 2.7	
04	7.7	7.7	9.6		7.7			4.0	5.9	5.3	3.1	
05	6.4	8.5	3.1		6.8			5.8	6.3	2.9	3.5	
06 07 f	4.3 5.1	12.1 7.1	8.8 3.2		6.0 5.5			17.5 16.9	11.5 11.2	6.6 5.0	5.6 0.0	
07 f 08 f	2.4	4.7	2.2		2.9			17.6	10.7	3.2	3.2	
					(Pe	rcentage Share of T	otal Drug Exp	enditure)				
985	20.3	4.1	0.2		24.5			37.4	61.9			
86 87	19.3 22.0	4.0 4.0	0.2		23.5 26.2			38.0 32.2	61.5 58.4			
88	23.7	4.6	0.2		28.5			33.9	62.5			
89	22.4	5.7	0.3		28.3			36.8	65.1			
90	21.6	6.1	0.3		28.0			38.4	66.4			
91 92	22.2 24.1	6.5 6.6	0.3 0.3		29.0 31.0			38.4 36.0	67.4 67.0	 18.3	 14.7	
93	22.6	7.3	0.2		30.1			39.3	69.4	16.7	13.9	
94	19.7	7.9	0.2		27.9			41.6	69.5	16.8	13.7	
95	22.8	8.0	0.2		31.0			42.4	73.5	14.6	12.0	
96 97	20.0 19.2	7.8 8.2	0.2		28.0 27.6			44.4 48.6	72.4 76.1	14.7 12.5	12.8 11.4	
98	20.7	8.1	0.2		29.0			45.4	74.4	13.3	12.2	
99	24.4	8.5	0.3		33.1			41.7	74.8	13.5	11.7	
00	26.8	7.8	0.3		34.9			42.0	76.8	12.4	10.7	
01 02	30.0 31.4	8.3 8.6	0.3 0.3		38.5 40.3			39.5 39.7	78.1 80.0	11.9 10.9	10.0 9.1	
03	32.4	9.0	0.3		41.8			39.7	81.5	10.2	8.4	
)4	33.1	9.2	0.3		42.6			39.1	81.7	10.1	8.2	
05 06	33.3	9.4	0.3		43.0			39.1	82.1	9.9	8.0	
)6)7 f	31.4 30.0	9.6 9.3	0.3 0.3		41.3 39.7			41.6 44.3	82.8 83.9	9.5 9.1	7.7 7.0	
08 f	28.1	8.9	0.3		37.3			47.6	84.9	8.6		

	E	xpenditure o		, by Source of Fin				Table B M	an. — Total	
			lotal Health Ex	penditures, Manit		o 2008 (cont'd)		in Public, Private		
	Public	All Drugs Private	Total	Public Heal	th Expenditure Private	Total	Total He Public	alth Expenditures Private	Total	
(ear			(\$ Millio	ns)			(Perc	entage Share)		
1985	39.2	121.0	160.2	1,310.9	415.6	1,726.5	3.0	29.1	9.3	
1986 1987	42.2 50.4	137.3 141.9	179.4 192.4	1,425.8 1,530.2	463.9 449.9	1,889.7 1,980.2	3.0 3.3	29.6 31.5	9.5 9.7	M
988	57.3	143.4	200.7	1,634.3	435.4	2,069.6	3.5	32.9	9.7	
1989	57.6	145.8	203.4	1,773.2	484.2	2,257.4	3.2	30.1	9.0	
1990 1991	62.9 72.4	161.5 177.3	224.4 249.6	1,951.1 2,006.0	533.2 570.0	2,484.3 2,576.0	3.2 3.6	30.3 31.1	9.0 9.7	
1992 1993	87.5 90.7	194.8 210.8	282.3 301.5	2,099.3 2,088.9	602.6 660.2	2,701.9 2,749.1	4.2 4.3	32.3 31.9	10.4 11.0	
1994	86.5	223.9	310.4	2,115.7	689.2	2,804.9	4.1	32.5	11.0	
1995	108.3	240.5	348.8	2,179.4	736.1	2,915.5	5.0	32.7	12.0	
1996 1997	103.2 106.0	264.9 278.5	368.2 384.5	2,185.3 2,251.9	786.8 848.6	2,972.1 3,100.5	4.7 4.7	33.7 32.8	12.4 12.4	
1998	120.5	295.2	415.8	2,388.6	893.3	3,281.9	5.0	33.0	12.7	
1999	143.6	289.8	433.4	2,714.9	979.7	3,694.6	5.3	29.6	11.7	
2000 2001	170.7 207.0	318.6 329.9	489.3 536.9	3,005.3 3,184.5	1,040.4 1,173.0	4,045.7 4,357.6	5.7 6.5	30.6 28.1	12.1 12.3	
2002	243.3	359.8	603.1	3,366.5	1,224.8	4,591.3	7.2	29.4	13.1	
2003 2004	280.4 302.2	391.2 407.1	671.7 709.3	3,654.0 3,896.5	1,264.5 1,322.0	4,918.4 5,218.5	7.7 7.8	30.9 30.8	13.7 13.6	
2005	322.7	427.4	750.1	4,199.1	1,408.1	5,607.2	7.7	30.4	13.4	
2006	342.2	487.1	829.3	4,415.1	1,459.3	5,874.4	7.7	33.4	14.1	
2007 f 2008 f	361.1 371.6	549.2 625.0	910.2 996.6	4,639.5 4,931.5	1,555.4 1,694.2	6,194.9 6,625.7	7.8 7.5	35.3 36.9	14.7 15.0	
			(Annual Percenta	age Change)						
1985			(Annual Fercente							
1986	7.4	13.5	12.0	8.8	11.6	9.5				
1987 1988	19.6 13.6	3.4 1.1	7.2 4.4	7.3 6.8	-3.0 -3.2	4.8 4.5				
1989	0.5	1.7	1.4	8.5	11.2	9.1				
1990	9.3	10.7	10.3	10.0	10.1	10.1				
1991 1992	15.0 20.9	9.8 9.9	11.2 13.1	2.8 4.7	6.9 5.7	3.7 4.9				
1993	3.6	8.2	6.8	-0.5	9.6	1.7				
1994	-4.7	6.2	3.0	1.3	4.4	2.0				
1995 1996	25.2 -4.6	7.4 10.1	12.4 5.6	3.0 0.3	6.8 6.9	3.9 1.9				
1997	2.7	5.1	4.4	3.0	7.9	4.3				
1998 1999	13.7 19.2	6.0 -1.8	8.1 4.3	6.1 13.7	5.3 9.7	5.8 12.6				
2000	18.8	10.0	12.9	10.7	6.2	9.5				
2001 2002	21.3 17.6	3.5 9.0	9.7 12.3	6.0 5.7	12.7 4.4	7.7 5.4				
2002	15.3	8.7	12.3	8.5	3.2	7.1				
2004	7.7	4.1	5.6	6.6	4.5	6.1				
2005 2006	6.8 6.0	5.0 14.0	5.8 10.5	7.8 5.1	6.5 3.6	7.4 4.8				
2007 f	5.5	12.7	9.8	5.1	6.6	5.5				
2008 f	2.9	13.8	9.5	6.3	8.9	7.0				
	(Percentag	e Share of Total Dr	ug Expenditure)	_						
1985 1986	24.5 23.5	75.5 76.5	100.0 100.0							
1986 1987	23.5 26.2	76.5	100.0							
1988 1989	28.5 28.3	71.5 71.7	100.0 100.0							
1989	28.3	71.7	100.0							
1991	29.0	71.0	100.0							
1992 1993	31.0 30.1	69.0 69.9	100.0 100.0							
1994	27.9	72.1	100.0							
1995	31.0	69.0	100.0							
1996 1997	28.0 27.6	72.0 72.4	100.0 100.0							
1998	29.0	71.0	100.0							
1999	33.1	66.9	100.0							
2000 2001	34.9 38.5	65.1 61.5	100.0 100.0							
2002	40.3	59.7	100.0							
2003 2004	41.8 42.6	58.2 57.4	100.0 100.0							
2005	43.0	57.0	100.0							
2006	41.3	58.7	100.0							
2007 f 2008 f	39.7 37.3	60.3 62.7	100.0 100.0							

n.

					Prescribe	ed Drugs					-Prescribed D	
(ear	Provincial	Federal		Funds Drug surance Fund	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter Drugs	te (Out-of-Poo Personal Health Supplies	rota Tota Non-Pr Drug
985	29.98	6.00	0.28		36.26	(* per	Capita)	55.40	91.67			
986 987	31.68 38.48	6.60 7.05	0.34 0.38		38.62 45.91			62.48 56.33	101.10 102.25			
988 989	43.10 41.26	8.42 10.44	0.47 0.51		51.99 52.20			61.78 67.91	113.77 120.11			
990	43.87	12.47	0.59		56.92			77.93	134.85			
991	49.95	14.63	0.63		65.21			86.34	151.55			
192 193	61.22 60.90	16.69 19.59	0.74 0.66		78.65 81.15			91.33 106.06	169.98 187.21	46.32 45.06	37.42 37.46	
94	54.43	21.86	0.69		76.99			114.94	191.92	46.55	37.86	
95 96	70.49 65.03	24.65 25.22	0.75 0.78		95.89 91.03			131.08 144.10	226.97 235.13	44.97 47.77	36.96 41.69	
97	64.88	27.59	0.84		93.31			164.30	257.61	42.34	38.45	
998 999	75.51 92.43	29.60 32.32	0.86 0.98		105.97 125.72			166.11 158.03	272.09 283.75	48.64 51.13	44.77 44.50	
000	114.11	33.47	1.17		148.75			178.93	327.68	52.97	45.82	
001	139.70	38.69	1.38		179.77			184.40	364.18	55.61	46.57	
002 003	164.09 187.38	45.00 52.22	1.48 1.77		210.57 241.36			207.17 229.51	417.74 470.87	56.75 58.76	47.43 48.47	
004	200.39	55.82	1.92		258.14			236.82	494.95	61.42	49.58	
005 006	212.51 220.81	60.36 67.39	1.98 2.14		274.85 290.34			249.84 292.56	524.69 582.90	63.01 66.93	51.18 53.84	
007 f	230.42	71.66	2.19		304.27			339.56	643.82	69.77	53.44	
08 f	234.65	74.67	2.23		311.54			397.40	708.94	71.67	54.89	
							ntage Change)					
	 5.6	 10.1	22.4		6.5			 12.8	10.3			
87 88	21.5 12.0	6.8 19.4	9.5 24.8		18.9 13.2			-9.8 9.7	1.1 11.3			
89	-4.3	23.9	8.3		0.4			9.9	5.6			
90	6.3	19.5	15.9		9.0			14.8	12.3			
91 92	13.9 22.6	17.3 14.1	6.8 17.5		14.6 20.6			10.8 5.8	12.4 12.2			
93 94	-0.5 -10.6	17.4 11.6	-10.8 4.8		3.2 -5.1			16.1 8.4	10.1 2.5	-2.7 3.3	0.1 1.1	
	29.5	12.7	8.7		24.6			14.0	18.3	-3.4	-2.4	
6	-7.7	2.3	4.2		-5.1			9.9	3.6	6.2	12.8	
7 8	-0.2 16.4	9.4 7.3	7.8 2.4		2.5 13.6			14.0 1.1	9.6 5.6	-11.4 14.9	-7.8 16.4	
	22.4	9.2	13.3		18.6			-4.9	4.3	5.1	-0.6	
) 1	23.5 22.4	3.5 15.6	20.1 17.6		18.3 20.9			13.2 3.1	15.5 11.1	3.6 5.0	3.0 1.6	
2	17.5	16.3	7.5		17.1			12.3	14.7	2.0	1.8	
03 04	14.2 6.9	16.1 6.9	19.2 8.8		14.6 6.9			10.8 3.2	12.7 5.1	3.5 4.5	2.2 2.3	
05	6.0	8.1	2.8		6.5			5.5	6.0	2.6	3.2	
006	3.9	11.6	8.4		5.6			17.1	11.1	6.2	5.2	
07 f 08 f	4.3 1.8	6.3 4.2	2.5 1.7		4.8 2.4			16.1 17.0	10.5 10.1	4.2 2.7	-0.7 2.7	
					(Annual Percentag	e Change in Excess	of Inflation in	the Canadian E	conomy)			
35												
86 87	2.8 16.7	7.3 2.0	19.6 4.8		3.7 14.1			10.0 -14.6	7.5 -3.6			
88 89	7.5 -8.8	14.9 19.4	20.2 3.8		8.7 -4.2			5.1 5.3	6.7 1.0			
90	-8.8	16.4	12.9		6.0			11.7	9.3			
91	11.1	14.6	4.0		11.8			8.0	9.6			
92 93	21.3 -2.0	12.8 16.0	16.3 -12.2		19.4 1.7			4.5 14.7	10.9 8.7	-4.2	 -1.3	
94	-11.7	10.5	3.7		-6.2			7.3	1.4	2.2	0.0	
95 96	27.2 -9.4	10.4 0.6	6.3 2.6		22.2 -6.7			11.7 8.3	15.9 1.9	-5.7 4.6	-4.7 11.1	
97	-1.2	8.4	6.8		1.5			13.0	8.6	-12.4	-8.8	
998 999	16.8 20.6	7.7 7.4	2.8 11.5		14.0 16.8			1.5 -6.7	6.1 2.5	15.3 3.3	16.9 -2.4	
000	19.4	-0.6	16.0		14.2			9.1	11.4	-0.5	-1.2	
01 02	21.1 16.4	14.3 15.2	16.2 6.4		19.5 16.1			1.7 11.3	9.8 13.7	3.6 1.0	0.3 0.8	
003	11.3	13.2	16.3		11.7			7.9	9.8	0.6	-0.7	
04 05	4.4 2.9	4.3	6.2 -0.3		4.4			0.6	2.5 2.9	-0.5	-0.3 0.1	
06	1.5	5.0 9.2	6.0		3.4 3.2			2.4 14.7	8.7	3.8	2.8	
007 f	1.1	3.1	-0.7		1.6			12.8	7.2	1.0	-4.0	

		Expenditure	on Drugs per Ca Total Health E		by Source of Fir anitoba, 1985 t		lic, Private and	B Man.—Per Capita
				• • • • • •			GDP Implicit	
-	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price Index—Canada	
(ear			(\$ per C	apita)			(1997 = 100)	
1985	36.26	111.76	148.02	1,211.28	383.98	1,595.25	73.6	
1986	38.62	125.74	164.36	1,306.04		1,731.01	75.6	
1987	45.91	129.27	175.18	1,393.62		1,803.40	79.2	
1988 1989	51.99 52.20	130.16 132.15	182.14 184.35	1,482.95 1,606.82		1,878.01 2,045.59	82.8 86.6	
1990				1,764.67				
1990	56.92 65.21	146.04 159.76	202.96 224.97	1,807.82		2,246.92 2.321.53	89.2 91.6	
1992	78.65	175.06	253.71	1,886.70	541.56	2,428.27	92.8	
1993 1994	81.15 76.99	188.58 199.34	269.73 276.33	1,869.05 1,883.55		2,459.81 2,497.17	94.1 95.2	
1995 1996	95.89 91.03	213.01 233.57	308.90 324.60	1,930.11 1,926.73		2,582.01 2,620.42	97.4 99.0	
1997	93.31	245.09	338.40	1,982.07		2,728.98	100.0	
1998	105.97	259.52	365.50	2,099.82		2,885.12	99.6	
1999	125.72	253.66	379.38	2,376.29		3,233.84	101.4	
2000	148.75	277.72	426.47	2,619.32		3,526.10	105.5	
2001 2002	179.77 210.57	286.58 311.35	466.36 521.92	2,766.07 2,913.23		3,784.95 3,973.14	106.9 108.1	
2003	241.36	336.73	578.10	3,144.82	1,088.30	4,233.12	111.2	
2004	258.14	347.82	605.96	3,328.73	1,129.39	4,458.12	114.1	
2005	274.85	364.03	638.88	3,576.26		4,775.53	117.6	
2006	290.34	413.33	703.67	3,746.40		4,984.64	120.5	
2007 f 2008 f	304.27 311.54	462.77 523.96	767.03 835.51	3,909.62 4,134.49		5,220.35 5,554.92	124.3 128.6	
_				Annual Percentage Ch				
1985								
1986	6.5	12.5	11.0	7.8		8.5	2.8	
1987 1988	18.9 13.2	2.8 0.7	6.6 4.0	6.7 6.4		4.2 4.1	4.7 4.5	
1989	0.4	1.5	1.2	8.4		8.9	4.6	
1990	9.0	10.5	10.1	9.8	9.9	9.8	3.0	
1991	14.6	9.4	10.8	2.4		3.3	2.8	
1992 1993	20.6 3.2	9.6 7.7	12.8 6.3	4.4		4.6 1.3	1.3 1.4	
1993	-5.1	5.7	2.4	0.8		1.5	1.4	
1995	24.6	6.9	11.8	2.5		3.4	2.3	
1996	-5.1	9.7	5.1	-0.2		1.5	1.7	
1997	2.5	4.9	4.3	2.9		4.1	1.0	
1998 1999	13.6 18.6	5.9 -2.3	8.0 3.8	5.9 13.2		5.7 12.1	-0.4 1.8	
2000	18.3	9.5		10.2		9.0	4.1	
2000	20.9	3.2	12.4 9.4	5.6		7.3	1.4	
2002	17.1	8.6	11.9	5.3		5.0	1.0	
2003	14.6	8.2	10.8	7.9		6.5	2.9	
2004	6.9	3.3	4.8	5.8	3.8	5.3	2.6	
2005	6.5	4.7	5.4	7.4		7.1	3.1	
2006 2007 f	5.6 4.8	13.5 12.0	10.1 9.0	4.8		4.4 4.7	2.4 3.2	
2008 f	2.4	13.2	8.9	5.8		6.4	3.4	
-		(Annual Percenta	age Change in Excess o	f Inflation in the Cana	dian Economy)			
1985								
1986 1987	3.7 14.1	9.7 -1.9	8.2 1.8	5.0		5.7 -0.6		
1987	8.7	-1.9	-0.5	1.9		-0.8		
1989	-4.2	-3.0	-3.4	3.8		4.4		
1990	6.0	7.5	7.1	6.8	6.9	6.8		
1991	11.8	6.6	8.1	-0.3	3.8	0.6		
1992 1993	19.4 1.7	8.3 6.3	11.5 4.9	3.1 -2.4		3.3 -0.1		
1994	-6.2	4.6	1.3	-0.3		0.4		
1995	22.2	4.5	9.4	0.1		1.1		
1996	-6.7	8.0	3.4	-1.8		-0.2		
1997	1.5	3.9	3.3	1.9		3.2		
1998 1999	14.0 16.8	6.3 -4.1	8.4 2.0	6.4 11.4		6.2 10.3		
2000 2001	14.2 19.5	5.4 1.8	8.3 8.0	6.1 4.2		4.9 6.0		
2002	16.1	7.6	10.9	4.3	3.0	3.9		
2003 2004	11.7 4 4	5.3 0.7	7.9 2.2	5.1		3.6 2.7		
	4.4			3.3				
2005 2006	3.4 3.2	1.6 11.1	2.3 7.7	4.3		4.0 2.0		
2006 2007 f	3.2	8.7	5.8	2.3		1.5		
2008 f	-1.0	9.8	5.5	2.3		3.0		

					Prescrib	ed Drugs				Non	-Prescribed Dr	ugs
	Provincial	Federal _	Public Social Secu WCB	Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Poo Personal Health Supplies	ket) No
Year				Fund		(\$ Mi	llions)			Drugs		
1985	67.6	6.3	0.1		74.0			26.8	100.8			
1986 1987	81.1 67.8	7.1 7.7	0.1		88.3 75.7			33.8 42.5	122.1 118.2			
1988	63.0	9.7	0.2		73.1			53.5	126.5			
1989	74.8	12.2	0.2		87.2			67.3	154.5			
1990	88.7	14.5	0.3		103.5			79.5	183.0			
1991 1992	93.5 85.0	16.8 19.0	0.3 0.3		110.6 104.3			89.2 99.5	199.8 203.8	40.6	35.6	
1993	57.8	22.4	0.4		80.6			126.7	207.3	49.9	44.9	
1994	56.2	25.0	0.4		81.6			141.3	222.9	51.7	45.5	
1995 1996	63.8 66.6	28.0 28.8	0.5 0.8		92.2 96.2			146.8 148.1	239.0 244.3	50.1 47.4	44.7 44.8	
1997	69.3	31.2	0.8		101.3			161.2	262.5	48.9	47.3	
1998 1999	78.9 89.1	33.7 38.8	0.9 1.1		113.6 129.0			167.4 174.0	280.9 303.0	47.6 52.8	46.7 48.7	
2000 2001	100.2 116.3	42.3 48.1	1.3 1.6		143.8 165.9			185.6 216.1	329.4 382.1	55.9 57.1	51.0 50.5	
2002	133.9	55.2	1.9		191.0			222.5	413.6	58.1	51.3	
2003 2004	151.4 168.1	62.5 64.9	2.2 2.5		216.1 235.5			252.3 274.1	468.4 509.6	57.4 60.4	50.0 51.8	
2005 2006	185.4 201.9	68.2 73.1	2.7 2.9		256.3 277.9			286.1 282.5	542.4 560.4	61.9 63.3	53.6 54.2	
2007 f	251.7	74.9	3.0		329.6			298.8	628.5	65.7	53.6	
2008 f	290.8	80.8	3.2		374.9			322.7	697.6	67.6	55.1	
						(Annual Perce	ntage Change					
1985 1986	20.0	 13.1	2.4		19.3			 25.8	21.1			
1986	-16.4	8.9	42.4		-14.2			25.8	-3.2			
1988	-7.1	26.1	58.9		-3.5			25.8	7.0			
1989	18.7	25.3	-28.9		19.4			25.8	22.1			
1990 1991	18.7 5.4	18.6 16.1	9.8 5.4		18.6 6.9			18.2 12.2	18.5 9.2			
992	-9.1	12.9	20.3		-5.7			12.2	2.0			
1993	-32.0	18.1	32.9		-22.7			27.3	1.7	22.7	26.3	
1994	-2.8	11.7	-2.2		1.3			11.5	7.5	3.6	1.3	
1995 1996	13.6 4.4	11.7 3.0	16.1 63.1		13.0 4.3			3.9 0.9	7.2 2.2	-3.0 -5.4	-1.9 0.4	
1997	4.0	8.3	4.3		5.3			8.8	7.4	3.1	5.5	
1998 1999	13.9 12.9	8.1 15.1	9.6 22.0		12.1 13.6			3.9 3.9	7.0 7.8	-2.5 10.8	-1.2 4.1	
2000	12.4	9.0	16.4		11.4			6.7	8.7	5.8	4.9	
2001	16.1	13.8	18.5		15.4			16.4	16.0	2.2	-1.0	
2002 2003	15.1 13.1	14.9 13.1	20.9 14.4		15.1 13.1			3.0 13.4	8.2 13.2	1.7 -1.2	1.5 -2.5	
2003	11.0	3.8	14.4		9.0			8.6	8.8	5.2	-2.5	
2005	10.3	5.1	5.4		8.8			4.4	6.4	2.5	3.4	
2006	8.9	7.3	8.4		8.5			-1.3	3.3	2.2	1.2	
2007 f 2008 f	24.7 15.5	2.4 7.9	3.8 7.6		18.6 13.7			5.8 8.0	12.1 11.0	3.8 2.8	-1.1 2.8	
	10.0	7.0	7.0						11.0	2.0	2.0	
1985	49.6	4.6	0.1		54.4	ercentage Share of 1	otal Drug Exp	19.7	74.1			
1986	50.0	4.4	0.1		54.5			20.8	75.3			
1987 1988	41.2 34.1	4.7 5.3	0.1 0.2		46.0 39.5			25.8 28.9	71.8 68.5			
1989	32.8	5.4	0.1		38.3			29.5	67.9			
1990	34.5	5.6	0.1		40.2			30.9	71.1			
1991	34.3	6.2	0.1		40.5			32.7	73.3			
992 993	30.3 19.1	6.8 7.4	0.1 0.1		37.2 26.7			35.5 41.9	72.8 68.6	14.5 16.5	12.7 14.9	
1994	17.5	7.8	0.1		25.5			44.1	69.6	16.1	14.2	
1995	19.1	8.4	0.1		27.6			44.0	71.6	15.0	13.4	
1996	19.8	8.6	0.2		28.6			44.0	72.6	14.1	13.3	
1997 1998	19.3 21.0	8.7 9.0	0.2		28.2 30.3			44.9 44.6	73.2 74.9	13.6 12.7	13.2 12.4	
1999	22.0	9.6	0.3		31.9			43.0	74.9	13.1	12.0	
2000	23.0	9.7	0.3		32.9			42.5	75.5	12.8	11.7	
2001	23.7	9.8	0.3		33.9			44.1	78.0	11.7	10.3	
2002 2003	25.6 26.3	10.6 10.9	0.4 0.4		36.5 37.5			42.6 43.8	79.1 81.3	11.1 10.0	9.8 8.7	
2003	27.0	10.5	0.4		37.9			44.1	81.9	9.7	8.3	
2005	28.2	10.4	0.4		39.0			43.5	82.4	9.4	8.1	
2006	29.8	10.8	0.4		41.0			41.7	82.7	9.3	8.0	
2007 f	33.7	10.0	0.4		44.1			40.0	84.0	8.8	7.2	

			n Drugs by Type, otal Health Expen				blic, Private and	able B Sas	sk. — Fotal	
		All Drugs			Health Expenditure		Share of Drugs i	in Public, Private Ith Expenditures	and	
_	Public	Private	Total	Public	Private	Total		Private	Total	
			(\$ Million	s)			(Perce	ntage Share)		
	74.0	62.1	136.1	1,195.5	333.2	1,528.8	6.2	18.6	8.9	
	88.3	73.7	162.0	1,325.9		1,703.6	6.7	19.5	9.5	Sas
	75.7 73.1	88.9 111.7	164.6 184.8	1,372.2 1,468.3		1,767.8 1,837.6	5.5 5.0	22.5 30.2	9.3 10.1	
	87.2	140.4	227.7	1,629.2		2,052.9	5.4	33.1	11.1	
	103.5	153.9	257.4	1,792.1	460.1	2,252.2	5.8	33.4	11.4	
	110.6	162.2	272.8	1,828.9		2,319.8	6.0	33.0	11.8	
	104.3 80.6	175.8 221.5	280.1 302.1	1,819.5 1,727.8		2,325.4 2,301.9	5.7 4.7	34.7 38.6	12.0 13.1	
	81.6	238.5	320.1	1,778.8		2,385.2	4.6	39.3	13.4	
	92.2	241.6	333.8	1,820.8	621.5	2,442.3	5.1	38.9	13.7	
	96.2	240.4	336.6	1,862.3		2,490.0	5.2	38.3	13.5	
	101.3	257.4	358.6 375.3	1,976.1		2,656.2	5.1	37.8 38.9	13.5 13.5	
	113.6 129.0	261.8 275.4	404.5	2,103.5 2,250.4		2,776.8 2,975.4	5.4 5.7	38.0	13.6	
	143.8	292.5	436.3	2,381.2	2 773.9	3,155.1	6.0	37.8	13.8	
	165.9	323.8	489.7	2,581.5	869.6	3,451.1	6.4	37.2	14.2	
	191.0	332.0	523.0	2,725.4		3,624.4	7.0	36.9	14.4	
	216.1 235.5	359.7 386.3	575.8 621.8	2,895.7 3,105.3		3,866.9 4,126.7	7.5 7.6	37.0 37.8	14.9 15.1	
	256.3 277.9	401.7 400.1	657.9 678.0	3,375.4 3,602.7		4,425.5 4,739.1	7.6 7.7	38.2 35.2	14.9 14.3	
f	329.6	418.2	747.8	3,894.5		5,091.7	8.5	34.9	14.7	
f	374.9	445.4	820.3	4,077.9	1,287.1	5,365.0	9.2	34.6	15.3	
			(Annual Percentag	e Change)						
-										
	19.3	18.7	19.0	10.9		11.4				
	-14.2	20.5	1.6	3.5	5 4.7	3.8				
	-3.5	25.7	12.3	7.0		4.0				
	19.4	25.7	23.2	11.0		11.7				
	18.6 6.9	9.6 5.4	13.0 6.0	10.0		9.7 3.0				
	-5.7	5.4 8.4	2.7	-0.5		0.2				
	-22.7	26.0	7.9	-5.0		-1.0				
	1.3	7.7	5.9	3.0	5.6	3.6				
	13.0	1.3	4.3	2.4		2.4				
	4.3	-0.5 7.1	0.8	2.3		2.0 6.7				
	5.3 12.1	1.7	6.6 4.6	6.1 6.4		4.5				
	13.6	5.2	7.8	7.0		7.2				
	11.4	6.2	7.9	5.8	6.7	6.0				
	15.4	10.7	12.2	8.4		9.4				
	15.1 13.1	2.5 8.3	6.8 10.1	5.6 6.2		5.0 6.7				
	9.0	7.4	8.0	7.2		6.7				
	8.8	4.0	5.8	8.7		7.2				
	8.5	-0.4	3.0	6.7		7.1				
f	18.6	4.5	10.3	8.1	5.3	7.4				
f	13.7	6.5	9.7	4.7	7.5	5.4				
	(Percenta	ge Share of Total Dru	ug Expenditure)	_						
-	54.4	45.6	100.0							
	54.5	45.5	100.0							
	46.0	54.0	100.0							
	39.5 38.3	60.5 61.7	100.0 100.0							
	40.2 40.5	59.8 59.5	100.0 100.0							
	37.2	62.8	100.0							
	26.7	73.3	100.0							
	25.5	74.5	100.0							
	27.6	72.4	100.0							
	28.6 28.2	71.4 71.8	100.0 100.0							
	30.3	69.7	100.0							
	31.9	68.1	100.0							
	32.9	67.1	100.0							
	33.9	66.1	100.0							
	36.5 37.5	63.5 62.5	100.0 100.0							
	37.9	62.1	100.0							
	39.0	61.0	100.0							
	41.0	59.0	100.0							
f	44.1	55.9	100.0							
f	45.7	54.3	100.0							

					Prescribe	ed Drugs					-Prescribed D	
	Provincial	Federal _	Public Social Securit WCB	ty Funds Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Poo Personal Health Supplies	N
Year				Fund		(\$ per	Capita)		Drugs	Drugs	Supplies	
1985	65.90	6.11	0.14		72.15			26.16	98.31			
1986 1987	78.76 65.64	6.89 7.48	0.14 0.20		85.79 73.32			32.80 41.13	118.59 114.45			
1988	61.28	9.47	0.32		71.08			52.00	123.08			
989	73.37	11.97	0.23		85.58			66.00	151.57			
990 991	88.11 93.26	14.37 16.75	0.26		102.73 110.29			78.97 89.00	181.70 199.30			
992	84.66	18.90	0.33		103.88			99.15	203.03	40.47	35.45	
93 94	57.37 55.63	22.26 24.80	0.44 0.43		80.07 80.85			125.84 139.94	205.90 220.79	49.53 51.18	44.64 45.12	
995	62.89	27.57	0.49		90.94			144.72	235.66	49.43	44.05	
96	65.33	28.25	0.80		94.39			145.37	239.76	46.51	44.00	
17 18	68.04 77.57	30.62 33.12	0.83 0.91		99.49 111.61			158.31 164.51	257.80 276.12	48.02 46.83	46.46 45.92	
99	87.81	38.23	1.12		127.15			171.45	298.60	52.05	47.95	
00	99.38	41.95	1.31		142.64			184.19	326.83	55.45	50.65	
01	116.26	48.10	1.56		165.92			216.10	382.02	57.12	50.52	
002 003	134.44 152.23	55.48 62.83	1.90 2.18		191.82 217.24			223.47 253.61	415.28 470.85	58.36 57.71	51.52 50.28	
004	168.98	65.19	2.55		236.72			275.48	512.20	60.72	52.11	
005	187.28	68.87	2.70		258.85			289.02	547.87	62.55	54.14	
006 007 f	204.44 252.50	74.07 75.15	2.94 3.02		281.44 330.66			286.09 299.76	567.53 630.43	64.11 65.95	54.93 53.82	
008 f	292.31	81.26	3.26		376.83			324.44	701.27	67.91	55.42	
						(Annual Perce	ntage Change)					
85												
986 987	19.5 -16.7	12.7 8.5	2.1 41.9		18.9 -14.5			25.4 25.4	20.6 -3.5			
88	-6.6	26.6	59.6		-3.1			26.4	7.5			
89	19.7	26.4	-28.3		20.4			26.9	23.2			
10 11	20.1 5.9	20.0 16.6	11.1 5.9		20.0 7.4			19.7 12.7	19.9 9.7			
2 3	-9.2	12.8	20.1		-5.8			11.4	1.9			
	-32.2 -3.0	17.8 11.4	32.6 -2.4		-22.9 1.0			26.9 11.2	1.4 7.2	22.4 3.3	25.9 1.1	
5	13.1	11.1	15.6		12.5			3.4	6.7	-3.4	-2.4	
	3.9	2.5	62.3		3.8			0.5	1.7	-5.9	-0.1	
7 B	4.1 14.0	8.4 8.2	4.4 9.7		5.4 12.2			8.9 3.9	7.5 7.1	3.3 -2.5	5.6 -1.2	
e e e e e e e e e e e e e e e e e e e	13.2	15.4	22.3		13.9			4.2	8.1	11.1	4.4	
C	13.2	9.8	17.2		12.2			7.4	9.5	6.5	5.6	
1	17.0 15.6	14.6 15.3	19.4 21.4		16.3 15.6			17.3 3.4	16.9 8.7	3.0 2.2	-0.3 2.0	
)2)3	13.2	13.3	14.6		13.3			13.5	13.4	-1.1	-2.4	
14	11.0	3.7	17.2		9.0			8.6	8.8	5.2	3.7	
5	10.8	5.6	5.9		9.3			4.9	7.0	3.0	3.9	
6 7 f	9.2 23.5	7.6 1.5	8.6 2.8		8.7 17.5			-1.0 4.8	3.6 11.1	2.5 2.9	1.5 -2.0	
8 f	15.8	8.1	7.8		14.0			8.2	11.2	3.0	3.0	
						e Change in Excess						
985 986	 16.7	 9.9	-0.7		 16.1			22.6	 17.8			
37	-21.4	3.7	37.2		-19.3			20.7	-8.2			
88 89	-11.2 15.2	22.1 21.9	55.1 -32.9		-7.6 15.8			21.9 22.4	3.0 18.6			
90	17.1	17.0	8.1		17.0			16.6	16.8			
1	3.1	13.8	3.1		4.6			10.0	6.9			
92 93	-10.5 -33.7	11.5 16.3	18.9 31.1		-7.1 -24.4			10.1 25.5	0.6 0.0	20.9	24.5	
94	-4.1	10.3	-3.5		-0.1			10.1	6.1	2.2	0.0	
95	10.7	8.8	13.3		10.1			1.1	4.4	-5.7	-4.7	
96 97	2.2 3.2	0.8 7.4	60.6 3.4		2.1 4.4			-1.2 7.9	0.1 6.5	-7.6 2.3	-1.8 4.6	
98	14.4	8.6	10.1		12.6			4.4	7.5	-2.0	-0.7	
99	11.4	13.6	20.5		12.1			2.4	6.3	9.3	2.6	
00 01	9.1 15.6	5.7 13.3	13.1 18.0		8.1 15.0			3.3 16.0	5.4 15.5	2.4 1.7	1.5 -1.6	
2	14.6	14.3	20.4		14.6			2.4	7.7	1.1	0.9	
1	10.3 8.4	10.4 1.2	11.7 14.7		10.4 6.4			10.6 6.0	10.5 6.2	-4.0 2.6	-5.3 1.1	
	7.7	2.5	2.8		6.2			1.8	3.9	-0.1	0.8	
5	6.7	5.1	6.2		6.3			-3.4	1.2	0.1	-0.9	
07 f 08 f	20.3	-1.8	-0.4		14.3			1.6	7.9	-0.4	-5.3	

				nditures, Saskato				
-	Public	All Drugs Private	Total	He Public	alth Expenditure Private	Total	GDP Implicit Price Index—Canada	
r _			(\$ per Ca	pita)			(1997 = 100)	
5	72.15	60.60	132.75	1,165.85	324.93	1,490.78	73.6	
6 7	85.79	71.65	157.44	1,288.21	366.97	1,655.19	75.6	
8	73.32 71.08	86.03 108.66	159.35 179.74	1,328.72 1,428.29	383.01 359.28	1,711.73 1,787.57	79.2 82.8	
- 9	85.58	137.80	223.37	1,598.43	415.71	2,014.15	86.6	
)	102.73	152.81	255.54	1,779.42	456.84	2,236.27	89.2	
	110.29	161.76	272.06	1,824.01	489.59	2,313.60	91.6	
2	103.88	175.07	278.95	1,812.37	503.84	2,316.20	92.8	
	80.07	220.01 236.23	300.07 317.09	1,716.06	570.20 600.67	2,286.26 2,362.72	94.1 95.2	
	80.85			1,762.05				
	90.94	238.20	329.14	1,795.42	612.84	2,408.26	97.4	
	94.39 99.49	235.89 252.79	330.27 352.28	1,827.39 1,941.01	615.97 668.05	2,443.36 2,609.05	99.0 100.0	
	111.61	257.26	368.86	2,067.33	661.74	2,729.07	99.6	
1	127.15	271.46	398.61	2,217.77	714.53	2,932.30	101.4	
•	142.64	290.28	432.93	2,362.85	767.94	3,130.79	105.5	
	165.92	323.74	489.66	2,581.17	869.48	3,450.65	106.9	
	191.82	333.35	525.17	2,736.70	902.69	3,639.39	108.1	
	217.24	361.60	578.84	2,911.00	976.42	3,887.42	111.2	
	236.72	388.31	625.04	3,121.26	1,026.59	4,147.85	114.1	
i .	258.85	405.71	664.56	3,409.32	1,060.73	4,470.05	117.6	
6 7 f	281.44 330.66	405.13	686.57 750.19	3,648.21	1,150.80	4,799.02	120.5 124.3	
r F	330.66	419.52 447.76	824.59	3,906.77 4,099.44	1,200.90 1,293.84	5,107.67 5,393.29	124.3	
				Innual Percentage Change		-,		
-								
;	18.9	18.2	18.6	10.5	12.9	11.0	2.8	
	-14.5	20.1	1.2	3.1	4.4	3.4	4.7	
	-3.1 20.4	26.3 26.8	12.8 24.3	7.5 11.9	-6.2 15.7	4.4 12.7	4.5 4.6	
	20.0	10.9	14.4	11.3	9.9	11.0 3.5	3.0 2.8	
1	7.4 -5.8	5.9 8.2	6.5 2.5	2.5 -0.6	7.2 2.9	0.1	1.3	
	-22.9	25.7	7.6	-5.3	13.2	-1.3	1.4	
	1.0	7.4	5.7	2.7	5.3	3.3	1.1	
i	12.5	0.8	3.8	1.9	2.0	1.9	2.3	
i	3.8	-1.0	0.3	1.8	0.5	1.5	1.7	
	5.4	7.2	6.7	6.2	8.5	6.8	1.0	
	12.2 13.9	1.8 5.5	4.7 8.1	6.5 7.3	-0.9 8.0	4.6 7.4	-0.4 1.8	
	12.2 16.3	6.9 11.5	8.6 13.1	6.5 9.2	7.5 13.2	6.8 10.2	4.1 1.4	
	15.6	3.0	7.3	6.0	3.8	5.5	1.0	
	13.3	8.5	10.2	6.4	8.2	6.8	2.9	
	9.0	7.4	8.0	7.2	5.1	6.7	2.6	
	9.3	4.5	6.3	9.2	3.3	7.8	3.1	
	8.7	-0.1	3.3	7.0	8.5	7.4	2.4	
f	17.5	3.6	9.3	7.1	4.4	6.4	3.2	
f	14.0	6.7	9.9	4.9	7.7	5.6	3.4	
-		(Annual Percenta	age Change in Excess of	Inflation in the Canadian	Economy)			
	16.1	15.4	15.8	7.7	10.1	8.2		
	-19.3	15.3	-3.5	-1.6	-0.4	-1.3		
	-7.6	21.8	8.3	3.0	-10.7	-0.1		
	15.8	22.2	19.7	7.3	11.1	8.1		
	17.0	7.9	11.4	8.3	6.9	8.0		
	4.6	3.1	3.7	-0.3	4.4	0.7		
	-7.1 -24.4	7.0 24.2	1.3 6.1	-1.9 -6.8	1.6 11.7	-1.1 -2.7		
	-0.1	6.3	4.6	1.6	4.2	2.2		
	10.1	-1.5	1.5	-0.4	-0.3	-0.4		
	2.1	-1.5	-1.3	-0.4	-0.3	-0.4		
	4.4	6.2	5.7	5.2	7.5	5.8		
	12.6	2.2	5.1	6.9	-0.5	5.0		
	12.1	3.7	6.3	5.5	6.2	5.6		
	8.1	2.8	4.5	2.4	3.4	2.7		
	15.0	10.2	11.8	7.9	11.9	8.9		
	14.6 10.4	1.9	6.2	5.0	2.8 5.3	4.4 3.9		
	10.4 6.4	5.6 4.8	7.3 5.4	3.5 4.6	5.3	3.9		
		1.4	3.2	6.1	0.2	4.7		
;	6.2	26	0.0	4.6	C 1	4 0		
i i f	6.3	-2.6 0.3	0.9 6.0	4.6 3.9	6.1 1.1	4.9 3.2		
		-2.6 0.3 3.3	0.9 6.0 6.5	4.6 3.9 1.5	6.1 1.1 4.3	4.9 3.2 2.2		

Sask.

					Prescrib	ed Drugs				Non	-Prescribed D
	Provincial	Federal	Public Social Secu WCB	urity Funds Drug Insurance Fund	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	<u>te (Out-of-Po</u> Personal Health Supplies
Year				Fulla		(\$ Mi	illions)			Drugs	
1985	69.5	6.4	0.9		76.7			134.5	211.2		
1986 1987	83.2 95.7	7.0 7.4	1.2 1.5		91.4 104.6			147.9 153.1	239.3 257.7		
1988	108.0	9.1	1.6		118.7			172.6	291.3		
1989	159.7	11.1	1.8		172.7			194.5	367.2		
1990 1991	179.5 189.2	13.2 15.3	2.2 2.7		194.9 207.1			219.0 241.2	413.9 448.3		
1992	205.6	17.1	3.0		225.6			256.8	482.4	103.3	91.2
1993 1994	205.8 208.1	20.4 22.8	3.7 3.3		229.9 234.2			297.0 309.4	526.9 543.7	114.2 119.3	98.7 106.1
1995 1996	212.5 232.6	26.0 26.3	3.1 3.5		241.5 262.4			323.6 360.2	565.1 622.6	119.8 128.3	108.9 112.5
1997	254.8	29.3	3.5		287.6			403.5	691.1	144.5	125.9
1998 1999	278.1 328.2	32.8 41.2	4.2 5.2		315.0 374.6			430.1 494.4	745.1 869.1	153.1 167.1	135.0 136.7
2000	387.1	45.1	5.7		437.8			556.5	994.3	173.4	150.0
2000	451.0	51.4	7.7		510.1			617.5	1,127.7	190.6	160.8
2002	515.2	57.7	8.7		581.7			686.9	1,268.6	199.0	169.6
2003 2004	588.2 646.8	64.9 67.8	10.2 10.9		663.2 725.5			754.3 800.9	1,417.5 1,526.4	220.0 236.8	177.3 187.2
2005	709.3	71.6	10.9		791.7			848.5	1,640.2	240.8	194.9
2006	758.9	75.3	11.6		845.8			995.1	1,840.9	271.9	213.9
2007 f 2008 f	858.0 909.3	78.6 83.8	11.3 11.3		947.9 1,004.3			1,128.8 1,284.0	2,076.7 2,288.3	294.8 308.4	224.8 235.2
2000 1	000.0	00.0	11.0		1,001.0				2,200.0	000.1	200.2
1985						(Annual Perce	ntage Change				
1986	19.8	9.8	33.7		19.1			10.0	13.3		
1987 1988	15.1 12.7	6.1 22.8	23.4 13.0		14.5 13.5			3.5 12.7	7.7 13.0		
1989	48.0	22.8	10.2		45.5			12.7	26.1		
1990	12.4	18.0	22.6		12.9			12.6	12.7		
1991	5.4	16.1	19.6		6.3			10.1	8.3		
1992 1993	8.7 0.1	11.8 19.6	11.9 23.9		8.9 1.9			6.5 15.7	7.6 9.2	 10.6	 8.3
1994	1.1	11.9	-11.4		1.9			4.2	3.2	4.5	7.4
1995	2.1	13.7	-5.1		3.1			4.6	3.9	0.4	2.6
1996	9.5	1.3	11.9		8.6			11.3	10.2	7.1	3.3
1997 1998	9.6 9.1	11.5 11.8	-0.3 21.3		9.6 9.5			12.0 6.6	11.0 7.8	12.6 6.0	11.9 7.2
1999	18.0	25.8	22.9		18.9			15.0	16.6	9.2	1.3
2000	17.9	9.2	9.8		16.9			12.6	14.4	3.8	9.7
2001 2002	16.5 14.2	14.1 12.2	36.1 13.6		16.5 14.0			11.0 11.2	13.4 12.5	9.9 4.4	7.3 5.4
2003	14.2	12.4	16.2		14.0			9.8	11.7	10.5	4.6
2004	10.0	4.5	6.9		9.4			6.2	7.7	7.6	5.6
2005 2006	9.7 7.0	5.6 5.2	0.1 6.7		9.1 6.8			5.9 17.3	7.5 12.2	1.7 12.9	4.1 9.8
2008 2007 f	13.1	5.2	-2.6		12.1			17.3	12.2	8.4	9.8
2008 f	6.0	6.5	-0.2		5.9			13.7	10.2	4.6	4.6
						ercentage Share of					
1985 1986	21.4 22.6	2.0 1.9	0.3 0.3		23.7 24.9			41.5 40.3	65.1 65.1		
1987	23.6	1.8	0.4		25.8			37.7	63.4		
1988 1989	23.7 29.2	2.0 2.0	0.4 0.3		26.1 31.6			38.0 35.6	64.1 67.2		
1990	30.0	2.0	0.4		32.6			36.6	69.2		
1991	29.5	2.4	0.4		32.3			37.6	69.9		
1992 1993	30.4 27.8	2.5 2.8	0.4 0.5		33.3 31.1			37.9 40.1	71.3 71.2	15.3 15.4	13.5 13.3
1993 1994	27.8	2.8 3.0	0.5		31.1 30.5			40.1 40.2	71.2	15.4 15.5	13.3 13.8
1995	26.8	3.3	0.4		30.4			40.8	71.2	15.1	13.7
1996	26.9	3.0	0.4		30.4			41.7	72.1	14.9	13.0
1997 1998	26.5 26.9	3.1 3.2	0.4 0.4		29.9 30.5			42.0 41.6	71.9 72.1	15.0 14.8	13.1 13.1
1999	28.0	3.5	0.4		31.9			42.2	74.1	14.8	11.7
2000	29.4	3.4	0.4		33.2			42.2	75.5	13.2	11.4
2001	30.5	3.5	0.5		34.5			41.7	76.2	12.9	10.9
2002 2003	31.5 32.4	3.5 3.6	0.5 0.6		35.5 36.5			42.0 41.6	77.5 78.1	12.2 12.1	10.4 9.8
2004	33.2	3.5	0.6		37.2			41.1	78.3	12.1	9.6
2005	34.2	3.4	0.5		38.1			40.9	79.0	11.6	9.4
2006 2007 f	32.6 33.0	3.2	0.5 0.4		36.4 36.5			42.8 43.5	79.1 80.0	11.7 11.4	9.2
200/1	33.0	3.0	0.4		30.5			43.5	80.0	11.4	8.7

	E	xpenditure or	• • • •	, by Source of F xpenditures, Alb		a Share of Publi 2008 (cont'd))					
				•		2000 (cont u)		ugs in Public, Privat				
_	Public	All Drugs Private	Total	Public H	ealth Expenditure Private	Total	Public	Health Expenditures Private	s Total			
			(\$ Millic				(D	ercentage Share)				
r <u> </u>	76.7	247.6	324.3	3,239.1	831.3	4,070.4	2.4	29.8	8.0			
6	91.4	247.6	367.4	3,239.1	910.6	4,448.5	2.4	30.3	8.3	A		
7	104.6	301.6	406.2	3,514.4	985.5	4,499.9	3.0	30.6	9.0			
8 9	118.7	335.9	454.6	3,645.6	1,184.9	4,830.6	3.3	28.3	9.4			
	172.7	374.0	546.7	4,031.0	1,318.8	5,349.8	4.3	28.4	10.2			
D 1	194.9 207.1	403.4 434.0	598.3 641.1	4,326.9 4,557.5	1,422.5 1,505.1	5,749.4 6,062.5	4.5 4.5	28.4 28.8	10.4 10.6			
2	207.1	451.2	676.9	4,557.5	1,505.1	6,430.7	4.5	28.5	10.5			
3	229.9	510.0	739.8	4,800.5	1,719.9	6,520.4	4.8	29.7	11.3			
1	234.2	534.8	769.1	4,527.8	1,785.7	6,313.4	5.2	30.0	12.2			
5	241.5	552.2	793.8	4,283.5	1,809.0	6,092.5	5.6	30.5	13.0			
6	262.4	601.0	863.4	4,466.5	1,854.2	6,320.6	5.9	32.4	13.7			
7 3	287.6 315.0	673.9 718.1	961.5 1,033.2	4,942.0 5,354.0	2,140.1 2,251.1	7,082.1 7,605.1	5.8 5.9	31.5 31.9	13.6 13.6			
)	374.6	798.3	1,172.9	6,140.2	2,539.9	8,680.1	6.1	31.4	13.5			
D	437.8	879.9	1,317.7	6,792.9	2,822.9	9,615.8	6.4	31.2	13.7			
1	510.1	968.9	1,479.1	7,745.0	3,258.1	11,003.2	6.6	29.7	13.4			
2	581.7	1,055.5	1,637.2	8,470.2	3,385.4	11,855.6	6.9	31.2	13.8			
3	663.2 725 5	1,151.6	1,814.8	9,127.1	3,563.2	12,690.3	7.3	32.3	14.3			
4	725.5	1,224.9	1,950.4	9,981.4	3,928.7	13,910.1	7.3	31.2	14.0			
5	791.7	1,284.1	2,075.8	11,092.2	4,177.2	15,269.4	7.1	30.7	13.6			
6 7 f	845.8 947.9	1,481.0 1,648.3	2,326.8 2,596.2	12,166.4 13,335.5	4,857.5 5,268.0	17,023.9 18,603.5	7.0 7.1	30.5 31.3	13.7 14.0			
8 f	1,004.3	1,827.5	2,831.8	14,444.6	5,688.4	20,133.0	7.0	32.1	14.1			
			(Annual Percent	age Change)								
5												
6	19.1	11.5	13.3	9.2	9.5	9.3						
7 8	14.5 13.5	9.3 11.3	10.6 11.9	-0.7 3.7	8.2 20.2	1.2 7.3						
9	45.5	11.4	20.3	10.6	11.3	10.7						
0	12.9	7.8	9.4	7.3	7.9	7.5						
1	6.3	7.6	7.2	5.3	5.8	5.4						
2	8.9	4.0	5.6	6.3	5.3	6.1						
3	1.9	13.0	9.3	-0.9	8.6	1.4						
4	1.9	4.9	4.0	-5.7	3.8	-3.2						
5	3.1	3.3	3.2	-5.4	1.3	-3.5						
6 7	8.6 9.6	8.8 12.1	8.8 11.4	4.3 10.6	2.5 15.4	3.7 12.0						
8	9.5	6.6	7.5	8.3	5.2	7.4						
9	18.9	11.2	13.5	14.7	12.8	14.1						
0	16.9	10.2	12.3	10.6	11.1	10.8						
1	16.5	10.1	12.2	14.0	15.4	14.4						
2 3	14.0	8.9	10.7	9.4	3.9	7.7						
4	14.0 9.4	9.1 6.4	10.8 7.5	7.8 9.4	5.3 10.3	7.0 9.6						
5												
6	9.1 6.8	4.8 15.3	6.4 12.1	11.1 9.7	6.3 16.3	9.8 11.5						
7 f	12.1	11.3	11.6	9.6	8.5	9.3						
8 f	5.9	10.9	9.1	8.3	8.0	8.2						
	(Percentar	e Share of Total Dru	ia Expenditure)									
5 6	23.7 24.9	76.3 75.1	100.0 100.0									
7	24.5	74.2	100.0									
В	26.1	73.9	100.0									
9	31.6	68.4	100.0									
0	32.6	67.4	100.0									
1	32.3	67.7	100.0									
2 3	33.3 31.1	66.7 68.9	100.0 100.0									
4	30.5	69.5	100.0									
5	30.4	69.6	100.0									
5	30.4	69.6	100.0									
7	29.9	70.1	100.0									
3	30.5	69.5 68 1	100.0									
9	31.9	68.1	100.0									
0	33.2	66.8	100.0									
1 2	34.5 35.5	65.5 64.5	100.0 100.0									
3	36.5 36.5	63.5	100.0									
4	37.2	62.8	100.0									
5	38.1	61.9	100.0									
6	36.4	63.6	100.0									
7 f	36.5	63.5	100.0									
	35.5	64.5	100.0									
B f												

					Prescribe	ed Drugs					-Prescribed D	
	Provincial	Federal	Public Social Security WCB	y Funds Drug nsurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Priva Over- the- Counter	te (Out-of-Poo Personal Health Supplies	cket) T Non- D
Year				Fund		(\$ per	Capita)		Diugs	Drugs	Supplies	
1985	28.91	2.65	0.37		31.93			55.96	87.89			
1986 1987	34.23 39.32	2.87 3.04	0.48 0.60		37.59 42.96			60.86 62.87	98.44 105.83			
1988	43.98	3.71	0.67		48.36			70.31	118.67			
1989	64.01	4.47	0.73		69.20			77.94	147.14			
990 991	70.48 72.98	5.16 5.89	0.87 1.02		76.52 79.89			86.00 93.03	162.51 172.92			
992 993	78.09 77.14	6.48 7.65	1.13 1.38		85.70 86.18			97.53 111.35	183.24 197.53	39.22 42.82	34.62 37.01	
94	77.07	8.46	1.21		86.74			114.58	201.32	44.18	39.28	
95	77.70	9.50	1.13		88.33			118.34	206.67	43.80	39.81	
96 97	83.81 90.05	9.49 10.37	1.25 1.22		94.55 101.64			129.79 142.56	224.34 244.20	46.23 51.05	40.53 44.49	
98	95.90	11.31	1.45		108.66			148.33	256.98	52.80	46.55	
99	111.14	13.97	1.74		126.85			167.42	294.27	56.59	46.29	
00 01	128.81 147.55	15.00 16.82	1.88 2.52		145.69 166.89			185.19 202.01	330.88 368.91	57.71 62.35	49.90 52.62	
002	165.33	18.51	2.81		186.65			220.43	407.08	63.86	54.41	
003 004	186.05 201.62	20.52 21.13	3.22 3.39		209.79 226.14			238.59 249.65	448.38 475.78	69.59 73.81	56.09 58.34	
005	216.20	21.81	3.31		241.33			258.63	499.96	73.38	59.40	
006	225.16	22.33	3.44		250.93			295.24	546.18	80.66	63.47	
07 f 08 f	246.98 258.79	22.63 23.84	3.25 3.21		272.87 285.84			324.92 365.42	597.79 651.26	84.85 87.76	64.71 66.93	
						(Annual Perce	ntage Change)					
85												
86 87	18.4 14.9	8.6 5.9	32.2 23.2		17.7 14.3			8.7 3.3	12.0 7.5			
38	14.9	21.8	12.1		14.3			11.8	12.1			
9	45.5	20.5	8.4		43.1			10.9	24.0			
0 1	10.1 3.5	15.6 14.0	20.1 17.5		10.6 4.4			10.3 8.2	10.4 6.4			
2	7.0	10.1	10.2		7.3			4.8	6.0			
13 14	-1.2 -0.1	18.0 10.5	22.3 -12.5		0.6 0.6			14.2 2.9	7.8 1.9	9.2 3.2	6.9 6.1	
5	0.8	12.3	-6.3		1.8			3.3	2.7	-0.8	1.4	
6	7.9	-0.2	10.3		7.0			9.7	8.6	5.5	1.8	
7 3	7.4 6.5	9.3 9.1	-2.2 18.4		7.5 6.9			9.8 4.0	8.9 5.2	10.4 3.4	9.8 4.6	
9	15.9	23.5	20.6		16.7			12.9	14.5	7.2	-0.6	
0	15.9	7.4	7.9		14.9			10.6	12.4	2.0	7.8	
)1)2	14.6 12.0	12.2 10.1	33.8 11.4		14.6 11.8			9.1 9.1	11.5 10.3	8.0 2.4	5.4 3.4	
03	12.5	10.8	14.6		12.4			8.2	10.1	9.0	3.1	
04	8.4	3.0	5.4		7.8			4.6	6.1	6.1	4.0	
105 106	7.2 4.1	3.3 2.4	-2.2 3.9		6.7 4.0			3.6 14.2	5.1 9.2	-0.6 9.9	1.8 6.9	
07 f 08 f	9.7 4.8	1.3 5.3	-5.5 -1.3		8.7 4.8			10.1 12.5	9.4 8.9	5.2 3.4	1.9 3.4	
	4.0	0.0	-1.3			e Change in Excess				3.4	3.4	
85												
86 87	15.6 10.1	5.8 1.1	29.4 18.5		14.9 9.5			5.9 -1.4	9.2 2.8			
88	7.3	17.3	7.6		8.1			7.3	7.6			
89	41.0	15.9	3.8		38.5			6.3	19.4			
90 91	7.1 0.8	12.6 11.3	17.1 14.8		7.5 1.6			7.3 5.4	7.4 3.6			
92	5.7	8.8	8.9		6.0			3.6	4.7	 7.7		
93 94	-2.6 -1.2	16.6 9.4	20.8 -13.6		-0.9 -0.4			12.7 1.8	6.4 0.8	7.7	5.5 5.0	
95	-1.5	10.0	-8.6		-0.5			0.9	0.3	-3.2	-1.0	
96	6.2	-1.9	8.6		5.4			8.0	6.9	3.9	0.1	
97 98	6.5 6.9	8.3 9.5	-3.2 18.8		6.5 7.3			8.8 4.5	7.9 5.7	9.4 3.9	8.8 5.1	
99	14.1	21.7	18.8		14.9			11.1	12.7	5.4	-2.4	
00 01	11.8 13.2	3.3 10.8	3.8 32.4		10.7 13.2			6.5 7.7	8.3 10.1	-2.1 6.7	3.7 4.1	
2	11.0	9.0	10.4		10.8			8.1	9.3	1.4	2.4	
13 14	9.6 5.8	7.9 0.4	11.7 2.8		9.5 5.2			5.3 2.0	7.2 3.5	6.1 3.5	0.2 1.4	
)5	4.1	0.1	-5.3		3.6			0.5	2.0	-3.7	-1.3	
6	1.7	0.0	1.4		1.6			11.7	6.8	7.5	4.4	
007 f 008 f	6.5	-1.9	-8.7		5.5			6.8	6.2	2.0	-1.3	

		Expenditure	• •	apita by Type, by S				Alta. – Per Capita
		All Drugs	Total Health	Expenditures, Albe	rta, 1985 to Ith Expenditure	2008 (cont'd)	GDP Implicit Price Index – Canada	
-	Public	Private	Total	Public	Private	Total		
Year			(\$ per C	Capita)			(1997 = 100)	
1985	31.93	103.03	134.95	1,347.98	345.94	1,693.92	73.6	
1986	37.59	113.54	151.13	1,455.36	374.58	1,829.95	75.6	
1987 1988	42.96 48.36	123.86 136.84	166.81 185.20	1,443.08 1,485.33	404.68 482.78	1,847.76 1,968.11	79.2 82.8	
1989	69.20	149.90	219.10	1,615.48	528.50	2,143.98	86.6	
1990	76.52	158.36	234.87	1,698.71	558.47	2,257.18	89.2	
1991 1992	79.89	167.40	247.29	1,757.86	580.52	2,338.38	91.6	
1992	85.70 86.18	171.37 191.18	257.08 277.36	1,840.71 1,799.67	601.71 644.78	2,442.42 2,444.45	92.8 94.1	
1994	86.74	198.04	284.78	1,676.53	661.19	2,337.72	95.2	
1995	88.33	201.95	290.28	1,566.45	661.54	2,227.99	97.4	
1996 1997	94.55	216.56	311.11	1,609.44	668.13	2,277.57	99.0	
1997	101.64 108.66	238.11 247.68	339.75 356.34	1,746.27 1,846.54	756.21 776.39	2,502.48 2,622.93	100.0 99.6	
1999	126.85	270.31	397.16	2,079.12	860.03	2,939.15	101.4	
2000	145.69	292.81	438.50	2,260.58	939.41	3,199.99	105.5	
2001	166.89	316.98	483.87	2,533.75	1,065.89	3,599.64	106.9	
2002 2003	186.65 209.79	338.71 364.28	525.36 574.06	2,718.01 2,887.07	1,086.35 1,127.09	3,804.36 4,014.16	108.1 111.2	
2004	226.14	381.80	607.94	3,111.23	1,224.59	4,335.82	114.1	
2005	241.33	391.41	632.74	3,381.03	1,273.26	4,654.29	117.6	
2006	250.93	439.38	690.31	3,609.56	1,441.15	5,050.71	120.5	
2007 f 2008 f	272.87 285.84	474.47 520.12	747.34 805.96	3,838.68 4,111.07	1,516.42 1,618.96	5,355.10 5,730.03	124.3 128.6	
						.,		
-				(Annual Percentage Change				
1985 1986	 17.7	10.2	12.0	 8.0	8.3	 8.0	2.8	
1987	14.3	9.1	10.4	-0.8	8.0	1.0	4.7	
1988	12.6	10.5	11.0	2.9	19.3	6.5	4.5	
1989	43.1	9.5	18.3	8.8	9.5	8.9	4.6	
1990 1991	10.6 4.4	5.6 5.7	7.2 5.3	5.2 3.5	5.7 3.9	5.3 3.6	3.0 2.8	
1992	4.4	2.4	4.0	4.7	3.9	4.4	1.3	
1993	0.6	11.6	7.9	-2.2	7.2	0.1	1.4	
1994	0.6	3.6	2.7	-6.8	2.5	-4.4	1.1	
1995 1996	1.8	2.0	1.9	-6.6	0.1	-4.7	2.3	
1997	7.0 7.5	7.2 10.0	7.2 9.2	2.7 8.5	1.0 13.2	2.2 9.9	1.7 1.0	
1998	6.9	4.0	4.9	5.7	2.7	4.8	-0.4	
1999	16.7	9.1	11.5	12.6	10.8	12.1	1.8	
2000	14.9	8.3	10.4	8.7	9.2	8.9	4.1	
2001 2002	14.6 11.8	8.3 6.9	10.3 8.6	12.1 7.3	13.5 1.9	12.5 5.7	1.4 1.0	
2003	12.4	7.5	9.3	6.2	3.8	5.5	2.9	
2004	7.8	4.8	5.9	7.8	8.7	8.0	2.6	
2005	6.7	2.5	4.1	8.7	4.0	7.3	3.1	
2006 2007 f	4.0 8.7	12.3 8.0	9.1 8.3	6.8 6.3	13.2 5.2	8.5 6.0	2.4 3.2	
2008 f	4.8	9.6	7.8	7.1	6.8	7.0	3.4	
		(Annual Percenta	age Change in Excess	of Inflation in the Canadian	Economy)			
-		(Annual Tercente	Excodd (
1986	14.9	7.4	9.2	5.2	5.5	5.2		
1987	9.5	4.3	5.6	-5.6	3.3	-3.8		
1988 1989	8.1 38.5	6.0 5.0	6.5 13.7	-1.6 4.2	14.8 4.9	2.0 4.4		
1990	7.5	2.6	4.2	2.1	2.6	2.3		
1990	7.5	3.0	4.2 2.5	0.7	1.2	0.8		
1992	6.0	1.1	2.7	3.5	2.4	3.2		
1993 1994	-0.9 -0.4	10.1 2.5	6.5 1.6	-3.7 -7.9	5.7 1.4	-1.4 -5.5		
1995	-0.5	-0.4	-0.4	-8.9	-2.3	-7.0		
1995	-0.5 5.4	-0.4 5.6	-0.4 5.5	-8.9	-2.3	-7.0		
1997	6.5	9.0	8.2	7.5	12.2	8.9		
1998 1999	7.3 14.9	4.5 7.3	5.3 9.6	6.2 10.8	3.1 9.0	5.3 10.2		
2000 2001	10.7 13.2	4.2 6.9	6.3 9.0	4.6 10.7	5.1 12.1	4.8 11.1		
2002	10.8	5.8	7.5	6.2	0.9	4.6		
2003 2004	9.5 5.2	4.7 2.2	6.4 3.3	3.3 5.2	0.9 6.1	2.6 5.4		
2005 2006	3.6 1.6	-0.6 9.8	1.0 6.7	5.6 4.3	0.9 10.8	4.2 6.1		
2007 f	5.5	4.8	5.0	3.1	2.0	2.8		
2008 f	1.3	6.2	4.4	3.7	3.3	3.6		
I								
f: forecast.								Source: NHEX, CIHI, 2008.

		Public		Prescrib	ed Drugs	Dist				Prescribed Dr	
Provincial	Federal _	Social Secu WCB	Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out-of-Poc Personal Health Supplies	To Non-P Dru
			Fund		(\$ Mi	llions)			Drugs		
128.5	7.8	1.4		137.7			121.1	258.8			
151.4	8.6	1.5		161.5			105.6	267.0			
153.5 169.8	9.2 14.0	1.7 2.0		164.4 185.7			134.9 159.6	299.2 345.3			
196.5	14.0	2.1		216.7			188.9	405.6			
		2.4									
232.6 275.4	21.2 24.4	2.4		256.3 302.4			216.8 241.1	473.0 543.5			
311.8	26.5	3.1		341.5			268.1	609.5	149.5	134.7	
346.0	32.1	3.5		381.6			303.1	684.7	164.4	146.0	
339.4	35.8	4.0		379.2			323.2	702.5	183.5	156.9	
349.5	40.5	4.2		394.1			353.5	747.6	186.0	163.8	
379.4	44.2	3.9		427.5			374.9	802.4	192.2	166.3	
418.7	45.3	4.0		468.0			412.2	880.2	196.5	172.7	
457.8 515.6	49.5 54.2	5.1 5.9		512.4 575.7			480.0 505.7	992.4 1,081.5	208.5 226.4	185.0 196.7	
595.4	58.2	6.8		660.4			570.1	1,230.5	235.6	199.6	
659.1 696.7	65.6 76.0	7.4 7.2		732.1 779.9			641.0 759.4	1,373.1 1,539.3	245.1 257.5	209.6 220.3	
698.1	76.0 88.0	7.2		793.7			759.4 892.7	1,686.4	257.5	220.3	
752.5	92.6	9.0		854.1			1,038.8	1,892.9	295.6	231.6	
813.3	96.5	9.8		919.6			1,089.8	2,009.4	299.1	239.4	
864.7	101.4	9.8		976.8			1,089.8	2,288.1	309.6	239.4	
908.2	107.0	11.3		1,026.5			1,584.2	2,610.7	288.8	223.4	
917.1	116.7	12.0		1,045.8			1,842.9	2,888.7	303.2	234.5	
					(Annual Perce	ntage Change)					
17.8	9.6	4.7		17.2			-12.8	3.2			
1.4	7.3	15.5		1.8			27.8	12.1			
10.6	51.5	16.5		13.0			18.4	15.4			
15.8	29.1	9.0		16.7			18.4	17.5			
18.3	17.9	14.0		18.2			14.7	16.6			
18.4	14.6	10.1		18.0			11.3	14.9			
13.2	9.0	16.1		12.9			11.2	12.1			
11.0 -1.9	21.0 11.6	11.6 14.1		11.7 -0.6			13.1 6.6	12.3 2.6	10.0 11.6	8.4 7.4	
3.0	12.9	5.7		3.9			9.4	6.4	1.4	4.4	
8.6 10.3	9.1 2.6	-6.0 2.1		8.5 9.5			6.1 10.0	7.3 9.7	3.3 2.3	1.5 3.9	
9.4	9.2	25.6		9.5			16.4	12.7	6.1	7.1	
12.6	9.6	17.2		12.4			5.4	9.0	8.6	6.3	
15.5	7.3	15.1		14.7			12.7	13.8	4.1	1.5	
10.7	12.7	8.3		10.9			12.4	11.6	4.0	5.0	
5.7	15.8	-3.0		6.5			18.5	12.1	5.1	5.1	
0.2	15.8	6.4		1.8			17.6	9.6	8.1	2.3	
7.8	5.1	17.9		7.6			16.4	12.2	6.2	2.7	
8.1	4.3	8.8		7.7			4.9	6.2	1.2	3.3	
6.3	5.0	10.4		6.2			20.3	13.9	3.5	2.5	
5.0	5.6	4.9		5.1			20.8	14.1	-6.7	-9.0	
1.0	9.0	6.2		1.9			16.3	10.6	5.0	5.0	
					ercentage Share of 1	Total Drug Expe					
30.9	1.9	0.3		33.1			29.1	62.1			
34.0 30.3	1.9 1.8	0.3 0.3		36.2 32.5			23.7 26.6	59.9 59.1			
30.3	2.5	0.3		32.9			28.3	61.2			
30.8	2.8	0.3		34.0			29.6	63.6			
32.2	2.9	0.3		35.5			30.0	65.5			
32.2 34.0	2.9 3.0	0.3		35.5			30.0 29.8	65.5			
34.9	3.0	0.3		38.2			30.0	68.2	16.7	15.1	
34.8	3.2	0.3		38.3			30.5	68.8	16.5	14.7	
32.5	3.4	0.4		36.4			31.0	67.4	17.6	15.0	
31.8	3.7	0.4		35.9			32.2	68.1	16.9	14.9	
32.7	3.8	0.3		36.8			32.3	69.1	16.6	14.3	
33.5	3.6	0.3		37.5			33.0	70.5	15.7	13.8	
33.0	3.6	0.4		37.0			34.6	71.6	15.0	13.4	
34.3	3.6	0.4		38.3			33.6	71.9	15.0	13.1	
35.7	3.5	0.4		39.6			34.2	73.9	14.1	12.0	
36.1	3.6	0.4		40.1			35.1	75.1	13.4	11.5	
34.5	3.8	0.4		38.7			37.6	76.3	12.8	10.9	
31.9	4.0	0.3		36.2			40.8	77.0	12.7	10.3	
31.1	3.8	0.4		35.3			42.9	78.2	12.2	9.6	
31.9	3.8	0.4		36.1			42.8	78.9	11.7	9.4	
30.4	3.6	0.4		34.4			46.1	80.5	10.9	8.6	
29.1 26.8	3.4 3.4	0.4 0.4		32.9 30.5			50.7 53.8	83.6 84.3	9.2 8.8	7.2 6.8	
20.0	0.4	0.4		00.0			55.5	00	0.0		

	E	-	• • • •	by Source of Fin ditures, British Co					
		I O	iai neaith Expen		IUMDIA, 198	5 10 2008 (CONT	Share of Drugs i	in Public, Private an Ith Expenditures	d
-	Public	Private	Total	Public	Private	Total			Total
			(\$ Millior	is)			(Perce	ntage Share)	
	137.7	278.8	416.5	3,410.1	1,227.1	4,637.3	4.0	22.7	9.0
	161.5	284.1	445.6	3,666.0	1,317.2	4,983.3	4.4	21.6	8.9
	164.4 185.7	341.9 378.9	506.3 564.6	3,895.3 4,241.2	1,444.9 1,597.1	5,340.3 5,838.3	4.2 4.4	23.7 23.7	9.5 9.7
	216.7	421.2	637.9	4,736.0	1,773.0	6,509.0	4.6	23.8	9.8
	256.3	465.4	721.7	5,386.7	1,986.0	7,372.6	4.8	23.4	9.8
	302.4	507.3	809.7	5,967.2	2,159.5	8,126.7	5.1	23.5	10.0
	341.5 381.6	552.2 613.5	893.7 995.1	6,477.9 6,869.8	2,291.2 2,427.0	8,769.1 9,296.8	5.3 5.6	24.1 25.3	10.2 10.7
	379.2	663.6	1,042.9	7,237.5	2,533.2	9,770.7	5.2	26.2	10.7
	394.1	703.2	1,097.3	7,538.4	2,574.3	10,112.7	5.2	27.3	10.9
	427.5	733.3	1,160.9	7,688.7	2,689.4	10,378.1	5.6	27.3	11.2
	468.0	781.4	1,249.4	7,942.6	2,889.4	10,832.0	5.9	27.0	11.5
	512.4 575.7	873.5 928.8	1,385.9 1,504.6	8,304.5 8,969.4	3,102.8 3,299.8	11,407.3 12,269.2	6.2 6.4	28.2 28.1	12.1 12.3
	660.4	1,005.4	1,665.8	9,825.9	3,556.5	13,382.4	6.7	28.3	12.4
	732.1	1,095.7	1,827.7	10,820.5	3,815.4	14,635.9	6.8	28.7	12.5
	779.9	1,237.2	2,017.1	11,478.0	4,162.6	15,640.6	6.8	29.7	12.9
	793.7 854.1	1,396.4 1,566.0	2,190.1 2,420.1	11,953.4 12,257.3	4,471.7 4,970.8	16,425.1 17,228.2	6.6 7.0	31.2 31.5	13.3 14.0
	919.6	1,628.3	2,547.9	13,243.1	5,238.9	18,482.0	6.9	31.1	13.8
	976.8	1,828.3	2,843.0	13,243.1	5,238.9 6,034.3	19,963.1	7.0	30.9	13.8
	1,026.5	2,096.3	3,122.8	14,780.7	6,370.7	21,151.3	6.9	32.9	14.8
	1,045.8	2,380.6	3,426.4	15,644.3	6,909.9	22,554.2	6.7	34.5	15.2
			(Annual Percenta	ge Change)					
	17.2	1.9	7.0	7.5	7.3	7.5			
	1.8 13.0	20.3 10.8	13.6 11.5	6.3 8.9	9.7 10.5	7.2 9.3			
	16.7	11.2	13.0	11.7	11.0	11.5			
	18.2	10.5	13.1	13.7	12.0	13.3			
	18.0	9.0	12.2	10.8	8.7	10.2			
	12.9	8.9	10.4	8.6	6.1	7.9			
	11.7 -0.6	11.1 8.2	11.3 4.8	6.0 5.4	5.9 4.4	6.0 5.1			
	3.9	6.0	5.2	4.2	1.6	3.5			
	8.5	4.3	5.8	2.0	4.5	2.6			
	9.5	6.6	7.6	3.3	7.4	4.4			
	9.5 12.4	11.8 6.3	10.9 8.6	4.6 8.0	7.4 6.3	5.3 7.6			
	14.7	8.2	10.7	9.5	7.8	9.1			
	10.9	9.0	9.7	10.1	7.3	9.4			
	6.5	12.9	10.4	6.1	9.1	6.9			
	1.8 7.6	12.9 12.1	8.6 10.5	4.1 2.5	7.4 11.2	5.0 4.9			
	7.7	4.0	5.3	8.0	5.4	7.3			
	6.2	14.6	11.6	5.2	15.2	8.0			
	5.1	12.3	9.8	6.1	5.6	6.0			
	1.9	13.6	9.7	5.8	8.5	6.6			
-		e Share of Total Dru		_					
	33.1	66.9	100.0						
	36.2 32.5	63.8 67.5	100.0 100.0						
	32.9	67.1	100.0						
	34.0	66.0	100.0						
	35.5	64.5	100.0						
	37.3 38.2	62.7 61.8	100.0 100.0						
	38.3	61.7	100.0						
	36.4	63.6	100.0						
	35.9	64.1	100.0						
	36.8 37.5	63.2 62.5	100.0 100.0						
	37.0	63.0	100.0						
	38.3	61.7	100.0						
	39.6	60.4	100.0						
	40.1	59.9	100.0						
	38.7 36.2	61.3 63.8	100.0 100.0						
	35.3	64.7	100.0						
	36.1	63.9	100.0						
	34.4	65.6	100.0						
	32.9 30.5	67.1 69.5	100.0 100.0						
	30.5	09.5	100.0						

Table B B.C. – Per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2008 Prescribed Drugs Non-Prescribed Drugs Public Private Private (Out-of-Pocket) Social Security Funds WCB Drug Provincial Federal Subtotal Insurers* Out-of-Subtotal Total Over Personal Total Pocket Prescribed Health Drug Public Private the Non-Presci Insurance Drugs Counter Supplies Drugs Fund Drugs (\$ per Capita) /ear 1985 43.21 2.63 0.47 46.31 40.72 87.03 53.01 986 50.41 2.86 0.49 53.75 35.14 88.89 59.43 1987 50.32 3.02 0.55 53.89 44.21 98.11 67.88 1988 54.50 4.48 0.63 59.62 51.23 110.85 70.39 1989 61.46 5.64 0.67 67.77 --------59.07 126.84 --------72.63 1990 70.67 6.46 0.74 77.87 65.87 143.74 75.56 1991 1992 81.63 89.90 7.22 7.65 0.79 89.64 98.45 71.48 77.29 161.12 175.73 78.90 81.93 ----43.10 38.83 1993 96.98 9.01 0.97 ----106.96 ----84.97 191.93 46.07 40.93 87.01 1994 92.34 9.75 103.18 ----42.69 1.08 87.94 191.11 49.92 92.60 1995 104.35 197.94 43.36 92.59 92.52 10.72 1.11 ------------93.59 49.24 1996 97.94 11.40 1.02 110.35 96.76 207.12 49.60 42.91 92.51 1997 106.03 11.47 1.02 ----118.52 104.40 222.92 49.77 43.73 93.50 1998 114.95 12.42 1.27 128.63 -------120.51 249.15 52.34 46.45 98.79 1999 128.53 13.52 1.48 143.52 126.07 269.60 56.44 49.04 105.48 2000 147.40 14.41 1.69 ----163.50 ----141.14 304.64 58.34 49.42 107.76 --------60.09 336.66 2001 161.60 16.09 1.81 179.50 157.17 51.39 111.48 2002 169.30 18.47 1.74 189.50 184.53 374.03 62.57 53.53 116.10 2003 167.99 21.19 1.83 191.01 214.83 405.84 66.96 54.26 121.22 2004 179.01 22.02 2.14 ----203.16 --------247.11 450.27 70.31 55.10 125.41 2005 190.90 22.66 2.29 215.86 255.81 471.67 70.20 56.19 126.39 2006 200.14 23.46 2.50 ----226.10 303.52 529.62 71.66 56.79 128.44 2007 1 207.33 24.44 2.58 ----234.36 --------361.67 596.03 65.92 50.99 116.91 2008 207.08 26.35 2.72 236.14 416.13 652.27 68.45 52.95 121.40 (Annual Percentage Change) 1985 16.7 -0.2 3.7 13.7 2.1 10.4 12.1 14.2 1986 8.5 ----16.1 -----13.7 --------1987 0.3 5.7 25.8 1988 8.3 48.3 14.1 ----10.6 --------15.9 13.0 --------3.7 1989 12.8 25.7 6.2 13.7 ----15.3 14.4 ----3.2 1990 15.0 14.9 11.5 13.3 4.0 14.5 10.8 ----11.8 --------1991 15.5 7.4 15.1 8.5 12.1 4.4 1992 12.9 ----10.1 6.0 9.8 8.1 9. 3.8 6.9 5.4 1993 7.9 17.7 8.5 8.6 9.9 9.2 6.2 1994 -4.8 8.3 10.7 -3.5 -------3.5 -0.4 8.3 4.3 6.4 1995 0.2 9.9 2.8 1.1 --------6.4 3.6 4.6 -1.4 1.6 0.0 --------0.7 -1.0 1996 5.9 6.4 -8.4 5.8 3.4 -0.1 1.1 1997 8.3 0.6 0.2 ----7.4 --------7.9 7.6 0.3 1.9 8.4 24.5 --------5.7 1998 8.2 8.5 15.4 11.8 5.2 6.2 1999 11.8 8.9 16.4 11.6 4.6 8.2 7.8 5.6 6.8 14.7 6.6 2.2 2000 14.3 ----13.9 --------11.9 13.0 3.4 0.8 9.6 11.6 7.3 --------3.4 2001 9.8 11.4 10.5 3.0 4.0 2002 4.8 14.8 -3.9 ----5.6 --------17.4 11.1 4.1 4.2 4.1 2003 -0.8 14.7 5.3 0.8 16.4 1.3 4.4 8.5 7.0 2004 6.6 3.9 16.6 ----6.4 --------15.0 10.9 5.0 1.6 3.5 2005 6.6 2.9 7.3 ----6.2 --------3.5 4.8 -0.2 2.0 0.8 2006 4.8 3.5 8.9 ----4.7 ----18.7 12.3 2.1 1.1 1.6 2007 3.6 4.2 3.5 ----3.7 --------19.2 12.5 -8.0 -10.2 -9.0 2008 -0.1 7.8 5.0 0.8 15.1 9.4 3.8 3.8 3.8 al Percentage Change in Excess of Inflation in the Ca idian Ec 1985 5.7 1.0 1986 13.9 0.9 13.3 -16.5 -0.7 ----9.3 --------1987 -4.9 9.0 -4.5 21.1 5.6 9.5 1988 3.8 8.2 43.8 21.2 9.6 1.6 6.1 9.1 11.4 8.5 -----0.8 -1.4 10.7 9.9 1989 ----1990 12.0 11.5 7.8 ----11.9 ----10.3 --------1.0 8.5 1.7 2.6 1991 12.7 9.0 4.6 12.4 5.8 9.3 ----1992 8.9 4.8 11.6 ----6.9 7.8 8.6 4.0 5.5 1993 6.4 16.3 7.0 7.2 8.5 7.8 4.8 1994 -5.9 2.4 7.2 3.2 5.3 7.2 9.6 -4.6 -1.5 1995 -2.1 4.2 7.6 4.7 0.5 -----1.2 4.1 --------4.1 1.7 1.2 3.0 -3.7 -0.9 -0.8 -2.7 -2.3 -1.8 -10.1 1996 1997 7.3 8.8 -0.4 -0.8 ----6.4 9.0 6.9 15.9 6.6 12.2 -0.7 0.9 6.7 0.1 6.1 1998 8.7 25.0 5.6 1999 10.0 7.1 14.6 ----9.8 2.8 6.4 6.0 3.8 5.0 10.6 2.5 9.8 -0.7 2000 10.2 ----7.8 8.9 -3.3 -1.9 10.3 --------2001 8.3 8.4 10.0 5.9 9.2 1.6 2.6 2.1 2002 3.7 13.8 -4.9 4.5 16.4 10.1 3.1 3.1 3.1 1.5 -3.7 4.0 11.8 1.3 -2.1 3.8 2003 2.4 13.5 5.6 4.1 -1.5 14.0 12.4 8.4 2.4 -1.0 2004 0.9 2005 3.5 -0.2 4.2 3.1 0.4 1.6 -3.3 -1.1 -2.3 2006 2.4 1.1 6.5 2.3 16.2 9.9 -0.3 -1.4 -0.8 2007 0.4 0.9 0.3 0.4 15.9 9.3 -11.2 -13.4 -12.2 ---------3.5 2008 f 4.4 1.6 -2.7 11.6 6.0 0.4 0.4 0.4 forecast. Note: Confidentiality precludes reporting provincial-level insurance data. Source: NHEX, CIHI, 2008.

			•	on Drugs per Cap tal Health Expend				lic, Private and	B B.C.—Per Capita
Pate Pate Tat Pate Tat 1000 1001 1001 1000 100								GDP Implicit	
	-	Public		Total			Total	Price Index—Canada	
	Year			(\$ per Capi	ita)			(1997 = 100)	
	-	46 31	93 73			412 58	1 559 13		
	1986	53.75	94.57	148.32	1,220.34	438.48	1,658.82	75.6	
1889 17.7 13.70 198.7 1.400.8 84.42 2.08.41 48.2 1990 1.44 10.54 2.40.2 1.744.8 44.01 2.40.20 1.82 1991 1.44 10.54 2.40.2 1.744.8 44.01 2.40.20 1.84 1992 1.40.3 110.4 2.40.2 1.84.1 2.40.2 1.84 1992 1.40.3 110.4 2.40.2 1.84.1 2.40.2 1.84.1 1992 1.40.3 110.4 2.40.2 1.84.1 2.40.3 1.84.1 1992 110.2 2.11.2 2.11.2 1.96.2	1987								
Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme Neme	1989								
9991 894 105.8 20.03 1,784 #5 640.15 2.420.00 91.6 9992 100.94 100.94 200.72 1,984.00 200.75 200.75 80.9 9994 100.94 100.94 200.72 1,984.00 601.10 200.75 80.9 9994 100.95 100.94 200.75 200.75 200.75 80.9 9995 100.95 100.94 200.75 200.75 200.75 80.9 9995 100.95 200.84 100.75 200.75 100.95 9995 100.25 200.84 100.75 200.84 100.75 9995 100.25 200.84 100.75 200.84 100.75 9995 100.95 200.84 100.75 200.84 100.75 9995 100.95 200.84 100.75 200.84 100.75 9995 200.84 200.75 200.84 100.75 200.84 9995 200.84 200.75 200.84 100.75 200.84 9995 200.84 200.75 200.75 200.75 100.75 9995 200.84 200.75 200.75 200.75 200.75 9995	1990	77.87	141.42	219.29	1,636.89	603.48	2,240.37	89.2	
	1991	89.64	150.38	240.03	1,768.85	640.15	2,409.00	91.6	
9941014105420721,90090112,917494,9194,9199610,65196,84296,951,954,5884,172,772,29100010132171,90326,02220,00220,00220,003,913,13100,6510132271,80271,90220,00220,00220,003,913,13100,651014296,00220,00220,00220,003,913,13100,651019290,00290,00290,00290,003,913,13100,651019290,00290,00290,00290,00290,003,913,131014290,00290,00440,00290,00120,00100,001019290,00410,00410,00292,00120,00110,001019290,00410,00410,00292,00120,00120,001019410,00410,00292,00120,00430,00120,001019410,00410,00120,00430,00120,00120,001019101100,00100,00100,00100,00100,001019101100,00100,00100,00100,00100,001019101100,00100,00100,00100,00100,001019101100,00100,00100,00100,00100,001019101100,00100,00100,00100,00100,001019101100,00100,00100,00									
9399 110.25 193.24 220.35 193.45 60.47 2.278.27 100.9 9399 14.25 223.69 327.09 2.226.09 427.25 100.9 9399 14.25 223.69 327.09 2.226.09 427.25 100.9 9390 14.25 224.09 427.25 82.260.09 3.318.60 100.9 9300 177.69 2.266.01 445.11 2.257.09 2.216.07 112.24 4.398.25 116.1 9300 120.31 27.25 977.69 2.216.07 1.322.24 4.398.25 116.1 9300 223.10 477.85 3.237.40 1.308.24 4.426.26 120.5 9300 223.10 477.85 3.237.40 1.308.24 4.426.26 120.5 9300 223.10 777.68 7.275.43 1.308.74 4.426.26 120.5 9300 1.5 1.5 2.246.0 1.308.95 1.308.95 1.308.95 1.308.95 9301 1.6 1.5 2.246.0 1.308.95 1.308.95 1.308.95 1.308.95 </td <td>1994</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1994								
9399 110.25 193.24 220.35 193.45 60.47 2.278.27 100.9 9399 14.25 223.69 327.09 2.226.09 427.25 100.9 9399 14.25 223.69 327.09 2.226.09 427.25 100.9 9390 14.25 224.09 427.25 82.260.09 3.318.60 100.9 9300 177.69 2.266.01 445.11 2.257.09 2.216.07 112.24 4.398.25 116.1 9300 120.31 27.25 977.69 2.216.07 1.322.24 4.398.25 116.1 9300 223.10 477.85 3.237.40 1.308.24 4.426.26 120.5 9300 223.10 477.85 3.237.40 1.308.24 4.426.26 120.5 9300 223.10 777.68 7.275.43 1.308.74 4.426.26 120.5 9300 1.5 1.5 2.246.0 1.308.95 1.308.95 1.308.95 1.308.95 9301 1.6 1.5 2.246.0 1.308.95 1.308.95 1.308.95 1.308.95 </td <td>1995</td> <td>104.35</td> <td>186.18</td> <td>290.53</td> <td>1,995.86</td> <td>681.57</td> <td>2,677.43</td> <td>97.4</td> <td></td>	1995	104.35	186.18	290.53	1,995.86	681.57	2,677.43	97.4	
198919631914.521914.531914.541914.541914.55191	1996				1,984.56	694.17	2,678.72		
1999 14.0.2 21.0.5 77.0.0 2.2.0.0 82.0.4 3.6.0.0 101.4 1000 17.0.0 220.0.6 448.1.4 2.603.0 83.0.1 3.000.00 100.9 1000 17.0.0 220.0.6 448.1.4 2.603.0 83.0.1 3.000.00 100.9 1000 120.0.0 437.5.2 107.60 2.010.0 100.9 100.9 1000 220.1.0 37.5.2 107.60 2.210.0 1.300.1.4 4.400.2 100.9 1000 220.1.0 473.80 100.2.0 2.210.0 1.300.1.4 4.400.2 120.0 1000 220.1.0 473.80 100.2.0 1.300.1.4 4.400.2 120.0 120.0 1000 220.1.0 17.2.2 1.300.1.4 4.400.2 120.0 120.0 1000 1.0.1 1.0.0 2.210.0 1.300.1.4 120.0 120.0 1000 1.0.1 1.0.0 2.210.0 1.300.1.4 140.0 120.0 1000 1.0.1 1.0.0 1.0.0 1.0.0 1.0.0 1.0.0 1.0.0 1000 1.0.1 1.0.0 1.0.0 1.0.0 1.0.0 1.0.0 1.0.0 1000 1									
	1999								
	2000	163.50	248.90	412.40	2,432.62	880.50	3,313.13	105.5	
2020 110.1 330.6 927.06 2.876.2 1.076.13 3.92.25 11.2 2020 215.6 332.20 686.06 3.106.53 1.228.72 4.388.25 117.6 226.10 471.86 772.24 3.373.20 1.268.72 4.388.25 117.6 226.10 471.86 772.24 3.373.20 1.268.72 4.288.79 12.3 226.10 471.86 772.24 3.373.20 1.268.72 4.288.79 12.3 226.10 471.86 772.24 3.373.20 1.268.72 4.288.79 12.3 1896 161 0.9 5.9 6.4 6.3 6.4 2.0 1997 0.3 15.3 10.4 6.3 6.4 2.0 2.0 1998 161 6.3 9.5 6.4 6.3 2.4 4.0 1992 151 6.4 9.3 3.3 3.0 3.1 1.4 1992 151 6.4 9.3 3.1 3.0 3.1 1.4 1992 151 6.4 1.0 7.0 2.3 1.1 1.4 1992 151 6.4 1.4 1.0 7.0 2.3	2001	179.50	268.64	448.14	2,653.08	935.51		106.9	
	2002 2003								
2009 224.0 431.8 656.0 3.224.07 1.387.4 4.4225 79 128.3 284.10 477.80 777.8 3.325.00 1.580.20 6.002.70 128.3 286.10 477.80 777.8 3.325.00 1.580.20 6.002.70 128.3 1985 1.3 0.3 5.9 4.4 4.02 6.002.70 4.5 1989 0.3 1.6 9.2 0.6 8.2 7.0 4.5 1989 0.3 1.6 9.2 0.6 8.2 7.0 4.5 1989 0.3 1.6 9.2 0.6 8.3 1.1 4.6 1989 1.4 7.4 9.2 1.3 0.4 4.6 1989 1.5 0.3 0.3 1.4 7.6 7.1 1980 0.6 0.0 0.3 1.4 7.0 7.1 1981 1.5 0.3 0.4 1.4 0.0 7.0 1982 0.4 1.4 1.4 1.4 0.0 7.0 7.2 1985 1.1 1.4 7.6 1.4 1.4 1.4 1.4 1986 0.3 1.4 7.6 1.4	2004								
20091 234.8 77.8.8 77.8.8 3.37.8.8 1.44.4 4.28.2.9 12.8.5 Image: String 17.8.8 String 17.8.8 String 17.8.8 String 17.8.8 108	2005								
20091 28,14 57,76 773,89 3,82,90 1,80,28 5,002,70 12,8 Lanual Precessage Charge!	2006								
Analysis in the interverse description of the interve	2007 f 2008 f								
1996 1997 0.3 10.5 1.9 4.7 8.0 5.4 4.7 1998 10.6 8.5 1.9 4.7 8.0 6.1 4.7 1998 10.7 8.3 10.1 8.8 8.1 6.1 7.0 4.5 1999 15.1 6.3 9.5 8.1 6.1 7.4 2.8 1992 2.8 5.9 7.3 5.6 3.2 4.0 1.1 1998 1.1 3.1 2.4 1.4 1.1 0.7 2.3 1998 1.5 1.6 3.6 5.6 6.4 0.4 1.4 1998 1.1 3.1 2.4 1.4 1.1 0.7 2.3 1998 1.5 1.6 0.6 1.4 0.4 0.4 1.4 1998 1.8 7.9 9.7 8.8 7.0 1.8 1.1 1000 3.6 1.6 1.6 1.6 1.6 1.6 1.6 11.8 7.4 9.7 8.8 7.0 8.8 1.0 2.0 1000 1.6 2.7				(Ap	nual Percentage Change	N N			
1989 16.1 0.9 5.9 6.4 6.3 6.4 2.8 1989 10.8 8.5 9.2 6.6 8.2 7.0 4.5 1980 14.9 7.4 9.6 0.5 6.8 10.6 4.6 1980 14.9 7.4 9.6 0.5 6.8 10.7 2.8 1982 9.8 6.9 0.7 2.2 2.0 2.0 1.1 1984 0.8 0.9 1.7 2.2 1.0 0.7 2.3 1.0 1.1 1984 0.4 0.4 0.4 1.4 1.1 0.7 2.3 1.0 1.1 1984 0.4 0.4 0.4 1.4 0.4 <td>-</td> <td></td> <td></td> <td></td> <td>nual Percentage Change</td> <td></td> <td></td> <td></td> <td></td>	-				nual Percentage Change				
1887 0.3 16.5 11.9 4.7 8.0 5.5 4.7 1899 0.6 8.5 4.2 7.0 6.5 4.6 1899 1.6 8.3 10.1 8.8 8.1 0.1 6.6 1891 16.1 8.3 8.5 8.1 6.1 7.5 2.5 1892 8.8 8.0 4.1 3.2 3.0 3.0 1.1 1892 1.1 3.1 3.4 1.6 1.4 0.7 2.3 1893 1.0 1.1 1.1 0.0 3.6 0.6 1.1 1894 1.4 1.6 1.4 0.4 0.4 0.4 0.4 1895 1.0.8 1.0.0 3.4 6.5 0.4 0.4 1995 1.1.8 9.4 5.1 0.1 6.5 0.2 10001 9.8 7.9 8.8 7.0 8.3 4.1 20024 0.8 1.1.8 9.4 5.1 0.1 5.5 2.4 20024					6.4				
1989 14.9 7.4 0.1 8.8 8.1 9.1 8.2 4.6 1991 15.1 0.3 9.5 8.1 0.1 7.5 2.8 1992 9.8 5.0 0.3 3.1 3.0 3.0 3.0 1.0 1.4 1993 0.8.6 0.0 1.7 2.2 1.0 1.4 1.4 1996 1.1 3.1 2.4 1.4 1.4 0.0 1.2 1.2 1997 7.4 4.6 5.6 1.4 6.4 0.2 1.2 1.2 1999 1.5 7.8 7.8 7.2 5.6 6.3 1.4 1999 1.5 7.8 7.2 5.6 6.3 1.4 1990 1.5 7.8 7.2 5.6 6.3 1.4 1000 3.7 7.0 8.1 6.1 6.5 2.3 1000 3.7 1.6 4.0 5.5 3.1 4.5 3.1 1000 1.2 3.1 6.5 4.5<	1987		18.5	11.9		8.0	5.5		
990 14.9 7.4 9.5 10.5 8.8 10.1 2.0 992 15.1 6.5 7.3 5.6 6.2 7.9 1.3 993 8.6 6.0 6.3 3.1 3.0 1.1 1.4 994 -3.5 5.0 1.7 2.2 1.3 2.0 1.1 995 1.1 5.1 7.7 2.2 1.3 2.0 1.0 995 5.8 1.7 3.1 0.6 1.8 2.0 1.0 996 8.5 10.8 10.0 3.4 6.5 0.4 0.4 997 7.4 4.6 5.8 1.1 5.4 1.4 0.4 0.4 2000 13.9 7.5 9.9 8.8 7.0 6.83 1.1 2001 9.8 7.9 7.4 4.6 5.1 6.3 4.1 2002 5.6 11.9 9.4 5.1 6.3 4.6 4.0 2.2 2004 6.4 10.9 9.2 1.4 </td <td>1988</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	1988								
191 0.3 0.5 0.1 0.1 0.5 0.1 0.1 0.1 1992 0.8 0.0 0.3 0.1 0.0 0.1 0.1 1993 0.1 0.1 0.2 0.1 0.0 0.1 0.0 1996 0.1 0.1 0.0 0.6 0.8 0.0 0.0 0.6 0.0 0.0 1997 7.4 0.6 0.0 0.6 0.6 0.0 0.0 0.6 0.0 <									
1992 9.8 5.9 7.3 5.6 2.2 4.9 1.3 1993 3.6 6.0 7.3 2.2 1.3 2.0 1.1 1994 3.5 5.0 1.7 2.2 1.3 2.0 1.1 1996 1.1 5.1 2.4 1.1 0.0 1.2 1996 5.8 1.7 3.1 0.4 1.8 0.0 1.7 1998 5.5 10.8 10.0 3.6 5.8 4.4 0.4 1999 1.6 5.6 7.8 9.1 6.2 6.3 1.1 2000 1.3.9 7.5 9.8 8.8 7.0 8.3 1.1 2001 1.8 7.5 9.4 5.1 6.1 6.9 1.0 2002 5.6 1.1.9 9.4 5.1 6.6 4.0 6.5 2.4 2004 6.4 1.9 9.2 1.4 9.9 3.7 2.6 2.4 2005 6.4 7.3 1.4 7.7 3.	1990								
1984 1.5 5.0 1.7 2.2 1.3 2.0 1.1 1985 1.5 5.1 3.1 0.4 1.1 0.0 2.3 1986 5.6 1.7 3.1 0.4 1.4 5.4 0.0 1.0 1986 6.5 1.4 5.4 0.0 3.6 6.5 4.4 0.0 1986 6.5 1.9 9.1 6.2 2.6 1.4 0.0 3.6 6.5 4.4 0.0 1001 9.8 7.9 9.7 9.1 6.2 6.3 1.1 4.1 2002 5.6 1.8 7.5 3.1 6.4 4.0 2.9 2.3 2003 0.8 1.1.8 7.5 3.1 6.4 4.0 2.9 2.4 2004 6.4 1.0 3.7 13.6 6.5 2.4 3.4 2006 4.7 1.3.0 1.0 3.7 1.3.6 3.6 3.4 20061 3.7 1.3.6 3.6 3.6 3.6 <td< td=""><td>1992</td><td>9.8</td><td>5.9</td><td>7.3</td><td>5.6</td><td>3.2</td><td>4.9</td><td>1.3</td><td></td></td<>	1992	9.8	5.9	7.3	5.6	3.2	4.9	1.3	
1995 1.1 3.1 2.4 1.4 1.1 0.7 2.3 1996 5.5 1.7 3.1 0.6 1.8 0.0 1.7 1997 7.4 4.6 5.6 1.4 5.6 2.4 1.0 1998 1.6 1.0.8 1.0.8 1.6 5.6 4.4 0.6 11.6 5.6 7.7 9.7 8.8 7.0 8.3 4.1 2000 1.3.8 7.5 9.9 8.8 7.0 8.3 1.4 2001 9.8 7.1 9.1 6.2 3.3 1.4 2002 5.6 1.1.9 9.4 5.1 8.1 5.9 1.0 2003 0.8 1.8 7.5 3.1 6.4 4.0 2.9 2.4 2004 6.4 1.0.9 3.1 7.3 6.5 3.1 3.1 4.5 3.2 2005 6.7 7.3 7.3 5.5 3.4 3.4 3.4 3.4 3.4 3.4 3.4 3.4 <td< td=""><td>1993</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	1993								
1986 5.8 1.7 3.1 0.6 1.8 0.0 1.7 1987 7.4 4.6 5.6 1.4 5.6 0.4 0.0 1989 1.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.5 9.7 8.7 8.8 7.0 8.3 1.4 2001 3.8 7.8 8.7 8.1 6.2 8.3 1.4 2002 5.6 11.9 9.4 5.1 8.1 5.9 2.6 2003 5.6 11.8 7.5 3.1 6.6 4.0 2.9 2004 6.4 10.9 9.2 1.4 9.9 3.7 2.6 2005 6.7 1.3 4.7 7.3 5.5 3.2 3.4 2006 4.7 13.8 7.2 4.1 3.6 3.6 3.4 2007 0.8 1.1 3.6 3.6 3.6 3.4 3.6 3.6 2006 1.2 0.5 4.2 3.6									
1997 7.4 4.6 5.6 1.4 5.4 2.4 1.0 1998 8.5 1.6 7.8 7.2 5.6 6.8 1.8 1999 1.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.9 8.0 8.1 6.2 8.3 1.4 2001 9.6 1.8 7.9 8.0 8.1 6.4 1.0 2003 0.6 1.1.8 7.5 2.1 6.4 5.9 2.1 2004 6.4 1.0.9 3.7 13.6 6.5 2.4 2005 6.2 2.6 3.9 6.6 4.0 5.9 3.1 2006 1.2.3 8.5 4.7 7.3 5.5 3.4 2007 3.7 13.0 3.6 3.6 3.6 3.6 2008 1.3.3 1.2.3 7.2 0.1 3.3 0.8 1989 13.3 1.9 3.1 3.6 3.6 7.6 1989 1.3	1995								
1989 11.6 5.6 7.8 7.2 5.6 6.8 1.8 2000 13.9 7.5 9.9 8.8 7.0 8.3 1.1 2002 6.6 11.9 9.4 5.1 8.1 5.9 1.0 2003 0.8 11.8 7.5 3.1 6.4 4.0 2.9 2004 6.4 10.9 9.2 1.4 9.9 3.7 2.6 2005 6.4 7.13.0 10.0 3.7 13.6 5.5 3.1 2006 4.7 13.0 10.0 3.7 13.6 5.5 3.4 2007 3.7 13.8 7.2 0.1 3.5 3.4 3.2 2008 12.3 8.5 4.7 7.3 5.5 3.4 3.9 1987 -1 -1 -1 -1 -1 -1 -1 1989 9.1 3.7 5.5 4.2 3.6 4.0 1989 9.1 3.7 5.5 3.3 4.8 -1	1997	7.4	4.6	5.6	1.4	5.4	2.4	1.0	
2000 13.9 7.5 9.9 8.8 7.0 8.3 4.1 2001 9.8 7.9 8.7 9.1 6.2 8.3 1.4 2003 0.8 11.3 7.5 3.1 6.4 4.0 2.9 2004 6.4 10.9 9.2 1.4 9.9 3.7 2.6 2005 6.2 2.6 3.9 6.6 4.0 5.9 3.1 2006 6.7 10.3 8.3 4.7 4.1 4.5 3.2 2007 10.8 8.5 4.7 7.3 5.5 3.4 2008 f 7.7 10.8 8.5 4.7 4.5 3.2 2008 f 7.3 1.8 7.5 5.4 3.0 5.5 3.4 1397 4.5 13.8 7.7 2.1 3.7 2.5 3.2 1398 6.1 4.0 4.7 2.1 3.7 2.5 3.3 4.8 1999 11.9 4.4 6.9 7.5 5.8 7.0									
2001 9,8 7,9 8,7 9,1 6,2 8,3 1,4 2002 6,6 11,8 7,5 3,1 6,4 4,0 2,8 2004 6,4 10,9 9,2 1,4 9,9 3,7 2,6 2005 6,2 2,6 3,9 6,6 4,0 5,9 3,1 2006 4,7 13,0 10,0 3,7 13,8 6,5 2,4 20071 3,7 10,8 8,3 4,7 7,3 6,5 3,2 20081 0.8 12,3 8,5 4,7 7,3 6,5 3,4 20081 0.8 12,3 8,5 4,7 7,3 6,5 3,2 20081 0.8 1,3 7,2 6,1 3,3 3,4 3,3 3,4 1887 -1,4 3,6 5,5 8,6 7,0 3,3 3,4 3,4 1989 1,1 4,0 4,7 2,3 3,3 4,4 3,4 3,9 3,3 4,4 3,8 6,0									
2003 0.8 1.8 7.5 3.1 0.4 4.0 2.9 2004 6.4 1.0 9.2 1.4 9.9 3.7 2.6 2005 6.2 2.6 3.9 6.6 4.0 5.9 3.1 2006 4.7 13.0 10.0 3.7 13.6 6.5 2.4 20071 3.7 10.8 8.3 4.7 7.3 5.5 3.4 (AnnuePrectange Change the Sect of Inflation In the Contome Tectors) (AnnuePrectange Change the Sect of Inflation In the Contome Tectors) (AnnuePrectange Change the Sect of Inflation In the Contome Tectors) 1980 13.3 1.9 3.1 3.6 3.5 3.6 1987 4.5 13.8 7.2 3.6 3.6 7.0 1980 1.9 3.7 5.5 4.2 3.6 4.0 1980 1.9 3.7 5.5 4.2 3.6 7.0 1980 1.1 4.6 6.7 5.3 3.3 4.8 1980 1.2 <td< td=""><td>2000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>	2000								
2004 6.4 1.9 9.2 1.4 9.9 3.7 2.6 2005 6.2 2.6 3.9 6.6 4.0 5.9 3.1 20061 3.7 10.8 8.3 4.7 1.1 4.5 3.2 20071 3.7 10.8 8.3 4.7 7.3 5.5 3.4 20081 0.8 1.3 4.7 7.3 5.5 3.4 20081 0.8 1.3 4.7 7.3 5.5 3.4 1886 1.3.3 -1.9 3.1 3.6 3.5 3.6 1886 1.3.3 -1.9 3.1 3.6 3.5 3.6 1987 4.1 4.0 4.7 2.1 3.7 2.5 1988 1.1 4.4 6.9 7.5 5.8 7.0 1989 1.2 0.6 1.7 1.6 1.6 1989 1.2 0.8 0.1 1.0 3.4 </td <td>2002</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	2002								
2005 6.2 2.6 3.9 6.6 4.0 5.9 3.1 2006 4.7 13.0 10.0 3.7 13.6 6.5 2.4 2008 12.3 8.5 4.7 7.3 5.5 3.2 Interactive character ch	2003								
2006 4,7 13,0 10,0 3,7 13,6 6,5 2,4 2007 1 0,8 12,3 8,5 4,7 7,3 5,5 3,2 2008 1 0,8 12,3 8,5 4,7 7,3 5,5 3,4 Image Change In Excess of Inflation In the Canceline Economy Image Change In Excess of Inflation In the Canceline Economy Image Change In Excess of Inflation In the Canceline Economy Image Change In Excess of Inflation In the Canceline Economy 1986 Image Interview Interv									
2007 3.7 10.8 8.3 4.7 4.1 4.5 3.2 0.8 1.23 8.5 4.7 7.3 5.5 3.4 Consister in Excess of Inflation In bendian Exonation Exonation 1986 1.3.3 1.9 3.1 3.6 3.5 3.6 1987 4.5 13.8 7.2 0.1 3.3 0.8 1987 4.5 13.8 7.2 0.1 3.7 2.5 1987 4.1 4.0 4.7 2.1 3.7 2.5 1989 9.1 3.7 5.5 4.2 3.6 4.0 1991 1.2.4 3.6 6.7 5.3 3.3 4.8 1992 1.6 4.6 6.1 1.2 0.2 0.9 1992 1.2 0.8 0.6 1.2 0.2 0.9 1994 -4.6 3.9 0.6 1.2 0.2 1.6 1995 -1.2 0	2005								
Anual Percentage Change in Excess of Inflation in the Canadian Economy 1985 1986 13.3 1.9 3.1 3.6 3.5 3.6 1987 4.5 13.8 7.2 -0.1 3.3 0.8 1988 6.1 4.0 4.7 2.1 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 4.6 3.9 0.6 1.2 0.2 0.9 1995 1.2 0.8 0.1 -1.0 -3.4 -1.6 1997 6.4 3.8 6.0 5.4 3.8 5.0 1996 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.4 5.8	2007 f	3.7	10.8	8.3	4.7	4.1	4.5	3.2	
1985 1986 13.3 -1.9 3.1 3.6 3.5 3.6 1987 14.5 13.8 7.2 0.1 3.3 0.8 1988 6.1 4.0 4.7 2.1 3.7 2.5 1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1994 9.6 1.3 0.4 4.4 4.4 1.4 1995 -1.2 0.8 3.8 6.0 5.4 3.8 5.0 2000 <td< td=""><td>2008 f</td><td>0.8</td><td>12.3</td><td>8.5</td><td>4.7</td><td>7.3</td><td>5.5</td><td>3.4</td><td></td></td<>	2008 f	0.8	12.3	8.5	4.7	7.3	5.5	3.4	
1986 13.3 1.9 3.1 3.6 3.5 3.6 1987 4.5 13.8 7.2 -0.1 3.3 0.8 1980 9.1 3.7 5.5 4.2 3.6 4.0 1980 1.9 3.7 5.5 4.2 3.6 4.0 1990 1.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.2 0.9 9.0 1994 -4.6 3.9 0.6 1.2 0.9 9.0 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 0.0 5.4 3.8 5.0 1999 9.8 3.8 6.0 5.4 3.8 5.0 2001	-		(Annual Percenta	ge Change in Excess of l	nflation in the Canadian	Economy)			
1987 -4.5 13.8 7.2 -0.1 3.3 0.8 1988 6.1 4.0 4.7 2.1 3.7 2.5 1989 9.1 3.7 5.5 4.2 3.6 4.0 1990 11.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1933 7.2 6.6 6.8 1.7 1.6 1.6 1994 4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002	1985								
1988 6.1 4.0 4.7 2.1 3.7 2.5 1990 1.9 4.4 6.9 7.5 5.8 7.0 1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 4.6 3.9 0.6 1.2 0.2 0.9 1995 1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 201 8.4 6.6 7.3 7.7 4.9 7.0 2020 9.8 3.4 5.8 4.1 7.1 4.9 2020 4.5 10.9 8.3 6.6 -1.2 7.3 1.1									
199011.94.46.97.55.87.0199112.43.66.75.33.34.819928.64.66.14.31.93.719937.26.66.81.71.61.61994-4.63.90.61.20.20.91995-1.20.80.1-1.03.4-1.619964.10.01.5-2.20.2-1.619976.43.64.60.44.41.419989.011.310.44.16.94.819999.83.86.05.43.85.020009.83.45.84.72.94.220108.46.67.37.74.97.020204.510.98.34.6-1.27.31.120043.88.36.6-1.27.31.120053.1-0.50.83.50.92.720062.310.67.61.311.24.120070.47.65.11.40.91.32008-2.78.95.11.33.92.0	1988	6.1	4.0	4.7	2.1	3.7	2.5		
1991 12.4 3.6 6.7 5.3 3.3 4.8 1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.4 5.8 4.7 2.9 4.2 2000 9.8 3.4 5.8 4.7 2.9 4.2 201 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 6.6 -1.2 7.3 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1	1989	9.1	3.7	5.5	4.2	3.6	4.0		
1992 8.6 4.6 6.1 4.3 1.9 3.7 1993 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.4 5.8 4.7 2.9 4.2 2000 9.8 3.4 5.8 4.7 2.9 4.2 201 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 6.6 -1.2 7.3 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7	1990								
1933 7.2 6.6 6.8 1.7 1.6 1.6 1994 -4.6 3.9 0.6 1.2 0.2 0.9 1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1989 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2005 3.1 0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	1991 1992								
1995 -1.2 0.8 0.1 -1.0 -3.4 -1.6 1996 4.1 0.0 1.5 -2.2 0.2 -1.6 1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2011 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f <td>1993</td> <td>7.2</td> <td></td> <td>6.8</td> <td>1.7</td> <td>1.6</td> <td>1.6</td> <td></td> <td></td>	1993	7.2		6.8	1.7	1.6	1.6		
19964.10.01.5 -2.2 0.2 -1.6 19976.43.64.60.44.41.419989.011.310.44.16.94.819999.83.86.05.43.85.020009.83.45.84.72.94.220118.46.67.37.74.97.020024.510.98.34.17.14.92003-2.18.94.60.23.51.120043.88.36.6-1.27.31.120053.1-0.50.83.50.92.720062.310.67.61.311.24.12007 f0.47.65.11.40.91.32008 f-2.78.95.11.33.92.0	1994	-4.6	3.9	0.6	1.2	0.2	0.9		
1997 6.4 3.6 4.6 0.4 4.4 1.4 1998 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	1995								
1988 9.0 11.3 10.4 4.1 6.9 4.8 1999 9.8 3.8 6.0 5.4 3.8 5.0 2000 9.8 3.4 5.8 4.7 2.9 4.2 2010 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2005 2.3 10.6 7.6 1.3 1.2 4.1 2006 2.3 10.6 7.6 1.3 1.2 4.1 2007 1 0.4 7.6 5.1 1.4 0.9 1.3 2008 1 -2.7 8.9 5.1 1.3 3.9 2.0									
2000 9.8 3.4 5.8 4.7 2.9 4.2 2001 8.4 6.6 7.3 7.7 4.9 7.0 2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 20071 0.4 7.6 5.1 1.4 0.9 1.3 20081 -2.7 8.9 5.1 1.3 3.9 2.0	1998	9.0	11.3	10.4	4.1	6.9	4.8		
20018.46.67.37.74.97.020024.510.98.34.17.14.92003-2.18.94.60.23.51.120043.88.36.6-1.27.31.120053.1-0.50.83.50.92.720062.310.67.61.311.24.12007 f0.47.65.11.40.91.32008 f-2.78.95.11.33.92.0			3.8						
2002 4.5 10.9 8.3 4.1 7.1 4.9 2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	2000								
2003 -2.1 8.9 4.6 0.2 3.5 1.1 2004 3.8 8.3 6.6 -1.2 7.3 1.1 2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	2001 2002								
2005 3.1 -0.5 0.8 3.5 0.9 2.7 2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	2003	-2.1	8.9	4.6	0.2	3.5	1.1		
2006 2.3 10.6 7.6 1.3 11.2 4.1 2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0									
2007 f 0.4 7.6 5.1 1.4 0.9 1.3 2008 f -2.7 8.9 5.1 1.3 3.9 2.0	2005								
2008 f -2.7 8.9 5.1 1.3 3.9 2.0	2007 f	0.4	7.6	5.1	1.4	0.9	1.3		
f: forecast. Source: NHEX, CIHI, 2	2008 f	-2.7							
f: forecast. Source: NHEX, CIHI, 2									
	f: forecast.								Source: NHEX, CIHI, 2008

				10	-	enditures, Yu	ikon, 190.	0 10 2000				
			Public		Prescrib	ed Drugs	Private				Prescribed Dr te (Out-of-Poo	
	Territorial	Federal	Social Secu WCB	rity Funds Drug Insurance	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Pres Drugs
ear				Fund		(¢ M)	llions)		Diuga	Drugs	oupplies	Diuga
985	0.2	0.3	0.0		0.5	(\$ 101		1.3	1.8			
86	0.2	0.3	0.0		0.5			1.3	1.8			
87	0.7	0.4	0.0		1.1			1.2	2.3			
88 89	1.0 1.2	0.6 0.8	0.0 0.0		1.7 2.1			1.0 1.0	2.7 3.1			
90 91	1.3 1.6	1.0 1.2	0.0 0.0		2.3 2.8			1.0 1.2	3.3 4.0			
92	2.0	1.3	0.0		3.4			1.2	4.5	1.2	1.1	
93 94	2.3	1.5	0.0		3.8			2.3 1.6	6.1	1.3	1.1	
	2.1	1.7	0.0		3.8				5.4	1.4	1.1	
95 96	1.5 1.5	1.8 1.9	0.0 0.0		3.4 3.4			1.7 2.2	5.1 5.6	1.4 1.7	1.2 1.5	
97	1.9	2.0	0.0		4.0			3.4	7.4	1.7	1.5	
98	2.2	2.1	0.0		4.4			2.9	7.3	1.8	1.6	
99	2.7	3.1	0.0		5.8			3.0	8.8	1.9	1.7	
00	3.3	3.0	0.1		6.4			3.2	9.6	1.9	2.1	
01 02	3.9 4.5	3.0 3.5	0.1 0.1		7.0 8.1			3.6 3.9	10.5 12.1	2.0 2.0	2.1 2.1	
03	5.1	3.8	0.1		9.0			4.8	13.8	2.2	1.8	
04	5.9	3.8	0.1		9.8			4.9	14.7	2.4	2.0	
05	6.5	4.1	0.2		10.8			5.2	16.0	2.5	2.0	
06	7.2	4.2	0.2		11.6			5.8	17.4	2.8	2.1	
07 f 08 f	7.4 7.5	4.3 4.7	0.3		12.1 12.5			6.6 7.5	18.6 20.0	2.5 2.6	2.2 2.3	
						(Annual Perce	ntage Change)					
85						(Annual 1 cicc						
86	53.7	10.9	-18.3		27.7			-6.2	3.5			
87	126.4	6.7	32.5		65.5			-2.6	21.4			
88 89	41.8 15.4	72.7 37.4	32.5 -42.2		51.6 23.0			-13.2 -0.3	18.0 14.1			-
90 91	5.9 26.2	17.1 16.5	98.0 -54.9		10.8 21.5			-6.5 25.0	5.1 22.5			:
92	23.5	15.7	303.9		21.0			-4.1	13.4			
93	13.2	14.3	-9.1		13.5			95.5	34.5	6.7	2.4	
94	-8.4	10.1	-3.4		-1.0			-29.3	-11.5	4.3	-0.1	
95	-26.3	9.1	40.5		-10.1			8.0	-4.7	2.1	13.0	:
96 97	-2.3 26.0	3.8 7.0	3.9 4.8		1.1 15.2			27.6 55.4	10.0 31.0	19.9 3.3	20.2 3.9	
98	17.8	4.0	-10.8		10.4			-15.7	-1.7	3.3	4.6	
99	21.9	44.5	28.0		32.9			4.8	21.7	7.5	4.7	
00	21.4	-0.9	15.1		9.6			6.0	8.4	-1.8	22.3	
01 02	17.7 17.6	0.4 14.9	59.6 10.3		9.8 16.4			10.7 10.8	10.1 14.5	5.6 2.9	0.3 1.7	
03	12.1	10.0	15.7		11.2			20.7	14.3	7.2	-11.9	
04	15.0	-1.2	26.8		8.3			3.2	6.5	8.6	6.1	
05	11.1	8.7	26.8		10.4			5.1	8.6	4.5	2.0	
06	10.2	1.2	24.7		7.0			12.4	8.8	12.3	7.0	
07 f 08 f	3.6 0.5	4.1 8.1	26.4 18.0		4.2 3.6			13.1 14.7	7.2 7.5	-11.7 6.5	2.1 6.5	
85		0.5	0.2			ercentage Share of 1			57.8			
86	6.7 10.3	9.5 10.6	0.3 0.3		16.6 21.2			41.3 38.8	57.8			
87	20.9	10.0	0.3		31.2			33.6	64.9			
88 89	27.6	16.2	0.4		44.1			27.2	71.4			
89	28.9	20.2	0.2		49.3			24.6	73.9			
90 91	30.0 30.7	23.1 21.9	0.4		53.5 52.7			22.6 22.9	76.1 75.7			
91 92	30.7 29.4	21.9 19.6	0.1		52.7 49.4			22.9 17.0	75.7 66.5	17.9	 15.6	
93	26.7	18.0	0.3		45.1			26.7	71.8	15.4	12.8	
94	26.5	21.5	0.3		48.3			20.5	68.8	17.4	13.9	
95	19.8	23.7	0.5		43.9			22.3	66.2	17.9	15.9	
96 97	17.0 17.7	21.7 19.1	0.4		39.1 37.2			25.1 32.3	64.3 69.4	18.9 16.2	16.8 14.4	
97 98	20.9	19.1	0.4		41.1			27.2	68.3	16.7	14.4	
99	21.8	24.6	0.4		46.7			24.4	71.1	15.4	13.5	
00	24.3	22.4	0.4		47.1			23.8	70.9	13.9	15.2	:
01	26.5	20.8	0.6		47.9			24.4	72.3	13.6	14.1	
02 03	28.1 28.6	21.6 21.6	0.6 0.6		50.2 50.7			24.3 26.7	74.5 77.4	12.6 12.2	12.9 10.3	
03 04	28.6	21.6 20.0	0.6		50.7 51.5			26.7 25.8	77.3	12.2	10.3	
05	31.8	20.0	0.8		52.9			25.3	78.1	12.0	9.8	
05	31.8	20.2 18.8	0.8		52.9 51.9			25.3	78.1	12.1	9.8 9.6	
07 f	32.0	18.7	1.1		51.8			28.2	80.1	10.6	9.4	
08 f	30.0	18.8	1.3		50.0			30.2	80.2	10.5	9.3	

					Yukon, 1985 to		olic, Private and			
	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total		f Drugs in Public, Privat otal Health Expenditure Private		
ır			(\$ Milli	ons)				(Percentage Share)		
15	0.5	2.6	3.2	32	2.9 6.8	39.7	1.		8.0	
36	0.7	2.5	3.2	37	7.0 5.6	42.6	1.	8 44.4	7.4	
37 38	1.1 1.7	2.4 2.1	3.5 3.8	39	9.1 5.6 0.6 5.2	44.7 45.8	2.		7.9 8.3	-
9	2.1	2.1	4.2		1.2 5.3	49.5	4.		8.5	
0	2.3	2.0	4.3	48		53.6	4.		8.0	
91 92	2.8 3.4	2.5 3.4	5.3 6.8	56		62.6 67.5	4. 5.		8.4 10.1	
3	3.8	4.7	8.5	69	9.0 10.6	79.6	5.	5 44.1	10.6	
14	3.8	4.0	7.8	83		93.2	4.		8.4	
95 96	3.4 3.4	4.3 5.3	7.7 8.8	84 91		94.9 109.5	4. 3.		8.2 8.0	
97	4.0	6.7	10.6	85	5.4 17.3	102.7	4.	6 38.7	10.4	
98 99	4.4 5.8	6.3 6.6	10.6 12.4	87 91		103.7 108.7	5. 6.		10.3 11.4	
00 01	6.4 7.0	7.1 7.6	13.5 14.6	98 115		123.6 143.4	6. 6.		10.9 10.2	
02	8.1	8.1	16.2	123	3.4 33.2	156.5	6.	6 24.3	10.4	
03 04	9.0 9.8	8.8 9.2	17.8 19.0	124 133		156.8 168.7	7. 7.		11.4 11.3	
05	10.8	9.6	20.4	152		188.7	7.		10.8	
06	10.8	9.6	22.3	178	3.1 39.5	217.6	6.	5 27.2	10.2	
07 f	12.1	11.2	23.3	187		233.7	6.		9.9	
08 f	12.5	12.5	25.0	194	49.7	243.6	6.	4 25.1	10.2	
			(Annual Percent	tage Change)						
35										
36 37	27.7 65.5	-5.6 -2.1	-0.1 12.2	12 F	2.3 -17.3 5.8 0.4	7.2 5.1				
88	51.6	-12.9	7.3	з	3.8 -7.5	2.3				
39	23.0	-0.1	10.1	9	9.1 1.2	8.2				
90	10.8	-6.3	2.1		9.7 -4.8	8.2				
91 92	21.5 21.0	25.1 38.2	23.2 29.1		5.4 20.9 7.2 14.1	16.8 7.9				
93	13.5	35.3	24.5	14	1.0 52.5	17.9				
94	-1.0	-13.1	-7.6	20		17.1				
95 96	-10.1 1.1	7.4 23.0	-1.1 13.4		1.3 6.1 3.2 73.0	1.8 15.4				
97	15.2	25.0	21.2		5.4 -5.2	-6.2				
98 99	10.4 32.9	-6.1	0.0		2.2 -5.4	0.9				
		5.5	16.8		5.1 3.3	4.8				
00 01	9.6 9.8	7.9 6.4	8.7 8.0		7.7 46.7 7.3 10.9	13.8 16.0				
02	16.4	6.3	11.1	e	3.4 20.8	9.2				
03 04	11.2 8.3	8.8 5.2	10.0 6.7		1.0 -2.8 3.9 10.3	0.2 7.6				
05	10.4	4.3	7.4		1.2 3.0	11.9				
06	7.0	11.3	9.0	17		15.3				
07 f 08 f	4.2 3.6	4.5	4.4		5.4 16.7	7.4				
J0 I	3.0	11.3	7.3		3.3 7.9	4.2				
	(Percentag	ge Share of Total Dr	ug Expenditure)							
35	16.6	83.4	100.0							
36 37	21.2 31.2	78.8 68.8	100.0 100.0							
38	44.1	55.9	100.0							
39	49.3	50.7	100.0							
90 91	53.5 52.7	46.5	100.0							
91 92	52.7 49.4	47.3 50.6	100.0 100.0							
93	45.1	54.9	100.0							
94	48.3	51.7	100.0							
5 6	43.9 39.1	56.1 60.9	100.0 100.0							
7	39.1	62.8	100.0							
8	41.1	58.9	100.0							
19	46.7	53.3	100.0							
00 01	47.1 47.9	52.9 52.1	100.0 100.0							
)2	50.2	49.8	100.0							
03	50.7	49.3	100.0							
)4	51.5	48.5	100.0							
05 06	52.9 51.9	47.1 48.1	100.0 100.0							
07 f	51.8	48.2	100.0							
08 f	50.0	50.0	100.0							

					Prescribe	ed Drugs				Non-	Prescribed Dr	ugs
	Territorial	Federal	Public Social Secu WCB	rity Funds Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Priva Over- the- Counter	te (Out-of-Poc Personal Health Supplies	cket) Total Non-Pres Drugs
ear				Fund		(\$ per	Capita)			Drugs		
85	8.73	12.38	0.40		21.51			53.66	75.17			54
986 987	13.36 28.81	13.65 13.87	0.33 0.41		27.34 43.10			50.07 46.44	77.41 89.54			5 48
88	39.46	23.14	0.53		63.12			38.94	102.06			40
89	44.68	31.20	0.30		76.17			38.08	114.25			40
90	46.19	35.65	0.58		82.41			34.77	117.18			30
91	56.02	39.91	0.25		96.18			41.78	137.95			44
92 93	66.44 74.64	44.31 50.24	0.97 0.87		111.72 125.74			38.47 74.59	150.19 200.34	40.52 42.89	35.28 35.83	75 78
94	69.86	56.56	0.86		127.28			53.92	181.20	45.73	36.58	83
95	50.23	60.17	1.18		111.59			56.82	168.41	45.56	40.31	8
96	47.63	60.58	1.19		109.40			70.33	179.73	53.00	47.00	100
97	59.26	63.97	1.23		124.46			107.92	232.38	54.06	48.20	10
198 199	71.27 87.87	67.89 99.30	1.12 1.45		140.28 188.62			92.92 98.53	233.20 287.15	57.00 62.00	51.46 54.53	108 116
000 001	107.91 128.25	99.59 100.91	1.69 2.73		209.19 231.89			105.64 118.12	314.83 350.02	61.61 65.69	67.49 68.33	129 134
01	150.84	115.93	3.01		269.78			130.84	400.62	67.55	69.46	13
003	166.67	125.70	3.43		295.81			155.61	451.43	71.39	60.31	13
004	189.79	122.99	4.31		317.10			159.07	476.17	76.78	63.36	140
005	209.60	132.99	5.43		348.03			166.25	514.28	79.79	64.23	144
006 007 f	229.90	133.90	6.74		370.54			185.97	556.51	89.11	68.36	157
07 f	239.97 240.45	140.36 151.20	8.58 10.09		388.91 401.75			211.90 242.23	600.81 643.97	79.27 84.18	70.33 74.68	149 158
						(Appual Paras	ntage Change					
85												
986 987	52.9 115.7	10.3 1.6	-18.7 26.2		27.1 57.6			-6.7 -7.2	3.0 15.7			
88	36.9	66.8	28.0		46.5			-16.2	14.0			-
89	13.2	34.8	-43.3		20.7			-2.2	12.0			
90	3.4	14.3	93.3		8.2			-8.7	2.6			
991	21.3	11.9	-56.6		16.7			20.1	17.7			2
92 93	18.6 12.3	11.0 13.4	287.7 -9.8		16.2 12.6			-7.9 93.9	8.9 33.4	 5.8	 1.6	-
94	-6.4	12.6	-1.2		1.2			-27.7	-9.6	6.6	2.1	
95	-28.1	6.4	37.1		-12.3			5.4	-7.1	-0.4	10.2	
96	-5.2	0.7	0.8		-2.0			23.8	6.7	16.3	16.6	1
97	24.4	5.6	3.5		13.8			53.5	29.3	2.0	2.6	
198 199	20.3 23.3	6.1 46.3	-9.0 29.5		12.7 34.5			-13.9 6.0	0.4 23.1	5.4 8.8	6.7 6.0	
000 001	22.8 18.9	0.3 1.3	16.5 61.1		10.9 10.9			7.2 11.8	9.6 11.2	-0.6 6.6	23.8 1.2	
02	17.6	14.9	10.3		16.3			10.8	14.5	2.8	1.7	
03	10.5	8.4	14.1		9.6			18.9	12.7	5.7	-13.2	
04	13.9	-2.2	25.5		7.2			2.2	5.5	7.5	5.1	
05	10.4	8.1	26.0		9.8			4.5	8.0	3.9	1.4	
006	9.7	0.7	24.1		6.5			11.9	8.2	11.7	6.4	
007 f 008 f	4.4 0.2	4.8 7.7	27.3 17.6		5.0 3.3			13.9 14.3	8.0 7.2	-11.0 6.2	2.9 6.2	
081	0.2	7.7	17.0							0.2	0.2	
					(Annual Percentag	ge Change in Excess	of Inflation in	the Canadian E	conomy)			
85												
186 187	50.1 110.9	7.5 -3.2	-21.5 21.5		24.3 52.9			-9.5 -12.0	0.2 10.9			
88	32.4	62.3	23.5		41.9			-12.0	9.5			-1
89	8.7	30.3	-47.9		16.1			-6.8	7.4			
90	0.4	11.2	90.3		5.2			-11.7	-0.5			-1
91	18.5	9.2	-59.4		13.9			17.4	15.0			1
92	17.3	9.8	286.5		14.9			-9.2	7.6			6
193 194	10.9 -7.5	11.9 11.5	-11.3 -2.3		11.1 0.1			92.5 -28.8	31.9 -10.7	4.4 5.5	0.1 1.0	
195 196	-30.4 -6.9	4.1 -1.0	34.7 -0.9		-14.7 -3.6			3.0 22.1	-9.4 5.1	-2.7 14.6	7.9 14.9	1
97	23.4	4.6	2.5		12.8			52.5	28.3	1.0	1.6	
98	20.7	6.6	-8.5		13.2			-13.5	0.8	5.9	7.2	
99	21.5	44.4	27.7		32.7			4.2	21.3	7.0	4.2	
000	18.7	-3.8	12.4		6.8			3.1	5.5	-4.7	19.7	
001 002	17.5 16.6	0.0 13.8	59.8 9.2		9.5 15.3			10.5 9.7	9.8 13.4	5.3 1.8	-0.1 0.6	
02 003	7.6	5.5	9.2 11.2		6.8			9.7 16.0	9.8	2.8	-16.1	
004	11.3	-4.7	22.9		4.6			-0.4	2.9	5.0	2.5	
05	7.3	5.0	22.9		6.6			1.4	4.9	0.8	-1.7	
006	7.3	-1.7	21.6		4.1			9.4	5.8	9.3	4.0	
07 f	1.2	1.6	24.1		1.7 -0.1			10.7	4.7	-14.3 2.8	-0.3	
08 f	-3.2	4.3	14.2		-U. I			10.9	3.8	2.8	2.8	

Y.T.

		Expenditure	• •			nance and Publi		ble B Y.T.—Per Capita
			Total Health I	Expenditures, `	Yukon, 1985 to	2008 (cont'd)		
		All Drugs			Health Expenditure		GDP Implicit Price Index-Canada	
-	Public	Private	Total	Public	Private	Total		
Year _			(\$ per Ca				(1997 = 100)	
1985 1986	21.51 27.34	108.45 101.85	129.96 129.19	1,351.18 1,510.29		1,630.07 1,739.80	73.6 75.6	
1987	43.10	94.95	138.05	1,521.49		1,741.02	79.2	
1988	63.12	79.90	143.03	1,524.93		1,720.95	82.8	
1989	76.17	78.36	154.53	1,632.10) 194.61	1,826.71	86.6	
1990	82.41	71.66	154.07	1,747.95		1,928.76	89.2	
1991 1992	96.18 111.72	86.16 114.27	182.33 225.99	1,954.71 2,011.98		2,164.74 2,242.01	91.6 92.8	
1993	125.74	153.32	279.06	2,274.52	2 347.90	2,622.42	94.1	
1994	127.28	136.24	263.52	2,805.59	334.47	3,140.06	95.2	
1995	111.59	142.69	254.28	2,771.86		3,117.96	97.4	
1996 1997	109.40 124.46	170.33 210.18	279.73 334.64	2,908.40 2,687.26		3,489.34 3,230.64	99.0 100.0	
1998	140.28	201.37	341.66	2,804.53		3,329.10	99.6	
1999	188.62	215.07	403.69	2,981.92		3,530.29	101.4	
2000	209.19	234.73	443.93	3,250.61	813.89	4,064.50	105.5	
2001	231.89	252.14	484.04	3,848.40	911.33	4,759.73	106.9	
2002 2003	269.78 295.81	267.85 287.31	537.63 583.12	4,093.61 4,074.28		5,194.39 5,128.99	108.1 111.2	
2003	317.10	299.21	616.30	4,311.73		5,463.63	114.1	
2005	348.03	310.27	658.30	4,897.85	5 1,179.36	6,077.21	117.6	
2006	370.54	343.43	713.97	5,706.53		6,970.73	120.5	
2007 f	388.91	361.50	750.41	6,057.02		7,542.63	124.3	
2008 f	401.75	401.08	802.83	6,239.22	2 1,597.38	7,836.60	128.6	
-			4)	Annual Percentage Ch	ange)			
1985								
1986	27.1	-6.1	-0.6	11.8		6.7	2.8	
1987 1988	57.6 46.5	-6.8 -15.8	6.9 3.6	0.7		0.1	4.7 4.5	
1989	20.7	-1.9	8.0	7.0		6.1	4.6	
1990	8.2	-8.5	-0.3	7.1	-7.1	5.6	3.0	
1991	16.7	20.2	18.3	11.8		12.2	2.8	
1992 1993	16.2 12.6	32.6 34.2	23.9 23.5	2.9		3.6 17.0	1.3 1.4	
1994	1.2	-11.1	-5.6	23.3		19.7	1.4	
1995	-12.3	4.7	-3.5	-1.2		-0.7	2.3	
1996	-2.0	19.4	10.0	4.9		11.9	1.7	
1997	13.8	23.4	19.6	-7.6		-7.4	1.0	
1998 1999	12.7 34.5	-4.2 6.8	2.1 18.2	4.4		3.0 6.0	-0.4 1.8	
2000 2001	10.9 10.9	9.1 7.4	10.0 9.0	9.0 18.4		15.1 17.1	4.1 1.4	
2002	16.3	6.2	11.1	6.4		9.1	1.0	
2003	9.6	7.3	8.5	-0.5		-1.3	2.9	
2004	7.2	4.1	5.7	5.8	9.2	6.5	2.6	
2005	9.8	3.7	6.8	13.6		11.2	3.1	
2006 2007 f	6.5 5.0	10.7 5.3	8.5 5.1	16.5 6.1		14.7 8.2	2.4 3.2	
2008 f	3.3	11.0	7.0	3.0		3.9	3.4	
		(Annual Percente	ge Change in Excess of	f Inflation in the Cons	idian Economy)			
- 1985		Annual Fercenta	ge change in Excess of					
1985	24.3	-8.9	-3.4	 9.0		3.9		
1987	52.9	-11.5	2.1	-4.0	.9.1	-4.7		
1988	41.9	-20.4	-0.9	-4.3		-5.7		
1989	16.1	-6.5	3.5	2.5		1.6		
1990 1991	5.2 13.9	-11.6 17.5	-3.3 15.6	4.1 9.1		2.6 9.5		
1992	14.9	31.4	22.7	9.1		2.3		
1993	11.1	32.7	22.0	11.6		15.5		
1994	0.1	-12.2	-6.7	22.3		18.6		
1995	-14.7	2.4	-5.8	-3.5		-3.0		
1996 1997	-3.6 12.8	17.7 22.4	8.3 18.6	3.3		10.2 -8.4		
1998	13.2	-3.8	2.5	4.8	-3.0	3.5		
1999	32.7	5.0	16.3	4.5	5 2.7	4.2		
2000	6.8	5.0	5.9	4.9		11.0		
2001 2002	9.5 15.3	6.1	7.7	17.0		15.8		
2002	15.3 6.8	5.2 4.4	10.0 5.6	5.3		8.1 -4.2		
2004	4.6	1.6	3.1	3.2		3.9		
2005	6.6	0.6	3.7	10.5	-0.7	8.1		
2006	4.1	8.3	6.0	14.1	4.8	12.3		
2007 f 2008 f	1.7 -0.1	2.0 7.5	1.9 3.6	2.9		5.0 0.5		
	-0.1	1.5	5.0	-0		0.0		
								<u> </u>
f: forecast.								Source: NHEX, CIHI, 2008

			Public		Prescrib	ed Drugs	Drivete					
	Territorial	Federal _	Social Securit WCB	y Funds Drug Insurance Fund	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	
Year							llions)					
1985 1986	1.1 1.4	2.4 2.7	0.0 0.0		3.5 4.1			2.7	6.8			
1987 1988	1.7 1.9	3.0 3.2	0.0 0.0		4.7 5.1			3.0 3.4	7.7 8.6			
1989	2.1	3.7	0.0		5.8			3.9	9.7			
1990 1991	2.4 3.0	4.3 4.9	0.0 0.0		6.6 7.9			3.9 5.0	10.6 12.9			
1992	3.6	5.7	0.0		9.3			4.9	14.2	2.4	2.1	
1993 1994	2.5 1.2	6.4 7.1	0.0 0.1		8.9 8.3			4.7	13.6	2.6	2.2 2.3	
1995	1.1	7.7	0.1		8.9			3.8	12.6	2.9	2.5	
1996 1997	1.3 1.4	8.0 8.5	0.0 0.0		9.3 9.9			3.5 4.4	12.8 14.4	2.7 3.1	2.4 2.8	
1998	1.7	8.8	0.0		10.5			4.5	15.0	3.2	2.9	
1999	1.8	7.6	0.0		9.4							
2000 2001	1.9 2.2	7.6 8.8	0.0 0.0		9.5 11.0			3.4	14.7	2.3	1.4	
2002 2003	2.4 3.2	10.7 9.0	0.0 0.0		13.1 12.3			4.0 5.3	17.2 17.5	d the- Counter Drugs Health Supplies Non- Drugs 5.8 0.7 0.7 0.7 0.7 0.7 8.6 0.7 0.7 0.7 0.7 0.7 2.9 0.6 0.7 0.7 0.7 0.7 2.9 0.6 2.9 2.5 0.2 0.6 2.0 3.6 2.6 2.2 1.4 0.3 2.1 0.3 3.0 2.3 1.4 0.5 0.2 1.4 4.7 2.2 1.4 0.5 0.2 1.4 7.0 2.0 1.4 0.5 0.7 0.7 7.2 2.2 1.5 0.7 0.7 0.7 0.7 7.1 0.7 0.7 0.7 0.7 0.7 0.7 8.7 0.7 - 0.7 - 0.7 - 0.7 - 0.7 - 0.7 1.1 4.2 7.3		
2004	3.6	8.1	0.1		11.8			Private Out-of Probate Subtrail Prescribed Drogs Prescribed Drogs Prescribed Drogs Drogs Prescribed Prescribed Drogs Total Prescribed Drogs Prescribed Drogs Drogs Drogs 2.3 5.8 2.7 6.8 3.4 8.6 3.9 0.6 3.9 0.6 3.8 1.8 2.6 2.2 3.6 1.2.8 2.7 2.4				
2005	3.7	6.2	0.1		10.0					Private [Out-of-Pocket] Personal T Over- Counter Drugs Supplies D Supplies D D 2.4 2.1 2.6 2.2 2.5 2.7 2.4 3.1 2.9 2.5 2.7 2.4 3.1 2.8 2.3 2.9 2.3 2.1 2.3 1.4 2.2 1.4 2.3 1.5 2.2 1.4 2.3 1.5 2.2 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.4 2.1 1.5		
2006 2007 f	4.3 4.4	6.3 6.5	0.1 0.1		10.6 11.0							
2008 f	4.3	7.8	0.1		12.2			10.6	22.8	2.2	1.5	
						(Annual Perce	ntage Change)					
1985 1986	 30.3	 12.3	 -5.7		 17.7							
1987 1988	22.0	8.5	6.9		13.1 9.2							
1989	12.6 7.6	6.9 17.3	67.7 -6.6		13.5							
1990	13.9	14.8	-0.9		14.4							
1991 1992	25.2 21.7	16.0 14.9	13.9 1.0		19.2 17.4							
1993 1994	-31.8 -50.0	13.3 10.0	27.0 32.1		-4.2							
1995												
1996	14.4	3.3	-15.9		4.6			-6.7	1.3	-6.2	-6.0	
1997 1998	16.2	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	5.4									
1999	$\begin{array}{cccccccccccccccccccccccccccccccccccc$											
2000 2001		5.2 16.0 13.9 19.2 25.8 21.7 7.7 14.9 1.0 17.4 -1.1 10.3 8.1 3.2 7.0 4.2 4.2 4.2 7.3 3.0 0.0 10.0 32.1 -6.5 -7.8 6.9 1.5 12.3 8.4 3.3 -15.9 4.6 6.7 1.3 -6.2 -6.0 9.9 6.5 -3.6 7.0 27.0 12.4 15.7 16.3 9.2 -3.3 1.1 5.1 27.4 -15.2 -27.8 29.0 0.2 -13.7 -14.2 9.9 27.4 -15.2 -27.8 29.0 0.2 -13.7 -14.2 9.9 <t< td=""><td></td></t<>										
2002 2003			$ \begin{array}{cccccccccccccccccccccccccccccccccccc$									
2003		$\begin{array}{c ccccccccccccccccccccccccccccccccccc$										
2005												
2006 2007 f												
2008 f	-3.2	19.9	14.1		10.6			18.5	14.2	3.4	3.4	
						ercentage Share of 1	otal Drug Exp					
1985 1986	10.9 12.6	24.5 24.3	0.2 0.1		35.6 37.1							
1987 1988	13.9 14.2	23.9 23.2	0.1 0.2		38.0 37.6							
1989	13.7	24.4	0.2		38.3							
1990 1991	15.1 15.7	27.1 26.1	0.2		42.4 41.9							
1992	19.3	30.3	0.2		49.7			26.2	75.9	12.9	11.2	
1993 1994	13.4 7.3	34.9 41.8	0.2 0.3		48.6 49.4							
1995	6.3	42.7	0.3		49.3							
1996	7.3	44.6	0.2		52.0			19.6	71.6	15.0	13.3	
1997 1998	7.0 7.8	41.8 41.4	0.2		49.1 49.5			21.4	70.9	15.3	13.8	
1999	10.7	44.2	0.2		55.1							
2000 2001	11.7 12.1	45.2 48.0	0.2		57.1 60.4							
2002	11.4	51.2	0.2		62.8			19.4	82.1	10.8	7.1	
2003 2004	15.1 17.4	42.4 39.3	0.2		57.7 57.1							
2005	18.3	30.2	0.3		48.8							
006 007 f	19.3 18.8	28.6 27.8	0.3 0.3		48.2 46.9			36.1 37.9	84.3 84.8			
2008 f	16.2	29.6	0.3		46.1			40.0	86.0			

		All Drugs			oolth Example			n Public, Private a	and	
	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total		th Expenditures Private	Total	
			(\$ Million				(Desse	ntage Share)		
_	3.5	6.4	9.9	118.9	19.6	138.5	3.0	32.4	7.1	
	4.1	7.0	11.2	145.2	21.7	166.9	2.9	32.5	6.7	N.V
	4.7 5.1	7.7 8.5	12.3 13.6	157.4 183.9	23.9 27.3	181.3 211.2	3.0 2.8	32.1 31.2	6.8 6.5	
	5.8	9.4	15.2	203.6	29.3	232.9	2.9	31.9	6.5	
	6.6	9.0	15.7	218.5	28.4	246.8	3.0	31.9	6.4	
	7.9 9.3	11.0 9.4	18.9 18.7	247.2 249.9	32.3 29.7	279.5 279.6	3.2 3.7	34.0 31.7	6.8 6.7	
	8.9	9.4	18.4	258.7	28.3	287.1	3.4	33.3	6.4	
	8.3	8.6	16.9	259.5	26.8	286.3	3.2	32.0	5.9	
	8.9 9.3	9.1 8.6	18.0 17.9	270.3 265.4	24.7 26.7	295.0 292.1	3.3 3.5	37.0 32.0	6.1 6.1	
	9.9	10.3	20.3	280.9	26.4	307.3	3.5	39.1	6.6	
	10.5 9.4	10.7 7.7	21.1 17.1	301.3 211.2	26.0 21.1	327.3 232.3	3.5 4.5	41.0 36.3	6.5 7.4	
				194.9			4.9	36.5	7.4	
	9.5 11.0	7.2	16.7 18.3	220.0	19.6 26.3	214.6 246.4	4.9	27.5	7.8	
	13.1	7.8	20.9	245.2	28.7	273.9	5.3	27.1	7.6	
	12.3 11.8	9.0 8.9	21.2 20.7	243.7 268.5	29.9 30.3	273.6 298.9	5.0 4.4	30.1 29.4	7.8 6.9	
	10.0	10.5	20.4	283.4	50.5	333.9	3.5	20.7	6.1	
	10.6	11.4	22.1	300.8	58.6	359.4	3.5	19.5	6.1	
	11.0 12.2	12.5 14.3	23.5 26.5	322.9 340.2	69.2 76.9	392.1 417.1	3.4 3.6	18.1 18.6	6.0 6.3	
	12.2	14.5			70.5	417.1	3.0	10.0	0.5	
-			(Annual Percentag							
	 17.7	 10.5	13.1	22.2	 10.5	20.5				
	13.1	8.7	10.3	8.4	10.0	8.6				
	9.2 13.5	11.3 10.0	10.5 11.3	16.8 10.7	14.4 7.5	16.5 10.3				
	14.4	-3.4	3.4	7.3	-3.3	6.0				
	19.2	21.3	20.4	13.2	13.7	13.2				
	17.4	-14.2	-1.0	1.1	-7.9	0.1				
	-4.2 -6.5	0.3 -9.4	-1.9 -8.0	3.5 0.3	-4.7 -5.5	2.7 -0.3				
	6.5	6.9	6.7	4.1	-7.8	3.0				
	4.6	-6.4	-0.9	-1.8	8.3	-1.0				
	7.0 5.1	20.5 3.4	13.4 4.3	5.8 7.3	-1.4 -1.3	5.2 6.5				
	-9.9	-28.1	-19.1	-29.9	-18.8	-29.0				
	1.3	-6.7	-2.3	-7.7	-7.0	-7.6				
	15.7	1.2	9.5	12.9	34.1	14.8				
	18.9 -6.5	7.4 15.5	14.3 1.7	11.4 -0.6	9.0 4.1	11.2 -0.1				
	-3.5	-0.9	-2.4	10.2	1.4	9.2				
	-15.7	17.6	-1.4	5.5	66.5	11.7				
	6.6 3.8	9.3 9.3	8.0 6.7	6.1 7.4	16.0 18.2	7.6 9.1				
	10.6	14.2	12.5	5.3	11.2	6.4				
_		ge Share of Total Dru		-						
	35.6 37.1	64.4 62.9	100.0 100.0							
	38.0	62.0	100.0							
	37.6	62.4	100.0							
	38.3	61.7	100.0							
	42.4 41.9	57.6 58.1	100.0 100.0							
	49.7	50.3	100.0							
	48.6 49.4	51.4 50.6	100.0 100.0							
	49.3 52.0	50.7 48.0	100.0 100.0							
	49.1	50.9	100.0							
	49.5 55.1	50.5 44.9	100.0 100.0							
			100.0							
	57.1 60.4	42.9 39.6	100.0							
	62.8	37.2	100.0							
	57.7 57.1	42.3 42.9	100.0 100.0							
	48.8	42.9	100.0							
	48.8 48.2	51.2 51.8	100.0							
	46.9	53.1	100.0							
	46.1	53.9	100.0							

Table B N.W.T.-Per Capita Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2008 Prescribed Drugs Non-Prescribed Drugs Public Private Private (Out-of-Pocket) Social Security Funds WCB Drug Territorial Federal Subtotal Insurers* Out-of-Subtotal Total Over Personal Total Pocket Prescribed Health Drug Public Private the Non-Presci Insurance Drugs Counter Supplies Drugs Fund Drugs (\$ per Capita) 1985 19.87 44.58 0.30 64.76 42.52 107.28 74.63 N.W.T. 986 25.75 49.79 0.29 75.83 48.45 124.28 80.32 31.22 987 53.68 0.30 85.21 54.27 139.47 84.79 988 34.75 56.71 0.50 91.96 61.91 153.87 91.01 1989 36.51 64.93 0.46 ----101.90 --------69.02 170.93 --------95.30 1990 40.26 72.19 0.44 112.88 66.93 179.82 86.68 1991 1992 48.72 57.90 0.48 0.48 130.14 149.18 81.44 78.63 211.58 227.81 98.76 72.26 80.93 ----38.63 33.63 90.80 1993 38.77 101.02 0.60 ----140.39 ----73.95 214.34 40.71 34.01 74.73 1994 18.92 108.39 ----181.52 34.62 0.77 128.08 53.43 43.27 77.89 1995 133.46 189.82 38.04 81.04 17.01 115.69 0.76 -----------56.36 43.00 1996 19.17 117.78 0.63 137.58 51.79 189.37 39.74 35.24 74.98 1997 21.03 125.16 0.60 ----146.79 65.59 212.38 45.87 40.90 86.77 ----1998 24.63 130.34 0.62 155.58 -------67.25 222.83 48.16 43.48 91.64 1999 44.84 185.89 0.87 231.61 ----80.64 312.25 57.48 50.56 108.04 186.46 215.04 0.88 1.07 34.51 35.15 2000 48.07 ----235.41 --------85.11 320.51 57.16 91.67 --------2001 54.18 270.29 89.29 359.58 53.05 88.20 2002 57.23 257.78 1.10 316.11 ----97.51 413.62 54.38 35.62 90.01 2003 75.78 213.37 1.09 290.24 125.20 415.44 52.20 35.46 87.66 2004 84.28 190.26 1.69 ----276.23 --------125.49 401.72 50.49 31.97 82.47 87.63 144.25 1.45 233.33 165.47 398.80 46.79 32.80 79.59 2005 2006 100.34 148.83 1.42 ----250.58 188.11 438.69 48.58 33.11 81.69 2007 1 103.79 153.41 1.59 ----258.79 --------209.33 468.12 49.85 33.99 83.84 2008 99.11 181.51 1.79 282.41 244.82 527.23 50.84 34.67 85.51 (Annual Percentage Change) 1985 29.6 21.2 17.1 12.4 1986 11.7 -6.3 ------------14.0 15.8 ----7.6 1987 5.6 12.0 7.8 6.3 12.2 1988 11.3 5.6 65.8 ----7.9 --------14.1 10.3 ----7.3 1989 14.5 -8.8 10.8 ... 11.5 11.1 ----4.7 5.1 1990 10.3 -4.0 10.8 -9.1 11.2 -----3.0 5.2 --------1991 21.0 12.1 10.2 15.3 21.7 17.7 13.9 18.8 -3.4 7.7 1992 12.2 1.4 ----14.6 -26.8 5.4 1.1 3.4 4.2 1993 -33.0 11.3 24.8 -5.9 -6.0 -5.9 1994 -51.2 7.3 28.8 -----8.8 -----27.7 -15.3 6.3 1.8 1995 -10.1 6.7 -1.3 4.2 3.1 --------5.5 46 -0.6 9.9 4.0 -7.5 -----17.1 12.7 -7.4 1996 1.8 -8.1 -0.2 -7.6 1997 9.7 6.3 -3.8 ----6.7 -------26.7 12.2 15.4 16.1 15.7 ----1998 17.1 4.1 1.9 6.0 2.5 4.9 5.0 5.6 6.3 1999 82.1 42.6 41.8 48.9 19.9 40.1 19.3 16.3 17.9 -15.2 2000 7.2 0.3 0.5 ----1.6 -------5.5 2.6 -0.6 -31.7 12.7 15.3 22.0 --------4.9 2001 14.8 12.2 -7.2 1.9 -3.8 2002 5.6 19.9 2.3 ----17.0 -------9.2 15.0 2.5 1.3 2.0 2003 32.4 -17.2 -0.1 -8.2 28.4 0.4 -4.0 -0.5 -2.6 2004 11.2 -10.8 54.4 -----4.8 -------0.2 -3.3 -3.3 -9.8 -5.9 2005 4.0 -24.2 -14.0 -----15.5 --------31.9 -0.7 -7.3 2.6 -3.5 2006 14.5 3.2 -2.4 ----7.4 ----13.7 10.0 3.8 1.0 2.6 2007 3.4 3.1 12.1 ----3.3 --------11.3 6.7 2.6 2.7 2.6 2008 -4.5 18.3 12.6 9.1 17.0 12.6 2.0 2.0 2.0 al Percentage Change in Excess of Inflation in the Ca dian Econor 1985 ----1986 26.8 8.9 -9.1 14.3 11.2 13.0 --------4.8 ----1987 16.5 7.6 3.1 1.5 7.3 7.5 0.8 1988 6.8 1.1 9.9 61.2 3.4 6.2 --------9.6 6.9 5.8 6.5 2.8 1989 0.5 -13.4 ----0.1 1990 7.2 8.1 -7.1 ----7.7 ---------6.1 2.2 ---------12.1 1991 18.3 9.4 7.4 12.5 ----18.9 14.9 ----11.2 -4.7 1992 17.6 10.9 -2.6 ----13.4 -28.1 6.4 4.0 -0.3 1993 -34.5 9.8 23.3 -7.3 -7.4 2.0 -52.3 6.2 27.7 0.7 3.1 1994 -9.9 -28.8 16.4 5.2 1995 -12.4 11.0 4.4 -3.6 1.9 1.4 --------3.1 2.2 -1.9 -3.0 7.6 1.7 -9.1 -18.8 1996 0.1 -9.8 -9.3 -9.0 1997 8.7 17.5 5.3 -4.8 2.3 5.7 6.4 ----25.7 3.0 11.2 14.4 15.1 14.7 ----1998 5.4 6.7 4.6 5.4 6.1 1999 80.3 40.8 40.0 47.1 18.1 38.3 17.5 14.5 16.1 -2.5 -4.7 -35.8 -19.3 2000 3.1 -3.8 -3.6 1.4 -1.5 11.4 14.0 ----13.5 10.8 -8.5 2001 20.6 3.6 0.5 -5.1 2002 4.6 18.8 1.2 15.9 8.2 14.0 1.5 0.3 1.0 2003 29.5 -20.1 -3.0 -11.1 ----25.5 -2.5 -6.9 -3.4 -5.5 51.8 -13.4 -2.4 -5.9 -12.4 2004 8.6 -7.4 -5.9 -8.5 2005 0.9 -27.3 -17.1 -18.6 28.8 -3.8 -10.4 -0.5 -6.6 ----2006 12.1 0.8 -4.9 5.0 11.3 7.6 1.4 -1.4 0.2 2007 0.2 -0.1 8.9 0.1 8.1 3.5 -0.6 -0.6 -0.6 ---------7.9 13.5 -1.4 -1.4 2008 f 14.9 9.2 5.7 9.2 -1.4 forecast * Note: Confidentiality precludes reporting territorial-level insurance data Source: NHEX, CIHI, 2008.

	Total	Health Expendit	ures, Northwest	Ferritories, 1	985 to 2008		
	All Drugs		Haa	Ith Expenditure		GDP Implicit	
 Public	Private	Total	Public	Private	Total	Price Index-Canada	
		(\$ per Cap	ita)			(1997 = 100)	
64.76 75.83	117.15 128.77	181.91 204.59	2,185.68 2,655.45	361.05 396.69	2,546.73 3,052.14	73.6 75.6	
85.21	139.05	204.59	2,859.77	433.59	3,293.37	79.2	
91.96	152.93	244.89	3,302.40	490.09	3,792.49	82.8	
101.90	164.33	266.23	3,570.18	514.33	4,084.51	86.6	
112.88	153.61	266.49	3,708.35	481.64	4,190.00	89.2	
130.14	180.20	310.34	4,057.16	529.44	4,586.61	91.6	
149.18 140.39	150.89 148.68	300.07 289.07	4,004.30 4,071.51	476.22 445.89	4,480.52 4,517.40	92.8 94.1	
128.08	131.32	259.40	3,983.42	410.95	4,394.37	95.2	
133.46	137.40	270.86	4,060.01	370.96	4,430.96	97.4	
133.46	126.77	264.35	3,927.17	395.82	4,322.99	99.0	
146.79	152.36	299.16	4,146.76	389.36	4,536.12	100.0	
155.58	158.89	314.48	4,484.12	387.25	4,871.36	99.6	
231.61	188.69	420.29	5,194.03	519.57	5,713.59	101.4	
235.41	176.78	412.19	4,812.89	484.88	5,297.76	105.5	
270.29	177.49	447.78	5,390.16	645.24	6,035.40	106.9	
316.11 290.24	187.52 212.86	503.63 503.10	5,909.52 5,771.41	692.07 708.11	6,601.59 6,479.52	108.1 111.2	
276.23	207.96	484.18	6,271.13	708.16	6,979.29	111.2	
233.33	245.05	478.38	6,632.95	1,181.96		117.6	
233.33 250.58	245.05 269.80	478.38 520.38	7,094.14	1,380.97	7,814.90 8,475.11	120.5	
258.79	293.18	551.97	7,574.24	1,622.91	9,197.15	124.3	
282.41	330.33	612.74	7,871.99	1,779.95	9,651.94	128.6	
		(Ar	nual Percentage Change				
17.1	9.9	12.5	21.5	9.9	19.8	2.8	
12.4	8.0	9.6	7.7	9.3	7.9	4.7	
7.9	10.0	9.2	15.5 8.1	13.0	15.2	4.5	
10.8	7.5	8.7		4.9	7.7	4.6	
10.8	-6.5 17.3	0.1 16.5	3.9 9.4	-6.4	2.6 9.5	3.0	
15.3 14.6	-16.3	-3.3	-1.3	9.9 -10.1	-2.3	2.8 1.3	
-5.9	-1.5	-3.7	1.7	-6.4	0.8	1.4	
-8.8	-11.7	-10.3	-2.2	-7.8	-2.7	1.1	
4.2	4.6	4.4	1.9	-9.7	0.8	2.3	
3.1	-7.7	-2.4	-3.3	6.7	-2.4	1.7	
6.7	20.2	13.2	5.6	-1.6	4.9	1.0	
6.0 48.9	4.3 18.8	5.1 33.6	8.1 15.8	-0.5 34.2	7.4 17.3	-0.4 1.8	
1.6 14.8	-6.3 0.4	-1.9 8.6	-7.3 12.0	-6.7 33.1	-7.3 13.9	4.1 1.4	
17.0	5.6	12.5	9.6	7.3	9.4	1.0	
-8.2	13.5	-0.1	-2.3	2.3	-1.8	2.9	
-4.8	-2.3	-3.8	8.7	0.0	7.7	2.6	
-15.5	17.8	-1.2	5.8	66.9	12.0	3.1	
7.4	10.1	8.8	7.0	16.8	8.4	2.4	
3.3 9.1	8.7 12.7	6.1 11.0	6.8 3.9	17.5 9.7	8.5 4.9	3.2 3.4	
5.1					4.5	3.4	
		age Change in Excess of					
 14.3	 7.1	9.7	 18.7	 7.1	 17.0		
7.6	3.2	4.9	3.0	4.6	3.2		
3.4	5.5	4.7	11.0	8.5	10.6		
6.2	2.9	4.2	3.5	0.4	3.1		
7.7	-9.5	-2.9	0.8	-9.4	-0.4		
12.5	14.5	13.7	6.6	7.2	6.7		
13.4	-17.5	-4.6	-2.6	-11.3	-3.6		
-7.3 -9.9	-2.9 -12.8	-5.1 -11.4	0.2 -3.3	-7.8 -8.9	-0.6 -3.8		
1.9	2.3	2.1	-0.4	-12.1	-1.5		
1.4 5.7	-9.4 19.2	-4.1 12.2	-4.9 4.6	5.0 -2.6	-4.1 3.9		
6.4	4.7	5.6	8.6	-0.1	7.8		
47.1	16.9	31.8	14.0	32.4	15.5		
-2.5	-10.4	-6.0	-11.4	-10.8	-11.4		
13.5	-0.9	7.3	10.6	31.7	12.6		
15.9	4.6	11.4	8.6	6.2	8.3		
-11.1	10.6	-3.0	-5.2	-0.6	-4.7		
-7.4	-4.9	-6.3	6.1	-2.6	5.1		
-18.6	14.7	-4.3	2.7	63.8	8.9		
5.0 0.1	7.7 5.4	6.4 2.8	4.5 3.5	14.4 14.3	6.0 5.3		
5.7	9.3	2.8 7.6	3.5 0.5	6.3	5.3		

					Prescrib	ed Drugs					-Prescribed D
	Territorial	Federal _	Public Social Sect WCB	Drug Insurance	Subtotal Public	Insurers*	Private Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	ate (Out-of-Po Personal Health Supplies
Year				Fund		(\$ Mi	llions)			Drugs	
1985										 	
1986 1987										 	
1988 1989										 	
1989										 	
1990										 	
1992 1993										 	
1994										 	
995										 	
996										 	
997 998										 	
1999	1.0	0.0	0.0		1.1			1.3	2.4	1.5	1.3
000	1.2	0.2	0.0		1.4			1.5	2.8	1.6	0.9
2001 2002	1.2 1.5	0.4	0.0 0.0		1.7 2.4			1.5 2.1	3.2 4.5	1.5 1.6	1.0 1.0
2003	2.1	4.1	0.0		6.3			3.3	9.6	1.5	1.0
2004	2.2	5.1	0.1		7.4			4.1	11.5	1.5	0.9
2005 2006	2.4 2.8	7.7 8.9	0.0 0.0		10.2 11.7			3.7 4.3	13.9 16.0	1.4 1.5	1.0 1.0
2007 f	2.8	10.9	0.0		13.8			5.0	18.7	1.6	1.1
2008 f	2.7	12.4	0.1		15.2			6.0	21.1	1.5	1.1
						(Annual Perce	ntage Change)			
1985											
1986 1987											
1988											
989											
990 991											
992											
1993 1994											
995											
996											
997 998											
999											
000	21.7	289.9	3.1		31.3			9.4	19.1	1.1	-30.6
2001 2002	3.7 23.4	174.5 88.4	24.7 4.5		23.1 39.2			4.7 36.1	13.6 37.7	-4.8 6.0	4.5
2003	36.7	421.2	1.4		165.5			56.6	114.5	-2.7	0.9
004	6.3	22.9	57.0		17.5			24.9	20.1	-1.6	-8.3
005 006	8.6 17.2	52.0 14.3	-13.5 -0.5		38.4 14.9			-9.3 15.1	21.4 15.0	-6.6 8.4	3.3 5.4
2007 f	-1.0	22.9	14.8		17.1			17.1	17.1	2.5	2.5
008 f	-5.7	14.3	9.7		10.2			20.1	12.8	-0.7	-0.7
						ercentage Share of 1					
1985 1986											
987											
988 989											
990											
991											
992 993											
1994											
995											
1996 1997											
1998											
1999	18.8	0.7	0.4		19.9			25.4	45.3	29.1	25.6
2000 2001	22.6 21.9	2.9 7.4	0.5 0.5		25.9 29.9			27.4 26.9	53.3 56.8	29.1 26.0	17.6 17.2
2002	21.9	11.3	0.4		33.6			29.6	63.2	22.2	14.6
2003 2004	17.4 16.1	34.2 36.6	0.3 0.4		51.9 53.1			27.0 29.3	78.9 82.4	12.6 10.8	8.5
2004	14.9	47.5	0.4		62.7			29.3	85.4	8.6	6.0
006	15.4	47.7	0.2		63.3			23.0	86.3	8.2	5.6
2007 f 2008 f	13.2 11.2	51.0 52.4	0.2		64.4			23.4	87.8	7.3	5.C

	Expenditure or		by Source of Fin penditures, Nuna		a Share of Public 2008 (cont'd)	c, Private and		
	All Drugs		•	th Expenditure	2000 (cont u)		in Public, Private a Ith Expenditures	nd
 Public	Private	Total	Public	Private	Total		Private	Total
		(\$ Millior	15)			(Perce	entage Share)	
1.1	4.2	5.3	133.6	9.1	142.6	0.8	46.5	3.7
1.4	4.0	5.3	159.2	9.3	168.5	0.9	42.5	3.2
1.7	4.0	5.7	173.7	10.6	184.3	1.0	37.5	3.1
2.4 6.3	4.7 5.8	7.0 12.1	203.8 279.2	11.2 13.3	214.9 292.5	1.2 2.3	41.9 43.8	3.3 4.1
7.4	6.5	13.9	294.0	13.9	307.9	2.5	47.0	4.5
10.2	6.1	16.3	287.0	16.6	303.7	3.6	36.6	5.4
11.7 13.8	6.8 7.6	18.6 21.4	318.6 331.9	17.6 19.1	336.2 351.0	3.7 4.1	38.6 39.7	5.5 6.1
15.2	8.6	23.7	335.2	21.2	356.4	4.5	40.6	6.7
		(Annual Percentag	ae Change)					
31.3 23.1	-6.4 0.9	1.1	19.2	2.5	18.1 9.4			
39.2	17.2	6.6 23.8	9.1 17.3	14.4 4.9	16.6			
165.5	24.5	71.9	37.0	19.1	36.1			
17.5	12.1	14.9	5.3	4.4	5.3			
38.4 14.9	-6.9 12.0	17.2 13.8	-2.4 11.0	19.7 6.0	-1.4 10.7			
17.1	11.6	15.1	4.2	8.7	4.4			
10.2	13.0	11.2	1.0	10.5	1.5			
 (Percenta	ge Share of Total Dru	ug Expenditure)	_					
		-						
 19.9	80.1	100.0						
25.9	74.1	100.0						
29.9	70.1	100.0						
33.6 51.9	66.4 48.1	100.0 100.0						
51.9	48.1 46.9	100.0						
62.7	37.3	100.0						
63.3	36.7	100.0						
64.4 63.8	35.6 36.2	100.0 100.0						

					Prescrib	ed Drugs				Non	-Prescribed D
_			Public				Private			Priva	te (Out-of-Po
ī	Ferritorial	Federal	Social Secu WCB	rity Funds Drug Insurance	Subtotal Public	Insurers*	Out-of- Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies
				Fund		(\$ per	Capita)			Drugs	
	36.87	1.47	0.87		39.22			49.87	89.09	57.22	50.3
	43.76 44.37	5.60 15.02	0.88 1.07		50.24 60.46			53.24 54.52	103.47 114.97	56.42 52.52	34.0 34.80
	44.37 53.59	27.68	1.10		82.36			54.52 72.60	154.96	52.52	34.8
	72.19	142.15	1.09		215.44			112.05	327.49	52.19	35.4
	75.53	172.02	1.69		249.24			137.73	386.97	50.53	32.00
	80.98	258.19	1.44		340.62			123.30	463.92	46.57	32.6
	93.73 90.66	291.30 349.93	1.42 1.59		386.45 442.17			140.17 160.33	526.62 602.50	49.82 49.88	33.9 34.0
	84.90	397.28	1.73		483.91			191.32	675.23	49.20	33.5
						(Annual Perce	ntage Change)				
	18.7	280.3	0.5		28.1			6.7	16.1	-1.4	-32.
	1.4	168.4	22.0		20.3			2.4	11.1	-6.9	2.2
	20.8	84.3	2.3		36.2			33.2	34.8	3.7	2.
	34.7 4.6	413.6 21.0	-0.1 54.5		161.6 15.7			54.3 22.9	111.3 18.2	-4.1 -3.2	-0.0 -9.1
	7.2	50.1	-14.6		36.7			-10.5	19.9	-7.8	2.0
	15.7	12.8	-1.8		13.5			13.7	13.5	7.0	4.0
	-3.3	20.1	12.1		14.4			14.4	14.4	0.1	0.1
	-6.3	13.5	9.0		9.4			19.3	12.1	-1.4	-1.4
					(Annual Percentag	ge Change in Excess	of Inflation in	the Canadian E	conomy)		
	14.6 0.0	276.2 167.0	-3.6 20.6		24.0 19.0			2.6 1.0	12.0 9.8	-5.5 -8.3	-36. 0.
	19.7	83.3	1.2		35.2			32.1	33.7	2.6	1.4
	31.8 2.0	410.7 18.4	-3.0 52.0		158.7 13.1			51.4 20.3	108.4 15.6	-7.0 -5.8	-3.! -12.:
	4.1 13.3	47.0 10.4	-17.7 -4.2		33.6 11.0			-13.6 11.3	16.8 11.1	-10.9 4.6	-1.1
	-6.5	16.9	8.9		11.2			11.2	11.2	-3.1	-3.1
	-9.8	10.1	5.6		6.0			15.9	8.6	-4.8	-4.8

Nun.

			Total Health Expen	ditures, Nuna	vut, 1985 to	2008 (cont o	GDP Implicit	
_	Public	All Drugs Private	Total	Hea Public	Ith Expenditure Private	Total	Price Index—Canada	
			(\$ per Capita)				(1997 = 100)	
							73.6 75.6	
							79.2	
							82.8 86.6	
							89.2 91.6	
							92.8	
							94.1 95.2	
							97.4	
							97.4	
							100.0	
	39.22	 157.43	196.64	4,979.28	338.43	 5,317.71	99.6 101.4	
)	50.24 60.46	143.73 141.83	193.96 202.29	5,787.57 6,175.93	338.32 378.42	6,125.90 6,554.35	105.5 106.9	
	82.36	162.72	245.08	7,089.84	388.55	7,478.39	108.1	
	215.44 249.24	199.69 220.25	415.13 469.50	9,574.08 9,922.53	456.01 468.60	10,030.09 10,391.13	111.2 114.1	
1 5	340.62	202.52			553.63			
3	386.45	202.52	543.14 610.41	9,563.79 10,481.25	553.63	10,117.42 11,060.69	117.6 120.5	
f	442.17	244.22	686.39	10,667.22	615.16	11,282.38	124.3	
f	483.91	274.07	757.99	10,703.46 Percentage Change	675.48	11,378.94	128.6	
							2.8	
							4.7 4.5	
,)							4.6	
)							3.0	
							2.8	
2							1.3	
3 4							1.4	
5							2.3	
6							1.7	
7 B							1.0 -0.4	
9							-0.4	
0	28.1	-8.7	-1.4	16.2	0.0	15.2	4.1	
1	20.3	-1.3	4.3	6.7	11.9	7.0	1.4	
2	36.2	14.7	21.2	14.8	2.7	14.1	1.0	
3 4	161.6 15.7	22.7 10.3	69.4 13.1	35.0 3.6	17.4 2.8	34.1 3.6	2.9 2.6	
5	36.7	-8.1	15.7	-3.6	18.1	-2.6	3.1	
5	13.5	10.6	12.4	9.6	4.7	9.3	2.4	
7 f	14.4	9.0	12.4	1.8	6.2	2.0	3.2	
3 f	9.4	12.2	10.4	0.3	9.8	0.9	3.4	
—			age Change in Excess of Inflat	ion in the Canadian				
5								
7								
3								
9								
) I								
2								
3								
ŧ.								
3								
)	24.0	-12.8	-5.5	12.1	-4.1	11.1		
1 2	19.0 35.2	-2.7 13.7	2.9 20.1	5.4 13.8	10.5 1.6	5.6 13.1		
3	158.7	19.8	66.5	32.1	14.5	31.2		
4	13.1	7.7	10.5	1.1	0.2	1.0		
5	33.6	-11.2 8.2	12.6 10.0	-6.7 7.2	15.0	-5.7		
				1.7	2.2	6.9		
5 6 7 f	11.0 11.2	5.8	9.2	-1.4	2.9	-1.2		

Series C

International Comparisons

Table C.1

The Share of Pharmaceutical Goods* in Total Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2005, 2006

1985		2005		2006	
	Percent		Percent		Percent
Korea	33.6	Slovak Republic	31.9	Hungary	31.0
Portugal	25.4	Hungary	30.5	Slovak Republic	29.7
Spain	20.3	Poland	28.0	Poland	27.2
Japan	18.0	Korea	26.4	Korea	25.9
Iceland	16.6	Czech Republic	25.1	Czech Republic	23.1
France	16.2	Spain	22.4	Mexico	22.9
Belgium	15.7	Portugal	21.6	Spain	21.7
Luxembourg	14.7	Mexico	21.3	Portugal	21.3
United Kingdom	14.1	Italy	20.3	Italy	20.0
Germany	13.8	Japan	19.8	Japan	19.6
New Zealand	13.3	Greece	18.5	Greece	17.6
Turkey	13.0	Canada	17.2	Canada	17.4
Switzerland	11.3	Belgium	17.1	Belgium	16.9
Finland	9.7	France	16.7	France	16.4
Canada	9.6	Finland	15.8	Germany	14.8
Netherlands	9.3	Germany	15.1	Finland	14.6
Norway	9.1	Australia	14.2	Australia	13.7
United States	9.0	Sweden	13.7	Sweden	13.3
Australia	8.9	Iceland	13.4	lceland	13.1
Sweden	7.0	United States	12.4	United States	12.6
Denmark	6.6	Austria	12.0	Austria	12.4
		Switzerland	10.5	Norway	8.5
		Norway	9.1	Denmark	8.5
		Denmark	8.6		
		Luxembourg	8.4		

Notes

* The OECD proposes the following standard definition: includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Hungary:	Excludes subsidies by local governments.
Switzerland:	Excludes other medical non-durables.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Table C.2

The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-Durables,* OECD Reporting Countries, 1985, 2005, 2006

0		1
		_

1985		2005		2006	
	Percent		Percent		Percent
Turkey	90.0	Greece	87.1	Greece	92.9
Luxembourg	86.0	Luxembourg	83.5	Germany	74.3
New Zealand	80.4	Czech Republic	75.5	Slovak Republic	72.9
Germany	71.9	Germany	73.5	Spain	72.3
Sweden	70.1	Slovak Republic	73.5	Japan	71.7
France	67.1	Spain	72.0	Czech Republic	70.8
Portugal	64.7	Japan	71.4	France	69.4
United Kingdom	64.1	Austria	70.0	Austria	68.9
Netherlands	63.3	France	69.3	Hungary	67.2
Spain	62.5	Switzerland	67.7	New Zealand	66.6
Iceland	61.9	New Zealand	66.2	Iceland	60.2
Japan	60.6	Hungary	64.7	Sweden	59.2
Belgium	51.0	Sweden	60.4	Norway	56.5
Australia	46.5	Iceland	58.7	Portugal	55.7
Denmark	45.5	Norway	58.4	Denmark	55.5
Finland	44.5	Portugal	57.5	Finland	55.4
Norway	43.2	Denmark	55.8	Australia	55.0
Canada	29.4	Australia	55.2	Korea	53.1
Korea	11.2	Finland	52.3	Belgium	50.1
United States	9.3	Belgium	51.1	Italy	50.1
		Korea	50.5	Canada	39.2
		Italy	49.7	Poland	38.6
		Canada	39.0	United States	30.2
		Poland	37.9	Mexico	15.4
		United States	24.4		
		Mexico	11.1		

Notes

* The OECD proposes the following standard definition: includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Hungary:	Excludes subsidies by local governments.
Switzerland:	Excludes other medical non-durables.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Table C.3

The Share of Pharmaceutical Goods* in Public Expenditure on Health, in Descending Order, OECD Countries Reporting, 1985, 2005, 2006

1985		2005		2006	
	Percent		Percent		Percent
Portugal	30.1	Slovak Republic	31.5	Slovak Republic	31.7
Turkey	23.1	Hungary	27.8	Hungary	29.4
Spain	15.7	Greece	25.7	Greece	26.6
Japan	15.4	Korea	24.8	Korea	24.8
Luxembourg	14.2	Spain	22.8	Spain	22.0
France	13.8	Czech Republic	21.4	Czech Republic	18.6
Germany	12.8	Portugal	17.3	Japan	17.3
New Zealand	12.3	Japan	17.0	Portugal	16.8
Iceland	11.8	Poland	15.3	Poland	15.0
Korea	11.4	France	14.5	Germany	14.3
United Kingdom	10.5	Germany	14.4	France	14.2
Netherlands	8.3	Italy	13.1	Italy	13.0
Australia	5.8	Switzerland	11.9	Austria	11.3
Finland	5.5	Australia	11.7	Australia	11.2
Sweden	5.4	Finland	11.0	Finland	10.6
Norway	4.6	Austria	11.0	Sweden	9.7
Canada	3.8	Sweden	10.1	Iceland	9.7
Denmark	3.5	Iceland	9.7	Canada	9.7
United States	2.1	Canada	9.6	United States	8.3
		Luxembourg	7.8	Mexico	8.0
		United States	6.7	Norway	5.7
		Norway	6.3	Denmark	5.6
		Denmark	5.7		
		Mexico	5.2		

Notes

* The OECD proposes the following standard definition: includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticated stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Country-specific definitions differ from the OECD proposed standard definition as follows:

Hungary:	Excludes subsidies by local governments.
Switzerland:	Excludes other medical non-durables.
Turkey:	Includes pharmaceutical consumption in hospitals.
United Kingdom:	Includes some household expenditure on orthopedic and surgical appliances.

Source

OECD Health Data 2008, December 2008. Organisation for Economic Co-operation and Development and IRDES, Paris.

Appendix A

Comparison of Provincial and Territorial Drug Subsidy Programs

Comparison of Provincial and Territorial Drug Subsidy Programs

Table 8 gives an overview of provincial and territorial drug subsidy programs as of December 31, 2008. The table was verified for accuracy with provincial/territorial programs. Information is also available from the following websites:

British Columbia Pharmacare www.health.gov.bc.ca/pharme/

Alberta Prescription Drug Program www.health.alberta.ca/AHCIP/prescription-program.html

Saskatchewan Drug Plan www.health.gov.sk.ca/drug-plan-benefits

Manitoba Pharmacare Program www.gov.mb.ca/health/pharmacare/index.html

Ontario Drug Benefits www.health.gov.on.ca/english/public/program/drugs/funded drug/funded drug.html

Régime général d'assurance médicaments du Québec (RGAM) www.ramq.gouv.qc.ca/en/citoyens/assurancemedicaments/index.shtml

New Brunswick Prescription Drug Program www.gnb.ca/0212/intro-e.asp

Nova Scotia Pharmacare www.gov.ns.ca/health/pharmacare/family_pharmacare/family_pharmacare.asp

Prince Edward Island Pharmacy Services www.gov.pe.ca/infopei/index.php3?number = 1019960&lang = E

Newfoundland and Labrador Prescription Drug Program www.health.gov.nl.ca/health/nlpdp/newoverview.htm

Yukon Pharmacare hss.gov.yk.ca/programs/insured_hearing/pharmacare/

Northwest Territories www.hlthss.gov.nt.ca/english/services/health_care_plan/default.htm

Nunavut Planning Commission www.drugcoverage.ca/p_benefit_nu.asp

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
British Columbia	Fair Pharmacare Enhanced Assistance	Families in which at least one family member is born in 1939 or earlier and are not covered by other plans	None	Based on family net income: \$0: <\$33K 1%: \$33K to \$50K 2%: >\$50K	Pharmacare pays 75%	1.25%: < \$33K 2%: \$33K to \$50K 3%: > \$50K
	Fair Pharmacare	Families in which all family members are born in 1940 or later and are not covered by other plans	None	Based on family net income: \$0: <\$15K 2%: \$15K to \$30K 3%: >\$30K	Pharmacare pays 70%	2%: <\$15K 3%: \$15K to \$30K 4%: >\$30K
	Pharmacare Plan B	Permanent residents of licensed residential care facilities	None	None	None	N/A
	Pharmacare Plan C	Recipients of B.C. Income Assistance	None	None	None	N/A
	Pharmacare Plan D	Cystic fibrosis patients registered with a provincial cystic fibrosis clinic	None	None	None	N/A
	Pharmacare Plan F	Severely handicapped children registered in the At Home Program	None	None	None	N/A
	Pharmacare Plan G	Clients of mental health service centres meeting clinical and low- income criteria	None	None	None	N/A
	Pharmacare Plan P	Palliative care patients treated at home	None	None	None	N/A
Alberta	Seniors	Seniors age 65 and older and their eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Widows	Residents age 55 to 64 who qualify for Alberta Widows' Pension and eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A

Note

* Costs incurred by the client choosing a high-cost product where cheaper alternatives are available are borne by the client.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Alberta (cont'd)	Palliative	Palliative residents treated at home	None	None	30% of prescription to a max. of \$25 per prescription*	The maximum amount palliative patients pay out of pocket is \$1,000
	Non-Group	A universal plan available to all residents under the age of 65	Quarterly (three-month) rate is \$61.50 for singles and \$123 for families. Subsidized rates are available at \$43.05 for singles and \$86.10 for families.	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Province-wide services	Residents with specific conditions may be eligible for high-cost drugs, mostly transplant and HIV drugs	None	None	None	N/A
	Income Support	Residents receiving social assistance and eligible dependants	None	None	None	N/A
	Assured Income for the Severely Handicapped (AISH)	Residents receiving AISH (an income- support program for adults with a permanent disability that severely impairs their ability to earn a living) and eligible dependants	None	None	None	N/A
	Alberta Adult Health Benefit	Qualified clients leaving Income Support for work	None	None	None	N/A
	Alberta Child Health Benefit	Children in low- income families	None	None	None	N/A

Note

* Costs incurred by the client choosing a high-cost product where cheaper alternatives are available are borne by the client.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan [↑]	Saskatchewan Drug Plan— Special Support Program	All residents with Saskatchewan health coverage (application required)	None	Income-tested (annual threshold based on 3.4% of adjusted family income)	Income-tested (based on benefit drug costs, to help spread cost out evenly over the year)	N/A
	Seniors' Drug Plan	Saskatchewan residents 65 and older. Effective July 1, 2007, seniors pay no more than \$15 per prescription for benefit drugs (not income-tested; no application required). Effective July 1, 2008, individual annual net income reported in 2006 must be less than \$64,044 to be eligible for the cap of \$15 per prescription (application required to determine eligibility)	None	None	Maximum \$15 per prescription	N/A
	Seniors (deductible programs)	Seniors receiving the Seniors Income Plan supplement or receiving the federal Guaranteed Income Supplement and residing in a special care home	None	\$100 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A
		Seniors receiving the Guaranteed Income Supplement and living in the community	None	\$200 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A

Note

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan (cont'd) [†]	Emergency Assistance Program	Residents who require immediate treatment with covered prescription drugs and are unable to cover their share of the cost. This is a one-time benefit, and individuals are encouraged to apply for income- tested coverage for future assistance	None	None	The level of assistance provided is in accordance with the consumer's ability to pay	N/A
	Family Health Benefits	Eligibility is established by the Department of Social Services, based on the number of children in the family and the family's annual income	None	\$100 semi- annual family deductible	No charge for benefit prescriptions for children; 35% consumer copayment after deductible has been paid for adult benefit prescriptions	N/A
	Supplementary Health	Persons nominated by Saskatchewan Social Services for special coverage, including persons on social assistance, wards, inmates, etc.	None	None	Up to \$2 per prescription (some drugs covered at no charge; individuals younger than 18 and certain other categories receive benefit prescriptions at no charge)	N/A

Note

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan (cont′d) [↑]	Saskatchewan Aids to Independent Living (SAIL)	Persons registered under the following SAIL programs receive formulary and approved non- formulary drugs at no charge: Paraplegia Program, Cystic Fibrosis Program and Chronic End- Stage Renal Disease Program	None	None	None	N/A
	Palliative Care Program	Residents who are in the late stages of a terminal illness	None	None	None	N/A
	Workers' Health Benefits Program [†]	Employed or self-employed residents younger than 65 without dependent children, without access to private or employer- sponsored health plan, and who are either: • single with income less than \$21,000; or • married or common law with income less than	None	\$100 semi- annual deductible	35% consumer copayment after deductible has been paid	N/A
		\$26,000 (application required)				

Notes

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

The Saskatchewan Workers' Health Benefits program was discontinued as of March 19, 2008.
 Working adults without children who are currently enrolled and receiving benefits will maintain coverage until June 2010, if they continue to remain eligible.

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan (cont'd)†	Children's Insulin Pump Program	Type 1 diabetic children (younger than 18) who require pumps to adequately stabilize blood sugar levels and are not eligible for benefits under a federal government program (such as the Non-Insured Health Benefits program)	None	None	No charge for insulin pump. Insulin pump supplies subject to coverage (family deductible/ copay)	N/A
	Children's Drug Plan	Children 14 and younger	None	None	Maximum \$15 per prescription	N/A
Manitoba	Pharmacare	All provincial residents who are eligible for benefits under <i>The Prescription</i> <i>Drug Cost</i> <i>Assistance Act</i>	None	Based on total adjusted family income; 2.69% of \leq \$15,000; 4.02% of \$15,000 to \$40,000; 4.63% of \$40,000 to \$75,000; 5.79% of > \$75,000; credit of \$3,000 for a spouse and each dependent younger than 18	None	N/A

Note

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 8	Comparison of Provincial and Territorial Drug Subsidy Programs
	as of December 2008 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Manitoba (cont'd)	Employment and Income Assistance Program	Individual Manitobans that are receiving drug benefits pursuant to the Employment and Income Assistance Program	None	None	None	N/A
	Personal Care Home	Manitoba residents of personal care homes	None	None	None	N/A
	Palliative Care	Residents who are terminally ill and wish to remain at home	None	None	None	N/A
Ontario	Ontario Drug Benefit Program	Seniors (65 and older). Single seniors with annual income \geq \$16,018 or seniors in couples with combined annual income of \geq \$24,175	None	\$100 per recipient	After deductible, up to \$6.11 per prescription	N/A
		Seniors (65 and older). Single seniors with annual income <\$16,018 or seniors in couples with combined annual income of <\$24,175	None	None	Up to \$2 per prescription	N/A
		Residents of long-term care facilities	None	None	Up to \$2 per prescription	N/A
		Residents of homes for special care	None	None	Up to \$2 per prescription	N/A
		Residents receiving professional services under the home care program	None	None	Up to \$2 per prescription	N/A
Pr		Residents receiving social assistance (Ontario Disability Support Program or Ontario Works Program)	None	None	Up to \$2 per prescription	N/A
	Trillium Drug Program	Residents with high drug costs in relation to income	None	Income- based	Up to \$2 per prescription	N/A
	Special Drugs Program	Residents with valid Ontario health insurance. Coverage is product-specific for a limited number of diseases or conditions.	None	None	None	N/A

Table 8	Comparison of Provincial and Territorial Drug Subsidy Programs
	as of December 2008 (cont'd)

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Quebec	Régime général d'assurance médicaments du Québec (RGAM)	Employment assistance (welfare) recipients (EAR) and other holders of a claim slip	None	None	None	None
		Seniors (65 and older) receiving at least 94% of the maximum Guaranteed Income Supplement (GIS)	None	None	None	None
		Seniors (65 and older) receiving less than 94% of the maximum GIS (partial GIS)	\$0 to \$570 per adult per year, depending on income	\$14.30 per month	31% of prescription costs	\$48.99 per month
		Seniors (65 and older) without GIS	\$0 to \$570 per adult per year, depending on income	\$14.30 per month	31% of prescription costs	\$77.21 per month
		General clientele (residents younger than 65 without access to a group plan)	\$0 to \$570 per adult per year, depending on income	\$14.30 per month	31% of prescription costs	\$77.21 per month
New Brunswick	Prescription Drug Program— Plan A	Seniors with Guaranteed Income Supplement (GIS)	None	None	\$9.05 for each prescription	\$250
		Seniors without GIS who qualify for benefits based on annual income as follows: a single senior with an annual income of \$17,198 or less; a senior couple (both \geq 65) with a combined annual income of \$26,955 or less; a senior couple with one spouse younger than 65, with a combined annual income of \$32,390 or less	None	None	\$15 per prescription	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
New Brunswick (cont'd)	Prescription Drug Program— Plan B	Cystic fibrosis patients or patients with juvenile or infant sclerosis of the pancreas	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan E	Individuals residing in a licensed residential facility who hold a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 for each prescription	\$250
	Prescription Drug Program— Plan F	Individuals holding a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 per prescription for adults (18 and older) and \$2 for children (younger than 18)	\$250 per family
	Prescription Drug Program— Plan G	Special-needs children and children under the care of the Minister of Social Development	None	None	None	N/A
	Prescription Drug Program— Plan H	Residents in possession of a prescription written by a neurologist for the medications Avonex, Rebif, Betaseron or Copaxone are eligible to apply for assistance	\$50 yearly registration fee	None	Income- tested (ranges from 0% to 100%)	N/A
	Prescription Drug Program— Plan R	Organ-transplant recipients who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan T	Individuals with growth hormone deficiency who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan U	Individuals who are HIV positive and are registered with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Prescription Drug Program— Plan V	Individuals who reside in a registered nursing home	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Nova Scotia	Seniors Pharmacare Program	Seniors (65 and older) receiving Guaranteed Income Supplement (GIS) and covered by Medical Services Insurance (MSI) and not having coverage through Veterans Affairs Canada, Non- Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan that covers most medications and supplies	None	None	33% prescription cost	\$382
		Seniors (65 and older) not receiving GIS and covered by MSI and not having coverage through Veterans Affairs Canada, Non-Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan that covers most medications and supplies	Up to \$424 per year	None	33% prescription cost	\$382
	Department of Community Services Programs	Eligible clients and their dependents in receipt of income assistance; any client and/or dependent having access to another drug plan, be it from a public or private entity, will be required to use that plan and will not be eligible for the pharmacare program	None	None	All income- assistance clients and dependents are required to copay a flat fee of \$5 per prescription, unless the client or dependent is eligible for copay exemption	N/A
	Drug Assistance for Cancer Patients	Residents having a gross family income no greater than \$15,720 per year and not eligible for coverage under other drug programs	None	None	None	N/A
	Family Pharmacare Program	Residents with a valid Nova Scotia health card	None	Income- based	20% of the total prescription cost	Income- based

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Nova Scotia (cont'd)	Nova Scotia Diabetes Assistance Program	Residents younger than 65 with a valid Nova Scotia health card and who do not have drug coverage through Veterans Affairs Canada, First Nations and Inuit Health or any private drug plans that cover diabetes supplies, who have a confirmed diagnosis of diabetes	None	Income- based	20% of the total prescription cost	N/A
Prince Edward Island	Seniors Drug Cost Assistance Plan	Seniors 65 or older and eligible for P.E.I. Medicare	None	None	First \$11 of the medication cost plus the pharmacy professional fee for each prescription	N/A
	Children-in-Care	Persons in the temporary or permanent care of the Director of Child Welfare	None	None	None	N/A
	Family Health Benefit Program	Families eligible for P.E.I. Medicare, with one or more children younger than 18, a total annual net family income of \$24,800 or less and approved by the program	None	None	The pharmacy professional fee for each prescription	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Prince Edward Island (cont'd)	Financial Assistance Program	Persons eligible under the <i>Social</i> Assistance Act	None	None	None	N/A
	Erythropoietin Program	Persons eligible for P.E.I. Medicare who have been diagnosed with chronic renal failure or are receiving kidney dialysis	None	None	None	N/A
	Diabetes Control Program	Persons with diabetes eligible for P.E.I. Medicare and who are registered with the program	None	None	Insulin: \$10 per 10 mL vial of insulin or box of 1.5 mL insulin cartridges; \$20 per box of 3.0 mL insulin cartridges	N/A
					Oral Medications and Urine Testing Materials: \$11 per prescription	
					High-Cost Diabetes Medications: an income- based portion of the medication	
					plus the professional fee for each high-cost medication obtained	

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Prince Edward Island (cont'd)	High Cost Drugs Program	Persons eligible for P.E.I. Medicare and approved for coverage of one or more of the medications included in the program	None	None	Income- based portion of the drug cost plus the pharmacy professional fee for each prescription	N/A
	Community Mental Health Program	Approved long-term psychiatric patients living in the community	None	None	None	N/A
	Sexually Transmitted Diseases (STD) Program	Persons diagnosed with sexually transmitted disease or identified contacts of a person with a sexually transmitted disease	None	None	None	N/A
	Institutional Pharmacy/ Nursing Home Program	Residents in private nursing homes eligible for coverage under the <i>Social Assistance</i> <i>Act</i> and regulations	None	None	None	N/A
	Disease-Specific Programs (for example, AIDS/HIV, cystic fibrosis, growth hormone, hepatitis, tuberculosis, hairy cell leukemia, AIDS- related Kaposi's sarcoma, basal cell carcinoma, and transplant drug programs delivered through the government-run Provincial Pharmacy)	Persons diagnosed with specific medical conditions or at risk for exposure to communicable diseases	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Prince Edward Island (cont'd)	Quit-Smoking Program	Persons eligible for P.E.I. Medicare and who have registered with the program	None	None	None	N/A
	Nutrition Program	Children and high-risk pregnant women diagnosed with a nutritional deficiency	None	None	None	N/A
Newfoundland and Labrador	The 65Plus Plan	Seniors (65 and older) who are in receipt of the Guaranteed Income Supplement and who are registered for Old Age Security benefits	None	None	Mark-up and professional fee for identified benefits	N/A
	The Foundation Plan	Residents of the province who qualify for full benefit coverage under the Department of Human Resources, Labour and Employment, and certain individuals receiving services through the regional health authorities, including children in the care of Child, Youth and Family Services and individuals in supervised care	None	None	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Newfoundland and Labrador (cont'd)	The Access Plan	Residents with low incomes who access eligible prescription medications. The amount of coverage is determined by net income level and family status	None	None	Based on family net income: Family (with children) Income Copay <\$21K 20.0% \$22K 25.6% \$23K 31.1% \$24K 36.7% \$25K 42.2% \$26K 47.8% \$27K 53.3% \$28K 58.9% \$29K 64.4% \$30K 70.0% Couple (with no children) Income Copay <\$15K 20.0% \$16K 28.3% \$17K 36.7% \$18K 45.0% \$19K 53.3% \$20K 61.7% \$21K 70.0% Single individuals: Income Copay <\$13K 20.0% \$14K 28.3% \$15K 36.7% \$16K 45.0% \$16K 45.0% \$18K 61.7% \$18K 61.7%	Between 20% and 70%, depending on family net income and family status (single, couple or family)
	The Assurance Plan	Residents who experience the financial burden of eligible high drug costs, whether it be from the cost of one extremely high- cost drug or the combined cost of different drugs	None	None	Based on a combination of family net income and eligible family drug costs	Based on family net income: Income Max. <\$40K 5.0% ≥\$40K to 7.5% <\$75K ≥\$75K to 10.0% <\$150K
	The Select Needs Plan	Residents with cystic fibrosis or growth hormone deficiency	None	None	None, for identified benefits	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Yukon	Pharmacare	Seniors 65 or older (and seniors' spouses age 60 and older) registered with Yukon Health Care Insurance Plan and not having coverage through First Nations and Inuit Health (residents must use private insurance plans first); program may also include clients receiving palliative care	None	None	None	N/A
	Chronic Disease Program	Residents who have a chronic disease or a serious functional disability as provided under the <i>Chronic</i> <i>Disease and Disability</i> <i>Benefits Regulations</i> and not having coverage through First Nations and Inuit Health (residents must use private insurance plans first); program may also include clients receiving palliative care	None	Maximum \$250 per individual and \$500 per family (deductible may be waived, depending on income)	None	N/A
	Children's Drug and Optical Program	Children younger than 19 from low- income families and not having coverage through First Nations and Inuit Health	None	Maximum \$250 per child and \$500 per family (deductible may be waived, depending on income)	None	N/A

Province/ Territory	Program/Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Northwest Territories	Extended Health Benefits Program for Specified Diseases	Resident, non-native or Métis, and have a specified disease condition	None	None	None	N/A
	Seniors' Benefit Program	Métis and non-native residents who are 60 years and older	None	None	None	N/A
	Métis Health Benefits Program	Resident, registered with territorial Health Care Plan, descendent of Chipewyan, Slavey, Gwich'in, Dogrib, Hare or Cree people; and resided in or used and occupied the Mackenzie Basin on or before January 1, 1921, or is a Community Acceptance Member, or was adopted as a minor	None	None	None	N/A
	Indigent Health Benefits Program	Indigent individuals or families resident of the Northwest Territories, who meet the eligibility requirements according to the Indigent Health Benefits Policy	None	None	None	N/A
Nunavut	Extended Health Benefits Program	Non-Aboriginal residents, including seniors, who have a specific chronic condition or have reached the age of 65	None	None	None	N/A
	Indigent Health Benefits Program	Residents receiving income support	None	None	None	N/A

Reference List

- 1. Canadian Institute for Health Information, *National Health Expenditure Trends,* 1975–2008 (Ottawa, Ont.: CIHI, 2008).
- 2. Health Canada, Non-Insured Health Benefits Program, *Annual Report 2006/2007* (Ottawa, Ont.: Health Canada, 2008).
- 3. S. Morgan, "Sources of Variation in Provincial Drug Spending," *Canadian Medical Association Journal* 170, 3 (2004): pp. 329–330.
- 4. S. Jacobzone, Organisation for Economic Co-operation and Development, *Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals*, Labour Market and Social Policy; Occasional Papers, No. 40 (Paris: OECD, April 2000).
- 5. Organisation for Economic Co-operation and Development, *System of Health Accounts—Germany 2006*. (Prepublication tables provided by the OECD in November 2008, before its planned posting on the OECD web page A System of Health Accounts.)
- Organisation for Economic Co-operation and Development, System of Health Accounts – France 2006. (Prepublication tables provided by the OECD in November 2008, before its planned posting on the OECD web page A System of Health Accounts.)
- M. Aaserud et al., *Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing and Purchasing Policies (Review)*, The Cochrane Collaboration, 4 (The Cochrane Library: John Wiley & Sons, Ltd., 2006): pp. 1–66, Cochrane Library Number CD005979.
- S. Morgan et al., "'Breakthrough' Drugs and Growth in Expenditure on Prescription Drugs in Canada," *British Medical Journal* 331, 7520 (October 8, 2005): pp. 815–816, [online], cited February 8, 2007, from <<u>http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 1246080></u>, catalogue no. 38582.703866.
- 9. Patented Medicine Prices Review Board, Patented Medicine Prices Review Board 2007 Annual Report (Ottawa, Ont.: Patented Medicine Prices Review Board, 2008): pp. 1–62, [online], cited January 2009, from <<u>http://www.pmprb-cepmb.gc.ca/</u> CMFiles/PMPRB-AR07-english42LFK-6182008-8285.pdf>.
- Z. Karaca and S. Wiggins, *The Impacts of Break-Through Drug Classes on Total Health Expenditures: Empirical Evidence From the 1996–2001 Medical Expenditure Panel Surveys*, eds., Z. Karaca and S. Wiggins (Texas: A&M University, November 11, 2006): pp. 1–40, [online], cited February 14, 2007, from <<u>http://ssrn.com/abstract = 947603</u>>, catalogue no. 947603.

- F. R. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS," *Health Affairs* 20, 5 (September/October 2001): pp. 241–251.
- Canadian Cancer Society, A National Home Care Program, [online], cited February 9, 2007, from <<u>http://www.cancer.ca/ccs/internet/standard/</u>0,3182,3172 335445 langld-en,00.html>.
- 13. Statistics Canada, Demography Division, *Demographic Estimates Compendium 2007* (Ottawa, Ont.: Statistics Canada, April 2008), catalogue no. 91-213-SCB.
- S. Morgan, "Drug Spending in Canada: Recent Trends and Causes," *Medical Care* 42, 7 (July 2004): pp. 635–642.
- 15. B. Mintzes et al., "Volume IV: Pills, Persuasion and Public Health Policies," in An Assessment of the Health System Impacts of Direct-to-Consumer Advertising of Prescription Medicines (DTCA), eds., B. Mintzes, A. Kazanjian, K. Bassett and J. Lexchin (Report of an Expert Survey on Direct-to-Consumer Advertising of Prescription Drugs in Canada, the United States and New Zealand) (Vancouver, B.C.: Health Policy and Research Unit, Centre for Health Services and Policy Research, August 2001): pp. 1–48, [online], cited February 14, 2007, from <http://www.chspr.ubc.ca/files/publications/2002/dtca-v4-expertsurvey.pdf>, catalogue no. HPRU 02:4D.
- 16. Statistics Canada, *Guide to the Income and Expenditure Accounts* (Ottawa, Ont.: Statistics Canada, 1996): pp. 137 and 139, catalogue no. 13-603E.
- 17. Organisation for Economic Co-operation and Development, *OECD Health Data 2008* (Paris: OECD, 2008).
- 18. Statistics Canada, *Family Expenditure in Canada* (Ottawa, Ont.: Statistics Canada), catalogue no. 65-555-XPB.
- 19. Statistics Canada, Your Guide to the Consumer Price Index (Ottawa, Ont.: Statistics Canada, 1996): pp. 7–9, [online], cited February 9, 2007, from <http://www.statcan.gc.ca/imdb-bmdi/document/2301_D6_T9_V1-eng.pdf>, catalogue no. 62-557-XPB.



www.cihi.caTaking health information furtherwww.icis.caÀ l'avant-garde de l'information sur la santé